Clinical trial NCT03677401
Conditions: Pruritus Prurigo Nodularis
Sponsor: Vyne Therapeutics Inc.
Start date: 2018-08-29; Completion date: 2020-02-06
Enrollment: 295 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis

Detailed description:

Arms: arm 1: None arm 2: None
Interventions: intervention 1: 5mg Serlopitant Tablets intervention 2: Placebo Tablets
Intervention descriptions: intervention 1: Serlopitant Tablets intervention 2: Placebo Tablets

Protocol documents:
Prot_001.pdf: 
Protocol: MTI-106 
Confidential - Proprietary Information 
 Protocol number: MTI-106. 
 Document title: A randomized, double-blind, placebo-controlled study of 
the efficacy, safety, and tolerability of serlopitant for the treatment of 
pruritus in adults with prurigo nodularis. 
 Version number: Protocol Version 4. 
 Date of the document: 16 December 2019. 
 NCT number: NCT03677401 


Abbreviated Clinical Study Report 
 
MTI-106 
16.1 Study Information 
CONFIDENTIAL 
 
Version 1.0 
16.1.1  
PROTOCOL AND PROTOCOL AMENDMENTS 
The following protocols under which subjects were enrolled and summaries of changes are 
provided: 
• Protocol Version 2.1 (02 July 2018) 
• Summary of Changes, Version 2.1 to 3.0 
• Protocol Version 3.0 (21 March 2019) 
• Summary of Changes, Version 3.0 to 4.0 
• Protocol Version 4.0 (16 December 2019) 
1


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 2.1 02 July 2018 
 
Page 1 
CLINICAL STUDY PROTOCOL 
 
TITLE:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, AND 
TOLERABILITY OF SERLOPITANT FOR THE TREATMENT 
OF PRURITUS IN ADULTS WITH PRURIGO NODULARIS  
IND No.: 
 
 
117780 
Eudra CT: 
 
 
2017-004210-25 
ClinicalTrials.gov ID:  
[Placeholder] 
Protocol No.:  
 
MTI-106   
Protocol Version/Date: 
Version 2.1/02 July 2018 
Development Phase:  
Phase 3 
Sponsor: 
 
 
Menlo Therapeutics Inc. 
200 Cardinal Way, 2nd Floor 
Redwood City, CA 94063 
USA  
 
 
 
 
Confidentiality Statement: 
This document is a confidential communication of Menlo Therapeutics Inc. As such, the 
recipients agree not to disclose or reproduce, without prior written approval, this document and 
any attachments, except to appropriate Ethics Committees, representatives of the US Food and 
Drug Administration, the European Medicines Agency, other Competent Authorities or 
regulatory agencies or as otherwise required by applicable laws or regulations.
2


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 2.1 02 July 2018 
 
Page 2 
SIGNATURE PAGE FOR PRINCIPAL INVESTIGATOR(S) 
 
TITLE:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, 
AND TOLERABILITY OF SERLOPITANT FOR THE 
TREATMENT OF PRURITUS IN ADULTS WITH 
PRURIGO NODULARIS  
IND No.: 
 
 
117780 
Eudra CT: 
 
 
2017-004210-25 
ClinicalTrials.gov ID:  
[Placeholder] 
Protocol No.:  
 
MTI-106 
Protocol Version/Date: 
Verson 2.1/02 July 2018   
Development Phase:  
Phase 3 
Sponsor: 
 
 
Menlo Therapeutics Inc. 
200 Cardinal Way, 2nd Floor 
Redwood City, CA 94063 
USA  
 
I have read the protocol and agree to conduct this study in accordance with the protocol, all 
relevant laws and regulations in force at the time, International Conference on Harmonisation 
Guidelines for Good Clinical Practices, and the Declaration of Helsinki.  
 
 
 
Principal Investigator’s printed name 
 
 
 
 
 
 
Principal Investigator’s signature 
 
Date (DD-MMM-YYYY) 
 
  
3


Version 2.1/02 July 2018 
SIGNATURE PAGE FOR COORDINATING INVESTIGATOR 
 
TITLE:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, 
AND TOLERABILITY OF SERLOPITANT FOR THE 
TREATMENT OF PRURITUS IN ADULTS WITH 
PRURIGO NODULARIS  
IND No.: 
 
 
117780 
Eudra CT: 
 
 
2017-004210-25 
ClinicalTrials.gov ID:  
[Placeholder] 
Protocol No.:  
 
MTI-106 
Protocol Version/Date: 
Version 2.1/02 July 2018 
Development Phase:  
Phase 3 
Sponsor: 
 
 
Menlo Therapeutics Inc. 
200 Cardinal Way, 2nd Floor 
Redwood City, CA 94063 
USA  
 
I have read the protocol and agree to conduct this study in accordance with the protocol, all 
relevant laws and regulations in force at the time, International Conference on Harmonisation 
Guidelines for Good Clinical Practices, and the Declaration of Helsinki.  
 
 
 
Coordinating Investigator’s printed name 
 
 
 
 
 
 
Coordinating Investigator’s signature 
 
Date (DD-MMM-YYYY) 
 
  
 
4




Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 2.1 02 July 2018 
 
Page 4 
PROTOCOL SYNOPSIS 
Study Title: 
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, 
Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults 
With Prurigo Nodularis  
Protocol Number: 
MTI-106 
Sponsor: 
Menlo Therapeutics Inc. 
Development Phase: 
Phase 3 
Study Objectives: 
Efficacy objective: To assess the efficacy of serlopitant for the treatment of 
pruritus in adults with prurigo nodularis. 
Safety objective: To assess the safety and tolerability of repeated oral doses of 
serlopitant in adults with prurigo nodularis.  
Study Design: 
This is a double-blind, randomized, placebo-controlled study to assess the 
efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in 
adults with prurigo nodularis (PN). Subjects who meet the study entry criteria 
will be randomized in a 1:1 ratio to receive daily oral doses of serlopitant 5 mg 
or placebo for 10 weeks. After completion of the treatment period or early 
discontinuation of study drug treatment, all subjects will enter a 3- or 5-week 
follow-up period.  
The study will consist of three periods, for a total study period of 15 to 
19 weeks: 
• 
Screening period: 2-4 weeks 
• 
Treatment period: 10 weeks 
• 
Follow-up period: 3 or 5 weeks  
 
During the screening period, all subjects will undergo eligibility evaluation and 
will be assessed for chronic pruritic conditions frequently associated with PN. 
Subjects who present with idiopathic PN at screening may require additional 
assessments as deemed necessary by the investigator (e.g. endomysial antibody 
with reflex to titer for subjects with signs or symptoms of dermatitis 
herpetiformis, skin biopsy for subjects with signs or symptoms of bullous 
pemphigoid or cutaneous T-cell lymphoma, urea breath test for 
Helicobacter pylori, or allergy testing).  
All screening procedures must be completed within 31 days before the Baseline 
visit. The minimum screening period for all subjects is 14 days to allow for 
collection of electronic diary (eDiary) screening data. Subjects who require a 
screening period longer than 14 days will have a telephone contact at least 15 
days prior to the scheduled Baseline visit to remind them to complete the eDiary 
as previously instructed at the Screening visit. 
Subjects will be provided an eDiary at the Screening visit. Subjects must be 
willing and able to complete the eDiary every day within a consistent 
timeframe, and comply with restrictions on allowable concomitant therapies, for 
the duration of the study.  
At the Baseline visit (Day 1), eligible subjects will be randomly assigned to 
receive study drug (serlopitant 5 mg or placebo). Subjects will take a loading 
dose (3 tablets taken orally) at the site on the first day of the treatment period 
(Day 1). Starting on Day 2, subjects will take one tablet per day. Study drug 
may be taken with or without food. 
6


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 5 
The primary efficacy endpoint will be assessed at Week 10 of treatment.  
Subjects who complete the 10-week treatment period and required follow-up 
period may be given the opportunity to enroll in a one-year open-label safety 
study with daily oral doses of serlopitant 5 mg. 
Safety Review: 
An internal safety monitoring team consisting of representatives from Menlo 
Therapeutics Inc. and its designees will monitor blinded safety data on a regular 
basis throughout the study. 
Planned Sample Size: 
Approximately 200 subjects will be randomized. 
Study Population: 
The study will consist of adult subjects with pruritus associated with PN.  
Inclusion Criteria (Subjects must meet the following criteria to be randomized 
into the study): 
1. Male or female, age 18 years or older at consent. 
2. A diagnosis of PN, defined by the presence of at least ten pruriginous 
nodules secondary to chronic pruritus present on at least two different body 
surface areas (e.g. both arms, one arm and one leg, one arm and the anterior 
trunk, or anterior and posterior trunk). 
3. The worst pruritus is identified to be within the areas of the PN lesions.  
4. Subject has idiopathic PN OR the subject has an identified pruritic 
condition associated with the PN and has persistent pruritus despite at least 
6 weeks of optimized and stable treatment of the underlying condition prior 
to the Baseline visit, and is willing to continue the treatment during the 
study.  
5. Worst-Itch Numeric Rating Scale (WI-NRS) score ≥ 7 in the 24-hour 
period prior to the Screening visit. 
6. Average weekly WI-NRS score ≥ 6.5 in each of the 2 weeks (14 days) 
immediately prior to Baseline visit, as recorded in the eDiary. 
7. All female subjects who are of childbearing potential must be willing to 
practice highly effective contraception (i.e., pregnancy prevention method 
with a failure rate of < 1% per year) from the time of the Screening visit 
until 5 weeks after last dose of study drug.   
8. Willing and able (as demonstrated by a ≥ 70% eDiary completion rate in 
the two weeks prior to Baseline visit) to complete daily eDiary entries 
within a consistent timeframe for the duration of the study. 
9. Willing and able (has adequate cognitive ability, in the investigator’s 
opinion) to comply with study visits and study related requirements 
including providing written informed consent. 
Exclusion Criteria (Subjects who meet any of the following criteria are not 
eligible for participation in the study): 
1. Prior treatment with serlopitant. 
2. Active pruritic skin disease, other than PN, within 6 months prior to 
randomization (with the exception of acute dermatoses such as contact 
dermatitis, sunburn, viral exanthem, which have been resolved for longer 
than 4 weeks).  
3. Treatment with any of the following therapies within 4 weeks prior to 
randomization. 
7


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 6 
a. 
Other neurokinin-1 receptor antagonists (e.g., aprepitant, 
fosaprepitant, rolapitant). 
b. Systemic or topical immunosuppressive/immunomodulatory 
therapies (including but not limited to corticosteroids, 
phosphodiesterase-4 inhibitors, cyclosporine, mycophenolate-
mofetil, tacrolimus, pimecrolimus, calcipotriene, methotrexate, 
azathioprine, interferon-gamma, thalidomide, or phototherapy).  
c. 
Systemic therapies with recognized anti-pruritic properties 
(including but not limited to H1 antihistamines, doxepin, 
gabapentin, pregabalin, cannabinoids, kappa-opioid receptor 
agonists, and mu-opioid receptor antagonists (e.g. naloxone, 
naltrexone)). 
d. Strong cytochrome-P 3A4 inhibitors. 
e. 
Use of an indoor tanning facility, or natural sun exposure resulting 
in significant tanning or sunburn. 
4. Treatment with topical anti-pruritic therapies (e.g., menthol, camphor, 
pramoxine, capsaicin) within 2 weeks prior to randomization. 
5. Treatment with biologic therapies within 8 weeks or 5 half-lives prior to 
randomization, whichever is longer. 
6. Treatment with any investigational therapy within 4 weeks (8 weeks for 
investigational biologic therapies) or 5 half-lives prior to randomization, 
whichever is longer. 
7. Serum creatinine, total bilirubin, alanine aminotransferase or aspartate 
aminotransferase > 2.5 times the upper limit of normal during screening. 
8. Untreated or inadequately treated thyroid, adrenal, or pituitary nodules or 
disease, or history of thyroid malignancy. 
9. History of malignancy within 5 years prior to randomization, with the 
exception of actinic keratosis, completely treated and non-metastatic 
cutaneous basal cell carcinoma or squamous cell carcinoma of the skin. 
10. Any known major psychiatric diagnosis, such as major depressive disorder, 
bipolar disorder, schizophrenia, psychotic disorder, intellectual disability, 
severe alcohol use disorder, which may confound the assessment of 
serlopitant safety or efficacy, or interfere with the subject’s ability to 
comply with protocol-mandated activities, within 3 years prior to 
randomization.  
11. Suicidal ideation within 3 years prior to randomization, or any history of 
suicide attempt. 
12. Documented history of parasitic infection, including skin parasites such as 
scabies, within 8 weeks prior to randomization. 
13. Presence of any medical condition or disability that, in the investigator’s 
opinion, could interfere with the assessment of safety or efficacy in this trial 
or compromise the safety of the subject. 
14. History of hypersensitivity to serlopitant or any of its components. 
15. Currently pregnant or breastfeeding female subject. 
16. Planned or anticipated major surgical procedure or other activity that would 
interfere with the subject’s ability to comply with protocol-mandated 
8


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 7 
assessments (e.g. extended international travel) during the subject’s 
participation in the study. 
Study Drug: 
Serlopitant 5 mg oral tablets and matching placebo. 
Dosage:  
Serlopitant: 5 mg once daily by mouth for 10 weeks, following a 3-tablet 
loading dose on the first day of the treatment period. 
Matching placebo: Once daily by mouth for 10 weeks, following a 3-tablet 
loading dose on the first day of the treatment period. 
Primary Efficacy 
Endpoint: 
The primary efficacy endpoint is the WI-NRS 4-point responder rate at Week 
10. 
Secondary Efficacy 
Endpoints: 
The key secondary efficacy endpoints are as follows: 
• 
WI-NRS 4-point responder rate at Week 4 
• 
Change from baseline in WI-NRS to Day 7 
• 
Change from baseline in WI-NRS to Day 3 
• 
Change from baseline in Dermatology Life Quality Index (DLQI) to Week 
10 
Additional secondary efficacy endpoints are as follows: 
• 
Change from baseline in WI-NRS to other timepoints 
• 
WI-NRS 4-point responder rate at Week 2 
• 
WI-NRS 3-point responder rate at Weeks 2, 4 and 10 
• 
Change from baseline in Investigator’s Global Assessment of PN Activity 
to Weeks 2, 4 and 10 
• 
Change from baseline in Investigator’s Global Assessment of PN Stage to 
Weeks 2, 4 and 10 
Safety Endpoints: 
Safety endpoints are as follows: 
• 
Incidence of treatment-emergent adverse events and serious adverse events 
(SAEs) 
• 
Changes from baseline in clinical laboratory parameters following study 
drug exposure 
• 
Changes from baseline in vital sign and electrocardiogram (ECG) 
parameters following study drug exposure 
• 
Changes from baseline in the Hospital Anxiety and Depression Scale 
(HADS)  
• 
Changes from baseline in the Epworth Sleepiness Scale (ESS) 
Decision Rule and 
Sample Size: 
This study will use a 5% two-sided alpha level. Hierarchical testing in which 
statistical significance for the key secondary efficacy endpoints requires 
statistical significance for the primary endpoint. 
The target sample size of 200 randomized and dosed subjects (100 per group) 
has been determined based upon a 1:1 allocation of subjects to treatment groups 
and a 5% alpha level. Two hundred subjects results in 90% power assuming a 
placebo responder rate of 
% and serlopitant rate of 
%. 
Statistical Methods: 
Efficacy analyses will be based upon an intent-to-treat philosophy. The primary 
9
CCI
CCI


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 8 
efficacy population will be the Intent-to-Treat (ITT) population that will include 
all randomized subjects who were dispensed study drug. Analyses performed on 
the Per Protocol population will be considered supportive. Subjects will be 
analyzed within the treatment group to which they are randomized. 
Efficacy Analyses: 
The primary efficacy endpoint is a binary variable taking on values of responder 
or non-responder. Subjects will be considered a responder if they have at least a 
4-point reduction in WI-NRS between baseline and Week 10. Missing data 
imputation will be used for subjects who fail to complete the eDiary at Week 10, 
unless the subject withdrew from the study due to a lack of efficacy, or the 
subject used an excluded therapy to treat worsening of pruritus or PN, in which 
case their responder status will be defined as non-responder. The primary 
endpoint will be summarized with descriptive statistics by treatment group and 
study week.  
The difference in the primary efficacy outcome measure between treatment 
groups will be tested using a Cochran Mantel Haenszel test controlling for the 
stratification factors. Testing of the key secondary efficacy endpoints will also 
be employed. 
Safety Analyses: 
The incidence of all adverse events (AEs) and treatment-related AEs will be 
tabulated by treatment received. These AEs will be classified by system organ 
class and preferred term using the Medical Dictionary for Regulatory Activities. 
For incidence reporting, if a subject reported more than one AE that was coded 
to the same system organ class or preferred term, the subject will be counted 
only once for that specific system organ class or preferred term. An overview of 
AEs, which includes subject incidence of AEs, treatment-related AEs, AEs by 
severity, SAEs, deaths, and AEs leading to discontinuation, will be presented.  
Clinical safety laboratory values will be measured by a central laboratory. 
Summary statistics for actual values and for changes from baseline will be 
tabulated for laboratory results by scheduled visit. Graphs of laboratory values 
over time will also be produced.  
Subjects with clinical laboratory values outside of the normal reference range at 
any post-baseline assessment will be summarized. Shifts from baseline 
laboratory values will be tabulated. 
The overall ECG assessment (abnormal or normal) will be summarized along 
with a summary of how many subjects developed a post treatment abnormal 
result.  
Summary statistics for the HADS and ESS actual values and change from 
baseline will be presented by scheduled visit. 
Study Sites: 
Approximately 50 study sites. 
Expected Duration of 
Subject’s Participation 
15-19 weeks: 2-4 weeks of screening, 10 weeks of treatment, and a follow-up 
period of 3 or 5 weeks. 
 
This study will be conducted in accordance with the Guidelines of Good Clinical Practice (GCP). 
10


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 9 
TABLE OF CONTENTS 
CLINICAL STUDY PROTOCOL ............................................................................................1 
SIGNATURE PAGE FOR PRINCIPAL INVESTIGATOR(S) ................................................2 
SPONSOR PROTOCOL APPROVAL SIGNATURE(S) .........................................................3 
PROTOCOL SYNOPSIS ..........................................................................................................4 
TABLE OF CONTENTS ...........................................................................................................9 
LIST OF APPENDICES ..........................................................................................................12 
LIST OF FIGURES .................................................................................................................12 
LIST OF TABLES ...................................................................................................................13 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ..........................................14 
1 
INTRODUCTION .................................................................................................16 
1.1 
Pruritus in Prurigo Nodularis ...........................................................................16 
1.2 
Conditions Associated With Prurigo Nodularis ...............................................16 
1.3 
Current Treatment Options for Prurigo Nodularis ...........................................17 
1.4 
Substance P and the Neurokinin-1 Receptor ...................................................17 
1.5 
Serlopitant ........................................................................................................18 
1.5.1 
Serlopitant Background and Nonclinical Summary ............................18 
1.5.2 
Serlopitant Clinical Summary ..............................................................19 
1.5.3 
Serlopitant in Pruritus-Related Studies ................................................19 
2 
STUDY OBJECTIVES ..........................................................................................21 
3 
STUDY DESIGN...................................................................................................21 
3.1 
Overall Study Design .......................................................................................21 
3.2 
Rationale for Study Design and Dose Selection ..............................................22 
3.3 
Study Endpoints ...............................................................................................23 
3.3.1 
Primary Efficacy Endpoint ..................................................................23 
3.3.2 
Key Secondary Efficacy Endpoints .....................................................23 
3.3.3 
Additional Secondary Efficacy Endpoints ...........................................23 
3.3.4 
Safety Endpoints ..................................................................................24 
3.4 
Safety Review ..................................................................................................24 
3.4.1 
Safety Monitoring Team ......................................................................24 
4 
SELECTION OF STUDY POPULATION ...........................................................24 
4.1 
Study Population ..............................................................................................24 
4.2 
Inclusion Criteria .............................................................................................24 
4.3 
Exclusion Criteria ............................................................................................25 
5 
STUDY DRUG ......................................................................................................26 
5.1 
Study Drug Supply, Route of Administration, and Storage.............................26 
5.2 
Labeling and Study Drug Accountability ........................................................28 
5.3 
Dosing Regimen...............................................................................................28 
11


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 10 
5.4 
Dose Modification ...........................................................................................28 
5.5 
Missed or Delayed Doses.................................................................................28 
5.6 
Study Drug Discontinuation ............................................................................28 
5.7 
Prior, Concomitant, and Excluded Therapies ..................................................29 
5.7.1 
Allowed Therapies and Treatment Goals for Underlying 
Conditions ............................................................................................29 
5.7.2 
Excluded Therapies ..............................................................................30 
5.7.3 
Rescue Therapies .................................................................................31 
5.8 
Assignment to Treatment .................................................................................31 
5.8.1 
Randomization .....................................................................................31 
5.8.2 
Blinding................................................................................................31 
5.9 
Treatment Compliance .....................................................................................32 
6 
STUDY SCHEDULE AND ASSESSMENTS ......................................................32 
6.1 
Efficacy Parameters .........................................................................................32 
6.1.1 
Itch Numeric Rating Scale ...................................................................32 
6.1.2 
Investigator’s Global Assessment of PN Activity ...............................32 
6.1.3 
Investigator’s Global Assessment of PN Stage ...................................33 
6.1.4 
Dermatology Life Quality Index ..........................................................33 
6.1.5 
PN Photographs ...................................................................................33 
6.2 
Safety Parameters.............................................................................................33 
6.2.1 
Vital Signs ............................................................................................33 
6.2.2 
Physical Examination...........................................................................34 
6.2.3 
Clinical Laboratory Assessments .........................................................34 
6.2.4 
Electrocardiogram ................................................................................35 
6.2.5 
Hospital Anxiety and Depression Scale ...............................................35 
6.2.6 
Epworth Sleepiness Scale ....................................................................35 
6.3 
Pharmacokinetic Measurements ......................................................................35 
6.4 
Subject Flow Diagram .....................................................................................35 
6.5 
Study Visits ......................................................................................................36 
6.5.1 
Screening Period ..................................................................................36 
6.5.2 
Screening Visit .....................................................................................37 
6.5.3 
Mid-Screening Telephone Contact (for subjects longer than 14 
days in Screening) ................................................................................38 
6.5.4 
Baseline Visit .......................................................................................39 
6.5.5 
Week 1 Telephone Contact Visit .........................................................40 
6.5.6 
Week 2 Visit ........................................................................................40 
6.5.7 
Week 4 Visit ........................................................................................41 
6.5.8 
Week 6 Visit ........................................................................................41 
6.5.9 
Week 10 Visit ......................................................................................42 
12


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 11 
6.5.10 
Follow-up Visit ....................................................................................43 
6.5.11 
Early Termination ................................................................................44 
7 
ASSESSMENT OF SAFETY ................................................................................44 
7.1 
Definitions........................................................................................................44 
7.1.1 
Adverse Event ......................................................................................44 
7.1.2 
Serious Adverse Event .........................................................................45 
7.1.3 
Abnormal Physical Exam, Laboratory, Vital Sign, and 
Electrocardiogram Findings .................................................................46 
7.1.4 
Deaths ..................................................................................................46 
7.1.5 
Pregnancies and Contraception Requirements for Females .................46 
7.1.6 
Worsening of Pruritus or PN................................................................47 
7.2 
Methods and Timing for Recording and Reporting Adverse Events ...............48 
7.2.1 
Adverse Event Reporting Period .........................................................48 
7.2.2 
Eliciting Adverse Events......................................................................48 
7.2.3 
Assessment of Severity ........................................................................48 
7.2.4 
Assessment of Causality ......................................................................49 
7.3 
Follow-up of Adverse Events and Serious Adverse Events ............................50 
7.4 
Reporting Serious Adverse Events to the Sponsor and Institutional Review 
Board or Ethics Committee ..............................................................................50 
7.5 
Reporting Serious Adverse Events to Regulatory Authorities and Study 
Investigators .....................................................................................................50 
7.6 
Emergency Unblinding ....................................................................................50 
8 
STATISTICAL METHODS ..................................................................................51 
8.1 
Decision Rule and Sample Size .......................................................................51 
8.2 
Handling of Missing Data ................................................................................52 
8.3 
Analysis Populations ........................................................................................53 
8.4 
Subject Disposition ..........................................................................................54 
8.5 
Subject Characteristics .....................................................................................54 
8.6 
Prior and Concomitant Medications ................................................................54 
8.7 
Treatment Compliance and Extent of Exposure ..............................................55 
8.8 
Efficacy Analyses ............................................................................................55 
8.8.1 
Primary Efficacy ..................................................................................55 
8.8.2 
Key Secondary Efficacy ......................................................................55 
8.8.3 
Additional Secondary Efficacy ............................................................56 
8.9 
Sensitivity Analyses .........................................................................................56 
8.9.1 
Last Observation Carried Forward.......................................................56 
8.9.2 
Repeated Measures Analysis ...............................................................56 
8.9.3 
Tipping Point Analysis ........................................................................56 
8.10 
Safety Analyses ................................................................................................56 
13


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 12 
8.10.1 
Adverse Events ....................................................................................56 
8.10.2 
Clinical Safety Laboratory Results ......................................................57 
8.10.3 
Vital Signs ............................................................................................57 
8.10.4 
Electrocardiograms ..............................................................................57 
8.10.5 
Physical Exams ....................................................................................57 
8.10.6 
Menstrual Diaries .................................................................................57 
8.10.7 
Hospital Anxiety and Depression Scale ...............................................57 
8.10.8 
Epworth Sleepiness Scale ....................................................................57 
8.11 
Population Pharmacokinetics Analysis ............................................................57 
9 
ADMINISTRATIVE ASPECTS ...........................................................................58 
9.1 
Changes to the Protocol ...................................................................................58 
9.2 
Study Termination ...........................................................................................58 
9.3 
Monitoring and Auditing Procedures...............................................................58 
9.4 
Transfer of Obligations ....................................................................................58 
9.5 
Informed Consent.............................................................................................59 
9.6 
Communication with the Institutional Review Board or Ethics Committee ...59 
9.7 
Disclosure and Confidentiality ........................................................................59 
9.8 
Records and Electronic Case Report Forms ....................................................59 
9.9 
Good Clinical Practices and Ethical Study Conduct........................................60 
9.10 
End of Study Notification ................................................................................60 
9.11 
Publication of Results ......................................................................................60 
9.12 
Final Report .....................................................................................................60 
10 
REFERENCES ......................................................................................................61 
 
LIST OF APPENDICES 
Appendix A  Schedule of Activities and Assessments ..........................................................64 
Appendix B  List of Strong CYP3A4 Inhibitors ...................................................................66 
Appendix C  Worst Itch Numeric Rating Scale Questionnaire .............................................67 
Appendix D 
Investigator’s Global Assessment of Prurigo Nodularis: Activity and Stage ..68 
Appendix E 
Dermatology Life Quality Index ......................................................................69 
Appendix F 
Hospital Anxiety and Depression Scale ...........................................................70 
Appendix G  Epworth Sleepiness Scale ................................................................................71 
 
LIST OF FIGURES 
Figure 1 
Subject Flow Diagram ...............................................................................36 
 
14


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 13 
LIST OF TABLES 
Table 1 
Adverse Event Grading ..............................................................................49 
Table 2 
Schedule of Visit Activities .......................................................................64 
Table 3 
Schedule of eDiary Assessments ...............................................................65 
  
15


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 14 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation 
Definition 
ACTH 
Adrenocorticotropic hormone, corticotropin 
AD 
Atopic dermatitis  
ADL 
Activities of daily living 
AE 
Adverse event 
ALT 
Alanine aminotransferase  
AMH 
Anti-Mullerian hormone 
ANOVA 
Analysis of variance 
AST 
Aspartate aminotransferase 
ATC 
Anatomical Therapeutic Classification 
CMH 
Cochran Mantel Haenszel test 
CNS 
Central Nervous System 
CRO 
Contract Research Organization 
CYP3A4 
Cytochrome-P 3A4 
DLQI 
Dermatology Life Quality Index 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eDiary 
Electronic diary 
ESS 
Epworth Sleepiness Scale 
FSH 
Follicle-stimulating hormone 
GCP 
Good Clinical Practice 
HAART 
Highly active antiretroviral therapy 
HADS 
Hospital Anxiety and Depression Scale 
HIV 
Human immunodeficiency virus 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonisation 
IGA PN-A 
Investigator’s Global Assessment of Prurigo Nodularis Activity 
IGA PN-S 
Investigator’s Global Assessment of Prurigo Nodularis Stage 
IRB 
Institutional Review Board 
ITT 
Intent-to-Treat 
IWRS 
Interactive Web Response System  
IVIG 
Intravenous immunoglobulin 
LDH 
Lactate dehydrogenase 
LFC 
Liquid filled capsule 
LH 
Luteinizing hormone 
LOCF 
Last Observation Carried Forward 
MCMC 
Markov Chain Monte Carlo 
MedDRA 
Medical Dictionary for Regulatory Activities  
NCI CTCAE 
National Cancer Institute Common Terminology Criteria for Adverse Events 
NK1-R 
Neurokinin-1 receptor 
16


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 15 
NOAEL 
No observed adverse effect level 
NRS 
Numeric Rating Scale  
PET 
Positron Emission Tomography 
PI 
Principal Investigator 
PD 
Pharmacodynamics 
PDE-4 
Phosphodiesterase-4 
PK 
Pharmacokinetics 
PN 
Prurigo nodularis 
PP 
Per Protocol 
QOL 
Quality of life 
RO 
Receptor occupancy 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SP 
Substance P 
TEAE 
Treatment-emergent adverse event 
TSH 
Thyroid stimulating hormone 
ULN 
Upper limit of normal 
US 
United States 
VAS 
Visual Analog Scale 
WI-NRS 
Worst-Itch Numeric Rating Scale 
17


Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 16 
1 
INTRODUCTION 
1.1 
Pruritus in Prurigo Nodularis 
Prurigo nodularis (PN) is a distinctive and easily diagnosable chronic skin condition 
characterized by the presence of multiple highly pruritic and often symmetrically distributed 
nodules and papules on the skin (Jorizzo 1981). The nodules and papules in PN can range in 
size from approximately 0.5 to 3.0 cm and often appear hyperkeratotic, sometimes 
crateriform, in appearance. Plaques are occasionally present, and the lesions of PN frequently 
exhibit other features secondary to prolonged and severe scratching behavior, such as post-
inflammatory hyperpigmentation, erosion, ulceration, crusting, and bleeding (Zeidler 2016).   
PN, a long-term reaction to the chronic scratching and picking of patients with chronic 
pruritus (Zeidler 2016), is a skin condition seen predominantly in older adults, with median 
prevalence age in the 50s and 60s and a slight female preponderance (Iking 2013, Tan 2014,  
Ständer 2013). In one patient population survey, pediatric patients accounted for <2% of the 
total population, with the youngest patient 11.9 years of age (Iking 2013). Although only 
limited epidemiology data for PN have been published, a claims-based analysis 
commissioned by Menlo Therapeutics suggest that the United States (US) prevalence may be 
in the range of ~ 355,000 affected individuals. Based on a quantitative survey of 
73 dermatologists conducted in parallel with the claims-based analysis, approximately 
23% of patients with PN have an underlying atopy-related condition, while over 50% are 
considered to be idiopathic (Navigant 2017). The median duration of disease burden has been 
reported to be 6-7 years (Iking 2013, Tan 2014, Schuhknecht 2011).  
The dominant symptom in PN is an intense and chronic pruritus that is associated with a high 
degree of patient burden and restricted quality of life (QOL) (Zeidler 2016). As measured by 
global scales of pruritus intensity (numeric rating scale (NRS) and visual analog scale 
(VAS)), median levels of pruritus intensity have been reported to be 7-8 points (Iking 2013, 
Tan 2014, Schuhknecht 2011). The pruritus experienced in PN can often prevent patients 
from adequately performing their daily activities (Vaidya 2008), and patients with PN have 
been found to suffer from greater rates of depression and anxiety than control groups in 
numerous studies (Jorgensen 2016, Rowland Payne 1985, Dazzi 2011).  
1.2 
Conditions Associated With Prurigo Nodularis 
As PN is considered to be a disease induced by chronic pruritus and ongoing scratching 
activity, a variety of chronic pruritic conditions have been identified as potential underlying 
etiologies for the pruritus, including atopic dermatitis (AD), other inflammatory or bullous 
skin diseases, chronic renal failure, human immunodeficiency virus (HIV) infection, hepatitis 
C infection, and multifactorial disease (i.e. two or more co-existent conditions associated 
with chronic pruritus) (Fostini 2013, Lee 2005). The mechanisms linking chronic pruritus to 
the development of PN are not clear, as only a subset of patients with chronic pruritus 
develop PN, and over half of patients with PN have no underlying etiology identified. Even 
when specific underlying conditions are identified, management of these condition(s) does 
not usually result in resolution of PN signs or symptoms, nor can all underlying conditions be 
treated. For example, PN has been observed in patients with HIV adequately managed with 
18


Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 17 
highly active antiretroviral therapy (HAART) (Zancanaro 2006), in patients with intractable 
cholestatic pruritus (Bergasa 2011), in patients with inactive hepatitis (Halvorsen 2015), and 
commonly in patients with renal failure despite hemodialysis therapy (Goeksel 2013). These 
data point to a high level of unmet medical need in the overall PN population, as the majority 
of patients with PN either have no underlying condition identified that can be treated, or 
treatment of the underlying condition is inadequate to control their PN (Wallengren 2004). 
1.3 
Current Treatment Options for Prurigo Nodularis 
Treatment of PN remains a challenging and extremely frustrating experience for both patients 
and physicians. In the majority of cases, responses are limited and unsatisfactory, and once 
the cycle of pruritus-excoriation-pruritus begins, it is difficult to stop. Identification and 
treatment of underlying chronic pruritic conditions is often the first step in management of 
PN. If this does not result in resolution of the pruritus, or if no underlying condition is 
identified, treatment specifically for PN and its associated pruritus is implemented.  
First-line pruritus therapies, including topical agents such as topical corticosteroids and 
calcineurin inhibitors, often provide inadequate response (Saco 2015) and the therapeutic 
ladder for PN involves systemic agents with progressively riskier safety profiles. These 
include naltrexone, gabapentin, mirtazapine, phototherapy, intravenous immunoglobulin 
(IVIG), powerful immunosuppressants such as methotrexate and cyclosporine, and 
thalidomide (Ständer 2015b, Spring 2014, Feldmeyer 2012, Lim 2016). None of these 
therapies are indicated for the treatment of PN, and their usage is often based on limited 
evidence, such as case reports or small open-label studies.  
1.4 
Substance P and the Neurokinin-1 Receptor 
Repeated itching, scratching, and picking over long time periods serve as the 
pathophysiological basis for the development of PN. Although different underlying disease 
states may be responsible for the chronic pruritus, the distinctive and easily recognizable 
features of PN point to a common final pathway resulting in this unique clinical presentation.  
Immunohistochemical staining studies of PN biopsies have demonstrated that nerve fibers 
immunoreactive for Substance P (SP) are found in increased numbers in lesional skin 
compared to non-lesional skin or controls (Abadía Molina 1992), suggesting a role for SP 
signaling in PN. These findings are consistent with the robust body of evidence indicating the 
key role of SP signaling through its primary receptor, the neurokinin-1 receptor (NK1-R), in 
the transmission of itch across multiple disease states (Santini 2012, Akiyama 2015, 
Crowe 1994, El-Nour 2006, Lotts 2014, Hon 2007, Ward 2004, Slattery 2011).   
SP is an undecapeptide that belongs to the tachykinin family of neuropeptides, a group that 
also includes neurokinin A and neurokinin B (Hökfelt 2001). SP has been implicated in a 
number of biological functions, both physiological and pathophysiological, including pruritus 
perception, vomiting reflex, pain perception, and immunomodulatory responses (Lotts 2014, 
Andoh 1998, Steinhoff 2014).  The biological actions of SP are mediated by tachykinin 
receptors, which consist of seven hydrophobic transmembrane domains coupled to G-
proteins. Three tachykinin receptors have been identified: the neurokinin-1, neurokinin-2, 
19


Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 18 
and neurokinin-3 receptors (Harrison 2001). The NK1-R in particular has been studied in 
great detail. NK1-R is the primary receptor for SP in the human body, and is found on 
multiple cell types, include central and peripheral neurons, keratinocytes, and mast cells.  
NK1-R stimulation has been shown to be an important pathway for pruritus perception 
(Ständer 2015a). Inhibition of this pathway results in decreased pruritus and scratching 
reflexes in animal models (Akiyama 2015). Preceding the development of serlopitant for 
pruritus-related conditions, a commercially available NK1-R antagonist (Emend USPI) has 
been used as a therapy to decrease pruritus in patients with chronic pruritus due to etiologies 
such as cutaneous T-cell lymphoma (Duval 2009, Torres 2012, Booken 2011) and 
erlotinib-induced pruritus (Santini 2012, Gerber 2010). Additionally, in a study of 20 patients 
with chronic pruritus of various etiologies treated with aprepitant, 16/20 patients (80%) 
experienced a considerable reduction of itch intensity (Ständer 2010).  
1.5 
Serlopitant 
1.5.1 
Serlopitant Background and Nonclinical Summary 
Serlopitant is a small molecule, highly selective NK1-R antagonist that is administered orally 
and metabolized by cytochrome P-450 3A4 (CYP3A4), with a plasma half-life of 45-86 
hours. It binds with high affinity to the human NK1-R with a dissociation constant (Kd) of 
46 pM; displacing SP binding with a half-maximal inhibition concentration (IC50) of 61 pM. 
Serlopitant is a potent functional antagonist of SP-induced inositol phosphate generation. 
Serlopitant has been extensively studied in animal toxicology studies, including chronic 
toxicology and carcinogenicity studies. In non-clinical chronic toxicology studies in rats, 
mice and dogs, treatment related findings of potential clinical significance included increased 
salivation, decreased body weight gain and food consumption, slight changes in hematology 
and serum biochemistry parameters, mild increases in liver weight and mild 
histomorphologic changes. The histomorphologic changes were seen only in rats (not in dogs 
or mice) and included: very slight ovarian interstitial cell hypertrophy, mammary gland and 
uterine atrophy; decreased corpora lutea; increased histiocytes in lung and mesenteric lymph 
nodes; slight skeletal and cardiac muscle degeneration; slight increased hematopoiesis in 
bone marrow; and slight to moderate vacuolation in kidney tubules. These nonclinical 
findings occurred at systemic exposures exceeding those anticipated to provide efficacy of 
serlopitant for pruritus indications in humans (1 to 5 mg tablet daily). No cardiac lesions have 
been observed in dog toxicity studies up to 9 months in duration nor in a 3-month mouse 
range-finding study and 2-year mouse carcinogenicity study at exposure higher than the 
lowest level which caused cardiotoxicity in rats. The no observed adverse effect level 
(NOAEL) in rats for histomorphological changes in the reproductive tract, mammary gland 
and bone marrow provides a 2.5-fold margin for the maximum-targeted exposure (5 mg 
tablet daily). The rat NOAEL for histomorphological changes in muscle and kidney provides 
a 5-fold margin for the maximum-targeted exposure (5 mg tablet daily).  
In summary, the nonclinical toxicity noted with serlopitant provides no contraindications to 
the continuation of clinical trials via the oral route. Findings in the developmental toxicity 
20


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 19 
studies support inclusion of women of childbearing potential in clinical trials in accordance 
with the study protocol and local regulatory guidances.  
1.5.2 
Serlopitant Clinical Summary 
In humans, serlopitant has been administered to over 1000 individuals. Single doses up to 
400 mg have been well tolerated in young adult males and single doses up to 25 mg have 
been well tolerated in the elderly. Multiple doses of up to 50 mg a day for 4 weeks have been 
well tolerated in healthy young males, and a single (loading) dose of 15 mg followed by daily 
doses of 5 mg for 2 weeks have been well tolerated in elderly males and females. Forty-one 
(41) subjects received 4 mg liquid filled capsule (LFC) daily (bioequivalent to 5 mg tablets) 
for 1 year. Plasma concentrations of serlopitant appear to increase in a dose-proportional 
fashion in both young males and elderly subjects (males and females). Peak plasma 
concentrations after a single oral dose occurred at ~2 to 4 hours in both young and elderly 
subjects. A single loading dose of up to 15 mg followed by 6 to 8 weeks of up to 5 mg daily 
doses has been well tolerated in adults with chronic pruritus and PN. 
Pharmacokinetic data demonstrate good plasma exposures with oral dosing, linear dose-
dependent increases in plasma concentration and systemic exposure, a plasma t1/2 
appropriate for once daily dosing, and mild effects of concomitant food ingestion. Central 
nervous system (CNS) positron emission tomography (PET) studies have demonstrated good 
CNS penetrance and > 90% NK1 receptor occupancy (RO) at plasma exposures anticipated 
to be safe and well tolerated. Three long-lived active hydroxylated metabolites are observed 
in humans: M1/M1a 
 M2/M2a 
, and M3 
. 
These metabolites were present at lower concentrations and were 2- to 9-fold less potent in 
vivo than the parent compound. The integrated pharmacokinetic/pharmacodynamic (PK/PD) 
analysis concluded that these metabolites are unlikely to contribute significantly to 
occupancy of the CNS NK1-R in humans. 
1.5.3 
Serlopitant in Pruritus-Related Studies 
Serlopitant has been evaluated in two completed Phase 2 studies of subjects with chronic 
pruritus (TCP-101 and TCP-102).  
TCP-101 
TCP-101 was a double-blind, placebo-controlled, multi-center study that compared 
serlopitant 0.25 mg, 1 mg, or 5 mg vs. placebo for the treatment of chronic pruritus. A total 
of 257 adult subjects 18-65 years of age with chronic pruritus were randomized to receive 
one of the four dose groups in a 1:1:1:1 randomization. Subjects received a loading dose of 
3 tablets on Day 1 and thereafter received 1 tablet per day for 6 weeks. The primary efficacy 
endpoint was itch severity as measured on a VAS, summarized as a percentage change from 
baseline. 
Mean percent decreases from Baseline in VAS score were larger in the active-treatment 
groups versus placebo at every scheduled post-baseline study visit. Overall, the results were 
the most profound for the serlopitant 1 mg and 5 mg groups. For the percent change from 
Baseline in VAS pruritus scores (the primary efficacy variable), the Week 6 pairwise least 
21
CCI
CCI
CCI


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 20 
squares mean difference compared to placebo was 5.8 mm, 13.2 mm, and 14.2 mm for 
serlopitant 0.25 mg, 1 mg, and 5 mg, respectively.   
The frequency of treatment-emergent adverse events (TEAEs) and study drug related adverse 
events (AEs) was higher in the serlopitant 1 mg and 5 mg groups compared to the serlopitant 
0.25 mg group, and the frequency in all three treatment groups were higher than in the 
placebo group. The frequency of AEs leading to study drug discontinuation was comparable 
in the serlopitant 5 mg and placebo group and higher than in the serlopitant 0.25 mg and 
1 mg groups. There was one serious adverse event (SAE) reported in the serlopitant 1 mg 
group (spontaneous abortion, considered not related). There were no deaths. The most 
common AEs in the serlopitant groups were diarrhea (6.2%, 1 mg group), upper respiratory 
tract infection (4.7%, 0.25 mg group), somnolence (4.7%, 5 mg group), nasopharyngitis 
(4.6%, 1 mg group), headache (4.7%, 5 mg group), urinary tract infection (3.1%, 5 mg 
group), dry mouth (3.1%, 1 mg group), nausea (3.1%, 1 mg group), arthralgia (3.1%, 
0.25 mg group), musculoskeletal pain (3.1%, 1 mg group) and pruritus (3.1%, 1 mg group). 
The most common AEs in the placebo group were headache (6.3%), nasopharyngitis (3.2%), 
upper respiratory tract infection (3.2%), urinary tract infection (3.2%) and asthma (3.2%).  
TCP-102 
TCP-102 was a randomized, double-blind, placebo-controlled multi-center study that 
evaluated serlopitant 5 mg vs. placebo for the treatment of PN. A total of 128 adult subjects 
18-80 years of age with PN were randomized to receive serlopitant or placebo in a 1:1 
randomization. Subjects received a loading dose of 3 tablets on Day 1 followed by 1 tablet 
per day for 8 weeks. The primary efficacy endpoint was the average VAS score as recorded 
at the study visits. Results at Week 4 and Week 8 were the primary timepoints. 
Serlopitant 5 mg was superior to placebo for the reduction of pruritus as measured by change 
in average VAS from baseline. For the primary endpoint, change from baseline at Week 4 
and Week 8 by repeated measures analysis, the decrease from baseline was significantly 
greater in the serlopitant group than the placebo group, with a mean difference (serlopitant 
minus placebo) of -1.0 at Week 4 and -1.7 at Week 8. The mean difference at Week 2 was 
also significant, -0.9. In a post-hoc analysis of the percentage of subjects who were 4-point 
responders on average VAS at Week 8, 25.0% of placebo subjects and 54.4% of serlopitant 
subjects were 4-point responders. 
TEAEs were reported for 71.9% of serlopitant-treated subjects and 61.9% of placebo-treated 
subjects. The most frequently reported TEAEs in the serlopitant group were nasopharyngitis 
(17.2% serlopitant, 3.2% placebo), diarrhea (10.9% serlopitant, 4.8% placebo), and fatigue 
(9.4% serlopitant, 6.3% placebo). Treatment-related TEAEs were reported for 48.4% of 
serlopitant-treated subjects and 34.9% of placebo-treated subjects. The most frequently 
reported treatment-related TEAEs in the serlopitant group were fatigue (7.8%) and diarrhea, 
peripheral edema, dizziness, and headache (each 6.3%). Most TEAEs were mild or moderate; 
severe TEAEs were reported for 9.4% of serlopitant-treated subjects and 4.8% of 
placebo-treated subjects. There were no deaths during the study. Five subjects (3 serlopitant, 
2 placebo) had SAEs. The SAEs were actinic elastosis, depression, dizziness, and vertigo in 
22


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 21 
the serlopitant group; and bradycardia, syncope, respiratory failure, and neurodermatitis in 
the placebo group. Nine subjects (3 serlopitant, 6 placebo) discontinued due to TEAEs. 
No clinically relevant changes were observed in chemistry, hematology, vital signs, or 
electrocardiogram (ECG) results. 
Potential Risks and Benefits: The results of the Phase 2 studies in PN and chronic pruritus, 
together with the extensive nonclinical and clinical safety data and experience with 
serlopitant to date and the scientific rationale for NK1-R inhibition in the treatment of 
pruritus, serve to support further evaluation of serlopitant for the treatment of pruritus in 
patients with PN. The potential benefits of continued clinical study outweigh the potential 
risks. 
Please refer to the Investigator’s Brochure (IB) for further information regarding serlopitant. 
2 
STUDY OBJECTIVES  
The efficacy objective of this study is to assess the efficacy of serlopitant for the treatment of 
pruritus in adults with PN. 
The safety objective of this study is to assess the safety and tolerability of repeated oral doses 
of serlopitant in adults with PN.  
3 
STUDY DESIGN 
3.1 
Overall Study Design 
This is a double-blind, randomized, placebo-controlled study to assess the efficacy, safety, 
and tolerability of serlopitant for the treatment of pruritus in adults with PN. The study will 
be conducted at approximately 50 study sites. Subjects who meet the study entry criteria will 
be randomized in a 1:1 ratio to receive daily oral doses of serlopitant 5 mg or placebo for 
10 weeks. After completion of the treatment period or early discontinuation of study drug 
treatment, all subjects will enter a 3 or 5-week follow-up period. The required follow-up 
period is defined as a minimum of 3 weeks for those subjects who will enroll in the one-year 
open-label safety study (MTI-107) on the date of the follow-up visit, and as 5 weeks for 
those subjects who will not be enrolled in the one-year open-label safety study of serlopitant. 
Should a subject present for the follow-up visit prior to 5 weeks after the last dose of study 
drug and be excluded from participation in the one-year study for any reason, the subject will 
be required to return at 5 weeks after the last dose of study drug for a complete follow-up 
visit. 
This study will consist of three periods, for a total study period of 15-19 weeks: 
• Screening period: 2-4 weeks 
• Treatment period: 10 weeks 
• Follow-up period: 3 or 5 weeks 
23


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 22 
Informed consent will occur prior to any protocol-mandated procedures, including the 
stopping of any excluded therapies. This may occur prior to the Screening visit. 
During the screening period, all subjects will undergo eligibility evaluation and will be 
assessed for chronic pruritic conditions frequently associated with PN. Subjects who present 
with idiopathic PN at screening may require additional assessments as deemed necessary by 
the investigator (e.g. endomysial antibody with reflex to titer for subjects with signs or 
symptoms of dermatitis herpetiformis, skin biopsy for subjects with signs or symptoms of 
bullous pemphigoid or cutaneous T-cell lymphoma, urea breath test for Helicobacter pylori, 
or allergy testing).  
All screening procedures must be completed within 31 days before the Baseline visit. The 
minimum screening period for all subjects is 14 days to allow for collection of electronic 
diary (eDiary) screening data. Subjects who require screening period longer than 14 days will 
have a telephone contact at least 15 days prior to the scheduled Baseline visit to remind them 
to complete the eDiary as previously instructed at the Screening visit. 
Screening procedures may be deferred following discussion with the medical monitor should 
more than 31 days be required (e.g. to wash out of certain excluded therapies or to treat their 
underlying condition).  
Screening procedures may be repeated (i.e., the subject may be rescreened) following 
discussion with the medical monitor should the subject have had difficulty complying with 
eDiary assessments, require further training in the assessments, or have other relevant needs 
that may delay enrollment in the study but are not expected to impact safety or efficacy 
assessments. 
Subjects will be provided an eDiary at the Screening visit. Subjects must be willing and able 
to complete the eDiary every day within a consistent timeframe, and comply with restrictions 
on allowable concomitant therapies, for the duration of the study.  
At the Baseline visit (Day 1), eligible subjects will be randomly assigned to receive study 
drug (serlopitant 5 mg or placebo). Subjects will take a loading dose (3 tablets taken orally) 
at the site on the first day of the treatment period (Day 1). Starting on Day 2, subjects will 
take one tablet per day. Study drug may be taken with or without food. 
 
The primary efficacy endpoint will be assessed at Week 10 of treatment.  
Subjects who complete the 10-week treatment period and required follow-up period may be 
given the opportunity to enroll in a one-year open-label safety study (MTI-107) with daily 
oral doses of serlopitant 5 mg. 
3.2 
Rationale for Study Design and Dose Selection 
In the TCP-102 study in patients with PN, serlopitant 5 mg taken daily for 8 weeks was 
superior to placebo for the reduction of pruritus, in both the overall study population as well 
as the subgroup of subjects with an atopic diathesis. Similarly, in the TCP-101 study in 
24


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 23 
patients with chronic pruritus, serlopitant 5 mg and 1 mg taken daily for 6 weeks were 
superior to placebo for the reduction of pruritus, in both the overall study population and the 
subgroup of subjects with an atopic diathesis.  
In both the TCP-102 and TCP-101 studies, serlopitant was generally well-tolerated and 
demonstrated an overall favorable safety profile at the doses evaluated. 
The current MTI-106 study is designed to confirm the efficacy, safety, and tolerability of 
serlopitant for the treatment of pruritus in patients with PN. The 5 mg dose of serlopitant was 
selected for this study based on the favorable efficacy, safety, and tolerability profile of 
serlopitant at this dose level. Over 250 subjects have been exposed to serlopitant at doses of 
5 mg tablet-equivalent daily for at least 6 weeks, and ~ 40 subjects have been exposed up to 
one year. Human CNS PET RO data for serlopitant in healthy young males (Study P002) 
demonstrated that a serlopitant 5 mg LFC once daily dose is likely to achieve ~ 94% NK1 RO 
at steady state.  
3.3 
Study Endpoints 
3.3.1 
Primary Efficacy Endpoint 
The primary efficacy endpoint is the Worst-Itch Numeric Rating Scale (WI-NRS) 4-point 
responder rate at Week 10. 
3.3.2 
Key Secondary Efficacy Endpoints 
The key secondary efficacy endpoints are as follows: 
• WI-NRS 4-point responder rate at Week 4 
• Change from baseline in WI-NRS to Day 7 
• Change from baseline in WI-NRS to Day 3 
• Change from baseline in Dermatology Life Quality Index (DLQI) to Week 10 
 
3.3.3 
Additional Secondary Efficacy Endpoints 
Additional secondary efficacy endpoints are as follows: 
• Change from baseline in WI-NRS to other timepoints 
• WI-NRS 4-point responder rate at Week 2 
• WI-NRS 3-point responder rate at Weeks 2, 4 and 10 
• Change from baseline in Investigator’s Global Assessment of PN Activity (IGA PN-A) to 
Weeks 2, 4 and 10 
• Change from baseline in Investigator’s Global Assessment of PN Stage (IGA PN-S) to 
Weeks 2, 4 and 10 
25


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 24 
3.3.4 
Safety Endpoints 
Safety endpoints are as follows: 
• Incidence of TEAEs and SAEs 
• Change from baseline in clinical laboratory parameters following study drug exposure 
• Change from baseline in vital sign and ECG parameters following study drug exposure 
• Change from baseline in the Hospital Anxiety and Depression Scale (HADS)  
• Change from baseline in the Epworth Sleepiness Scale (ESS) 
 
3.4 
Safety Review 
3.4.1 
Safety Monitoring Team 
An internal safety monitoring team consisting of representatives from Menlo Therapeutics 
Inc. and its designees will monitor blinded safety data on a regular basis throughout the 
study. 
4 
SELECTION OF STUDY POPULATION 
4.1 
Study Population 
Approximately 200 adult subjects with pruritus associated with PN will be enrolled in this 
study. 
4.2 
Inclusion Criteria 
Subjects must meet the following criteria to be randomized into the study: 
1. Male or female, age 18 years or older at consent. 
2. A diagnosis of PN, defined by the presence of at least ten pruriginous nodules secondary 
to chronic pruritus present on at least two different body surface areas (e.g. both arms, one 
arm and one leg, one arm and the anterior trunk, or anterior and posterior trunk). 
3. The worst pruritus is identified to be within the areas of the PN lesions.  
4. Subject has idiopathic PN OR the subject has an identified pruritic condition associated 
with the PN and has persistent pruritus despite at least 6 weeks of optimized and stable 
26


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 25 
treatment of the underlying condition prior to the Baseline visit, and is willing to continue 
the treatment during the study. Please refer to Section 5.7.1. 
5. WI-NRS score ≥ 7 in the 24-hour period prior to the Screening visit. 
6. Average weekly WI-NRS score ≥ 6.5 in each of the 2 weeks (14 days) immediately prior 
to Baseline visit, as recorded in the eDiary. 
7. All female subjects who are of childbearing potential must be willing to practice highly 
effective contraception (i.e., pregnancy prevention method with a failure rate of < 1% per 
year) from the time of the Screening visit until 5 weeks after last dose of study drug.  Please 
refer to Section 7.1.5 for acceptable methods of contraception. 
8. Willing and able (as demonstrated by a ≥ 70% eDiary completion rate in the two weeks 
prior to Baseline visit) to complete daily eDiary entries within a consistent timeframe for 
the duration of the study.  
9. Willing and able (has adequate cognitive ability, in the investigator’s opinion) to comply 
with study visits and study related requirements including providing written informed 
consent. 
 
4.3 
Exclusion Criteria 
Subjects who meet any of the following criteria are not eligible for participation in the study: 
1. Prior treatment with serlopitant. 
2. Active pruritic skin disease, other than PN, within 6 months prior to randomization (with 
the exception of acute dermatoses such as contact dermatitis, sunburn, viral exanthem, 
which have been resolved for longer than 4 weeks). Please refer to Section 5.7.1. 
3. Treatment with any of the following therapies within 4 weeks prior to randomization. 
a. Other NK1-R antagonists (e.g., aprepitant, fosaprepitant, rolapitant). 
b. Systemic or topical immunosuppressive/immunomodulatory therapies (including 
but not limited to corticosteroids, phosphodiesterase-4 (PDE-4) inhibitors, 
cyclosporine, mycophenolate-mofetil, tacrolimus, pimecrolimus, calcipotriene, 
methotrexate, azathioprine, interferon-gamma, thalidomide, or phototherapy).  
c. Systemic therapies with recognized anti-pruritic properties (including but not 
limited to H1 antihistamines, doxepin, gabapentin, pregabalin, cannabinoids, 
kappa-opioid receptor agonists, and mu-opioid receptor antagonists (e.g. 
naloxone, naltrexone)). 
d. Strong CYP3A4 inhibitors (see Appendix B). 
e. Use of an indoor tanning facility, or natural sun exposure resulting in significant 
tanning or sunburn. 
4. Treatment with topical anti-pruritic therapies (e.g., menthol, camphor, pramoxine, 
capsaicin) within 2 weeks prior to randomization (see Section 5.7.2). 
27


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 26 
5. Treatment with biologic therapies within 8 weeks or 5 half-lives prior to randomization, 
whichever is longer. 
6. Treatment with any investigational therapy within 4 weeks (8 weeks for investigational 
biologic therapies) or 5 half-lives prior to randomization, whichever is longer. 
7. Serum creatinine, total bilirubin, alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) > 2.5 times the upper limit of normal (ULN) during screening. 
8. Untreated or inadequately treated thyroid, adrenal, or pituitary nodules or disease or 
history of thyroid malignancy.  
9. History of malignancy within 5 years prior to randomization, with the exception of 
actinic keratosis, completely treated and non-metastatic cutaneous basal cell carcinoma or 
squamous cell carcinoma of the skin. 
10. Any known major psychiatric diagnosis, such as major depressive disorder, bipolar 
disorder, schizophrenia, psychotic disorder, intellectual disability, severe alcohol use 
disorder, which may confound the assessment of serlopitant safety or efficacy, or 
interfere with the subject’s ability to comply with protocol-mandated activities, within 
3 years prior to randomization.  
11. Suicidal ideation within 3 years prior to randomization, or any history of suicide attempt. 
12. Documented history of parasitic infection, including skin parasites such as scabies, within 
8 weeks prior to randomization. 
13. Presence of any medical condition or disability that, in the investigator’s opinion, could 
interfere with the assessment of safety or efficacy in this trial or compromise the safety of 
the subject. 
14. History of hypersensitivity to serlopitant or any of its components. 
15. Currently pregnant or breastfeeding female subject. 
16. Planned or anticipated major surgical procedure or other activity that would interfere with 
the subject’s ability to comply with protocol-mandated assessments (e.g. extended 
international travel) during the subject’s participation in the study. 
5 
STUDY DRUG 
5.1 
Study Drug Supply, Route of Administration, and Storage 
The study drug in this study is serlopitant 5 mg or placebo in a film-coated tablet formulation 
for oral administration. The serlopitant tablets contain microcrystalline cellulose, mannitol, 
croscarmellose sodium, silicon dioxide, sodium lauryl sulfate, and magnesium stearate, and 
are film coated with Opadry® Brown. The placebo tablets contain microcrystalline cellulose, 
lactose monohydrate, and magnesium stearate, and are film coated with Opadry® Brown.  
The study drug will be provided in bottles that can be stored at room temperature (59-86°F, 
15-30°C). 
28


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 27 
The tablets will be supplied in bottles, with 18 tablets per bottle. One bottle will be issued via 
Interactive Web Response System (IWRS) at baseline and at Weeks 2 and 4, and two bottles 
will be issued via IWRS at Week 6. A total of 5 bottles will be dispensed to subjects 
completing 10 weeks of study drug treatment. 
Additional details regarding study drug supplies can be found in the Pharmacy Manual. 
29


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 28 
5.2 
Labeling and Study Drug Accountability 
The study drug will be appropriately packaged and labeled in bottles with 18 tablets per 
bottle. The study drug supplied for this study is not to be used for any purpose other than this 
study, and study drug accountability must be maintained for all bottles distributed to the 
investigative site. 
Additional details regarding study drug labeling and accountability can be found in the 
Pharmacy Manual. 
5.3 
Dosing Regimen 
Subjects will take a loading dose (3 tablets taken orally) at the site on the first day of the 
treatment period (Study Day 1). Starting on Study Day 2, subjects will take one tablet per day 
taken orally. Subjects will be instructed to take all doses from Study Day 2 onward once a 
day. Study drug may be taken with or without food. 
5.4 
Dose Modification 
No dose modification of study drug will be allowed during this study. 
5.5 
Missed or Delayed Doses 
Each dose of study drug after the first dose must be administered once daily. If a dose is 
missed, that dose will be considered and documented as a missed dose. Dosing should 
resume the next day. 
5.6 
Study Drug Discontinuation 
Subjects should be discontinued from study drug treatment in the following situations: 
• A female subject desires to become pregnant at the current time, stops contraception or 
expels her intrauterine device/implant, or becomes pregnant  
• A female subject has new breast findings (e.g. a palpable mass or abnormal 
mammography, discharge), or has abnormal vaginal discharge or bleeding 
• The subject decides to discontinue study drug treatment, or withdraws consent from the 
study 
• The subject receives a strong CYP3A4 inhibitor (See Appendix B) 
• Any medical condition that may jeopardize the subject’s safety if study drug is continued, 
in the investigator’s and/or Sponsor’s opinion; this may include the development of 
persistently (2 successive occasions) abnormal thyroid function tests (TSH >10, or 
TSH > 6 with low free T4; TSH <0.1, or TSH < 0.35 with high free T4); abnormal 
morning prolactin, cortisol, or corticotropin levels; or signs and symptoms of adrenal 
insufficiency 
30


Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 29 
•
Discontinuation is deemed to be in the best interest of the subject, in the investigator’s
and/or Sponsor’s opinion, including evidence that the subject does not meet
inclusion/exclusion criteria intended primarily for safety reasons, or a persistent lack of
adherence to study procedures
The Sponsor or designee should be contacted within 24 hours of investigator’s awareness of 
any study drug treatment discontinuation. Investigators should make every effort to contact 
the Sponsor or designee before discontinuing study drug treatment, if possible. 
Subjects who discontinue treatment with study drug prior to completing the treatment period 
will enter a 5-week follow-up period following the last dose of study drug in addition to a 
Follow-up visit (see Section 3.1, Section 6.5.10). Every effort should be made for subjects to 
complete the Follow-up visit after a subject has discontinued from study drug.  
5.7 
Prior, Concomitant, and Excluded Therapies 
Prior therapies (including over-the-counter medications) used to treat the signs and 
symptoms of PN within the prior 2 years will be recorded for each subject at the Baseline 
visit. 
Concomitant therapies include any therapies (including over-the-counter medications and 
bland emollients) used by a subject from initiation of study drug treatment through the 
follow-up period. A record of all medications used will be maintained for each subject 
throughout the study. Reported information will include a description of the type of drug, 
treatment period, dosing regimen, the route of administration, and drug indication. The use of 
any concomitant medication must relate to the subject’s medical history or to an AE, except 
for vitamins/nutritional supplements, emollient use, and routine preventative immunizations.  
5.7.1 
Allowed Therapies and Treatment Goals for Underlying Conditions 
Treatment of an underlying, treatable chronic pruritic condition is allowed, if stable for at 
least 6 weeks prior to the Baseline visit, and continued throughout the treatment period.  
Treatment of the underlying systemic pruritic condition should be optimized per standard of 
care and treatment goals must be tailored based on age, sex, and concurrent health status and 
drug tolerance. While resolution of metabolic or endocrine disorders or eradication of an 
underlying infection may not always be feasible, every effort should be made to ensure the 
condition is well controlled, to prevent or reduce exacerbations and to prevent limitation on 
the activities of daily living. When applicable, laboratory evidence of control should be 
obtained. For example, if renal insufficiency is implicated as causal for pruritus, treatment 
would be expected to have meaningfully reduced the creatinine (compared to that at the time 
of diagnosis) and to maintain the creatinine at < 2.5 the ULN; control of diabetes is supported 
by a hemoglobin-A1c of < 7.5%; control of thyroid disease is supported by normalization of 
the thyroid stimulating hormone (TSH) or by a TSH within 1.5 times the ULN in elderly 
patients; iron deficiency is corrected with a serum iron within 0.8 times the lower limit of 
normal; eradication of Helicobacter pylori infection generally requires a negative urea breath 
31


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 30 
test and fecal antigen test and endoscopy; and the viral load should be undetectable if viral 
infections such as hepatitis B or hepatitis C, or HIV were previously diagnosed. Any 
previously active skin disease is considered to be well controlled if it is globally considered 
clear or almost clear (permissible to have post-inflammatory pigmentation, fine scale, faint 
pink erythema, barely perceptible induration/papulation, and no oozing or crusting).   
Use of gentle cleansers and bland emollients (including those with urea) is encouraged for all 
subjects. If bland emollient use is elected, it must be initiated at least 2 weeks (14 days) prior 
to Baseline visit, and continued throughout the treatment period.  
Treatment with non-systemic corticosteroids or antihistamines that do not involve skin 
application (e.g. inhaled, intranasal, ophthalmic, or intra-articular) is allowed.  
Leukotriene inhibitors will be permitted for treatment of conditions other than PN (e.g. 
asthma). 
5.7.2 
Excluded Therapies 
Initiation or use of topical therapy with corticosteroids, calcineurin inhibitors, calcipotriene, 
PDE-4 inhibitors is not permitted within 4 weeks prior to the Baseline visit or throughout the 
treatment period, but such therapy may be initiated during the follow-up period if needed.  
Initiation of bland emollient is not permitted within 2 weeks (14 days) prior to Baseline visit 
or throughout the treatment period, but such therapy may be initiated during the follow-up 
period if needed.  
The following therapies and activities are excluded from the Screening visit through the 
treatment period, and through the follow-up period: 
• NK1-R antagonists (other than study drug) 
• Systemic immunosuppressive/ immunomodulatory therapies (including but not limited to 
systemic corticosteroids, PDE-4 inhibitors, cyclosporine, mycophenolate-mofetil, 
methotrexate, azathioprine, thalidomide, interferon-gamma, or phototherapy) 
• Biologic therapies (other than therapies such as insulins, vaccines) 
• Strong CYP3A4 inhibitors (See Appendix B) 
• Use of an indoor tanning facility, or natural sun exposure resulting in significant tanning 
or sunburn 
• Any investigational therapy 
 
The following therapies and activities are excluded from the Screening visit through the 
treatment period, and use is discouraged, though permitted, through the follow-up period: 
32


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 31 
• Topical therapies or emollients with anti-pruritic properties (including but not limited to 
anti-histamines, menthol or menthol derivatives, polidocanol, camphor, pramoxine, and 
capsaicin) 
• Systemic therapies with recognized anti-pruritic properties (including but not limited to 
H1 antihistamines, doxepin, gabapentin, pregabalin, cannabinoids, kappa-opioid receptor 
agonists, and mu-opioid receptor antagonists)  
 
Use of any excluded therapies (including those for the treatment of pruritus or PN lesions, or 
as rescue therapy) should be reported as soon as possible, and will be recorded as protocol 
deviations for subjects who receive them.  
5.7.3 
Rescue Therapies 
The initiation of non-study drug therapy to treat worsening of pruritus or PN lesions, or flare 
of previously inactive skin disease, is strongly discouraged throughout the treatment period. 
However, should rescue therapy be required for the safety and well-being of the subject, such 
use will be recorded and analyzed (see Section 8.2). The subject may remain on study drug, 
unless the rescue therapy is an NK1-R antagonist, a systemic biologic therapy, a strong 
CYP3A4 inhibitor, an investigational therapy, or any therapy that may jeopardize the 
subject’s safety if study drug is continued, in the investigator’s and/or Sponsor’s opinion. 
5.8 
Assignment to Treatment  
5.8.1 
Randomization 
Eligible subjects will be randomized to receive serlopitant 5 mg or placebo in a 1:1 ratio. 
Stratified permuted block randomization will be used. Randomization will be stratified by the 
subject’s reported WI-NRS score for the 1-week period prior to the Baseline visit (6.5 to < 9, 
9 to 10).  
An IWRS will be used to perform the randomization.  
5.8.2 
Blinding 
This study will be conducted as a double-blind study with the treatment assignment 
concealed from the subjects, the investigators and their staff, the Sponsor, and any designees 
of the Sponsor as required. The placebo will be formulated to be indistinguishable from the 
active study product. Study materials will be packaged and issued in a manner designed to 
maintain the blind for subjects and all study personnel involved in the direction and 
execution of study procedures, study assessments, and collection of data. The randomization 
code for each subject will be available to the sites for use only in an emergency situation. For 
details of the procedure for unblinding of individual subjects in cases of emergency see 
Section 7.6.  
33


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 32 
5.9 
Treatment Compliance 
Records of study drug used, dosages administered, and intervals between visits will be kept 
during the study. Subjects will record in the eDiary the doses administered, as well as 
whether a dose was taken within 2 hours of eating a meal. Subjects will be asked to return all 
partially used and empty bottles to the study site at each visit. The site staff will count and 
record the number of remaining tablets in each returned bottle. The site staff will review the 
subject’s eDiary to help evaluate compliance with dosing at each study visit. Discrepancies 
between compliance as assessed by tablet counts and doses recorded in the eDiary will be 
reconciled and documented. Dosing dates and times will be recorded. A subject who has 
deviated significantly from the once-daily dosing regimen will be counseled. 
6 
STUDY SCHEDULE AND ASSESSMENTS 
When applicable, efficacy and safety instruments will be provided with instructions for 
administration, in study-specific manuals for site reference.  
6.1 
Efficacy Parameters 
6.1.1 
Itch Numeric Rating Scale 
The Itch NRS is a validated, self-reported instrument for measurement of itch intensity. It 
uses a 24-hour recall period and asks subjects to rate the intensity of their itch on an 11-point 
scale ranging from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicate greater 
itch intensity. In this study, the subject is asked to rate the intensity of their worst itch 
(WI-NRS) during a 24-hour recall period; the questionnaire is provided in Appendix C. 
Initial WI-NRS score collected during Screening visit will be collected on paper. All 
subsequent WI-NRS assessments will be reported by subject via eDiary. Subjects will record 
their WI-NRS scores once daily via eDiary at approximately the same time each day 
(+/- 3 hours) throughout the screening, treatment, and follow-up periods, as outlined in 
Appendix A. Subjects may be allowed to adjust the timing of eDiary completion within the 
first week of Screening as needed. Standardized training and instructions will be provided to 
all subjects prior to eDiary use.  
6.1.2 
Investigator’s Global Assessment of PN Activity  
The IGA PN-A is an instrument used to assess the overall activity of PN lesions at a given 
time point, as determined by the investigator. It consists of a 5-point scale ranging from 
0 (clear) to 4 (severe), as provided in Appendix D. The IGA PN-A uses clinical 
characteristics of excoriations, crusting, and/or bleeding as guidelines for the overall activity 
assessment. The number of pruriginous lesions should not be considered for this assessment. 
IGA PN-A scores will be captured as outlined in Appendix A. Each assessment during the 
study must be done by the Principal Investigator (PI) or designee. Every effort should be 
made to ensure that all assessments for a given subject are done by the same individual 
throughout the study. However, a change in assessor for a given subject, though not ideal, 
will not be considered a protocol deviation. 
34


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 33 
6.1.3 
Investigator’s Global Assessment of PN Stage  
The IGA PN-S is an instrument used to assess the overall number and thickness of PN 
lesions at a given time point, as determined by the investigator. It consists of a 5-point scale 
ranging from 0 (clear) to 4 (severe), as provided in Appendix D. The IGA-PN-S uses clinical 
characteristics of number of nodules and their thickness as guidelines for the overall severity 
assessment. IGA-PN-S scores will be captured as outlined in Appendix A. Each assessment 
during the study must be done by the PI or designee. Every effort should be made to ensure 
that all assessments for a given subject are done by the same individual throughout the study. 
However, a change in assessor for a given subject, though not ideal, will not be considered a 
protocol deviation. 
6.1.4 
Dermatology Life Quality Index  
Dermatology Life Quality Index (DLQI) is a dermatology specific QOL instrument designed 
to assess the impact of the skin disease on a subject’s QOL over the prior week. It is a ten-
item questionnaire that assesses overall QOL and six aspects that may affect QOL 
(symptoms and feelings, daily activities, leisure, work or school performance, personal 
relationships, and treatment), and is provided in Appendix E. The DLQI questionnaire will be 
collected as outlined in Appendix A. 
6.1.5 
PN Photographs 
At selected investigative sites, optional photographs of representative areas with PN 
involvement will be taken at multiple time points, as outlined in Appendix A. These areas 
may include the extensor surfaces of both arms and both legs (overview of both legs, detail 
of lower legs), and the abdomen and back. The central photography vendor will provide 
photographic equipment to the sites for use during the study. The PI and designees will be 
trained on the use of the camera and the appropriate lighting and positioning of the 
representative area with PN involvement. Detailed instructions will be provided in the 
Photography manual. 
6.2 
Safety Parameters 
Safety assessments will consist of monitoring and recording protocol-defined AEs and SAEs; 
vital signs; physical examinations; clinical laboratory assessments; ECGs; and other 
protocol-specified tests that are deemed critical to the safety evaluation of the study drug as 
outlined in Appendix A. 
6.2.1 
Vital Signs 
Vital signs will include measurements of heart rate, blood pressure, respiration rate, and 
temperature after the subject has been calmly resting (seated or supine) for a minimum of 
5 minutes. Vital signs will be assessed as outlined in Appendix A and at unscheduled study 
visits when clinically indicated. On study visits when clinical laboratory tests are performed, 
assessment of vital signs should precede blood draw.  
35


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 34 
6.2.2 
Physical Examination 
Physical examinations, including height and weight measurements, will be performed as 
outlined in Appendix A and at unscheduled study visits when clinically indicated. A 
complete physical examination will be performed at the screening visit, while subsequent 
examinations will be abbreviated and targeted to changes in disease activity and/or subjects’ 
symptoms. For female subjects with targeted breast examinations, please perform breast 
examination after blood draw for clinical laboratory tests.   
6.2.3 
Clinical Laboratory Assessments 
Samples for clinical laboratory assessments will be collected as outlined in Appendix A and 
at unscheduled study visits when clinically indicated, and analyzed at a central laboratory 
unless otherwise specified.  
Detailed instructions regarding sample collection, preparation, and shipment can be found in 
the laboratory manual. Laboratory assessments will include the following, and are ideally 
performed in the morning, particularly at visits with endocrine assessments (Screening, Week 
10, Follow-up): 
• Hematology: hematocrit, hemoglobin, red blood cell count, red blood cell indices, 
platelets, white blood cell count, white blood cell differential (neutrophils, lymphocytes, 
monocytes, basophils, eosinophils) 
• Chemistry: sodium, potassium, chloride, bicarbonate, glucose, blood urea nitrogen, 
creatinine, calcium, phosphorus, magnesium, albumin, uric acid, total protein, ALT, 
AST, alkaline phosphatase, total bilirubin, lactate dehydrogenase (LDH), lipid panel 
• Iron studies: ferritin, serum iron  
• Serology: hepatitis B and C serology, HIV 
• Serum IgE 
• Pregnancy testing: all females of childbearing potential will have a local urine pregnancy 
test performed. Positive or equivocal urine pregnancy test results will be confirmed by a 
serum pregnancy test analyzed at a central laboratory 
• Endocrine: TSH, free T4, cortisol, corticotropin (adrenocorticotropic hormone, ACTH), 
prolactin  
• Reproductive endocrinology (for all female subjects under 55 years of age at consent): 
serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, 
progesterone, anti-Mullerian hormone (AMH)  
• Optional study provided in lab test kits for use at Screening only: endomysial antibody 
with reflex to titer for subjects with signs or symptoms of dermatitis herpetiformis 
36


Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 35 
•
Additional optional studies will be supported through local procedural and/or laboratory
assessments, including, but not limited to, skin biopsy and pathology interpretation, urea
breath test for Helicobacter pylori, and allergy testing (patch, prick, or blood testing); the
investigator should discuss the need for such studies with the medical monitor during the
Screening period.
•
Standard cosyntropin stimulation testing should be performed on subjects with low
cortisol level (i.e. < 3.0 mcg/dL); the investigator should discuss low cortisol (and
relevant low corticotropin) results with the medical monitor.
6.2.4 
Electrocardiogram 
A standard 12-lead ECG will be performed after the subject has been calmly resting in a 
supine position for a minimum of 5 minutes before obtaining the ECG. ECGs should precede 
measurement of vital signs and blood draw for clinical laboratory tests and will be performed 
as outlined in Appendix A and at unscheduled study visits when clinically indicated and read 
centrally. ECG machine and detailed instructions will be provided by the ECG vendor. 
6.2.5 
Hospital Anxiety and Depression Scale 
The HADS is a QOL instrument designed to assess the severity of anxiety and depression 
over the prior week, developed in a hospital outpatient clinic, but also valid in community 
settings and primary care medical practice.  The questionnaire takes approximately 2 to 5 
minutes to complete, and is provided in Appendix F. The HADS questionnaire will be 
collected as outlined in Appendix A. 
6.2.6 
Epworth Sleepiness Scale 
The ESS is a QOL instrument intended to measure daytime sleepiness by use of a very short 
questionnaire. The questionnaire takes approximately 2 to 3 minutes to complete, and is 
provided in Appendix G. The ESS questionnaire will be collected as outlined in Appendix A. 
6.3 
Pharmacokinetic Measurements 
Sparse PK sampling will involve collecting one PK sample at each of the Week 2, Week 4, 
and Week 10 visits as outlined in Appendix A. The date and time of dosing prior to PK 
sample collection and date and time of PK sample collection will be collected. The plasma 
concentrations of serlopitant and metabolites will be determined and data used for population 
PK analysis. Detailed instructions regarding PK sample collection, preparation, and shipment 
can be found in the laboratory manual. 
6.4 
Subject Flow Diagram 
The visit schedule and assessments are summarized in Appendix A. The following subject 
flow diagram provides a summary of assessments and decision points for each subject. The 
eDiary assessments are performed throughout the study and are not confined to scheduled 
visits.  
37


Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 36 
Figure 1 
Subject Flow Diagram  
6.5 
Study Visits 
The following sections describe the procedures and assessments to be performed at each 
study visit. Details of each procedure and assessment can be found in Sections 6.1, 6.2, and 
6.3. The timing of each study visit is relative to the day of randomization (Baseline). 
Unscheduled visits may be performed as necessary, and may include procedures or 
assessments deemed necessary by the investigator. 
The eDiary assessments are performed throughout the study and are not confined to 
scheduled visits. Refer to Appendix A for frequency and duration of these assessments. 
Female subjects who report periodic menstruation will be asked to complete a menstrual 
diary (paper form) throughout the study. 
6.5.1 
Screening Period 
Informed consent will occur prior to any protocol-mandated procedures, including the 
stopping of any excluded therapies. This may occur prior to the Screening visit. 
38


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 37 
All screening procedures must be completed within 31 days before the Baseline visit. The 
minimum screening period for all subjects is 14 days to allow for collection of eDiary 
screening data. Subjects who require screening period longer than 14 days will have a 
telephone contact at least 15 days prior to the scheduled Baseline visit to remind them to 
complete the eDiary as previously instructed at the Screening visit. 
Screening procedures may be deferred following discussion with the medical monitor should 
more than 31 days be required (e.g. to wash out of certain excluded therapies or to treat their 
underlying condition).  
Screening procedures may be repeated (i.e., the subject may be rescreened) following 
discussion with the medical monitor should the subject have had difficulty complying with 
eDiary assessments, require further training in the WI-NRS assessments, or have other 
relevant needs that may delay enrollment in the study but are not expected to impact safety or 
efficacy assessments. 
6.5.2 
Screening Visit 
The following screening procedures are to be performed at the Screening visit, preferably in 
the order shown below: 
• Obtain written informed consent prior to any protocol-mandated procedures, including 
the stopping of any excluded therapies 
• Collect demographic information (sex, date of birth, race, ethnicity)  
• Ask subject to complete the WI-NRS scale on paper 
• Register Screening visit into the IWRS 
• Obtain ECG  
• Obtain vital signs  
• Review subject’s medical history (including prior medications) 
- 
Record only significant/relevant medical history, to include the onset date of PN (as 
specifically as known) and presence of an underlying condition (if any) 
- 
Designate the primary and any concurrent medical conditions that are identified as 
pruritic conditions underlying the PN  
- 
Female subjects should be queried regarding history of, or current, breast masses or 
abnormal discharge, and history of mammography (if applicable), and history of 
abnormal vaginal bleeding or discharge 
• Perform complete physical examination (including height and weight) and confirm 
clinical diagnosis of PN  
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
39


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 38 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent  
- 
Endocrine  
- 
Hematology 
- 
Chemistry 
- 
Serology 
- 
Serum IgE 
- 
Iron studies 
- 
Optional: endomysial antibody with reflex to titer for subjects with signs or 
symptoms of dermatitis herpetiformis 
- 
Optional: additional assessments (refer to Section 6.2.3) 
• Review subject’s tentative eligibility according to the Inclusion/Exclusion criteria 
- 
The results of all screening evaluations, including laboratory and ECG results, must 
be reviewed for clinical significance by the PI or designee, and may require further 
evaluation, prior to randomization of the subject on Baseline visit 
• Schedule the Baseline visit and all future study visits to ensure subject’s availability and 
visit compliance with the protocol visit windows 
• Provide a menstrual diary to female subjects who report periodic menstruation   
• Provide eDiary with instructions 
• Confirm next scheduled visit 
 
6.5.3 
Mid-Screening Telephone Contact (for subjects longer than 14 days in 
Screening) 
During this telephone contact the following procedures are to be performed: 
• Assess and record any changes in medications since the Screening visit 
• Review subject’s tentative eligibility according to Inclusion/Exclusion criteria 
• Assess AEs and record SAEs caused by protocol-mandated interventions 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
40


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 39 
6.5.4 
Baseline Visit 
The Baseline visit occurs between 14 to 31 days after the screening visit, depending on the 
required washout period following discontinuation of excluded therapies. Eligibility must be 
confirmed prior to randomization. At the Baseline visit, the following procedures and 
assessments are to be performed, preferably in the order shown below: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires  
• Assess and record any changes in the subject’s concomitant medications 
• Assess and record any changes in the subject’s medical history  
- 
Female subjects should be queried regarding history of, or current, breast masses or 
abnormal discharge, and history of mammography (if applicable), and history of 
abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Assess AE’s and record SAEs caused by protocol-mandated interventions 
• Obtain vital signs  
• Perform a urine pregnancy test for females of childbearing potential and confirm the 
subject has a negative urine pregnancy test result prior to randomization (with positive or 
equivocal results confirmed by a serum pregnancy test) 
• Confirm subject’s eligibility based on the inclusion/exclusion criteria (to include review 
of eDiary compliance for eligibility) 
• Randomize subject in IWRS if eligibility confirmed 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Dispense study drug; subjects will take loading dose of 3 tablets while on site 
• Review eDiary for compliance, re-train subject as needed 
• Assess and record any post-dose AEs and SAEs 
• Confirm next scheduled visit 
 
41


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 40 
6.5.5 
Week 1 Telephone Contact Visit 
The Week 1 visit is a telephone visit that occurs 7 days (± 3 days) after the Baseline visit. At 
the Week 1 visit, the following procedures and assessments are to be performed:  
• Assess and record any changes in the subject’s concomitant medications 
• Assess and record any AEs and SAEs 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
6.5.6 
Week 2 Visit 
The Week 2 visit occurs 14 days (± 3 days) after the Baseline visit. At the Week 2 visit, the 
following procedures and assessments are to be performed:  
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Draw blood for clinical laboratory tests 
- 
Hematology 
- 
Chemistry 
• Collect PK blood sample  
• Assess and record any AEs and SAEs 
• Review eDiary for compliance, re-train subject as needed 
• Review study drug compliance with re-training as required 
• Collect returned study drug 
42


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 41 
• Utilize IWRS to assign new bottle of study drug 
• Confirm next scheduled visit date 
 
6.5.7 
Week 4 Visit 
The Week 4 visit occurs 28 days (± 3 days) after the Baseline visit. At the Week 4 visit, the 
following procedures and assessments are to be performed: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test)  
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Collect PK blood sample  
• Assess and record any AEs and SAEs 
• Collect returned study drug 
• Utilize IWRS to assign new bottle of study drug 
• Review eDiary for compliance, re-train subject as needed 
• Review study drug compliance with re-training as required 
• Confirm next scheduled visit date 
 
6.5.8 
Week 6 Visit 
The Week 6 visit occurs 42 days (± 3 days) after the Baseline visit. At the Week 6 visit, the 
following procedures and assessments are to be performed: 
43


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 42 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain vital signs 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test)  
• Perform targeted physical examination, including weight 
• Assess and record any AEs and SAEs 
• Collect returned study drug 
• Utilize IWRS to assign new bottle of study drug 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
6.5.9 
Week 10 Visit 
The Week 10 visit occurs 70 days (± 7 days) after the Baseline visit. At the Week 10 visit, 
the following procedures and assessments are to be performed: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
44


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 43 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent 
- 
Endocrine 
- 
Hematology 
- 
Chemistry 
• Collect PK blood sample 
• Assess and record any AEs and SAEs 
• Collect returned study drug  
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Review eDiary for compliance, inform subject to continue entering WI-NRS score until 
Follow-up visit 
• Review study drug compliance with re-training as required 
• Confirm next scheduled visit date 
 
6.5.10 
Follow-up Visit 
The required Follow-up visit occurs 21 or 35 (+7 days) after the Week 10 visit or the last 
dose of study drug for subjects who discontinue study drug early. The required follow-up 
period is defined as a minimum of 3 weeks for those subjects who will enroll in the one-year 
open-label safety study on the date of the follow-up visit, and as 5 weeks for those subjects 
who will not be enrolled in the one-year open-label safety study of serlopitant. Should a 
subject present for the follow-up visit prior to 5 weeks after the last dose of study drug and be 
excluded from participation in the one-year study for any reason, the subject will be required 
to return at 5 weeks after the last dose of study drug for a complete follow-up visit. 
At the Follow-up visit, the following procedures and assessments are to be performed: 
• Register visit into the IWRS 
• Ask the subject to complete the HADS and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain vital signs 
45


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 44 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Obtain ECG  
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent  
- 
Endocrine  
- 
Hematology 
- 
Chemistry 
• Assess and record any AEs and SAEs 
• Collect eDiary device, review eDiary for compliance 
 
6.5.11 
Early Termination 
Early termination of a subject from the study may occur due to loss to follow-up or 
withdrawal of consent by the subject. In accordance with legal requirements and 
International Conference on Harmonization (ICH) –GCP guidelines, every subject or his/her 
legal representative has the right to withdraw from the study at any time and without 
providing reasons. If provided, the reason (adverse event, study burden, lack of efficacy, 
other) a subject withdrew consent will be recorded in the electronic Case Report Form 
(eCRF). The PI or site staff must make every effort to contact subjects who are suspected of 
being lost to follow-up. Attempts to contact such subjects must be documented in the 
subject’s source documents. 
7 
ASSESSMENT OF SAFETY 
7.1 
Definitions 
7.1.1 
Adverse Event 
An AE is any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. An AE can be any unfavorable and unintended sign 
(e.g. an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a drug, without any judgment about causality. 
46


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 45 
AEs include treatment emergent exacerbations of pre-existing illnesses and AEs that occur as 
a result of protocol-mandated interventions. 
7.1.2 
Serious Adverse Event  
An AE is considered “serious” if it results in any of the following outcomes: 
• Death 
• Life-threatening AE (i.e. the subject was at immediate risk of death from the event as it 
occurred. An event that might have led to death if it had occurred with greater severity is 
not “life-threatening”) 
• Inpatient hospitalization or prolongation of existing hospitalization  
• Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
• Congenital anomaly/ birth defect 
• Important medical event (i.e. an event that may not result in death, be life-threatening, or 
require hospitalization, but which may be considered serious by the investigator or 
Sponsor, as it may jeopardize the subject and may require medical/surgical intervention 
to prevent one of the outcomes listed above). Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, 
blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse. 
 
The following are not considered SAEs: a visit to the emergency room or other hospital 
department < 24 hours that does not result in admission (unless considered an important 
medical or life-threatening event), an elective surgery planned prior to signing consent, 
admission as per protocol for planned medical/surgical procedure, and/or routine health 
assessments requiring admission for baseline/trending of health status (e.g. routine 
colonoscopy). 
The terms “severe” and “serious” are not synonymous. Severity refers to the intensity of an 
AE (e.g. mild, moderate, or severe pain); the event itself may be of minor medical 
significance (e.g. severe back pain). “Serious” is a regulatory definition, as defined above. 
Seriousness (not severity) serves as the basis for defining regulatory reporting obligations.  
Severity and seriousness should be independently assessed when recording AEs and SAEs on 
the eCRF. 
47


Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 46 
7.1.3 
Abnormal Physical Exam, Laboratory, Vital Sign, and 
Electrocardiogram Findings  
Abnormal physical exam findings that are clinically significant and are identified prior to the 
first dose of study drug should be recorded as medical history. New or worsening clinically 
significant abnormal physical exam findings identified after the first dose of study drug 
should be recorded as AEs.   
Only abnormal laboratory, vital sign, and ECG findings that are considered clinically 
significant by the investigator (e.g. require active management or are associated with 
accompanying symptoms/signs) will be recorded as medical history or AEs on the eCRF. 
Abnormal laboratory, vital sign, and ECG findings that occur prior to the first dose of study 
drug should be recorded as medical history, and abnormal findings that occur after the first 
dose of study drug should be recorded as AEs. 
If the clinically significant laboratory, vital sign, or ECG abnormality is a sign associated 
with a confirmed disease or condition (e.g. elevated creatinine in a subject diagnosed with 
chronic kidney disease), only the diagnosis (chronic kidney disease) needs to be recorded on 
the AE eCRF (rather than listing individual test findings as AEs).  
Separate instances of the same clinically significant laboratory, vital sign, or ECG 
abnormality across visits should not be recorded as separate AEs or SAEs. 
7.1.4 
Deaths 
Any deaths that occur from the time of informed consent to the follow-up visit, regardless of 
attribution, must be reported within 24 hours of investigator’s awareness of the death. See 
Safety Form Completion Instructions for complete instructions. 
The Sponsor should be provided a copy of any post-mortem findings and/or relevant medical 
reports, including histopathology. 
7.1.5 
Pregnancies and Contraception Requirements for Females 
For the purposes of this study, a female of childbearing potential is defined as any female 
who has experienced menarche and is pre-menopausal, unless permanently surgically sterile 
(e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy). A postmenopausal 
state is defined as no menses for 12 months without an alternative medical cause in a 
previously menstruating female.  
For the purposes of this study, acceptable contraception is defined below based on 
Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals: ICH M3(R2) dated January 2010, and other available 
guidelines (“U.S. Medical Eligibility Criteria for Contraceptive Use” 2010; 
“Recommendations related to contraception and pregnancy testing in clinical trials” 2014; 
“M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals” 2010):  
48


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 47 
All female subjects of childbearing potential must use highly effective contraception, which 
includes the use of one or more of the following acceptable methods:  
1. Surgical sterilization (e.g., bilateral tubal occlusion or ligation, hysterectomy, bilateral 
salpingectomy, bilateral oophorectomy) 
2. Total (as opposed to periodic or cyclic) abstinence from heterosexual intercourse, 
only if planned for the entire duration of the study period and consistent with the 
preferred and usual lifestyle for the subject 
3. Hormonal contraception associated with consistent inhibition of ovulation; these may 
include (but are not necessarily limited to) oral, intravaginal, implantable, injectable, 
or transdermal delivery methods  
4. Intrauterine device/system  
5. Exclusive (sole) monogamous intercourse with a sterilized (i.e., vasectomized) or 
otherwise non-fertile (e.g., castrated) male partner; the male partner must have 
received medical assessment of the surgical success 
Progesterone-only oral contraceptives are excluded as a highly effective method of 
contraception, as they do not consistently inhibit ovulation. Male or female condoms with or 
without spermicide, and female caps, diaphragms, and sponges with spermicide, or 
combinations (double barrier) are also excluded as highly effective contraceptive methods. 
Any pregnancy occurring in a female subject or the female partner of a male subject, from 
the first study drug administration through the required follow-up visit must be reported 
within 24 hours of the investigator’s awareness of the pregnancy. See Safety Form 
Completion Instructions for complete instructions.  
The investigator will follow the pregnancy to delivery or other pregnancy outcome.  
Pregnancy in a female clinical trial subject or female partner of a male clinical trial subject is 
not an SAE per se. Complications of such pregnancies (for example, spontaneous abortion) 
may qualify as SAEs and should be reported as such even if they occur after the Follow-up 
visit. Any congenital anomalies/birth defects must be recorded and reported as SAEs. See 
Safety Form Completion Instructions for complete instructions.  
7.1.6 
Worsening of Pruritus or PN 
Pruritus or PN should be recorded as an AE or SAE only if considered by the investigator to 
have worsened in severity beyond the subject’s typical fluctuations. It is important to include 
a description of the nature of the unexpected worsening when recording the AE or SAE (e.g. 
new PN lesions in previously uninvolved skin). 
49


Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 48 
7.2 
Methods and Timing for Recording and Reporting Adverse Events 
7.2.1 
Adverse Event Reporting Period 
Any AE occurrence during the study must be recorded on source documentation and eCRF at 
the site, in accordance with protocol instructions.  
AEs and SAEs will be recorded from the first study drug administration through the 
follow-up visit. After the required follow-up visit, only SAEs that are believed to be drug-
related should be reported. 
After informed consent, but prior to initiation of study drug, only SAEs considered by the 
investigator to be caused by a protocol-mandated intervention will be collected (e.g. SAEs 
related to invasive procedures such as blood collection). These procedure-related SAEs 
should only be reported on the source documents and SAE form, not on the AE eCRF. 
Subjects who undergo screening procedures but are not randomized into the study will not 
have SAEs recorded in the clinical database. 
7.2.2 
Eliciting Adverse Events 
Investigators will seek information on AEs and SAEs at each subject contact through the 
follow-up visit. All AEs and SAEs, whether reported by the subject or noted by authorized 
study personnel, will be recorded in the subject’s medical record and on the AE eCRF page, 
and, if serious, on the SAE form. For each AE and SAE recorded, the investigator will make 
an assessment of seriousness, severity, and causality. 
7.2.3 
Assessment of Severity 
All AEs entered into the eCRF will be graded for severity using the National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 (“Common 
Terminology Criteria for Adverse Events (CTCAE)” 2010) to describe the maximum 
intensity of the adverse event.   
If the AE cannot be found in the event-specific NCI CTCAE grading criteria, the investigator 
should use the definitions for Grade 1, 2, 3, and 4 in Table 1. 
50


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 49 
Table 1 
Adverse Event Grading 
Grade 
Severity 
Alternate Descriptiona 
1 
Mild (apply event-specific NCI 
CTCAE grading criteria) 
Asymptomatic or mild symptoms; clinical 
or diagnostic observations only; 
intervention not indicated. 
2 
Moderate (apply event-specific NCI 
CTCAE grading criteria) 
Minimal, local or noninvasive intervention 
indicated; limiting age-appropriate 
instrumental activities of daily living 
(ADLb) 
3 
Severe (apply event-specific NCI 
CTCAE grading criteria) 
Severe or medically significant but not 
immediately life-threatening; 
hospitalization or prolongation of 
hospitalization indicated; disabling; 
limiting self care ADLc 
4 
Very severe, life threatening, or 
disabling (apply event-specific NCI 
CTCAE grading criteria) 
Life-threatening consequences; urgent 
intervention indicated. 
5 
Death related to AE 
 
a 
Use these alternative definitions for Grade 1, 2, 3, and 4 events when the observed or reported AE is not 
in the NCI CTCAE listing. A semi-colon indicates ‘or’ within the alternate description of the grade. 
b 
Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc. 
c 
Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
Source: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 
 
Note that severity, a measure of intensity, is not equivalent to seriousness, a regulatory 
definition of outcome. Regardless of severity, some AEs may meet the criteria for 
seriousness. See Section 7.1.2 for the definition of an SAE. 
If an adverse event changes in severity during the same study period (e.g., treatment period), 
only the highest severity grade will be recorded on the eCRF.  
7.2.4 
Assessment of Causality 
The investigator’s assessment of causality must be provided for all AEs (serious and 
non-serious). An investigator’s causality assessment is the determination of whether there 
exists a reasonable possibility that the investigational product caused or contributed to an AE. 
Causality of an AE will be assessed by the investigator using the following terms: 
• Likely Related: A reaction that follows a reasonable temporal sequence from 
administration of the study drug; that follows a known or expected response pattern to the 
suspected study drug; and for which other potential etiologies are considered less likely 
factors than the study drug. 
• Likely Unrelated: A reaction that, considering all potential etiologies, is most likely due 
to factors other than the study drug. 
51


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 50 
7.3 
Follow-up of Adverse Events and Serious Adverse Events 
The investigator must make every effort to follow all AEs and SAEs regardless of attribution 
until judged resolved or stabilized, the subject is lost to follow-up, or it has been determined 
that study drug treatment or participation in the study is not the cause of the AE or SAE. 
7.4 
Reporting Serious Adverse Events to the Sponsor and Institutional 
Review Board or Ethics Committee   
The Sponsor or designee is under obligation to report certain SAEs to regulatory authorities 
related to investigational drugs in clinical trials. The Sponsor or designee must be notified 
within 24 hours of an AE when the investigator determines that an AE meets the protocol 
definition of an SAE, regardless of the cause or relationship to study drug.  
An SAE related to study participation occurring before study drug administration and after 
informed consent should be promptly reported to the Sponsor. If the investigator learns of 
any SAE at any time after a participant has been discharged from the study, and the SAE is 
considered likely related to study drug, the SAE should be promptly reported to the Sponsor. 
Please see the Safety Form Report Completion Instructions for safety reporting instructions.  
The investigator must also comply with applicable requirements concerning reporting of 
SAEs to the IRB or Ethics Committee (EC). This may include initial or follow-up 
notification of an SAE or other safety information. 
7.5 
Reporting Serious Adverse Events to Regulatory Authorities and Study 
Investigators 
The Sponsor, or its designee, is responsible for submitting reports of serious, unexpected 
related adverse events to regulatory authorities on an expedited basis, according to the ICH 
E2A Guideline and to other regulatory authorities according to national and local regulations 
as required. The Sponsor, or its designee, is responsible for prompt submission to the IRB or 
EC of any expedited SAE reports submitted to regulatory authorities. All investigators 
participating in ongoing clinical studies with serlopitant will receive copies of the SAE 
reports submitted on an expedited basis to regulatory authorities. 
7.6 
Emergency Unblinding 
Emergency unblinding is available 24 hours per day/7 days per week and will be performed 
via IVRS. An investigator may unblind a subject’s treatment assignment only when 
knowledge of the investigational product is essential for the welfare of a subject. There is no 
specific antidote for serlopitant and usual supportive medical management is recommended 
in the case of a medical emergency. 
52


Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 51 
8 
STATISTICAL METHODS 
All statistical processing will be performed using SAS® unless otherwise stated. No interim 
analyses are planned. Endpoints will be summarized with descriptive statistics by treatment 
group and visit. For continuous variables, the following information will be presented: 
n (number of subjects), mean, standard deviation, median, minimum and maximum. For 
categorical variables counts and percentages will be used. Summary statistics for imputed 
efficacy data will be reported based upon imputed data. 
The primary method of handling missing efficacy data will be the method of Markov Chain 
Monte Carlo (MCMC) multiple imputation. Subjects who withdrew from the study due to a 
lack of efficacy, or used an excluded therapy to treat worsening of pruritus or PN, will be 
defined as non-responder.  
As one sensitivity analysis, the last observation carried forward method (LOCF) will be used 
(i.e., the last available on-therapy observation for a subject will be used to estimate 
subsequent missing data points). As a second sensitivity analysis, a repeated measures model 
will be used on observed data. Additionally, a tipping point analysis will be done as a 
sensitivity analysis for the primary endpoint. 
Baseline for measures other than the eDiary daily measures will be the last recorded value 
prior to the start of treatment. For daily measures including the WI-NRS, baseline will be the 
average result measured over the week prior to treatment.  
A statistical analysis plan (SAP), describing all statistical analyses will be provided as a 
separate document. The SAP will be finalized prior to unblinding of the study treatments. 
8.1 
Decision Rule and Sample Size  
This study will use a 5% two-sided alpha level. While the alpha level is two-sided, clinically 
relevant results require a serlopitant benefit. Statistical significance for the key secondary 
efficacy endpoints requires statistical significance for the primary efficacy endpoint (i.e. 
stepdown testing from primary to key secondary endpoints). The key secondary efficacy 
endpoints will be tested in order starting with the Week 4 WI-NRS 4-point responder rate, 
then change from baseline to Day 7, and then Day 3, and finally the change from baseline to 
Week 10 in DLQI.  
The target sample size of 200 randomized and dosed subjects (100 per group) has been 
determined based upon a 1:1 allocation of subjects to treatment groups and a 5% alpha level. 
A sample size of two hundred subjects results in 90% power assuming a placebo responder 
rate of 
% and serlopitant rate of 
%. 
The sample size calculations have been performed in PASS 13 (“PASS 13 Power Analysis 
and Sample Size Software” 2014) and use a Chi-Squared test. The primary analysis will 
control for the stratification factors. It is expected that this unstratified power estimate will 
under-estimate the true power as it does not take the variance reduction resulting from 
stratification into account (Matts 1988).  
53
CCI
CCI


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 52 
8.2 
Handling of Missing Data  
Should a determination of treatment period (on treatment, pre-treatment, follow-up) be 
required for adverse events or concomitant medication but the corresponding date is missing, 
or is a partial date, the event/medication will be considered on treatment unless the portions 
of the date that are available indicate this is not possible. 
The primary method of handling missing efficacy data will be MCMC multiple imputation. 
Subjects who withdrew from the study due to a lack of efficacy, or used an excluded therapy 
to treat worsening of pruritus or PN, will be defined as non-responder. Imputation will be 
conducted within each treatment group independently, so the pattern of missing observations 
in one treatment group cannot influence missing value estimations in another. For each 
imputation process, 25 imputations will be performed. 
If a subject fails to complete their eDiary for the week prior to Week 10, the primary 
endpoint (WI-NRS) data will be missing, unless the subject withdrew from the study due to a 
lack of efficacy, or the subject used an excluded therapy to treat worsening of pruritus or PN, 
in which case their responder status will be defined as non-responder. If the Week 10 value is 
missing for any other reason, the change from baseline value will be based on imputed data. 
Missing Week 10 WI-NRS values from which the 4-point responder status is derived will be 
estimated by MCMC. 
Missing WI-NRS data will be derived for the analysis using the method of MCMC multiple 
imputation. Since both primary and key secondary efficacy endpoints require WI-NRS, the 
following steps will be followed: 
1. Using the daily eDiary data, calculate Baseline and Week 2 through Week 10 
values by averaging available values. If any values are available, these will be used 
i.e. a minimum of 1 observation is required to compute a week’s average.  
2. From step 1, create a dataset for each treatment group, of subjects with observed 
values and those needing estimation by MCMC. The missing WI-NRS values in each 
dataset will be filled in using the MCMC method to generate 25 datasets. The 
resulting datasets for each treatment arm will be combined into one complete dataset. 
Syntax: 
proc mi data=datain out=dataout seed=&seed. Nimpute=25 <options>; 
  where trtpn=(TRT);   /* Note TRT = [1, 2]; depending on treatment group */; 
  mcmc chain=single; 
  var baseline d2 d3 d4 d5 d6 d7 week2 week3 week4 week5 week6 week7 week8 
week9 week10; 
run; 
 
3. From each complete dataset, the dichotomous responder rate will be determined. 
Each complete dataset will be analyzed as specified for the particular analysis. 
54


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 53 
Missing Week 10 DLQI data will be derived for the analysis using the method of MCMC 
multiple imputation. The following steps will be followed: 
1. DLQI for Week 10 will be calculated as per scoring instructions.  
2. From step 1, create a dataset for each treatment group, of subjects with observed 
values and those needing estimation by MCMC. The missing values in each dataset 
will be filled in using the MCMC method to generate 25 datasets. The resulting 
datasets for each treatment arm will be combined into one complete dataset. 
Syntax: 
proc mi data=datain out=dataout seed=&seed. Nimpute=25 <options>; 
  where trtpn=(TRT);   /* Note TRT = [1, 2]; depending on treatment group */; 
  mcmc chain=single; 
  var baseline week4 week10; 
run; 
 
3. Each complete dataset will be analyzed as specified for the particular analysis. 
Each complete dataset formed by multiply imputed data will be analyzed as specified for the 
particular analysis. The results from the analyses will be combined into a single inference 
using SAS® PROC MIANALYZE. In the case of the primary analysis and the secondary 
responder analyses, the Cochran Mantel Haenszel (CMH) statistics computed in the analyses 
of WI-NRS responder rates will be normalized using the Wilson-Hilferty transformation 
prior to combining them using SAS® PROC MIANALYZE 
A total of 4 random seeds will be needed to impute missing data. Those random seeds have 
been pre-specified by using a random number generator: 
8.3 
Analysis Populations  
The primary efficacy population will be the Intent-to-Treat (ITT) and will include all 
randomized subjects who were dispensed study drug. Subjects will be analyzed within the 
treatment group to which they are randomized.  
The primary safety population will be all treated subjects with at least one post-baseline 
assessment. For safety analyses, subjects will be classified based upon the treatment 
received.  
55
CCI


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 54 
The Per Protocol (PP) population will include all subjects in the safety population who 
complete the Week 10 evaluations without any significant protocol violations (i.e., any 
subject or investigator activity that could have possibly interfered with the therapeutic 
administration of the treatment or the precise evaluation of treatment efficacy). Analyses 
performed on the Per Protocol population will be considered supportive. The PP population 
will include subjects in the safety population who do not meet any of the following criteria: 
• Violated the inclusion/exclusion criteria; 
• Receives a strong CYP3A4 inhibitor (See Appendix B); 
• Receives an excluded medication for treatment of pruritus or PN; 
• Have not been compliant with the dosing regimen (i.e. subjects must comply with 
80−120% of the expected dosage of study medication during participation in the study); 
• Out of visit window at the Week 10 visit by ±7 days 
Subjects that discontinue from the study drug due to an adverse event related to study 
treatment or documented lack of treatment effect will be included in the PP population. Prior 
to breaking the blind, other additional criteria may be added to the list to accommodate for 
unforeseen events that occurred during the conduct of the trial that result in noteworthy study 
protocol violations. 
8.4 
Subject Disposition  
An accounting of all randomized subjects by disposition will be presented. Subjects who 
discontinue study drug prematurely or withdraw from the study will be summarized and 
listed, with a description of the reason for early termination/withdrawal. 
8.5 
Subject Characteristics  
Demographic and other baseline characteristics will be summarized. 
8.6 
Prior and Concomitant Medications  
Prior and concomitant medications will be coded by the World Health Organization Drug 
Dictionary to Anatomical Therapeutic Classification (ATC) and preferred drug name.  
Prior therapies (including over-the-counter medications) used to treat the signs and 
symptoms of PN within the prior 2 years will be reported. Prior medications will be 
summarized by ATC level and preferred drug name and listed. 
Concomitant medications will be summarized by ATC level and preferred drug name and 
listed. Concomitant medication use will be quantified and analyzed. 
56


Menlo Therapeutics Inc. 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 55 
8.7 
Treatment Compliance and Extent of Exposure 
Compliance with study drug dosing will be determined based on tablet counts recorded on the 
eCRF. Compliance will be calculated by analyzing expected number of tablets returned versus 
actual number of tablets returned. Summaries of treatment exposure will also be produced.  
8.8 
Efficacy Analyses  
All efficacy endpoints will be summarized within the ITT and PP populations using 
descriptive statistics by time point and treatment. Results including averaged imputed values 
will be summarized at Baseline, Week 2 (if available), 4, 10 and Follow-up, and the change 
from baseline for these measures will be summarized at Week 2, 4, 10 and Follow-up. The 
WI-NRS and change from baseline will also be presented for each study day.  
8.8.1 
Primary Efficacy 
The difference in the primary efficacy outcome measure (WI-NRS 4-point responder rate at 
Week 10) will be tested using a CMH test controlling for the ‘as randomized’ stratification 
factors. Conceptually the hypotheses being tested are: 
H0:PPlacebo ≥ PSerlopitant  
Ha: PPlacebo < PSerlopitant 
where PPlacebo is the percent of placebo responders and PSerlopitant is the similar percent for 
serlopitant. The primary endpoint will utilize the missing data rules as outlined in Section 8.2.  
8.8.2 
Key Secondary Efficacy 
The differences between treatment groups for the key secondary efficacy endpoint, Week 4 
WI-NRS 4-point responder rate, will be the CMH test identical to the one used for the 
primary endpoint.  
The remaining key secondary efficacy endpoints will be analyzed using an analysis of 
covariance (ANCOVA) model with treatment group and stratification factor as fixed effects and 
the respective baseline values as a covariate.  Both least squares means and observed means will 
be presented. 
To confirm the assumptions for the ANCOVA model (i.e., that the errors are normally 
distributed with equal variances), residuals will be examined using the Shapiro-Wilk test. If 
there is overwhelmingly strong evidence that the assumptions are not satisfied, the data will 
be rank-transformed prior to submitting to the ANCOVA. Results of the rank-transformed 
analysis then will be considered the primary analysis; however, results of the non-rank-
transformed analysis will also be presented.  
The preceding tests are to be conducted for the ITT population and the PP populations. 
57


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 56 
8.8.3 
Additional Secondary Efficacy  
Additional secondary efficacy endpoints will include analyses analogous to the primary and 
key secondary efficacy analyses. Additional secondary efficacy endpoints which may be 
drawn from the primary and key secondary imputations (including all WI-NRS endpoints) 
will be analyzed using the imputed data. Additional secondary efficacy endpoints otherwise 
will be analyzed using available data. P-values will be included for descriptive purposes 
only. 
8.9 
Sensitivity Analyses  
8.9.1 
Last Observation Carried Forward  
In the first set of sensitivity analysis, missing values will be imputed using LOCF. Data will 
be imputed using LOCF unless the subject withdrew from the study due to a lack of efficacy, 
or the subject used an excluded therapy to treat worsening of pruritus or PN, in which case 
their responder status will be defined as non-responder. Each primary and key secondary 
endpoint will be analyzed as it was using the multiply imputed data.  
8.9.2 
Repeated Measures Analysis 
The second set of sensitivity analyses will be performed on observed data. 
The dichotomized primary/key secondary efficacy endpoints will each be analyzed with a 
repeated measures logistic regression model (generalized estimating equations), with the 
dichotomized endpoint as the dependent variable and treatment, stratification factor and visit 
(Weeks 2, 4, 10) as independent factors 
The remaining key secondary efficacy variables will be analyzed with a repeated measures 
ANCOVA, with treatment, stratification factor and applicable timepoints as independent 
factors and a covariate of baseline value. 
8.9.3 
Tipping Point Analysis 
A sensitivity analysis for the handling of missing data for the primary efficacy endpoint will 
be carried out using a tipping point analysis. 
8.10 
Safety Analyses  
8.10.1 
Adverse Events  
The incidence of all AEs and treatment-related AEs will be tabulated by treatment received. 
These AEs will be classified by system organ class and preferred term using the Medical 
Dictionary for Regulatory Activities (MedDRA). For incidence reporting, if a subject 
reported more than one AE that was coded to the same system organ class or preferred term, 
the subject will be counted only once for that specific system organ class or preferred term. 
An overview of AEs, which includes subject incidence of AEs, treatment-related AEs, AEs 
by severity, SAEs, deaths, and AEs leading to discontinuation, will be presented.  
58


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 57 
SAEs will be listed and summarized in a similar manner to AEs. 
8.10.2 
Clinical Safety Laboratory Results  
Clinical safety laboratory values will be measured by a central laboratory. Summary statistics 
for actual values and for changes from baseline will be tabulated for laboratory results by 
scheduled visit. Graphs of laboratory values over time will also be produced.  
Subjects with clinical laboratory values outside of the normal reference range at any 
post-baseline assessment will be summarized. Shifts from baseline laboratory values will be 
tabulated. 
8.10.3 
Vital Signs  
The observed data and change from baseline for each measurement day will be summarized 
with descriptive statistics.  
8.10.4 
Electrocardiograms  
The overall ECG assessment (abnormal or normal) will be summarized and descriptively 
characterized, along with a summary of how many subjects developed a post treatment 
abnormal result.  
8.10.5 
Physical Exams  
Physical exam finds will be recorded by the sites within medical history or adverse events and 
otherwise not summarized. 
8.10.6 
Menstrual Diaries 
Menstrual diary dates will be used to summarize number and duration of menses.  
8.10.7 
Hospital Anxiety and Depression Scale   
The observed data and change from baseline for the HADS will be summarized with 
descriptive statistics by scheduled visit. Both the Depression and the Anxiety subscales will 
be reported. 
8.10.8 
Epworth Sleepiness Scale   
The observed data and change from baseline for the ESS will be summarized with descriptive 
statistics by scheduled visit.  
8.11 
Population Pharmacokinetics Analysis  
The plasma concentrations of serlopitant and metabolites will be combined with the data 
from other serlopitant clinical studies for population PK analysis with PK endpoint of 
individual model parameter estimates and covariates identification. A specific population PK 
data analysis plan will be developed that will outline the detailed approach to data handling, 
59


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 58 
model development and diagnostics, individual model parameter estimation, exploration of 
covariate effects, and final model evaluation techniques. The population PK analysis report 
will not be a part of the clinical study report. 
9 
ADMINISTRATIVE ASPECTS 
9.1 
Changes to the Protocol 
Protocol amendments must be made only with the prior written approval of the Sponsor. An 
investigator signature will be obtained for the initial protocol and any amendments. 
Substantial amendments will be provided to the appropriate regulatory authorities. No 
protocol changes affecting the following will be made without the written approval of the 
Sponsor and the responsible IRB or EC: 
• Safety and/or eligibility of subjects 
• Data integrity 
• Study design or conduct 
• Willingness of a subject to participate in the study 
9.2 
Study Termination 
The Sponsor has the right to terminate this study at any time. Reasons may include, but are 
not limited to, evidence of a potential safety risk in this study or other serlopitant studies or 
poor enrollment. The study may be terminated at the request of the US Food and Drug 
Administration, the European Medicines Agency, other Competent Authorities or regulatory 
agencies with appropriate jurisdiction, or if the approval to manufacture or to import study 
drug is revoked by those with jurisdiction. A written statement fully documenting the reasons 
for study termination will be provided to the IRB or EC. 
9.3 
Monitoring and Auditing Procedures 
The Sponsor will designate study monitors who will be responsible for monitoring the 
conduct of this study. A separate study Monitoring Plan will include details regarding the 
responsibilities of the study monitors, investigator responsibilities in providing access to 
records and addressing issues identified, the frequency and structure of monitoring visits, and 
adherence to subject confidentiality as outlined in the Informed Consent Form (ICF). 
9.4 
Transfer of Obligations 
The Sponsor will delegate certain aspects of study oversight to Contract Research 
Organizations (CROs). The specific responsibilities will be detailed in Transfer of 
Obligations documents.  
60


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 59 
9.5 
Informed Consent 
The purpose of the study, the procedures to be carried out, and any potential risks of study 
participation will be described in non-technical terms in the ICF. After having reviewed and 
understood the ICF, subjects will be required to read, sign, and date an IRB-approved or 
EC-approved consent form before any study-specific procedures are carried out. Subjects 
will be assured that they may withdraw from the study at any time without jeopardizing 
medical care related to or required as a result of study participation. The original signed 
consent form will be maintained in the investigator site file. Copies of signed consent forms 
will be provided to the subject. 
9.6 
Communication with the Institutional Review Board or Ethics Committee 
The IRB or EC is constituted and operates in accordance with the principles and 
requirements described in the ICH E6 guideline. The protocol, ICF, other written subject 
information, and any proposed study advertising material must be submitted to the IRB or 
EC for written approval. IRB or EC approval of these documents will be provided to the 
investigator. The study will not start until the IRB or EC has granted its approval of the study 
materials and procedures. 
Protocol amendments will be submitted to the IRB or EC as explained in Section 9.1. SAE 
information will be submitted to the IRB or EC as explained in Section 7.4.  
If the study is terminated by the Sponsor, a written statement fully documenting the reason(s) 
for study termination will be provided to the IRB or EC. 
9.7 
Disclosure and Confidentiality 
By signing this protocol, the investigator agrees to keep all information provided by the 
Sponsor in strict confidence and to require the same confidentiality from site staff and the 
IRB or EC. Study documents provided by the Sponsor (e.g. protocol, IB, eCRFs) will be 
stored appropriately to ensure their confidentiality. The information provided by the Sponsor 
to the investigator may not be disclosed to others without direct written authorization from 
the Sponsor, except to the extent necessary to obtain informed consent from subjects who 
wish to participate in the study.  
The investigator must ensure that the subjects be identified by a unique subject study 
number. Other study-related documents that may contain confidential participant information 
(e.g. signed ICFs) will be kept in strict confidence by the investigator and be stored in a 
secure location with access restricted to the study staff. 
9.8 
Records and Electronic Case Report Forms 
All study data except central laboratory, PK, eDiary, photography and ECG data will be 
recorded in an eCRF system. Data will be entered at the site by the appropriately designated 
and trained site personnel. All source documents from which eCRF entries are derived should 
be placed in the subject’s medical records. eCRFs will be completed for every subject 
screened in the study. 
61


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 60 
The study monitor will review all eCRFs in detail and will have access to participant medical 
records, laboratory data, and other source documentation to allow required eCRF fields to be 
verified by source data. 
Data consistency and plausibility checks against data entered into the eCRF will be included 
in the eCRF system. Data corrections can be performed in the eCRFs by the site. For each 
instance of data modification, the system requires a reason for change. The system keeps a 
full audit trail of the data values, the date and time of modification, and the electronic 
signature of the user who performed the change. 
After a full review of the eCRFs by the study monitor and resolution of any data 
clarifications, the investigator will review, sign, and approve the subject’s eCRF. All 
essential documents, source data, clinical records, and laboratory data will be retained by the 
site in accordance with the ICH E6 guideline and the site’s data retention policies. These 
records must be available for inspection by the Sponsor, monitor, and regulatory authorities. 
Further detail regarding data management and eCRFs is included in the Data Management 
Plan. 
9.9 
Good Clinical Practices and Ethical Study Conduct 
The study procedures outlined in this protocol will be conducted in accordance with 
applicable ICH Guidelines, including ICH E6: Good Clinical Practices. As this study is 
conducted under a US IND, the investigator will also ensure that the basic principles of 
“Good Clinical Practice”, as outlined in 21 CFR 312, subpart D, “Responsibilities of 
Sponsors and Investigators”, 21 CFR, part 50 and 21 CFR, part 56 are adhered to. 
The study procedures outlined in this protocol will also be conducted in accordance with the 
principles of the Declaration of Helsinki. 
9.10 
End of Study Notification 
The Sponsor will notify appropriate regulatory authorities and the IRB or EC within 90 days 
from the end of the clinical study. The end of the clinical study is defined as the last study 
visit for the last subject. 
9.11 
Publication of Results 
All publications (e.g. manuscripts, abstracts, oral/slide presentations, book chapters) based on 
this study or relying on data from this study must be submitted to the Sponsor for review and 
release before submission for publication. The Sponsor is responsible for final approval of all 
publications. 
9.12 
Final Report 
A clinical trial summary report will be provided to the appropriate regulatory authorities 
within one year of the end of the clinical study. 
62


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 61 
10 
REFERENCES 
Abadía Molina F, Burrows NP, Jones RR, Terenghi G, Polak JM. Increased sensory 
neuropeptides in nodular prurigo: A quantitative immunohistochemical analysis. Br J 
Dermatol. 1992;127:344-351. 
Akiyama T, Nguyen T, Curtis E, et al. A central role for spinal dorsal horn neurons that express 
neurokinin-1 receptors in chronic itch. Pain. 2015;156(7):1240-1246. 
Andoh T, Nagasaw T, Satoh M, Kuraishi Y. Substance P induction of itch-associated response 
mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther. 
1998;286(3):1140-1145. 
Bergasa NV. The itch of liver disease. Semin Cutan Med Surg. 2011;30(2):93-98. 
Booken N, Heck M, Nicolay JP, et al. Oral aprepitant in the therapy of refractory pruritus in 
erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011;164(3):665-667. 
Common Terminology Criteria for Adverse Events (CTCAE). 4.03 ed: National Institutes of 
Health; 2010. 
Crowe R, Parkhouse N, MacGrouther D, Burnstock G. Neuropeptide-containing nerves in painful 
hypertrophic human scar tissue. Br J Dermatol. 1994;130:444-452. 
Dazzi C, Erma D, Piccinno R, Veraldi S, Caccialanza M. Psychological factors involved in 
prurigo nodularis: A pilot study. J Dermatolog Treat. 2011;22(4):211-214. 
Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Eng J Med. 
2009;361(14):1415-1416. 
El-Nour H, Lundeberg L, Al-Tawil R, Granlund A, Lonne-Rahm SB, Nordlind K. Upregulation 
of the axonal growth and the expression of substance P and its NK1 receptor in human 
allergic contact dermatitis. Immunopharmacol Immunotoxicol. 2006;28(4):621-631. 
Emend® (aprepitant) capsule for oral use. U.S. Prescribing Information. Merck Sharp and Dohme 
Corp. Revised August 2015. 
Examples of clinical inhibitors for P450-mediated metabolisms (for concomitant use clinical DDI 
studies and/or drug labeling) (9/26/2016). U.S. Food and Drug Administration; 2016. 
Feldmeyer L, Werner S, Kamarashev J, French LE, Hofbauer GF. Atopic prurigo nodularis 
responds to intravenous immunoglobulins. Br J Dermatol. 2012;166(2):461-462. 
Fostini AC, Girolomoni G, Tessari G. Prurigo nodularis: an update on etiopathogenesis and 
therapy. J Dermatolog Treat. 2013;24(6):458-462. 
Gerber PA, Buhren BA, Cevikbas F, et al. Preliminary evidence for a role of mast cells in 
epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol. 
2010;63(1):163-165. 
Goeksel T, Xie W, Ritzerfeld M, Heidenreich S, Mann H. Prurigo nodularis and dialyzer 
membrane. Blood Purif. 2013;35(2):26-27. 
Halvorsen JA, Aasebø W. Oral tacrolimus treatment of pruritus in prurigo nodularis. Acta Derm 
Venereol. 2015;95(7):866-867. 
Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol. 2001;33(6):555-576. 
63


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 62 
Hökfelt T, Pernow B, Wahren J. Substance P: A pioneer amongst neuropeptides. J Intern Med. 
2001;249(1):27-40. 
Hon KL, Lam MC, Wong KY, Leung TF, Ng PC. Pathophysiology of nocturnal scratching in 
childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance 
P. Br J Dermatol. 2007;157(5):922-925. 
Iking A, Grundmann S, Chatzigeorgakidis E, et al. Prurigo as a symptom of atopic and non-
atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad 
Dermatol Venereol. 2013;27(5):550-557. 
Jorgensen KM, Egeberg A, Gislason GH, Skov L, Thyssen JP. Anxiety, depression and suicide in 
patients with prurigo nodularis. J Eur Acad Dermatol Venereol. 2017;31(2):e106-107. 
Jorizzo JL, Gatti S, Smith EB. Prurigo: a clinical review. J Am Acad Dermatol. 1981;4(6): 
723-728. 
Lee MR, Shumack S. Prurigo nodularis: a review. Australas J Dermatol 2005;46:211-220. 
Lim VM, Maranda EL, Patel V, Simmons BJ, Jimenez JJ. A review of the efficacy of 
thalidomide and lenalidomide in the treatment of refractory prurigo nodularis. Dermatol 
Ther (Heidelb). 2016;6(3):397-411. 
Lotts T, Ständer S. Research in practice: substance P antagonism in chronic pruritus. J Dtsch 
Dermatol Ges. 2014;12(7):557-559. 
M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals. Food and Drug Administration; 2010. 
Matts JP, Lachin JM. Properties of permuted-block randomization in clinical trials. Control Clin 
Trials. 1988;9(4):327-344. 
Navigant Consulting, Inc. (2017). Report: Market Landscapes and Evaluation of Serlopitant for 
Use in Atopic Dermatitis and Prurigo Nodularis. (proprietary data). 
PASS 13 Power Analysis and Sample Size Software [computer program]. Kaysville, Utah, USA, 
ncss.com/software/pass.: NCSS, LLC; 2014. 
Recommendations related to contraception and pregnancy testing in clinical trials. Clinical Trial 
Facilitation Group; 2014. 
Rowland Payne CM, Wilkinson JD, McKee PH, Jurecka W, Black MM. Nodular prurigo – a 
clinicopathological study of 46 patients. Br J Dermatol. 1985;113(4):431-439. 
Saco M, Cohen G. Prurigo nodularis: Picking the right treatment. J Fam Pract. 2015;64(4):221-
226. 
Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to 
biological cancer treatments: a pilot study. Lancet Oncol. 2012;13(10):1020-1024. 
Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in 
lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical 
cutaneous neuropathy. Br J Dermatol. 2011;165(1):85-91. 
Slattery MJ, Essex MJ, Paletz EM, et al. Depression, anxiety, and dermatologic quality of life in 
adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011;128(3):668-671. 
64


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 2.1 02 July 2018 
 
Page 63 
Spring P, Gschwind I, Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with 
methotrexate. Clin Exp Dermatol. 2014;39:468-473. 
Ständer S, Pogatzki-Zahn E, Stumpf A, et al. Facing the challenges of chronic pruritus: a report 
from a multi-disciplinary medical itch centre in Germany. Acta Derm Venereol. 
2015b;95(3):266-271. 
Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 
1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968. doi: 
10.1371/journal.pone.0010968.  
Ständer S, Weisshaar E, Raap U. Emerging drugs for the treatment of pruritus. Exp Opin Emerg 
Drugs. 2015a;20:515-521. 
Ständer S, Stumpf A, Osada N, et al. Gender differences in chronic pruritus: women present 
different morbidity, more scratch lesions and higher burden. Br J Dermatol. 
2013;168(6):1273-1280. 
Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their 
receptors: contributions to physiological control and the mechanisms of disease. Physiol 
Rev. 2014;94(1):265-301. 
Tan WS, Tey HL. Extensive prurigo nodularis: characterization and etiology. Dermatol. 
2014;228(3):276-280. 
Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: Evidence of its effectiveness in 
patients with refractory pruritus continues. J Am Acad Dermatol. 2012;66(1):e14-15. doi: 
10.1016/j.jaad.2011.01.016. 
U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Vol 20172010. 
Vaidya DC, Schwartz RA. Prurigo nodularis: a benign dermatosis derived from a persistent 
pruritus. Acta Dermatovenerol Croat. 2008;16(1):38-44. 
Wallengren J. Prurigo: Diagnosis and management. Am J Clin Dermatol. 2004;5(2):85-95.  
Ward RS, Tuckett RP, English KB, Johansson O, Saffle JR. Substance P axons and sensory 
threshold increase in burn-graft human skin. J Surg Res. 2004;118(2):154-160. 
Zancanaro PC, McGirt LY, Mamelak AJ, Nguyen RH, Martins CR. Cutaneous manifestations of 
HIV in the era of highly active antiretroviral therapy: An institutional urban clinical 
experience. J Am Acad Dermatol. 2006;54(4):581-588. 
Zeidler C, Ständer S. The pathogenesis of prurigo nodularis--'Super-Itch' in exploration. Eu J 
Pain. 2016;20(1):37-40. 
 
65


Menlo Therapeutics Inc 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 64 
APPENDIX A 
SCHEDULE OF ACTIVITIES AND ASSESSMENTS 
Table 2 
Schedule of Visit Activities 
Examination 
Screening 
Mid-
ScreeningTC  
Baseline1  
Week 1TC 
(± 3 days) 
Week 2 
(± 3 days) 
Week 4 
(± 3 days) 
Week 6 
(± 3 days) 
Week 10 
(± 7 days) 
F/U2 
Early Treatment 
Discontinuation 
Demographics 
X 
Informed consent 
X 
WI-NRS3 
X 
X 
X 
X 
X 
X 
X 
X 
DLQI 
X 
X 
X 
X 
HADS, ESS 
X 
X 
X 
X 
X 
ECG 
X 
X 
X 
X 
X 
X 
Vital signs 
X 
X 
X 
X 
X 
X 
X 
X 
Medical history (and prior medications)  
X 
X 
X 
Physical exam4 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant medications  
X 
X 
X 
X 
X 
X 
X 
X 
Labs5 
X 
X 
X 
X 
X 
Urine pregnancy test6 
X 
X 
X 
 X 
X 
X 
X 
PK blood draw  
X 
X 
X 
Review of I/E criteria 
X 
X 
X 
IGA PN-A and IGA PN-S 
X 
X 
X 
X 
X 
X 
Photography (selected sites) 
X 
X 
X 
X 
Dispense/review menstrual diary (if 
applicable) 
X 
X 
X 
X 
X 
X 
X 
X 
Dispense/collect eDiary  
X 
X  
X 
eDiary review/compliance7 
X 
X 
X 
X 
X 
X 
X 
X 
Dispense and/or collect study drug 
X 
X 
X 
X 
X 
X 
Review study drug compliance 
X 
X 
X 
X 
AEs/SAEs8 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
TCTelephone Contact: The Mid-Screening telephone contact should only occur for subjects who require a washout longer than 2 weeks, at least 15 days prior to the scheduled Baseline visit.  
1All visits and windows should be scheduled based on the Baseline Visit (Day 1) 
2The Follow-up (F/U) visit occurs 21-35 days (+ 7 days) after the Week 10 visit or the last dose of study drug for subjects who discontinue study drug early.  
3WI-NRS at Screening visit will be collected manually on paper for Inclusion/Exclusion criteria. All subsequent WI-NRS are collected daily via eDiary. 
4Screening physical exam is complete and includes height and weight; other physical exams are targeted and include weight.  
5Labs are ideally performed in the morning, particularly at visits with endocrine assessments (including Reproductive Endocrinology for females under 55 at age of consent) at Screening, Week 10 
and Follow Up.  Iron Studies, serum IgE and Serology labs are done only at Screening visit; endomysial antibody test and other optional studies only performed at Screening;  
6Female subjects of childbearing potential only. Serum pregnancy test is required for positive or equivocal results 
7See Table 3 for eDiary assessments 
8During the period between informed consent and first study drug dose, only SAEs caused by a protocol-mandated intervention will be collected. 
66


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 2.1 02 July 2018 
 
Page 65 
Table 3 
Schedule of eDiary Assessments 
An eDiary device is provided to subjects at the Screening visit and collected at the Follow-up visit.   
Device 
Assessment 
Frequency and Duration of Assessment 
eDiary 
WI-NRS 
Once daily from Screening/Mid-Screening visit through the Follow-up visit 
eDiary 
Dosing 
Once daily from Baseline visit through Week 10 visit or study drug discontinuation 
 
 
67


Menlo Therapeutics Inc 
Confidential 
Protocol MTI-106 
Version 2.1 02 July 2018 
Page 66 
APPENDIX B  
LIST OF STRONG CYP3A4 INHIBITORS 
The list of strong CYP3A4 inhibitors is based on the FDA list effective September 26, 2016, 
Examples of clinical inhibitors for P450-mediated metabolisms (for concomitant use clinical 
DDI studies and/or drug labeling (“Examples of clinical inhibitors for P450-mediated 
metabolisms (for concomitant use clinical DDI studies and/or drug labeling (9/26/2016)”).  
Note: This Appendix may be replaced if applicable (e.g., if updated by the FDA) through site 
communications without requiring a protocol amendment. 
1.
boceprevir
2.
clarithromycin
3.
cobicistat
4.
conivaptan
5.
danoprevir and ritonavir
6.
diltiazem
7.
elvitegravir and ritonavir
8.
idelalisib
9.
indinavir and ritonavir
10.
itraconazolea
11.
ketoconazolea
12.
lopinavir and ritonavir
13.
nefazodone
14.
nelfinavir
15.
paritaprevir and ritonavir and (ombitasvir and/or dasabuvir)
16.
posaconazolea
17.
ritonavir
18.
saquinavir and ritonavir
19.
telaprevir
20.
tipranavir and ritonavir
21.
troleandomycin
22.
voriconazolea
23.
regular grapefruit juice consumption (note: The effect of grapefruit juice varies
widely among brands and is concentration-, dose-, and preparation-dependent.
Grapefruit juice may be a strong or a moderate CYP3A inhibitor depending on the
preparation)b
a 
When administered topically, it may not be considered a strong CYP3A4 inhibitor due to limited systemic 
absorption. 
b 
The occasional consumption of grapefruit juice or the consumption of grapefruit or other citrus fruits (e.g., 
pomelo, lemon, lime, Seville orange, bitter orange, starfruit) is not contraindicated. 
68


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 2.1 02 July 2018 
 
Page 67 
APPENDIX C  
WORST ITCH NUMERIC RATING SCALE QUESTIONNAIRE 
 
69


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 2.1 02 July 2018 
 
Page 68 
APPENDIX D 
INVESTIGATOR’S GLOBAL ASSESSMENT OF PRURIGO 
NODULARIS: ACTIVITY AND STAGE 
Score 
Category 
Description: Activity (IGA PN-A) 
0 
Clear 
No nodules have excoriations or crusts  
1 
Almost 
Clear 
Very small proportion of nodules have excoriations or crusts (up to 
approximately 10% of all nodules) 
2 
Mild 
Minority of nodules have excoriations or crusts (approximately 11- 25% of 
all nodules) 
3 
Moderate 
Many nodules have excoriations or crusts (approximately 26- 75% of all 
nodules) 
4 
Severe 
Majority of nodules have excoriations or crusts (approximately 76-100% of 
all nodules) 
 
Score 
Category 
Description: Stage (IGA PN-S) 
0 
Clear 
No nodules (0 nodules) 
1 
Almost 
Clear 
Rare, flattened lesions, with no more than 5 dome-shaped palpable nodules 
(approximately 1-5 nodules) 
2 
Mild 
Few, mostly flattened lesions, with small number of dome-shaped palpable 
nodules (approximately 6-19 nodules) 
3 
Moderate 
Many lesions, partially flattened, and dome-shaped palpable nodules 
(approximately 20-100 nodules) 
4 
Severe 
Abundant lesions, majority are dome-shaped palpable nodules (over 
100 nodules) 
 
70


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 2.1 02 July 2018 
 
Page 69 
APPENDIX E 
DERMATOLOGY LIFE QUALITY INDEX 
Different language versions may be used. 
 
71


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 2.1 02 July 2018 
 
Page 70 
APPENDIX F 
HOSPITAL ANXIETY AND DEPRESSION SCALE 
 
To be used under license. 
  
72


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 2.1 02 July 2018 
 
Page 71 
APPENDIX G  
EPWORTH SLEEPINESS SCALE   
 
73


 
1 
CLINICAL STUDY PROTOCOL MTI-106 
SUMMARY OF CHANGES 
 
Drug Product Name: 
Serlopitant 
 
Study Title:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, 
AND TOLERABILITY OF SERLOPITANT FOR THE 
TREATMENT OF PRURITUS IN ADULTS WITH 
PRURIGO NODULARIS  
 
IND No.: 
 
 
117780 
EudraCT No.:  
 
2017-004210-25 
ClinicalTrials.gov ID:  
NCT03677401 
Protocol Version: 
 
3.0 
Protocol Date: 
 
21 March 2019 
Replaces Version/Date: 
2.1 / 02 July 2018 
 
74


Serlopitant 
 
Menlo Therapeutics Inc. 
MTI-106 Protocol, Summary of Changes Version 2.1 to Version 3.0 
 
 
 
2 
The following changes were made to the MTI-106 Clinical Study Protocol from Version 2.1 to Version 3.0. 
KEY CHANGES: 
Section(s) 
Summary of Change 
Reason for Change 
Protocol Synopsis  
Updated consistent with changes to the protocol body. 
Ensure consistency between synopsis and protocol 
body.  
8.8.2 Key 
Secondary Efficacy; 
8.9.2 Repeated 
Measures Analysis 
Removed two key secondary efficacy endpoints 
These secondary efficacy endpoints were unnecessary 
for evaluation of the study drug. 
4.1 Study 
Population 
Increased study population to 280 subjects 
In completed Phase 2 pruritus studies, with variations 
in screening methodologies, placebo responder rates 
have varied between 
% and 
% and serlopitant 
rates between 
% and 
%. The sample size was 
recalculated as a result of this observation. 
8. Statistical 
methods; 8.11 
Interim Analyses 
Added optional interim analysis 
An interim analysis may be performed to assess the 
adequacy of the sample size assumptions. 
8.1 Decision Rule 
and Sample Size 
Removed two key secondary efficacy endpoints, increased 
sample size 
Please see comments for section 4.1 and 8/8.1. 
 
8.2 Statistical 
methods 
Updated Syntax to replace individual day calculations with 
week 1 calculation 
Correction as key secondary endpoints were removed. 
 
ADMINISTRATIVE CHANGES: 
Section(s) 
Summary of Change 
Title page 
Updated protocol version number and release date, added Clinical Trials.gov ID number 
Signature Page for Investigator(s)   
Updated protocol version number and release date, added Clinical Trials.gov ID number 
Sponsor Protocol Approval Signature(s) 
Updated protocol version number and release date, added Clinical Trials.gov ID number 
Table of Contents 
Updated  
75
CCI
CCI
CCI
CCI


Serlopitant 
 
Menlo Therapeutics Inc. 
MTI-106 Protocol, Summary of Changes Version 2.1 to Version 3.0 
 
 
 
3 
Throughout  
Updated protocol version in footer; Edited formatting and corrected minor typos and 
inconsistencies 
 
76




Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 3.0/21 March 2019 
 
Page 2 
SIGNATURE PAGE FOR PRINCIPAL INVESTIGATOR(S) 
 
TITLE:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, 
AND TOLERABILITY OF SERLOPITANT FOR THE 
TREATMENT OF PRURITUS IN ADULTS WITH 
PRURIGO NODULARIS  
IND No.: 
 
 
117780 
Eudra CT: 
 
 
2017-004210-25 
ClinicalTrials.gov ID:  
NCT03677401 
Protocol No.:  
 
MTI-106 
Protocol Version/Date: 
Verson 3.0/21 March 2019 
Development Phase:  
Phase 3 
Sponsor: 
 
 
Menlo Therapeutics Inc. 
200 Cardinal Way, 2nd Floor 
Redwood City, CA 94063 
USA  
 
I have read the protocol and agree to conduct this study in accordance with the protocol, all 
relevant laws and regulations in force at the time, International Conference on Harmonisation 
Guidelines for Good Clinical Practices, and the Declaration of Helsinki.  
 
 
 
Principal Investigator’s printed name 
 
 
 
 
 
 
Principal Investigator’s signature 
 
Date (DD-MMM-YYYY) 
 
  
78




Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 3.0/21 March 2019 
 
Page 4 
PROTOCOL SYNOPSIS 
Study Title: 
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, 
Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults 
With Prurigo Nodularis  
Protocol Number: 
MTI-106 
Sponsor: 
Menlo Therapeutics Inc. 
Development Phase: 
Phase 3 
Study Objectives: 
Efficacy objective: To assess the efficacy of serlopitant for the treatment of 
pruritus in adults with prurigo nodularis. 
Safety objective: To assess the safety and tolerability of repeated oral doses of 
serlopitant in adults with prurigo nodularis.  
Study Design: 
This is a double-blind, randomized, placebo-controlled study to assess the 
efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in 
adults with prurigo nodularis (PN). Subjects who meet the study entry criteria 
will be randomized in a 1:1 ratio to receive daily oral doses of serlopitant 5 mg 
or placebo for 10 weeks. After completion of the treatment period or early 
discontinuation of study drug treatment, all subjects will enter a 3- or 5-week 
follow-up period.  
The study will consist of three periods, for a total study period of 15 to 
19 weeks: 
 
Screening period: 2-4 weeks 
 
Treatment period: 10 weeks 
 
Follow-up period: 3 or 5 weeks  
 
During the screening period, all subjects will undergo eligibility evaluation and 
will be assessed for chronic pruritic conditions frequently associated with PN. 
Subjects who present with idiopathic PN at screening may require additional 
assessments as deemed necessary by the investigator (e.g. endomysial antibody 
with reflex to titer for subjects with signs or symptoms of dermatitis 
herpetiformis, skin biopsy for subjects with signs or symptoms of bullous 
pemphigoid or cutaneous T-cell lymphoma, urea breath test for 
Helicobacter pylori, or allergy testing).  
All screening procedures must be completed within 31 days before the Baseline 
visit. The minimum screening period for all subjects is 14 days to allow for 
collection of electronic diary (eDiary) screening data. Subjects who require a 
screening period longer than 14 days will have a telephone contact at least 15 
days prior to the scheduled Baseline visit to remind them to complete the eDiary 
as previously instructed at the Screening visit. 
Subjects will be provided an eDiary at the Screening visit. Subjects must be 
willing and able to complete the eDiary every day within a consistent 
timeframe, and comply with restrictions on allowable concomitant therapies, for 
the duration of the study.  
At the Baseline visit (Day 1), eligible subjects will be randomly assigned to 
receive study drug (serlopitant 5 mg or placebo). Subjects will take a loading 
dose (3 tablets taken orally) at the site on the first day of the treatment period 
(Day 1). Starting on Day 2, subjects will take one tablet per day. Study drug 
may be taken with or without food. 
80


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 5 
The primary efficacy endpoint will be assessed at Week 10 of treatment.  
Subjects who complete the 10-week treatment period and required follow-up 
period may be given the opportunity to enroll in a one-year open-label safety 
study with daily oral doses of serlopitant 5 mg. 
Safety Review: 
An internal safety monitoring team consisting of representatives from Menlo 
Therapeutics Inc. and its designees will monitor blinded safety data on a regular 
basis throughout the study. 
Planned Sample Size: 
Approximately 280 subjects will be randomized. 
Study Population: 
The study will consist of adult subjects with pruritus associated with PN.  
Inclusion Criteria (Subjects must meet the following criteria to be randomized 
into the study): 
1. Male or female, age 18 years or older at consent. 
2. A diagnosis of PN, defined by the presence of at least ten pruriginous 
nodules secondary to chronic pruritus present on at least two different body 
surface areas (e.g. both arms, one arm and one leg, one arm and the anterior 
trunk, or anterior and posterior trunk). 
3. The worst pruritus is identified to be within the areas of the PN lesions.  
4. Subject has idiopathic PN OR the subject has an identified pruritic 
condition associated with the PN and has persistent pruritus despite at least 
6 weeks of optimized and stable treatment of the underlying condition prior 
to the Baseline visit, and is willing to continue the treatment during the 
study.  
5. Worst-Itch Numeric Rating Scale (WI-NRS) score ≥ 7 in the 24-hour 
period prior to the Screening visit. 
6. Average weekly WI-NRS score ≥ 6.5 in each of the 2 weeks (14 days) 
immediately prior to Baseline visit, as recorded in the eDiary. 
7. All female subjects who are of childbearing potential must be willing to 
practice highly effective contraception (i.e., pregnancy prevention method 
with a failure rate of < 1% per year) from the time of the Screening visit 
until 5 weeks after last dose of study drug.   
8. Willing and able (as demonstrated by a ≥ 70% eDiary completion rate in 
the two weeks prior to Baseline visit) to complete daily eDiary entries 
within a consistent timeframe for the duration of the study. 
9. Willing and able (has adequate cognitive ability, in the investigator’s 
opinion) to comply with study visits and study related requirements 
including providing written informed consent. 
Exclusion Criteria (Subjects who meet any of the following criteria are not 
eligible for participation in the study): 
1. Prior treatment with serlopitant. 
2. Active pruritic skin disease, other than PN, within 6 months prior to 
randomization (with the exception of acute dermatoses such as contact 
dermatitis, sunburn, viral exanthem, which have been resolved for longer 
than 4 weeks).  
3. Treatment with any of the following therapies within 4 weeks prior to 
randomization. 
81


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 6 
a. 
Other neurokinin-1 receptor antagonists (e.g., aprepitant, 
fosaprepitant, rolapitant). 
b. Systemic or topical immunosuppressive/immunomodulatory 
therapies (including but not limited to corticosteroids, 
phosphodiesterase-4 inhibitors, cyclosporine, mycophenolate-
mofetil, tacrolimus, pimecrolimus, calcipotriene, methotrexate, 
azathioprine, interferon-gamma, thalidomide, or phototherapy).  
c. 
Systemic therapies with recognized anti-pruritic properties 
(including but not limited to H1 antihistamines, doxepin, 
gabapentin, pregabalin, cannabinoids, kappa-opioid receptor 
agonists, and mu-opioid receptor antagonists (e.g. naloxone, 
naltrexone)). 
d. Strong cytochrome-P 3A4 inhibitors. 
e. 
Use of an indoor tanning facility, or natural sun exposure resulting 
in significant tanning or sunburn. 
4. Treatment with topical anti-pruritic therapies (e.g., menthol, camphor, 
pramoxine, capsaicin) within 2 weeks prior to randomization. 
5. Treatment with biologic therapies within 8 weeks or 5 half-lives prior to 
randomization, whichever is longer. 
6. Treatment with any investigational therapy within 4 weeks (8 weeks for 
investigational biologic therapies) or 5 half-lives prior to randomization, 
whichever is longer. 
7. Serum creatinine, total bilirubin, alanine aminotransferase or aspartate 
aminotransferase > 2.5 times the upper limit of normal during screening. 
8. Untreated or inadequately treated thyroid, adrenal, or pituitary nodules or 
disease, or history of thyroid malignancy. 
9. History of malignancy within 5 years prior to randomization, with the 
exception of actinic keratosis, completely treated and non-metastatic 
cutaneous basal cell carcinoma or squamous cell carcinoma of the skin. 
10. Any known major psychiatric diagnosis, such as major depressive disorder, 
bipolar disorder, schizophrenia, psychotic disorder, intellectual disability, 
severe alcohol use disorder, which may confound the assessment of 
serlopitant safety or efficacy, or interfere with the subject’s ability to 
comply with protocol-mandated activities, within 3 years prior to 
randomization.  
11. Suicidal ideation within 3 years prior to randomization, or any history of 
suicide attempt. 
12. Documented history of parasitic infection, including skin parasites such as 
scabies, within 8 weeks prior to randomization. 
13. Presence of any medical condition or disability that, in the investigator’s 
opinion, could interfere with the assessment of safety or efficacy in this trial 
or compromise the safety of the subject. 
14. History of hypersensitivity to serlopitant or any of its components. 
15. Currently pregnant or breastfeeding female subject. 
16. Planned or anticipated major surgical procedure or other activity that would 
interfere with the subject’s ability to comply with protocol-mandated 
82


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 7 
assessments (e.g. extended international travel) during the subject’s 
participation in the study. 
Study Drug: 
Serlopitant 5 mg oral tablets and matching placebo. 
Dosage:  
Serlopitant: 5 mg once daily by mouth for 10 weeks, following a 3-tablet 
loading dose on the first day of the treatment period. 
Matching placebo: Once daily by mouth for 10 weeks, following a 3-tablet 
loading dose on the first day of the treatment period. 
Primary Efficacy 
Endpoint: 
The primary efficacy endpoint is the WI-NRS 4-point responder rate at Week 
10. 
Secondary Efficacy 
Endpoints: 
The key secondary efficacy endpoints are as follows: 
 
WI-NRS 4-point responder rate at Week 4 
 
Change from baseline in Dermatology Life Quality Index (DLQI) to Week 
10 
Additional secondary efficacy endpoints are as follows: 
 
Change from baseline in WI-NRS to other timepoints 
 
WI-NRS 4-point responder rate at Week 2 
 
WI-NRS 3-point responder rate at Weeks 2, 4 and 10 
 
Change from baseline in Investigator’s Global Assessment of PN Activity 
to Weeks 2, 4 and 10 
 
Change from baseline in Investigator’s Global Assessment of PN Stage to 
Weeks 2, 4 and 10 
Safety Endpoints: 
Safety endpoints are as follows: 
 
Incidence of treatment-emergent adverse events and serious adverse events 
(SAEs) 
 
Changes from baseline in clinical laboratory parameters following study 
drug exposure 
 
Changes from baseline in vital sign and electrocardiogram (ECG) 
parameters following study drug exposure 
 
Changes from baseline in the Hospital Anxiety and Depression Scale 
(HADS)  
 
Changes from baseline in the Epworth Sleepiness Scale (ESS) 
Decision Rule and 
Sample Size: 
This study will use a 5% two-sided alpha level. Hierarchical testing in which 
statistical significance for the key secondary efficacy endpoints requires 
statistical significance for the primary endpoint. 
The target sample size of 280 randomized and dosed subjects (140 per group) 
has been determined based upon a 1:1 allocation of subjects to treatment groups 
and a 5% alpha level. Completed Phase 2 studies indicate that placebo responder 
rates vary between 
% and 
% and serlopitant rates between 
% and 
%. 
A sample size of 280 subjects provides >90% power assuming a placebo 
responder rate of 
% and a serlopitant rate of 
%.  
Statistical Methods: 
Efficacy analyses will be based upon an intent-to-treat philosophy. The primary 
efficacy population will be the Intent-to-Treat (ITT) population that will include 
83
CCI
CCI
CCI
CCI
CCI
CCI


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 8 
all randomized subjects who were dispensed study drug. Analyses performed on 
the Per Protocol population will be considered supportive. Subjects will be 
analyzed within the treatment group to which they are randomized. 
Efficacy Analyses: 
The primary efficacy endpoint is a binary variable taking on values of responder 
or non-responder. Subjects will be considered a responder if they have at least a 
4-point reduction in WI-NRS between baseline and Week 10. Missing data 
imputation will be used for subjects who fail to complete the eDiary at Week 10, 
unless the subject withdrew from the study due to a lack of efficacy, or the 
subject used an excluded therapy to treat worsening of pruritus or PN, in which 
case their responder status will be defined as non-responder. The primary 
endpoint will be summarized with descriptive statistics by treatment group and 
study week.  
The difference in the primary efficacy outcome measure between treatment 
groups will be tested using a Cochran Mantel Haenszel test controlling for the 
stratification factors. Testing of the key secondary efficacy endpoints will also 
be employed. 
Safety Analyses: 
The incidence of all adverse events (AEs) and treatment-related AEs will be 
tabulated by treatment received. These AEs will be classified by system organ 
class and preferred term using the Medical Dictionary for Regulatory Activities. 
For incidence reporting, if a subject reported more than one AE that was coded 
to the same system organ class or preferred term, the subject will be counted 
only once for that specific system organ class or preferred term. An overview of 
AEs, which includes subject incidence of AEs, treatment-related AEs, AEs by 
severity, SAEs, deaths, and AEs leading to discontinuation, will be presented.  
Clinical safety laboratory values will be measured by a central laboratory. 
Summary statistics for actual values and for changes from baseline will be 
tabulated for laboratory results by scheduled visit. Graphs of laboratory values 
over time will also be produced.  
Subjects with clinical laboratory values outside of the normal reference range at 
any post-baseline assessment will be summarized. Shifts from baseline 
laboratory values will be tabulated. 
The overall ECG assessment (abnormal or normal) will be summarized along 
with a summary of how many subjects developed a post treatment abnormal 
result.  
Summary statistics for the HADS and ESS actual values and change from 
baseline will be presented by scheduled visit. 
Study Sites: 
Approximately 50 study sites. 
Expected Duration of 
Subject’s Participation 
15-19 weeks: 2-4 weeks of screening, 10 weeks of treatment, and a follow-up 
period of 3 or 5 weeks. 
 
This study will be conducted in accordance with the Guidelines of Good Clinical Practice (GCP). 
84


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 9 
TABLE OF CONTENTS 
CLINICAL STUDY PROTOCOL ............................................................................................1 
SIGNATURE PAGE FOR PRINCIPAL INVESTIGATOR(S) ................................................2 
SPONSOR PROTOCOL APPROVAL SIGNATURE(S) .........................................................3 
PROTOCOL SYNOPSIS...........................................................................................................4 
TABLE OF CONTENTS ...........................................................................................................9 
LIST OF APPENDICES ..........................................................................................................12 
LIST OF FIGURES .................................................................................................................12 
LIST OF TABLES ...................................................................................................................13 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ..........................................14 
1 
INTRODUCTION .................................................................................................16 
1.1 
Pruritus in Prurigo Nodularis ...........................................................................16 
1.2 
Conditions Associated With Prurigo Nodularis ...............................................16 
1.3 
Current Treatment Options for Prurigo Nodularis ...........................................17 
1.4 
Substance P and the Neurokinin-1 Receptor ...................................................17 
1.5 
Serlopitant ........................................................................................................18 
1.5.1 
Serlopitant Background and Nonclinical Summary ............................18 
1.5.2 
Serlopitant Clinical Summary ..............................................................19 
1.5.3 
Serlopitant in Pruritus-Related Studies ................................................19 
2 
STUDY OBJECTIVES ..........................................................................................21 
3 
STUDY DESIGN...................................................................................................21 
3.1 
Overall Study Design .......................................................................................21 
3.2 
Rationale for Study Design and Dose Selection ..............................................22 
3.3 
Study Endpoints ...............................................................................................23 
3.3.1 
Primary Efficacy Endpoint ..................................................................23 
3.3.2 
Key Secondary Efficacy Endpoints .....................................................23 
3.3.3 
Additional Secondary Efficacy Endpoints ...........................................23 
3.3.4 
Safety Endpoints ..................................................................................23 
3.4 
Safety Review ..................................................................................................24 
3.4.1 
Safety Monitoring Team ......................................................................24 
4 
SELECTION OF STUDY POPULATION ...........................................................24 
4.1 
Study Population ..............................................................................................24 
4.2 
Inclusion Criteria .............................................................................................24 
4.3 
Exclusion Criteria ............................................................................................25 
5 
STUDY DRUG ......................................................................................................26 
5.1 
Study Drug Supply, Route of Administration, and Storage.............................26 
5.2 
Labeling and Study Drug Accountability ........................................................27 
5.3 
Dosing Regimen...............................................................................................27 
85


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 10 
5.4 
Dose Modification ...........................................................................................27 
5.5 
Missed or Delayed Doses.................................................................................27 
5.6 
Study Drug Discontinuation ............................................................................27 
5.7 
Prior, Concomitant, and Excluded Therapies ..................................................28 
5.7.1 
Allowed Therapies and Treatment Goals for Underlying 
Conditions ............................................................................................28 
5.7.2 
Excluded Therapies ..............................................................................29 
5.7.3 
Rescue Therapies .................................................................................30 
5.8 
Assignment to Treatment .................................................................................30 
5.8.1 
Randomization .....................................................................................30 
5.8.2 
Blinding................................................................................................30 
5.9 
Treatment Compliance .....................................................................................31 
6 
STUDY SCHEDULE AND ASSESSMENTS ......................................................31 
6.1 
Efficacy Parameters .........................................................................................31 
6.1.1 
Itch Numeric Rating Scale ...................................................................31 
6.1.2 
Investigator’s Global Assessment of PN Activity ...............................31 
6.1.3 
Investigator’s Global Assessment of PN Stage ...................................32 
6.1.4 
Dermatology Life Quality Index ..........................................................32 
6.1.5 
PN Photographs ...................................................................................32 
6.2 
Safety Parameters .............................................................................................32 
6.2.1 
Vital Signs ............................................................................................32 
6.2.2 
Physical Examination...........................................................................33 
6.2.3 
Clinical Laboratory Assessments .........................................................33 
6.2.4 
Electrocardiogram ................................................................................34 
6.2.5 
Hospital Anxiety and Depression Scale ...............................................34 
6.2.6 
Epworth Sleepiness Scale ....................................................................34 
6.3 
Pharmacokinetic Measurements ......................................................................34 
6.4 
Subject Flow Diagram .....................................................................................34 
6.5 
Study Visits ......................................................................................................35 
6.5.1 
Screening Period ..................................................................................35 
6.5.2 
Screening Visit .....................................................................................36 
6.5.3 
Mid-Screening Telephone Contact (for subjects longer than 14 
days in Screening) ................................................................................37 
6.5.4 
Baseline Visit .......................................................................................38 
6.5.5 
Week 1 Telephone Contact Visit .........................................................39 
6.5.6 
Week 2 Visit ........................................................................................39 
6.5.7 
Week 4 Visit ........................................................................................40 
6.5.8 
Week 6 Visit ........................................................................................40 
6.5.9 
Week 10 Visit ......................................................................................41 
86


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 11 
6.5.10 
Follow-up Visit ....................................................................................42 
6.5.11 
Early Termination ................................................................................43 
7 
ASSESSMENT OF SAFETY ................................................................................43 
7.1 
Definitions........................................................................................................43 
7.1.1 
Adverse Event ......................................................................................43 
7.1.2 
Serious Adverse Event .........................................................................44 
7.1.3 
Abnormal Physical Exam, Laboratory, Vital Sign, and 
Electrocardiogram Findings .................................................................45 
7.1.4 
Deaths ..................................................................................................45 
7.1.5 
Pregnancies and Contraception Requirements for Females .................45 
7.1.6 
Worsening of Pruritus or PN................................................................46 
7.2 
Methods and Timing for Recording and Reporting Adverse Events ...............47 
7.2.1 
Adverse Event Reporting Period .........................................................47 
7.2.2 
Eliciting Adverse Events ......................................................................47 
7.2.3 
Assessment of Severity ........................................................................47 
7.2.4 
Assessment of Causality ......................................................................48 
7.3 
Follow-up of Adverse Events and Serious Adverse Events ............................49 
7.4 
Reporting Serious Adverse Events to the Sponsor and Institutional Review 
Board or Ethics Committee ..............................................................................49 
7.5 
Reporting Serious Adverse Events to Regulatory Authorities and Study 
Investigators .....................................................................................................49 
7.6 
Emergency Unblinding ....................................................................................49 
8 
STATISTICAL METHODS ..................................................................................50 
8.1 
Decision Rule and Sample Size .......................................................................50 
8.2 
Handling of Missing Data ................................................................................51 
8.3 
Analysis Populations ........................................................................................52 
8.4 
Subject Disposition ..........................................................................................53 
8.5 
Subject Characteristics .....................................................................................53 
8.6 
Prior and Concomitant Medications ................................................................53 
8.7 
Treatment Compliance and Extent of Exposure ..............................................54 
8.8 
Efficacy Analyses ............................................................................................54 
8.8.1 
Primary Efficacy ..................................................................................54 
8.8.2 
Key Secondary Efficacy ......................................................................54 
8.8.3 
Additional Secondary Efficacy ............................................................55 
8.9 
Sensitivity Analyses .........................................................................................55 
8.9.1 
Last Observation Carried Forward.......................................................55 
8.9.2 
Repeated Measures Analysis ...............................................................55 
8.9.3 
Tipping Point Analysis ........................................................................55 
8.10 
Safety Analyses ................................................................................................55 
87


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 12 
8.10.1 
Adverse Events ....................................................................................55 
8.10.2 
Clinical Safety Laboratory Results ......................................................56 
8.10.3 
Vital Signs ............................................................................................56 
8.10.4 
Electrocardiograms ..............................................................................56 
8.10.5 
Physical Exams ....................................................................................56 
8.10.6 
Menstrual Diaries .................................................................................56 
8.10.7 
Hospital Anxiety and Depression Scale ...............................................56 
8.10.8 
Epworth Sleepiness Scale ....................................................................56 
8.11 
Interim Analyses ..............................................................................................56 
8.12 
Population Pharmacokinetics Analysis ............................................................57 
9 
ADMINISTRATIVE ASPECTS ...........................................................................57 
9.1 
Changes to the Protocol ...................................................................................57 
9.2 
Study Termination ...........................................................................................57 
9.3 
Monitoring and Auditing Procedures...............................................................57 
9.4 
Transfer of Obligations ....................................................................................58 
9.5 
Informed Consent.............................................................................................58 
9.6 
Communication with the Institutional Review Board or Ethics Committee ...58 
9.7 
Disclosure and Confidentiality ........................................................................58 
9.8 
Records and Electronic Case Report Forms ....................................................59 
9.9 
Good Clinical Practices and Ethical Study Conduct ........................................59 
9.10 
End of Study Notification ................................................................................59 
9.11 
Publication of Results ......................................................................................59 
9.12 
Final Report .....................................................................................................60 
10 
REFERENCES ......................................................................................................61 
 
LIST OF APPENDICES 
Appendix A  
Schedule of Activities and Assessments ..............................................64 
Appendix B  
List of Strong CYP3A4 Inhibitors .......................................................66 
Appendix C  
Worst Itch Numeric Rating Scale Questionnaire .................................67 
Appendix D 
Investigator’s Global Assessment of Prurigo Nodularis: Activity 
and Stage ..........................................................................................................68 
Appendix E 
Dermatology Life Quality Index ..........................................................69 
Appendix F 
Hospital Anxiety and Depression Scale ...............................................70 
Appendix G  
Epworth Sleepiness Scale ....................................................................71 
 
LIST OF FIGURES 
Figure 1 
Subject Flow Diagram ...............................................................................35 
 
88


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 13 
LIST OF TABLES 
Table 1 
Adverse Event Grading ..............................................................................48 
Table 2 
Schedule of Visit Activities .......................................................................64 
Table 3 
Schedule of eDiary Assessments ...............................................................65 
  
89


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 14 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation 
Definition 
ACTH 
Adrenocorticotropic hormone, corticotropin 
AD 
Atopic dermatitis  
ADL 
Activities of daily living 
AE 
Adverse event 
ALT 
Alanine aminotransferase  
AMH 
Anti-Mullerian hormone 
ANOVA 
Analysis of variance 
AST 
Aspartate aminotransferase 
ATC 
Anatomical Therapeutic Classification 
CMH 
Cochran Mantel Haenszel test 
CNS 
Central Nervous System 
CRO 
Contract Research Organization 
CYP3A4 
Cytochrome-P 3A4 
DLQI 
Dermatology Life Quality Index 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eDiary 
Electronic diary 
ESS 
Epworth Sleepiness Scale 
FSH 
Follicle-stimulating hormone 
GCP 
Good Clinical Practice 
HAART 
Highly active antiretroviral therapy 
HADS 
Hospital Anxiety and Depression Scale 
HIV 
Human immunodeficiency virus 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonisation 
IGA PN-A 
Investigator’s Global Assessment of Prurigo Nodularis Activity 
IGA PN-S 
Investigator’s Global Assessment of Prurigo Nodularis Stage 
IRB 
Institutional Review Board 
ITT 
Intent-to-Treat 
IWRS 
Interactive Web Response System  
IVIG 
Intravenous immunoglobulin 
LDH 
Lactate dehydrogenase 
LFC 
Liquid filled capsule 
LH 
Luteinizing hormone 
LOCF 
Last Observation Carried Forward 
MCMC 
Markov Chain Monte Carlo 
MedDRA 
Medical Dictionary for Regulatory Activities  
NCI CTCAE 
National Cancer Institute Common Terminology Criteria for Adverse Events 
NK1-R 
Neurokinin-1 receptor 
90


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 15 
NOAEL 
No observed adverse effect level 
NRS 
Numeric Rating Scale  
PET 
Positron Emission Tomography 
PI 
Principal Investigator 
PD 
Pharmacodynamics 
PDE-4 
Phosphodiesterase-4 
PK 
Pharmacokinetics 
PN 
Prurigo nodularis 
PP 
Per Protocol 
QOL 
Quality of life 
RO 
Receptor occupancy 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SP 
Substance P 
TEAE 
Treatment-emergent adverse event 
TSH 
Thyroid stimulating hormone 
ULN 
Upper limit of normal 
US 
United States 
VAS 
Visual Analog Scale 
WI-NRS 
Worst-Itch Numeric Rating Scale 
91


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 16 
1 
INTRODUCTION 
1.1 
Pruritus in Prurigo Nodularis 
Prurigo nodularis (PN) is a distinctive and easily diagnosable chronic skin condition 
characterized by the presence of multiple highly pruritic and often symmetrically distributed 
nodules and papules on the skin (Jorizzo 1981). The nodules and papules in PN can range in 
size from approximately 0.5 to 3.0 cm and often appear hyperkeratotic, sometimes 
crateriform, in appearance. Plaques are occasionally present, and the lesions of PN frequently 
exhibit other features secondary to prolonged and severe scratching behavior, such as post-
inflammatory hyperpigmentation, erosion, ulceration, crusting, and bleeding (Zeidler 2016).   
PN, a long-term reaction to the chronic scratching and picking of patients with chronic 
pruritus (Zeidler 2016), is a skin condition seen predominantly in older adults, with median 
prevalence age in the 50s and 60s and a slight female preponderance (Iking 2013, Tan 2014,  
Ständer 2013). In one patient population survey, pediatric patients accounted for <2% of the 
total population, with the youngest patient 11.9 years of age (Iking 2013). Although only 
limited epidemiology data for PN have been published, a claims-based analysis 
commissioned by Menlo Therapeutics suggest that the United States (US) prevalence may be 
in the range of ~ 355,000 affected individuals. Based on a quantitative survey of 
73 dermatologists conducted in parallel with the claims-based analysis, approximately 
23% of patients with PN have an underlying atopy-related condition, while over 50% are 
considered to be idiopathic (Navigant 2017). The median duration of disease burden has been 
reported to be 6-7 years (Iking 2013, Tan 2014, Schuhknecht 2011).  
The dominant symptom in PN is an intense and chronic pruritus that is associated with a high 
degree of patient burden and restricted quality of life (QOL) (Zeidler 2016). As measured by 
global scales of pruritus intensity (numeric rating scale (NRS) and visual analog scale 
(VAS)), median levels of pruritus intensity have been reported to be 7-8 points (Iking 2013, 
Tan 2014, Schuhknecht 2011). The pruritus experienced in PN can often prevent patients 
from adequately performing their daily activities (Vaidya 2008), and patients with PN have 
been found to suffer from greater rates of depression and anxiety than control groups in 
numerous studies (Jorgensen 2016, Rowland Payne 1985, Dazzi 2011).  
1.2 
Conditions Associated With Prurigo Nodularis 
As PN is considered to be a disease induced by chronic pruritus and ongoing scratching 
activity, a variety of chronic pruritic conditions have been identified as potential underlying 
etiologies for the pruritus, including atopic dermatitis (AD), other inflammatory or bullous 
skin diseases, chronic renal failure, human immunodeficiency virus (HIV) infection, hepatitis 
C infection, and multifactorial disease (i.e. two or more co-existent conditions associated 
with chronic pruritus) (Fostini 2013, Lee 2005). The mechanisms linking chronic pruritus to 
the development of PN are not clear, as only a subset of patients with chronic pruritus 
develop PN, and over half of patients with PN have no underlying etiology identified. Even 
when specific underlying conditions are identified, management of these condition(s) does 
not usually result in resolution of PN signs or symptoms, nor can all underlying conditions be 
treated. For example, PN has been observed in patients with HIV adequately managed with 
92


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 17 
highly active antiretroviral therapy (HAART) (Zancanaro 2006), in patients with intractable 
cholestatic pruritus (Bergasa 2011), in patients with inactive hepatitis (Halvorsen 2015), and 
commonly in patients with renal failure despite hemodialysis therapy (Goeksel 2013). These 
data point to a high level of unmet medical need in the overall PN population, as the majority 
of patients with PN either have no underlying condition identified that can be treated, or 
treatment of the underlying condition is inadequate to control their PN (Wallengren 2004). 
1.3 
Current Treatment Options for Prurigo Nodularis 
Treatment of PN remains a challenging and extremely frustrating experience for both patients 
and physicians. In the majority of cases, responses are limited and unsatisfactory, and once 
the cycle of pruritus-excoriation-pruritus begins, it is difficult to stop. Identification and 
treatment of underlying chronic pruritic conditions is often the first step in management of 
PN. If this does not result in resolution of the pruritus, or if no underlying condition is 
identified, treatment specifically for PN and its associated pruritus is implemented.  
First-line pruritus therapies, including topical agents such as topical corticosteroids and 
calcineurin inhibitors, often provide inadequate response (Saco 2015) and the therapeutic 
ladder for PN involves systemic agents with progressively riskier safety profiles. These 
include naltrexone, gabapentin, mirtazapine, phototherapy, intravenous immunoglobulin 
(IVIG), powerful immunosuppressants such as methotrexate and cyclosporine, and 
thalidomide (Ständer 2015b, Spring 2014, Feldmeyer 2012, Lim 2016). None of these 
therapies are indicated for the treatment of PN, and their usage is often based on limited 
evidence, such as case reports or small open-label studies.  
1.4 
Substance P and the Neurokinin-1 Receptor 
Repeated itching, scratching, and picking over long time periods serve as the 
pathophysiological basis for the development of PN. Although different underlying disease 
states may be responsible for the chronic pruritus, the distinctive and easily recognizable 
features of PN point to a common final pathway resulting in this unique clinical presentation.  
Immunohistochemical staining studies of PN biopsies have demonstrated that nerve fibers 
immunoreactive for Substance P (SP) are found in increased numbers in lesional skin 
compared to non-lesional skin or controls (Abadía Molina 1992), suggesting a role for SP 
signaling in PN. These findings are consistent with the robust body of evidence indicating the 
key role of SP signaling through its primary receptor, the neurokinin-1 receptor (NK1-R), in 
the transmission of itch across multiple disease states (Santini 2012, Akiyama 2015, 
Crowe 1994, El-Nour 2006, Lotts 2014, Hon 2007, Ward 2004, Slattery 2011).   
SP is an undecapeptide that belongs to the tachykinin family of neuropeptides, a group that 
also includes neurokinin A and neurokinin B (Hökfelt 2001). SP has been implicated in a 
number of biological functions, both physiological and pathophysiological, including pruritus 
perception, vomiting reflex, pain perception, and immunomodulatory responses (Lotts 2014, 
Andoh 1998, Steinhoff 2014).  The biological actions of SP are mediated by tachykinin 
receptors, which consist of seven hydrophobic transmembrane domains coupled to G-
proteins. Three tachykinin receptors have been identified: the neurokinin-1, neurokinin-2, 
93


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 18 
and neurokinin-3 receptors (Harrison 2001). The NK1-R in particular has been studied in 
great detail. NK1-R is the primary receptor for SP in the human body, and is found on 
multiple cell types, include central and peripheral neurons, keratinocytes, and mast cells.  
NK1-R stimulation has been shown to be an important pathway for pruritus perception 
(Ständer 2015a). Inhibition of this pathway results in decreased pruritus and scratching 
reflexes in animal models (Akiyama 2015). Preceding the development of serlopitant for 
pruritus-related conditions, a commercially available NK1-R antagonist (Emend USPI) has 
been used as a therapy to decrease pruritus in patients with chronic pruritus due to etiologies 
such as cutaneous T-cell lymphoma (Duval 2009, Torres 2012, Booken 2011) and 
erlotinib-induced pruritus (Santini 2012, Gerber 2010). Additionally, in a study of 20 patients 
with chronic pruritus of various etiologies treated with aprepitant, 16/20 patients (80%) 
experienced a considerable reduction of itch intensity (Ständer 2010).  
1.5 
Serlopitant  
1.5.1 
Serlopitant Background and Nonclinical Summary 
Serlopitant is a small molecule, highly selective NK1-R antagonist that is administered orally 
and metabolized by cytochrome P-450 3A4 (CYP3A4), with a plasma half-life of 45-86 
hours. It binds with high affinity to the human NK1-R with a dissociation constant (Kd) of 
46 pM; displacing SP binding with a half-maximal inhibition concentration (IC50) of 61 pM. 
Serlopitant is a potent functional antagonist of SP-induced inositol phosphate generation. 
Serlopitant has been extensively studied in animal toxicology studies, including chronic 
toxicology and carcinogenicity studies. In non-clinical chronic toxicology studies in rats, 
mice and dogs, treatment related findings of potential clinical significance included increased 
salivation, decreased body weight gain and food consumption, slight changes in hematology 
and serum biochemistry parameters, mild increases in liver weight and mild 
histomorphologic changes. The histomorphologic changes were seen only in rats (not in dogs 
or mice) and included: very slight ovarian interstitial cell hypertrophy, mammary gland and 
uterine atrophy; decreased corpora lutea; increased histiocytes in lung and mesenteric lymph 
nodes; slight skeletal and cardiac muscle degeneration; slight increased hematopoiesis in 
bone marrow; and slight to moderate vacuolation in kidney tubules. These nonclinical 
findings occurred at systemic exposures exceeding those anticipated to provide efficacy of 
serlopitant for pruritus indications in humans (1 to 5 mg tablet daily). No cardiac lesions have 
been observed in dog toxicity studies up to 9 months in duration nor in a 3-month mouse 
range-finding study and 2-year mouse carcinogenicity study at exposure higher than the 
lowest level which caused cardiotoxicity in rats. The no observed adverse effect level 
(NOAEL) in rats for histomorphological changes in the reproductive tract, mammary gland 
and bone marrow provides a 2.5-fold margin for the maximum-targeted exposure (5 mg 
tablet daily). The rat NOAEL for histomorphological changes in muscle and kidney provides 
a 5-fold margin for the maximum-targeted exposure (5 mg tablet daily).  
In summary, the nonclinical toxicity noted with serlopitant provides no contraindications to 
the continuation of clinical trials via the oral route. Findings in the developmental toxicity 
94


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 19 
studies support inclusion of women of childbearing potential in clinical trials in accordance 
with the study protocol and local regulatory guidances.  
1.5.2 
Serlopitant Clinical Summary 
In humans, serlopitant has been administered to over 1000 individuals. Single doses up to 
400 mg have been well tolerated in young adult males and single doses up to 25 mg have 
been well tolerated in the elderly. Multiple doses of up to 50 mg a day for 4 weeks have been 
well tolerated in healthy young males, and a single (loading) dose of 15 mg followed by daily 
doses of 5 mg for 2 weeks have been well tolerated in elderly males and females. Forty-one 
(41) subjects received 4 mg liquid filled capsule (LFC) daily (bioequivalent to 5 mg tablets) 
for 1 year. Plasma concentrations of serlopitant appear to increase in a dose-proportional 
fashion in both young males and elderly subjects (males and females). Peak plasma 
concentrations after a single oral dose occurred at ~2 to 4 hours in both young and elderly 
subjects. A single loading dose of up to 15 mg followed by 6 to 8 weeks of up to 5 mg daily 
doses has been well tolerated in adults with chronic pruritus and PN. 
Pharmacokinetic data demonstrate good plasma exposures with oral dosing, linear dose-
dependent increases in plasma concentration and systemic exposure, a plasma t1/2 
appropriate for once daily dosing, and mild effects of concomitant food ingestion. Central 
nervous system (CNS) positron emission tomography (PET) studies have demonstrated good 
CNS penetrance and > 90% NK1 receptor occupancy (RO) at plasma exposures anticipated 
to be safe and well tolerated. Three long-lived active hydroxylated metabolites are observed 
in humans: M1/M1a 
, M2/M2a 
, and M3 
. 
These metabolites were present at lower concentrations and were 2- to 9-fold less potent in 
vivo than the parent compound. The integrated pharmacokinetic/pharmacodynamic (PK/PD) 
analysis concluded that these metabolites are unlikely to contribute significantly to 
occupancy of the CNS NK1-R in humans. 
1.5.3 
Serlopitant in Pruritus-Related Studies 
Serlopitant has been evaluated in two completed Phase 2 studies of subjects with chronic 
pruritus (TCP-101 and TCP-102).  
TCP-101 
TCP-101 was a double-blind, placebo-controlled, multi-center study that compared 
serlopitant 0.25 mg, 1 mg, or 5 mg vs. placebo for the treatment of chronic pruritus. A total 
of 257 adult subjects 18-65 years of age with chronic pruritus were randomized to receive 
one of the four dose groups in a 1:1:1:1 randomization. Subjects received a loading dose of 
3 tablets on Day 1 and thereafter received 1 tablet per day for 6 weeks. The primary efficacy 
endpoint was itch severity as measured on a VAS, summarized as a percentage change from 
baseline. 
Mean percent decreases from Baseline in VAS score were larger in the active-treatment 
groups versus placebo at every scheduled post-baseline study visit. Overall, the results were 
the most profound for the serlopitant 1 mg and 5 mg groups. For the percent change from 
Baseline in VAS pruritus scores (the primary efficacy variable), the Week 6 pairwise least 
95
CCI
CCI
CCI


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 20 
squares mean difference compared to placebo was 5.8 mm, 13.2 mm, and 14.2 mm for 
serlopitant 0.25 mg, 1 mg, and 5 mg, respectively.   
The frequency of treatment-emergent adverse events (TEAEs) and study drug related adverse 
events (AEs) was higher in the serlopitant 1 mg and 5 mg groups compared to the serlopitant 
0.25 mg group, and the frequency in all three treatment groups were higher than in the 
placebo group. The frequency of AEs leading to study drug discontinuation was comparable 
in the serlopitant 5 mg and placebo group and higher than in the serlopitant 0.25 mg and 
1 mg groups. There was one serious adverse event (SAE) reported in the serlopitant 1 mg 
group (spontaneous abortion, considered not related). There were no deaths. The most 
common AEs in the serlopitant groups were diarrhea (6.2%, 1 mg group), upper respiratory 
tract infection (4.7%, 0.25 mg group), somnolence (4.7%, 5 mg group), nasopharyngitis 
(4.6%, 1 mg group), headache (4.7%, 5 mg group), urinary tract infection (3.1%, 5 mg 
group), dry mouth (3.1%, 1 mg group), nausea (3.1%, 1 mg group), arthralgia (3.1%, 
0.25 mg group), musculoskeletal pain (3.1%, 1 mg group) and pruritus (3.1%, 1 mg group). 
The most common AEs in the placebo group were headache (6.3%), nasopharyngitis (3.2%), 
upper respiratory tract infection (3.2%), urinary tract infection (3.2%) and asthma (3.2%).  
TCP-102 
TCP-102 was a randomized, double-blind, placebo-controlled multi-center study that 
evaluated serlopitant 5 mg vs. placebo for the treatment of PN. A total of 128 adult subjects 
18-80 years of age with PN were randomized to receive serlopitant or placebo in a 1:1 
randomization. Subjects received a loading dose of 3 tablets on Day 1 followed by 1 tablet 
per day for 8 weeks. The primary efficacy endpoint was the average VAS score as recorded 
at the study visits. Results at Week 4 and Week 8 were the primary timepoints. 
Serlopitant 5 mg was superior to placebo for the reduction of pruritus as measured by change 
in average VAS from baseline. For the primary endpoint, change from baseline at Week 4 
and Week 8 by repeated measures analysis, the decrease from baseline was significantly 
greater in the serlopitant group than the placebo group, with a mean difference (serlopitant 
minus placebo) of -1.0 at Week 4 and -1.7 at Week 8. The mean difference at Week 2 was 
also significant, -0.9. In a post-hoc analysis of the percentage of subjects who were 4-point 
responders on average VAS at Week 8, 25.0% of placebo subjects and 54.4% of serlopitant 
subjects were 4-point responders. 
TEAEs were reported for 71.9% of serlopitant-treated subjects and 61.9% of placebo-treated 
subjects. The most frequently reported TEAEs in the serlopitant group were nasopharyngitis 
(17.2% serlopitant, 3.2% placebo), diarrhea (10.9% serlopitant, 4.8% placebo), and fatigue 
(9.4% serlopitant, 6.3% placebo). Treatment-related TEAEs were reported for 48.4% of 
serlopitant-treated subjects and 34.9% of placebo-treated subjects. The most frequently 
reported treatment-related TEAEs in the serlopitant group were fatigue (7.8%) and diarrhea, 
peripheral edema, dizziness, and headache (each 6.3%). Most TEAEs were mild or moderate; 
severe TEAEs were reported for 9.4% of serlopitant-treated subjects and 4.8% of 
placebo-treated subjects. There were no deaths during the study. Five subjects (3 serlopitant, 
2 placebo) had SAEs. The SAEs were actinic elastosis, depression, dizziness, and vertigo in 
96


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 21 
the serlopitant group; and bradycardia, syncope, respiratory failure, and neurodermatitis in 
the placebo group. Nine subjects (3 serlopitant, 6 placebo) discontinued due to TEAEs. 
No clinically relevant changes were observed in chemistry, hematology, vital signs, or 
electrocardiogram (ECG) results. 
Potential Risks and Benefits: The results of the Phase 2 studies in PN and chronic pruritus, 
together with the extensive nonclinical and clinical safety data and experience with 
serlopitant to date and the scientific rationale for NK1-R inhibition in the treatment of 
pruritus, serve to support further evaluation of serlopitant for the treatment of pruritus in 
patients with PN. The potential benefits of continued clinical study outweigh the potential 
risks. 
Please refer to the Investigator’s Brochure (IB) for further information regarding serlopitant. 
2 
STUDY OBJECTIVES  
The efficacy objective of this study is to assess the efficacy of serlopitant for the treatment of 
pruritus in adults with PN. 
The safety objective of this study is to assess the safety and tolerability of repeated oral doses 
of serlopitant in adults with PN.  
3 
STUDY DESIGN 
3.1 
Overall Study Design 
This is a double-blind, randomized, placebo-controlled study to assess the efficacy, safety, 
and tolerability of serlopitant for the treatment of pruritus in adults with PN. The study will 
be conducted at approximately 50 study sites. Subjects who meet the study entry criteria will 
be randomized in a 1:1 ratio to receive daily oral doses of serlopitant 5 mg or placebo for 
10 weeks. After completion of the treatment period or early discontinuation of study drug 
treatment, all subjects will enter a 3 or 5-week follow-up period. The required follow-up 
period is defined as a minimum of 3 weeks for those subjects who will enroll in the one-year 
open-label safety study (MTI-107) on the date of the follow-up visit, and as 5 weeks for 
those subjects who will not be enrolled in the one-year open-label safety study of serlopitant. 
Should a subject present for the follow-up visit prior to 5 weeks after the last dose of study 
drug and be excluded from participation in the one-year study for any reason, the subject will 
be required to return at 5 weeks after the last dose of study drug for a complete follow-up 
visit. 
This study will consist of three periods, for a total study period of 15-19 weeks: 
• Screening period: 2-4 weeks 
• Treatment period: 10 weeks 
• Follow-up period: 3 or 5 weeks 
97


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 22 
Informed consent will occur prior to any protocol-mandated procedures, including the 
stopping of any excluded therapies. This may occur prior to the Screening visit. 
During the screening period, all subjects will undergo eligibility evaluation and will be 
assessed for chronic pruritic conditions frequently associated with PN. Subjects who present 
with idiopathic PN at screening may require additional assessments as deemed necessary by 
the investigator (e.g. endomysial antibody with reflex to titer for subjects with signs or 
symptoms of dermatitis herpetiformis, skin biopsy for subjects with signs or symptoms of 
bullous pemphigoid or cutaneous T-cell lymphoma, urea breath test for Helicobacter pylori, 
or allergy testing).  
All screening procedures must be completed within 31 days before the Baseline visit. The 
minimum screening period for all subjects is 14 days to allow for collection of electronic 
diary (eDiary) screening data. Subjects who require screening period longer than 14 days will 
have a telephone contact at least 15 days prior to the scheduled Baseline visit to remind them 
to complete the eDiary as previously instructed at the Screening visit. 
Screening procedures may be deferred following discussion with the medical monitor should 
more than 31 days be required (e.g. to wash out of certain excluded therapies or to treat their 
underlying condition).  
Screening procedures may be repeated (i.e., the subject may be rescreened) following 
discussion with the medical monitor should the subject have had difficulty complying with 
eDiary assessments, require further training in the assessments, or have other relevant needs 
that may delay enrollment in the study but are not expected to impact safety or efficacy 
assessments. 
Subjects will be provided an eDiary at the Screening visit. Subjects must be willing and able 
to complete the eDiary every day within a consistent timeframe, and comply with restrictions 
on allowable concomitant therapies, for the duration of the study.  
At the Baseline visit (Day 1), eligible subjects will be randomly assigned to receive study 
drug (serlopitant 5 mg or placebo). Subjects will take a loading dose (3 tablets taken orally) 
at the site on the first day of the treatment period (Day 1). Starting on Day 2, subjects will 
take one tablet per day. Study drug may be taken with or without food. 
 
The primary efficacy endpoint will be assessed at Week 10 of treatment.  
Subjects who complete the 10-week treatment period and required follow-up period may be 
given the opportunity to enroll in a one-year open-label safety study (MTI-107) with daily 
oral doses of serlopitant 5 mg. 
3.2 
Rationale for Study Design and Dose Selection 
In the TCP-102 study in patients with PN, serlopitant 5 mg taken daily for 8 weeks was 
superior to placebo for the reduction of pruritus, in both the overall study population as well 
as the subgroup of subjects with an atopic diathesis. Similarly, in the TCP-101 study in 
98


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 23 
patients with chronic pruritus, serlopitant 5 mg and 1 mg taken daily for 6 weeks were 
superior to placebo for the reduction of pruritus, in both the overall study population and the 
subgroup of subjects with an atopic diathesis.  
In both the TCP-102 and TCP-101 studies, serlopitant was generally well-tolerated and 
demonstrated an overall favorable safety profile at the doses evaluated. 
The current MTI-106 study is designed to confirm the efficacy, safety, and tolerability of 
serlopitant for the treatment of pruritus in patients with PN. The 5 mg dose of serlopitant was 
selected for this study based on the favorable efficacy, safety, and tolerability profile of 
serlopitant at this dose level. Over 250 subjects have been exposed to serlopitant at doses of 
5 mg tablet-equivalent daily for at least 6 weeks, and ~ 40 subjects have been exposed up to 
one year. Human CNS PET RO data for serlopitant in healthy young males (Study P002) 
demonstrated that a serlopitant 5 mg LFC once daily dose is likely to achieve ~ 94% NK1 RO 
at steady state.  
3.3 
Study Endpoints 
3.3.1 
Primary Efficacy Endpoint 
The primary efficacy endpoint is the Worst-Itch Numeric Rating Scale (WI-NRS) 4-point 
responder rate at Week 10. 
3.3.2 
Key Secondary Efficacy Endpoints 
The key secondary efficacy endpoints are as follows: 
 WI-NRS 4-point responder rate at Week 4 
 Change from baseline in Dermatology Life Quality Index (DLQI) to Week 10 
 
3.3.3 
Additional Secondary Efficacy Endpoints 
Additional secondary efficacy endpoints are as follows: 
• Change from baseline in WI-NRS to other timepoints 
• WI-NRS 4-point responder rate at Week 2 
• WI-NRS 3-point responder rate at Weeks 2, 4 and 10 
• Change from baseline in Investigator’s Global Assessment of PN Activity (IGA PN-A) to 
Weeks 2, 4 and 10 
• Change from baseline in Investigator’s Global Assessment of PN Stage (IGA PN-S) to 
Weeks 2, 4 and 10 
3.3.4 
Safety Endpoints 
Safety endpoints are as follows: 
99


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 24 
• Incidence of TEAEs and SAEs 
• Change from baseline in clinical laboratory parameters following study drug exposure 
• Change from baseline in vital sign and ECG parameters following study drug exposure 
• Change from baseline in the Hospital Anxiety and Depression Scale (HADS)  
• Change from baseline in the Epworth Sleepiness Scale (ESS) 
 
3.4 
Safety Review 
3.4.1 
Safety Monitoring Team 
An internal safety monitoring team consisting of representatives from Menlo Therapeutics 
Inc. and its designees will monitor blinded safety data on a regular basis throughout the 
study. 
4 
SELECTION OF STUDY POPULATION 
4.1 
Study Population 
Approximately 280 adult subjects with pruritus associated with PN will be enrolled in this 
study. 
4.2 
Inclusion Criteria 
Subjects must meet the following criteria to be randomized into the study: 
1. Male or female, age 18 years or older at consent. 
2. A diagnosis of PN, defined by the presence of at least ten pruriginous nodules secondary 
to chronic pruritus present on at least two different body surface areas (e.g. both arms, one 
arm and one leg, one arm and the anterior trunk, or anterior and posterior trunk). 
3. The worst pruritus is identified to be within the areas of the PN lesions.  
4. Subject has idiopathic PN OR the subject has an identified pruritic condition associated 
with the PN and has persistent pruritus despite at least 6 weeks of optimized and stable 
treatment of the underlying condition prior to the Baseline visit, and is willing to continue 
the treatment during the study. Please refer to Section 5.7.1. 
5. WI-NRS score ≥ 7 in the 24-hour period prior to the Screening visit. 
6. Average weekly WI-NRS score ≥ 6.5 in each of the 2 weeks (14 days) immediately prior 
to Baseline visit, as recorded in the eDiary. 
7. All female subjects who are of childbearing potential must be willing to practice highly 
effective contraception (i.e., pregnancy prevention method with a failure rate of < 1% per 
100


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 25 
year) from the time of the Screening visit until 5 weeks after last dose of study drug.  Please 
refer to Section 7.1.5 for acceptable methods of contraception. 
8. Willing and able (as demonstrated by a ≥ 70% eDiary completion rate in the two weeks 
prior to Baseline visit) to complete daily eDiary entries within a consistent timeframe for 
the duration of the study.  
9. Willing and able (has adequate cognitive ability, in the investigator’s opinion) to comply 
with study visits and study related requirements including providing written informed 
consent. 
 
4.3 
Exclusion Criteria 
Subjects who meet any of the following criteria are not eligible for participation in the study: 
1. Prior treatment with serlopitant. 
2. Active pruritic skin disease, other than PN, within 6 months prior to randomization (with 
the exception of acute dermatoses such as contact dermatitis, sunburn, viral exanthem, 
which have been resolved for longer than 4 weeks). Please refer to Section 5.7.1. 
3. Treatment with any of the following therapies within 4 weeks prior to randomization. 
a. Other NK1-R antagonists (e.g., aprepitant, fosaprepitant, rolapitant). 
b. Systemic or topical immunosuppressive/immunomodulatory therapies (including 
but not limited to corticosteroids, phosphodiesterase-4 (PDE-4) inhibitors, 
cyclosporine, mycophenolate-mofetil, tacrolimus, pimecrolimus, calcipotriene, 
methotrexate, azathioprine, interferon-gamma, thalidomide, or phototherapy).  
c. Systemic therapies with recognized anti-pruritic properties (including but not 
limited to H1 antihistamines, doxepin, gabapentin, pregabalin, cannabinoids, 
kappa-opioid receptor agonists, and mu-opioid receptor antagonists (e.g. 
naloxone, naltrexone)). 
d. Strong CYP3A4 inhibitors (see Appendix B). 
e. Use of an indoor tanning facility, or natural sun exposure resulting in significant 
tanning or sunburn. 
4. Treatment with topical anti-pruritic therapies (e.g., menthol, camphor, pramoxine, 
capsaicin) within 2 weeks prior to randomization (see Section 5.7.2). 
5. Treatment with biologic therapies within 8 weeks or 5 half-lives prior to randomization, 
whichever is longer. 
6. Treatment with any investigational therapy within 4 weeks (8 weeks for investigational 
biologic therapies) or 5 half-lives prior to randomization, whichever is longer. 
7. Serum creatinine, total bilirubin, alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) > 2.5 times the upper limit of normal (ULN) during screening. 
8. Untreated or inadequately treated thyroid, adrenal, or pituitary nodules or disease or 
history of thyroid malignancy.  
101


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 26 
9. History of malignancy within 5 years prior to randomization, with the exception of 
actinic keratosis, completely treated and non-metastatic cutaneous basal cell carcinoma or 
squamous cell carcinoma of the skin. 
10. Any known major psychiatric diagnosis, such as major depressive disorder, bipolar 
disorder, schizophrenia, psychotic disorder, intellectual disability, severe alcohol use 
disorder, which may confound the assessment of serlopitant safety or efficacy, or 
interfere with the subject’s ability to comply with protocol-mandated activities, within 
3 years prior to randomization.  
11. Suicidal ideation within 3 years prior to randomization, or any history of suicide attempt. 
12. Documented history of parasitic infection, including skin parasites such as scabies, within 
8 weeks prior to randomization. 
13. Presence of any medical condition or disability that, in the investigator’s opinion, could 
interfere with the assessment of safety or efficacy in this trial or compromise the safety of 
the subject. 
14. History of hypersensitivity to serlopitant or any of its components. 
15. Currently pregnant or breastfeeding female subject. 
16. Planned or anticipated major surgical procedure or other activity that would interfere with 
the subject’s ability to comply with protocol-mandated assessments (e.g. extended 
international travel) during the subject’s participation in the study. 
5 
STUDY DRUG 
5.1 
Study Drug Supply, Route of Administration, and Storage 
The study drug in this study is serlopitant 5 mg or placebo in a film-coated tablet formulation 
for oral administration. The serlopitant tablets contain microcrystalline cellulose, mannitol, 
croscarmellose sodium, silicon dioxide, sodium lauryl sulfate, and magnesium stearate, and 
are film coated with Opadry® Brown. The placebo tablets contain microcrystalline cellulose, 
lactose monohydrate, and magnesium stearate, and are film coated with Opadry® Brown.  
The study drug will be provided in bottles that can be stored at room temperature (59-86°F, 
15-30°C). 
The tablets will be supplied in bottles, with 18 tablets per bottle. One bottle will be issued via 
Interactive Web Response System (IWRS) at baseline and at Weeks 2 and 4, and two bottles 
will be issued via IWRS at Week 6. A total of 5 bottles will be dispensed to subjects 
completing 10 weeks of study drug treatment. 
Additional details regarding study drug supplies can be found in the Pharmacy Manual. 
102


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 27 
5.2 
Labeling and Study Drug Accountability 
The study drug will be appropriately packaged and labeled in bottles with 18 tablets per 
bottle. The study drug supplied for this study is not to be used for any purpose other than this 
study, and study drug accountability must be maintained for all bottles distributed to the 
investigative site. 
Additional details regarding study drug labeling and accountability can be found in the 
Pharmacy Manual. 
5.3 
Dosing Regimen 
Subjects will take a loading dose (3 tablets taken orally) at the site on the first day of the 
treatment period (Study Day 1). Starting on Study Day 2, subjects will take one tablet per day 
taken orally. Subjects will be instructed to take all doses from Study Day 2 onward once a 
day. Study drug may be taken with or without food. 
5.4 
Dose Modification 
No dose modification of study drug will be allowed during this study. 
5.5 
Missed or Delayed Doses 
Each dose of study drug after the first dose must be administered once daily. If a dose is 
missed, that dose will be considered and documented as a missed dose. Dosing should 
resume the next day. 
5.6 
Study Drug Discontinuation 
Subjects should be discontinued from study drug treatment in the following situations: 
• A female subject desires to become pregnant at the current time, stops contraception or 
expels her intrauterine device/implant, or becomes pregnant  
• A female subject has new breast findings (e.g. a palpable mass or abnormal 
mammography, discharge), or has abnormal vaginal discharge or bleeding 
• The subject decides to discontinue study drug treatment, or withdraws consent from the 
study 
• The subject receives a strong CYP3A4 inhibitor (See Appendix B) 
• Any medical condition that may jeopardize the subject’s safety if study drug is continued, 
in the investigator’s and/or Sponsor’s opinion; this may include the development of 
persistently (2 successive occasions) abnormal thyroid function tests (TSH >10, or 
TSH > 6 with low free T4; TSH <0.1, or TSH < 0.35 with high free T4); abnormal 
morning prolactin, cortisol, or corticotropin levels; or signs and symptoms of adrenal 
insufficiency 
103


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 28 
• Discontinuation is deemed to be in the best interest of the subject, in the investigator’s 
and/or Sponsor’s opinion, including evidence that the subject does not meet 
inclusion/exclusion criteria intended primarily for safety reasons, or a persistent lack of 
adherence to study procedures 
 
The Sponsor or designee should be contacted within 24 hours of investigator’s awareness of 
any study drug treatment discontinuation. Investigators should make every effort to contact 
the Sponsor or designee before discontinuing study drug treatment, if possible. 
Subjects who discontinue treatment with study drug prior to completing the treatment period 
will enter a 5-week follow-up period following the last dose of study drug in addition to a 
Follow-up visit (see Section 3.1, Section 6.5.10). Every effort should be made for subjects to 
complete the Follow-up visit after a subject has discontinued from study drug.  
5.7 
Prior, Concomitant, and Excluded Therapies 
Prior therapies (including over-the-counter medications) used to treat the signs and 
symptoms of PN within the prior 2 years will be recorded for each subject at the Baseline 
visit. 
Concomitant therapies include any therapies (including over-the-counter medications and 
bland emollients) used by a subject from initiation of study drug treatment through the 
follow-up period. A record of all medications used will be maintained for each subject 
throughout the study. Reported information will include a description of the type of drug, 
treatment period, dosing regimen, the route of administration, and drug indication. The use of 
any concomitant medication must relate to the subject’s medical history or to an AE, except 
for vitamins/nutritional supplements, emollient use, and routine preventative immunizations.  
5.7.1 
Allowed Therapies and Treatment Goals for Underlying Conditions 
Treatment of an underlying, treatable chronic pruritic condition is allowed, if stable for at 
least 6 weeks prior to the Baseline visit, and continued throughout the treatment period.  
Treatment of the underlying systemic pruritic condition should be optimized per standard of 
care and treatment goals must be tailored based on age, sex, and concurrent health status and 
drug tolerance. While resolution of metabolic or endocrine disorders or eradication of an 
underlying infection may not always be feasible, every effort should be made to ensure the 
condition is well controlled, to prevent or reduce exacerbations and to prevent limitation on 
the activities of daily living. When applicable, laboratory evidence of control should be 
obtained. For example, if renal insufficiency is implicated as causal for pruritus, treatment 
would be expected to have meaningfully reduced the creatinine (compared to that at the time 
of diagnosis) and to maintain the creatinine at < 2.5 the ULN; control of diabetes is supported 
by a hemoglobin-A1c of < 7.5%; control of thyroid disease is supported by normalization of 
the thyroid stimulating hormone (TSH) or by a TSH within 1.5 times the ULN in elderly 
patients; iron deficiency is corrected with a serum iron within 0.8 times the lower limit of 
normal; eradication of Helicobacter pylori infection generally requires a negative urea breath 
104


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 29 
test and fecal antigen test and endoscopy; and the viral load should be undetectable if viral 
infections such as hepatitis B or hepatitis C, or HIV were previously diagnosed. Any 
previously active skin disease is considered to be well controlled if it is globally considered 
clear or almost clear (permissible to have post-inflammatory pigmentation, fine scale, faint 
pink erythema, barely perceptible induration/papulation, and no oozing or crusting).   
Use of gentle cleansers and bland emollients (including those with urea) is encouraged for all 
subjects. If bland emollient use is elected, it must be initiated at least 2 weeks (14 days) prior 
to Baseline visit, and continued throughout the treatment period.  
Treatment with non-systemic corticosteroids or antihistamines that do not involve skin 
application (e.g. inhaled, intranasal, ophthalmic, or intra-articular) is allowed.  
Leukotriene inhibitors will be permitted for treatment of conditions other than PN (e.g. 
asthma). 
5.7.2 
Excluded Therapies 
Initiation or use of topical therapy with corticosteroids, calcineurin inhibitors, calcipotriene, 
PDE-4 inhibitors is not permitted within 4 weeks prior to the Baseline visit or throughout the 
treatment period, but such therapy may be initiated during the follow-up period if needed.  
Initiation of bland emollient is not permitted within 2 weeks (14 days) prior to Baseline visit 
or throughout the treatment period, but such therapy may be initiated during the follow-up 
period if needed.  
The following therapies and activities are excluded from the Screening visit through the 
treatment period, and through the follow-up period: 
• NK1-R antagonists (other than study drug) 
• Systemic immunosuppressive/ immunomodulatory therapies (including but not limited to 
systemic corticosteroids, PDE-4 inhibitors, cyclosporine, mycophenolate-mofetil, 
methotrexate, azathioprine, thalidomide, interferon-gamma, or phototherapy) 
• Biologic therapies (other than therapies such as insulins, vaccines) 
• Strong CYP3A4 inhibitors (See Appendix B) 
• Use of an indoor tanning facility, or natural sun exposure resulting in significant tanning 
or sunburn 
• Any investigational therapy 
 
The following therapies and activities are excluded from the Screening visit through the 
treatment period, and use is discouraged, though permitted, through the follow-up period: 
105


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 30 
• Topical therapies or emollients with anti-pruritic properties (including but not limited to 
anti-histamines, menthol or menthol derivatives, polidocanol, camphor, pramoxine, and 
capsaicin) 
• Systemic therapies with recognized anti-pruritic properties (including but not limited to 
H1 antihistamines, doxepin, gabapentin, pregabalin, cannabinoids, kappa-opioid receptor 
agonists, and mu-opioid receptor antagonists)  
 
Use of any excluded therapies (including those for the treatment of pruritus or PN lesions, or 
as rescue therapy) should be reported as soon as possible, and will be recorded as protocol 
deviations for subjects who receive them.  
5.7.3 
Rescue Therapies 
The initiation of non-study drug therapy to treat worsening of pruritus or PN lesions, or flare 
of previously inactive skin disease, is strongly discouraged throughout the treatment period. 
However, should rescue therapy be required for the safety and well-being of the subject, such 
use will be recorded and analyzed (see Section 8.2). The subject may remain on study drug, 
unless the rescue therapy is an NK1-R antagonist, a systemic biologic therapy, a strong 
CYP3A4 inhibitor, an investigational therapy, or any therapy that may jeopardize the 
subject’s safety if study drug is continued, in the investigator’s and/or Sponsor’s opinion. 
5.8 
Assignment to Treatment  
5.8.1 
Randomization 
Eligible subjects will be randomized to receive serlopitant 5 mg or placebo in a 1:1 ratio. 
Stratified permuted block randomization will be used. Randomization will be stratified by the 
subject’s reported WI-NRS score for the 1-week period prior to the Baseline visit (6.5 to < 9, 
9 to 10).  
An IWRS will be used to perform the randomization.  
5.8.2 
Blinding 
This study will be conducted as a double-blind study with the treatment assignment 
concealed from the subjects, the investigators and their staff, the Sponsor, and any designees 
of the Sponsor as required. The placebo will be formulated to be indistinguishable from the 
active study product. Study materials will be packaged and issued in a manner designed to 
maintain the blind for subjects and all study personnel involved in the direction and 
execution of study procedures, study assessments, and collection of data. The randomization 
code for each subject will be available to the sites for use only in an emergency situation. For 
details of the procedure for unblinding of individual subjects in cases of emergency see 
Section 7.6.  
106


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 31 
5.9 
Treatment Compliance 
Records of study drug used, dosages administered, and intervals between visits will be kept 
during the study. Subjects will record in the eDiary the doses administered, as well as 
whether a dose was taken within 2 hours of eating a meal. Subjects will be asked to return all 
partially used and empty bottles to the study site at each visit. The site staff will count and 
record the number of remaining tablets in each returned bottle. The site staff will review the 
subject’s eDiary to help evaluate compliance with dosing at each study visit. Discrepancies 
between compliance as assessed by tablet counts and doses recorded in the eDiary will be 
reconciled and documented. Dosing dates and times will be recorded. A subject who has 
deviated significantly from the once-daily dosing regimen will be counseled. 
6 
STUDY SCHEDULE AND ASSESSMENTS 
When applicable, efficacy and safety instruments will be provided with instructions for 
administration, in study-specific manuals for site reference.  
6.1 
Efficacy Parameters 
6.1.1 
Itch Numeric Rating Scale 
The Itch NRS is a validated, self-reported instrument for measurement of itch intensity. It 
uses a 24-hour recall period and asks subjects to rate the intensity of their itch on an 11-point 
scale ranging from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicate greater 
itch intensity. In this study, the subject is asked to rate the intensity of their worst itch 
(WI-NRS) during a 24-hour recall period; the questionnaire is provided in Appendix C. 
Initial WI-NRS score collected during Screening visit will be collected on paper. All 
subsequent WI-NRS assessments will be reported by subject via eDiary. Subjects will record 
their WI-NRS scores once daily via eDiary at approximately the same time each day 
(+/- 3 hours) throughout the screening, treatment, and follow-up periods, as outlined in 
Appendix A. Subjects may be allowed to adjust the timing of eDiary completion within the 
first week of Screening as needed. Standardized training and instructions will be provided to 
all subjects prior to eDiary use.  
6.1.2 
Investigator’s Global Assessment of PN Activity  
The IGA PN-A is an instrument used to assess the overall activity of PN lesions at a given 
time point, as determined by the investigator. It consists of a 5-point scale ranging from 
0 (clear) to 4 (severe), as provided in Appendix D. The IGA PN-A uses clinical 
characteristics of excoriations, crusting, and/or bleeding as guidelines for the overall activity 
assessment. The number of pruriginous lesions should not be considered for this assessment. 
IGA PN-A scores will be captured as outlined in Appendix A. Each assessment during the 
study must be done by the Principal Investigator (PI) or designee. Every effort should be 
made to ensure that all assessments for a given subject are done by the same individual 
throughout the study. However, a change in assessor for a given subject, though not ideal, 
will not be considered a protocol deviation. 
107


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 32 
6.1.3 
Investigator’s Global Assessment of PN Stage  
The IGA PN-S is an instrument used to assess the overall number and thickness of PN 
lesions at a given time point, as determined by the investigator. It consists of a 5-point scale 
ranging from 0 (clear) to 4 (severe), as provided in Appendix D. The IGA-PN-S uses clinical 
characteristics of number of nodules and their thickness as guidelines for the overall severity 
assessment. IGA-PN-S scores will be captured as outlined in Appendix A. Each assessment 
during the study must be done by the PI or designee. Every effort should be made to ensure 
that all assessments for a given subject are done by the same individual throughout the study. 
However, a change in assessor for a given subject, though not ideal, will not be considered a 
protocol deviation. 
6.1.4 
Dermatology Life Quality Index  
Dermatology Life Quality Index (DLQI) is a dermatology specific QOL instrument designed 
to assess the impact of the skin disease on a subject’s QOL over the prior week. It is a ten-
item questionnaire that assesses overall QOL and six aspects that may affect QOL 
(symptoms and feelings, daily activities, leisure, work or school performance, personal 
relationships, and treatment), and is provided in Appendix E. The DLQI questionnaire will be 
collected as outlined in Appendix A. 
6.1.5 
PN Photographs 
At selected investigative sites, optional photographs of representative areas with PN 
involvement will be taken at multiple time points, as outlined in Appendix A. These areas 
may include the extensor surfaces of both arms and both legs (overview of both legs, detail 
of lower legs), and the abdomen and back. The central photography vendor will provide 
photographic equipment to the sites for use during the study. The PI and designees will be 
trained on the use of the camera and the appropriate lighting and positioning of the 
representative area with PN involvement. Detailed instructions will be provided in the 
Photography manual. 
6.2 
Safety Parameters 
Safety assessments will consist of monitoring and recording protocol-defined AEs and SAEs; 
vital signs; physical examinations; clinical laboratory assessments; ECGs; and other 
protocol-specified tests that are deemed critical to the safety evaluation of the study drug as 
outlined in Appendix A. 
6.2.1 
Vital Signs 
Vital signs will include measurements of heart rate, blood pressure, respiration rate, and 
temperature after the subject has been calmly resting (seated or supine) for a minimum of 
5 minutes. Vital signs will be assessed as outlined in Appendix A and at unscheduled study 
visits when clinically indicated. On study visits when clinical laboratory tests are performed, 
assessment of vital signs should precede blood draw.  
108


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 33 
6.2.2 
Physical Examination 
Physical examinations, including height and weight measurements, will be performed as 
outlined in Appendix A and at unscheduled study visits when clinically indicated. A 
complete physical examination will be performed at the screening visit, while subsequent 
examinations will be abbreviated and targeted to changes in disease activity and/or subjects’ 
symptoms. For female subjects with targeted breast examinations, please perform breast 
examination after blood draw for clinical laboratory tests.   
6.2.3 
Clinical Laboratory Assessments 
Samples for clinical laboratory assessments will be collected as outlined in Appendix A and 
at unscheduled study visits when clinically indicated, and analyzed at a central laboratory 
unless otherwise specified.  
Detailed instructions regarding sample collection, preparation, and shipment can be found in 
the laboratory manual. Laboratory assessments will include the following, and are ideally 
performed in the morning, particularly at visits with endocrine assessments (Screening, Week 
10, Follow-up): 
• Hematology: hematocrit, hemoglobin, red blood cell count, red blood cell indices, 
platelets, white blood cell count, white blood cell differential (neutrophils, lymphocytes, 
monocytes, basophils, eosinophils) 
• Chemistry: sodium, potassium, chloride, bicarbonate, glucose, blood urea nitrogen, 
creatinine, calcium, phosphorus, magnesium, albumin, uric acid, total protein, ALT, 
AST, alkaline phosphatase, total bilirubin, lactate dehydrogenase (LDH), lipid panel 
• Iron studies: ferritin, serum iron  
• Serology: hepatitis B and C serology, HIV 
• Serum IgE 
• Pregnancy testing: all females of childbearing potential will have a local urine pregnancy 
test performed. Positive or equivocal urine pregnancy test results will be confirmed by a 
serum pregnancy test analyzed at a central laboratory 
• Endocrine: TSH, free T4, cortisol, corticotropin (adrenocorticotropic hormone, ACTH), 
prolactin  
• Reproductive endocrinology (for all female subjects under 55 years of age at consent): 
serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, 
progesterone, anti-Mullerian hormone (AMH)  
• Optional study provided in lab test kits for use at Screening only: endomysial antibody 
with reflex to titer for subjects with signs or symptoms of dermatitis herpetiformis 
109


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 34 
• Additional optional studies will be supported through local procedural and/or laboratory 
assessments, including, but not limited to, skin biopsy and pathology interpretation, urea 
breath test for Helicobacter pylori, and allergy testing (patch, prick, or blood testing); the 
investigator should discuss the need for such studies with the medical monitor during the 
Screening period. 
• Standard cosyntropin stimulation testing should be performed on subjects with low 
cortisol level (i.e. < 3.0 mcg/dL); the investigator should discuss low cortisol (and 
relevant low corticotropin) results with the medical monitor. 
6.2.4 
Electrocardiogram  
A standard 12-lead ECG will be performed after the subject has been calmly resting in a 
supine position for a minimum of 5 minutes before obtaining the ECG. ECGs should precede 
measurement of vital signs and blood draw for clinical laboratory tests and will be performed 
as outlined in Appendix A and at unscheduled study visits when clinically indicated and read 
centrally. ECG machine and detailed instructions will be provided by the ECG vendor. 
6.2.5 
Hospital Anxiety and Depression Scale 
The HADS is a QOL instrument designed to assess the severity of anxiety and depression 
over the prior week, developed in a hospital outpatient clinic, but also valid in community 
settings and primary care medical practice.  The questionnaire takes approximately 2 to 5 
minutes to complete, and is provided in Appendix F. The HADS questionnaire will be 
collected as outlined in Appendix A. 
6.2.6 
Epworth Sleepiness Scale 
The ESS is a QOL instrument intended to measure daytime sleepiness by use of a very short 
questionnaire. The questionnaire takes approximately 2 to 3 minutes to complete, and is 
provided in Appendix G. The ESS questionnaire will be collected as outlined in Appendix A. 
6.3 
Pharmacokinetic Measurements 
Sparse PK sampling will involve collecting one PK sample at each of the Week 2, Week 4, 
and Week 10 visits as outlined in Appendix A. The date and time of dosing prior to PK 
sample collection and date and time of PK sample collection will be collected. The plasma 
concentrations of serlopitant and metabolites will be determined and data used for population 
PK analysis. Detailed instructions regarding PK sample collection, preparation, and shipment 
can be found in the laboratory manual. 
6.4 
Subject Flow Diagram 
The visit schedule and assessments are summarized in Appendix A. The following subject 
flow diagram provides a summary of assessments and decision points for each subject. The 
eDiary assessments are performed throughout the study and are not confined to scheduled 
visits.  
110


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 35 
Figure 1 
Subject Flow Diagram   
   
 
6.5 
Study Visits 
The following sections describe the procedures and assessments to be performed at each 
study visit. Details of each procedure and assessment can be found in Sections 6.1, 6.2, and 
6.3. The timing of each study visit is relative to the day of randomization (Baseline). 
Unscheduled visits may be performed as necessary, and may include procedures or 
assessments deemed necessary by the investigator. 
The eDiary assessments are performed throughout the study and are not confined to 
scheduled visits. Refer to Appendix A for frequency and duration of these assessments. 
Female subjects who report periodic menstruation will be asked to complete a menstrual 
diary (paper form) throughout the study. 
6.5.1 
Screening Period 
Informed consent will occur prior to any protocol-mandated procedures, including the 
stopping of any excluded therapies. This may occur prior to the Screening visit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 36 
All screening procedures must be completed within 31 days before the Baseline visit. The 
minimum screening period for all subjects is 14 days to allow for collection of eDiary 
screening data. Subjects who require screening period longer than 14 days will have a 
telephone contact at least 15 days prior to the scheduled Baseline visit to remind them to 
complete the eDiary as previously instructed at the Screening visit. 
Screening procedures may be deferred following discussion with the medical monitor should 
more than 31 days be required (e.g. to wash out of certain excluded therapies or to treat their 
underlying condition).  
Screening procedures may be repeated (i.e., the subject may be rescreened) following 
discussion with the medical monitor should the subject have had difficulty complying with 
eDiary assessments, require further training in the WI-NRS assessments, or have other 
relevant needs that may delay enrollment in the study but are not expected to impact safety or 
efficacy assessments. 
6.5.2 
Screening Visit 
The following screening procedures are to be performed at the Screening visit, preferably in 
the order shown below: 
• Obtain written informed consent prior to any protocol-mandated procedures, including 
the stopping of any excluded therapies 
• Collect demographic information (sex, date of birth, race, ethnicity)  
• Ask subject to complete the WI-NRS scale on paper 
• Register Screening visit into the IWRS 
• Obtain ECG  
• Obtain vital signs  
• Review subject’s medical history (including prior medications) 
- 
Record only significant/relevant medical history, to include the onset date of PN (as 
specifically as known) and presence of an underlying condition (if any) 
- 
Designate the primary and any concurrent medical conditions that are identified as 
pruritic conditions underlying the PN  
- 
Female subjects should be queried regarding history of, or current, breast masses or 
abnormal discharge, and history of mammography (if applicable), and history of 
abnormal vaginal bleeding or discharge 
• Perform complete physical examination (including height and weight) and confirm 
clinical diagnosis of PN  
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
112


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 37 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent  
- 
Endocrine  
- 
Hematology 
- 
Chemistry 
- 
Serology 
- 
Serum IgE 
- 
Iron studies 
- 
Optional: endomysial antibody with reflex to titer for subjects with signs or 
symptoms of dermatitis herpetiformis 
- 
Optional: additional assessments (refer to Section 6.2.3) 
• Review subject’s tentative eligibility according to the Inclusion/Exclusion criteria 
- 
The results of all screening evaluations, including laboratory and ECG results, must 
be reviewed for clinical significance by the PI or designee, and may require further 
evaluation, prior to randomization of the subject on Baseline visit 
• Schedule the Baseline visit and all future study visits to ensure subject’s availability and 
visit compliance with the protocol visit windows 
• Provide a menstrual diary to female subjects who report periodic menstruation   
• Provide eDiary with instructions 
• Confirm next scheduled visit 
 
6.5.3 
Mid-Screening Telephone Contact (for subjects longer than 14 days in 
Screening) 
During this telephone contact the following procedures are to be performed: 
• Assess and record any changes in medications since the Screening visit 
• Review subject’s tentative eligibility according to Inclusion/Exclusion criteria 
• Assess AEs and record SAEs caused by protocol-mandated interventions 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
113


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 38 
6.5.4 
Baseline Visit 
The Baseline visit occurs between 14 to 31 days after the screening visit, depending on the 
required washout period following discontinuation of excluded therapies. Eligibility must be 
confirmed prior to randomization. At the Baseline visit, the following procedures and 
assessments are to be performed, preferably in the order shown below: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires  
• Assess and record any changes in the subject’s concomitant medications 
• Assess and record any changes in the subject’s medical history  
- 
Female subjects should be queried regarding history of, or current, breast masses or 
abnormal discharge, and history of mammography (if applicable), and history of 
abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Assess AE’s and record SAEs caused by protocol-mandated interventions 
• Obtain vital signs  
• Perform a urine pregnancy test for females of childbearing potential and confirm the 
subject has a negative urine pregnancy test result prior to randomization (with positive or 
equivocal results confirmed by a serum pregnancy test) 
• Confirm subject’s eligibility based on the inclusion/exclusion criteria (to include review 
of eDiary compliance for eligibility) 
• Randomize subject in IWRS if eligibility confirmed 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Dispense study drug; subjects will take loading dose of 3 tablets while on site 
• Review eDiary for compliance, re-train subject as needed 
• Assess and record any post-dose AEs and SAEs 
• Confirm next scheduled visit 
 
114


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 39 
6.5.5 
Week 1 Telephone Contact Visit 
The Week 1 visit is a telephone visit that occurs 7 days (± 3 days) after the Baseline visit. At 
the Week 1 visit, the following procedures and assessments are to be performed:  
• Assess and record any changes in the subject’s concomitant medications 
• Assess and record any AEs and SAEs 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
6.5.6 
Week 2 Visit 
The Week 2 visit occurs 14 days (± 3 days) after the Baseline visit. At the Week 2 visit, the 
following procedures and assessments are to be performed:  
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Draw blood for clinical laboratory tests 
- 
Hematology 
- 
Chemistry 
• Collect PK blood sample  
• Assess and record any AEs and SAEs 
• Review eDiary for compliance, re-train subject as needed 
• Review study drug compliance with re-training as required 
• Collect returned study drug 
115


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 40 
• Utilize IWRS to assign new bottle of study drug 
• Confirm next scheduled visit date 
 
6.5.7 
Week 4 Visit 
The Week 4 visit occurs 28 days (± 3 days) after the Baseline visit. At the Week 4 visit, the 
following procedures and assessments are to be performed: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test)  
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Collect PK blood sample  
• Assess and record any AEs and SAEs 
• Collect returned study drug 
• Utilize IWRS to assign new bottle of study drug 
• Review eDiary for compliance, re-train subject as needed 
• Review study drug compliance with re-training as required 
• Confirm next scheduled visit date 
 
6.5.8 
Week 6 Visit 
The Week 6 visit occurs 42 days (± 3 days) after the Baseline visit. At the Week 6 visit, the 
following procedures and assessments are to be performed: 
116


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 41 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain vital signs 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test)  
• Perform targeted physical examination, including weight 
• Assess and record any AEs and SAEs 
• Collect returned study drug 
• Utilize IWRS to assign new bottle of study drug 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
6.5.9 
Week 10 Visit 
The Week 10 visit occurs 70 days (± 7 days) after the Baseline visit. At the Week 10 visit, 
the following procedures and assessments are to be performed: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
117


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 42 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent 
- 
Endocrine 
- 
Hematology 
- 
Chemistry 
• Collect PK blood sample 
• Assess and record any AEs and SAEs 
• Collect returned study drug  
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Review eDiary for compliance, inform subject to continue entering WI-NRS score until 
Follow-up visit 
• Review study drug compliance with re-training as required 
• Confirm next scheduled visit date 
 
6.5.10 
Follow-up Visit 
The required Follow-up visit occurs 21 or 35 (+7 days) after the Week 10 visit or the last 
dose of study drug for subjects who discontinue study drug early. The required follow-up 
period is defined as a minimum of 3 weeks for those subjects who will enroll in the one-year 
open-label safety study on the date of the follow-up visit, and as 5 weeks for those subjects 
who will not be enrolled in the one-year open-label safety study of serlopitant. Should a 
subject present for the follow-up visit prior to 5 weeks after the last dose of study drug and be 
excluded from participation in the one-year study for any reason, the subject will be required 
to return at 5 weeks after the last dose of study drug for a complete follow-up visit. 
At the Follow-up visit, the following procedures and assessments are to be performed: 
• Register visit into the IWRS 
• Ask the subject to complete the HADS and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain vital signs 
118


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 43 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Obtain ECG  
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent  
- 
Endocrine  
- 
Hematology 
- 
Chemistry 
• Assess and record any AEs and SAEs 
• Collect eDiary device, review eDiary for compliance 
 
6.5.11 
Early Termination 
Early termination of a subject from the study may occur due to loss to follow-up or 
withdrawal of consent by the subject. In accordance with legal requirements and 
International Conference on Harmonization (ICH) –GCP guidelines, every subject or his/her 
legal representative has the right to withdraw from the study at any time and without 
providing reasons. If provided, the reason (adverse event, study burden, lack of efficacy, 
other) a subject withdrew consent will be recorded in the electronic Case Report Form 
(eCRF). The PI or site staff must make every effort to contact subjects who are suspected of 
being lost to follow-up. Attempts to contact such subjects must be documented in the 
subject’s source documents. 
7 
ASSESSMENT OF SAFETY 
7.1 
Definitions 
7.1.1 
Adverse Event 
An AE is any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. An AE can be any unfavorable and unintended sign 
(e.g. an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a drug, without any judgment about causality. 
119


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 44 
AEs include treatment emergent exacerbations of pre-existing illnesses and AEs that occur as 
a result of protocol-mandated interventions. 
7.1.2 
Serious Adverse Event  
An AE is considered “serious” if it results in any of the following outcomes: 
• Death 
• Life-threatening AE (i.e. the subject was at immediate risk of death from the event as it 
occurred. An event that might have led to death if it had occurred with greater severity is 
not “life-threatening”) 
• Inpatient hospitalization or prolongation of existing hospitalization  
• Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
• Congenital anomaly/ birth defect 
• Important medical event (i.e. an event that may not result in death, be life-threatening, or 
require hospitalization, but which may be considered serious by the investigator or 
Sponsor, as it may jeopardize the subject and may require medical/surgical intervention 
to prevent one of the outcomes listed above). Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, 
blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse. 
 
The following are not considered SAEs: a visit to the emergency room or other hospital 
department < 24 hours that does not result in admission (unless considered an important 
medical or life-threatening event), an elective surgery planned prior to signing consent, 
admission as per protocol for planned medical/surgical procedure, and/or routine health 
assessments requiring admission for baseline/trending of health status (e.g. routine 
colonoscopy). 
The terms “severe” and “serious” are not synonymous. Severity refers to the intensity of an 
AE (e.g. mild, moderate, or severe pain); the event itself may be of minor medical 
significance (e.g. severe back pain). “Serious” is a regulatory definition, as defined above. 
Seriousness (not severity) serves as the basis for defining regulatory reporting obligations.  
Severity and seriousness should be independently assessed when recording AEs and SAEs on 
the eCRF. 
120


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 45 
7.1.3 
Abnormal Physical Exam, Laboratory, Vital Sign, and Electrocardiogram 
Findings  
Abnormal physical exam findings that are clinically significant and are identified prior to the 
first dose of study drug should be recorded as medical history. New or worsening clinically 
significant abnormal physical exam findings identified after the first dose of study drug 
should be recorded as AEs.   
Only abnormal laboratory, vital sign, and ECG findings that are considered clinically 
significant by the investigator (e.g. require active management or are associated with 
accompanying symptoms/signs) will be recorded as medical history or AEs on the eCRF. 
Abnormal laboratory, vital sign, and ECG findings that occur prior to the first dose of study 
drug should be recorded as medical history, and abnormal findings that occur after the first 
dose of study drug should be recorded as AEs. 
If the clinically significant laboratory, vital sign, or ECG abnormality is a sign associated 
with a confirmed disease or condition (e.g. elevated creatinine in a subject diagnosed with 
chronic kidney disease), only the diagnosis (chronic kidney disease) needs to be recorded on 
the AE eCRF (rather than listing individual test findings as AEs).  
Separate instances of the same clinically significant laboratory, vital sign, or ECG 
abnormality across visits should not be recorded as separate AEs or SAEs. 
7.1.4 
Deaths  
Any deaths that occur from the time of informed consent to the follow-up visit, regardless of 
attribution, must be reported within 24 hours of investigator’s awareness of the death. See 
Safety Form Completion Instructions for complete instructions. 
The Sponsor should be provided a copy of any post-mortem findings and/or relevant medical 
reports, including histopathology. 
7.1.5 
Pregnancies and Contraception Requirements for Females 
For the purposes of this study, a female of childbearing potential is defined as any female 
who has experienced menarche and is pre-menopausal, unless permanently surgically sterile 
(e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy). A postmenopausal 
state is defined as no menses for 12 months without an alternative medical cause in a 
previously menstruating female.  
For the purposes of this study, acceptable contraception is defined below based on 
Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals: ICH M3(R2) dated January 2010, and other available 
guidelines (“U.S. Medical Eligibility Criteria for Contraceptive Use” 2010; 
“Recommendations related to contraception and pregnancy testing in clinical trials” 2014; 
“M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals” 2010):  
121


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 46 
All female subjects of childbearing potential must use highly effective contraception, which 
includes the use of one or more of the following acceptable methods:  
1. Surgical sterilization (e.g., bilateral tubal occlusion or ligation, hysterectomy, bilateral 
salpingectomy, bilateral oophorectomy) 
2. Total (as opposed to periodic or cyclic) abstinence from heterosexual intercourse, 
only if planned for the entire duration of the study period and consistent with the 
preferred and usual lifestyle for the subject 
3. Hormonal contraception associated with consistent inhibition of ovulation; these may 
include (but are not necessarily limited to) oral, intravaginal, implantable, injectable, 
or transdermal delivery methods  
4. Intrauterine device/system  
5. Exclusive (sole) monogamous intercourse with a sterilized (i.e., vasectomized) or 
otherwise non-fertile (e.g., castrated) male partner; the male partner must have 
received medical assessment of the surgical success 
Progesterone-only oral contraceptives are excluded as a highly effective method of 
contraception, as they do not consistently inhibit ovulation. Male or female condoms with or 
without spermicide, and female caps, diaphragms, and sponges with spermicide, or 
combinations (double barrier) are also excluded as highly effective contraceptive methods. 
Any pregnancy occurring in a female subject or the female partner of a male subject, from 
the first study drug administration through the required follow-up visit must be reported 
within 24 hours of the investigator’s awareness of the pregnancy. See Safety Form 
Completion Instructions for complete instructions.  
The investigator will follow the pregnancy to delivery or other pregnancy outcome.  
Pregnancy in a female clinical trial subject or female partner of a male clinical trial subject is 
not an SAE per se. Complications of such pregnancies (for example, spontaneous abortion) 
may qualify as SAEs and should be reported as such even if they occur after the Follow-up 
visit. Any congenital anomalies/birth defects must be recorded and reported as SAEs. See 
Safety Form Completion Instructions for complete instructions.  
7.1.6 
Worsening of Pruritus or PN 
Pruritus or PN should be recorded as an AE or SAE only if considered by the investigator to 
have worsened in severity beyond the subject’s typical fluctuations. It is important to include 
a description of the nature of the unexpected worsening when recording the AE or SAE (e.g. 
new PN lesions in previously uninvolved skin). 
122


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 47 
7.2 
Methods and Timing for Recording and Reporting Adverse Events 
7.2.1 
Adverse Event Reporting Period 
Any AE occurrence during the study must be recorded on source documentation and eCRF at 
the site, in accordance with protocol instructions.  
AEs and SAEs will be recorded from the first study drug administration through the 
follow-up visit. After the required follow-up visit, only SAEs that are believed to be drug-
related should be reported. 
After informed consent, but prior to initiation of study drug, only SAEs considered by the 
investigator to be caused by a protocol-mandated intervention will be collected (e.g. SAEs 
related to invasive procedures such as blood collection). These procedure-related SAEs 
should only be reported on the source documents and SAE form, not on the AE eCRF. 
Subjects who undergo screening procedures but are not randomized into the study will not 
have SAEs recorded in the clinical database. 
7.2.2 
Eliciting Adverse Events 
Investigators will seek information on AEs and SAEs at each subject contact through the 
follow-up visit. All AEs and SAEs, whether reported by the subject or noted by authorized 
study personnel, will be recorded in the subject’s medical record and on the AE eCRF page, 
and, if serious, on the SAE form. For each AE and SAE recorded, the investigator will make 
an assessment of seriousness, severity, and causality. 
7.2.3 
Assessment of Severity 
All AEs entered into the eCRF will be graded for severity using the National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 (“Common 
Terminology Criteria for Adverse Events (CTCAE)” 2010) to describe the maximum 
intensity of the adverse event.   
If the AE cannot be found in the event-specific NCI CTCAE grading criteria, the investigator 
should use the definitions for Grade 1, 2, 3, and 4 in Table 1. 
123


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 48 
Table 1 
Adverse Event Grading 
Grade 
Severity 
Alternate Descriptiona 
1 
Mild (apply event-specific NCI 
CTCAE grading criteria) 
Asymptomatic or mild symptoms; clinical 
or diagnostic observations only; 
intervention not indicated. 
2 
Moderate (apply event-specific NCI 
CTCAE grading criteria) 
Minimal, local or noninvasive intervention 
indicated; limiting age-appropriate 
instrumental activities of daily living 
(ADLb) 
3 
Severe (apply event-specific NCI 
CTCAE grading criteria) 
Severe or medically significant but not 
immediately life-threatening; 
hospitalization or prolongation of 
hospitalization indicated; disabling; 
limiting self care ADLc 
4 
Very severe, life threatening, or 
disabling (apply event-specific NCI 
CTCAE grading criteria) 
Life-threatening consequences; urgent 
intervention indicated. 
5 
Death related to AE 
 
a 
Use these alternative definitions for Grade 1, 2, 3, and 4 events when the observed or reported AE is not 
in the NCI CTCAE listing. A semi-colon indicates ‘or’ within the alternate description of the grade. 
b 
Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc. 
c 
Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
Source: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 
 
Note that severity, a measure of intensity, is not equivalent to seriousness, a regulatory 
definition of outcome. Regardless of severity, some AEs may meet the criteria for 
seriousness. See Section 7.1.2 for the definition of an SAE. 
If an adverse event changes in severity during the same study period (e.g., treatment period), 
only the highest severity grade will be recorded on the eCRF.  
7.2.4 
Assessment of Causality 
The investigator’s assessment of causality must be provided for all AEs (serious and 
non-serious). An investigator’s causality assessment is the determination of whether there 
exists a reasonable possibility that the investigational product caused or contributed to an AE. 
Causality of an AE will be assessed by the investigator using the following terms: 
• Likely Related: A reaction that follows a reasonable temporal sequence from 
administration of the study drug; that follows a known or expected response pattern to the 
suspected study drug; and for which other potential etiologies are considered less likely 
factors than the study drug. 
• Likely Unrelated: A reaction that, considering all potential etiologies, is most likely due 
to factors other than the study drug. 
124


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 49 
7.3 
Follow-up of Adverse Events and Serious Adverse Events 
The investigator must make every effort to follow all AEs and SAEs regardless of attribution 
until judged resolved or stabilized, the subject is lost to follow-up, or it has been determined 
that study drug treatment or participation in the study is not the cause of the AE or SAE. 
7.4 
Reporting Serious Adverse Events to the Sponsor and Institutional 
Review Board or Ethics Committee   
The Sponsor or designee is under obligation to report certain SAEs to regulatory authorities 
related to investigational drugs in clinical trials. The Sponsor or designee must be notified 
within 24 hours of an AE when the investigator determines that an AE meets the protocol 
definition of an SAE, regardless of the cause or relationship to study drug.  
An SAE related to study participation occurring before study drug administration and after 
informed consent should be promptly reported to the Sponsor. If the investigator learns of 
any SAE at any time after a participant has been discharged from the study, and the SAE is 
considered likely related to study drug, the SAE should be promptly reported to the Sponsor. 
Please see the Safety Form Report Completion Instructions for safety reporting instructions.  
The investigator must also comply with applicable requirements concerning reporting of 
SAEs to the IRB or Ethics Committee (EC). This may include initial or follow-up 
notification of an SAE or other safety information. 
7.5 
Reporting Serious Adverse Events to Regulatory Authorities and Study 
Investigators 
The Sponsor, or its designee, is responsible for submitting reports of serious, unexpected 
related adverse events to regulatory authorities on an expedited basis, according to the ICH 
E2A Guideline and to other regulatory authorities according to national and local regulations 
as required. The Sponsor, or its designee, is responsible for prompt submission to the IRB or 
EC of any expedited SAE reports submitted to regulatory authorities. All investigators 
participating in ongoing clinical studies with serlopitant will receive copies of the SAE 
reports submitted on an expedited basis to regulatory authorities. 
7.6 
Emergency Unblinding 
Emergency unblinding is available 24 hours per day/7 days per week and will be performed 
via IVRS. An investigator may unblind a subject’s treatment assignment only when 
knowledge of the investigational product is essential for the welfare of a subject. There is no 
specific antidote for serlopitant and usual supportive medical management is recommended 
in the case of a medical emergency. 
125


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 50 
8 
STATISTICAL METHODS  
All statistical processing will be performed using SAS® unless otherwise stated. One interim 
analysis may be performed. Endpoints will be summarized with descriptive statistics by 
treatment group and visit. For continuous variables, the following information will be 
presented: n (number of subjects), mean, standard deviation, median, minimum and 
maximum. For categorical variables counts and percentages will be used. Summary statistics 
for imputed efficacy data will be reported based upon imputed data. 
The primary method of handling missing efficacy data will be the method of Markov Chain 
Monte Carlo (MCMC) multiple imputation. Subjects who withdrew from the study due to a 
lack of efficacy, or used an excluded therapy to treat worsening of pruritus or PN, will be 
defined as non-responder.  
As one sensitivity analysis, the last observation carried forward method (LOCF) will be used 
(i.e., the last available on-therapy observation for a subject will be used to estimate 
subsequent missing data points). As a second sensitivity analysis, a repeated measures model 
will be used on observed data. Additionally, a tipping point analysis will be done as a 
sensitivity analysis for the primary endpoint. 
Baseline for measures other than the eDiary daily measures will be the last recorded value 
prior to the start of treatment. For daily measures including the WI-NRS, baseline will be the 
average result measured over the week prior to treatment.  
A statistical analysis plan (SAP), describing all statistical analyses will be provided as a 
separate document. The SAP will be finalized prior to unblinding of the study treatments. 
8.1 
Decision Rule and Sample Size  
This study will use a 5% two-sided alpha level. While the alpha level is two-sided, clinically 
relevant results require a serlopitant benefit. Statistical significance for the key secondary 
efficacy endpoints requires statistical significance for the primary efficacy endpoint (i.e. 
stepdown testing from primary to key secondary endpoints). The key secondary efficacy 
endpoints will be tested in order starting with the Week 4 WI-NRS 4-point responder rate, 
and then the change from baseline to Week 10 in DLQI.  
The target sample size of 280 randomized and dosed subjects (140 per group) has been 
determined based upon a 1:1 allocation of subjects to treatment groups and a 5% alpha level. 
Completed Phase 2 studies indicate that placebo responder rates vary between 
% and 
% 
and serlopitant rates between 
% and 
%. A sample size of 280 subjects provides >90% 
power assuming a placebo responder rate of 
% and a serlopitant rate of 
%. 
The sample size calculations have been performed in PASS 13 (“PASS 13 Power Analysis 
and Sample Size Software” 2014) and use a Chi-Squared test. The primary analysis will 
control for the stratification factors. It is expected that this unstratified power estimate will 
under-estimate the true power as it does not take the variance reduction resulting from 
stratification into account (Matts 1988).  
126
CCI
CCI
CCI
CCI
CCI
CCI


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 51 
8.2 
Handling of Missing Data  
Should a determination of treatment period (on treatment, pre-treatment, follow-up) be 
required for adverse events or concomitant medication but the corresponding date is missing, 
or is a partial date, the event/medication will be considered on treatment unless the portions 
of the date that are available indicate this is not possible. 
The primary method of handling missing efficacy data will be MCMC multiple imputation. 
Subjects who withdrew from the study due to a lack of efficacy, or used an excluded therapy 
to treat worsening of pruritus or PN, will be defined as non-responder. Imputation will be 
conducted within each treatment group independently, so the pattern of missing observations 
in one treatment group cannot influence missing value estimations in another. For each 
imputation process, 25 imputations will be performed. 
If a subject fails to complete their eDiary for the week prior to Week 10, the primary 
endpoint (WI-NRS) data will be missing, unless the subject withdrew from the study due to a 
lack of efficacy, or the subject used an excluded therapy to treat worsening of pruritus or PN, 
in which case their responder status will be defined as non-responder. If the Week 10 value is 
missing for any other reason, the change from baseline value will be based on imputed data. 
Missing Week 10 WI-NRS values from which the 4-point responder status is derived will be 
estimated by MCMC. 
Missing WI-NRS data will be derived for the analysis using the method of MCMC multiple 
imputation. Since both primary and key secondary efficacy endpoints require WI-NRS, the 
following steps will be followed: 
1. Using the daily eDiary data, calculate Baseline and Week 2 through Week 10 
values by averaging available values. If any values are available, these will be used 
i.e. a minimum of 1 observation is required to compute a week’s average.  
2. From step 1, create a dataset for each treatment group, of subjects with observed 
values and those needing estimation by MCMC. The missing WI-NRS values in each 
dataset will be filled in using the MCMC method to generate 25 datasets. The 
resulting datasets for each treatment arm will be combined into one complete dataset. 
Syntax: 
proc mi data=datain out=dataout seed=&seed. Nimpute=25 <options>; 
  where trtpn=(TRT);   /* Note TRT = [1, 2]; depending on treatment group */; 
  mcmc chain=single; 
  var baseline week1 week2 week3 week4 week5 week6 week7 week8 week9 
week10; 
run; 
 
3. From each complete dataset, the dichotomous responder rate will be determined. 
Each complete dataset will be analyzed as specified for the particular analysis. 
127


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 52 
Missing Week 10 DLQI data will be derived for the analysis using the method of MCMC 
multiple imputation. The following steps will be followed: 
1. DLQI for Week 10 will be calculated as per scoring instructions.  
2. From step 1, create a dataset for each treatment group, of subjects with observed 
values and those needing estimation by MCMC. The missing values in each dataset 
will be filled in using the MCMC method to generate 25 datasets. The resulting 
datasets for each treatment arm will be combined into one complete dataset. 
Syntax: 
proc mi data=datain out=dataout seed=&seed. Nimpute=25 <options>; 
  where trtpn=(TRT);   /* Note TRT = [1, 2]; depending on treatment group */; 
  mcmc chain=single; 
  var baseline week4 week10; 
run; 
 
3. Each complete dataset will be analyzed as specified for the particular analysis. 
Each complete dataset formed by multiply imputed data will be analyzed as specified for the 
particular analysis. The results from the analyses will be combined into a single inference 
using SAS® PROC MIANALYZE. In the case of the primary analysis and the secondary 
responder analyses, the Cochran Mantel Haenszel (CMH) statistics computed in the analyses 
of WI-NRS responder rates will be normalized using the Wilson-Hilferty transformation 
prior to combining them using SAS® PROC MIANALYZE 
A total of 4 random seeds will be needed to impute missing data. Those random seeds have 
been pre-specified by using a random number generator: 
8.3 
Analysis Populations  
The primary efficacy population will be the Intent-to-Treat (ITT) and will include all 
randomized subjects who were dispensed study drug. Subjects will be analyzed within the 
treatment group to which they are randomized.  
The primary safety population will be all treated subjects with at least one post-baseline 
assessment. For safety analyses, subjects will be classified based upon the treatment 
received.  
128
CCI


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 53 
The Per Protocol (PP) population will include all subjects in the safety population who 
complete the Week 10 evaluations without any significant protocol violations (i.e., any 
subject or investigator activity that could have possibly interfered with the therapeutic 
administration of the treatment or the precise evaluation of treatment efficacy). Analyses 
performed on the Per Protocol population will be considered supportive. The PP population 
will include subjects in the safety population who do not meet any of the following criteria: 
• Violated the inclusion/exclusion criteria; 
• Receives a strong CYP3A4 inhibitor (See Appendix B); 
• Receives an excluded medication for treatment of pruritus or PN; 
• Have not been compliant with the dosing regimen (i.e. subjects must comply with 
80120% of the expected dosage of study medication during participation in the study); 
• Out of visit window at the Week 10 visit by ±7 days 
Subjects that discontinue from the study drug due to an adverse event related to study 
treatment or documented lack of treatment effect will be included in the PP population. Prior 
to breaking the blind, other additional criteria may be added to the list to accommodate for 
unforeseen events that occurred during the conduct of the trial that result in noteworthy study 
protocol violations. 
8.4 
Subject Disposition  
An accounting of all randomized subjects by disposition will be presented. Subjects who 
discontinue study drug prematurely or withdraw from the study will be summarized and 
listed, with a description of the reason for early termination/withdrawal. 
8.5 
Subject Characteristics  
Demographic and other baseline characteristics will be summarized. 
8.6 
Prior and Concomitant Medications  
Prior and concomitant medications will be coded by the World Health Organization Drug 
Dictionary to Anatomical Therapeutic Classification (ATC) and preferred drug name.  
Prior therapies (including over-the-counter medications) used to treat the signs and 
symptoms of PN within the prior 2 years will be reported. Prior medications will be 
summarized by ATC level and preferred drug name and listed. 
Concomitant medications will be summarized by ATC level and preferred drug name and 
listed. Concomitant medication use will be quantified and analyzed. 
129


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 54 
8.7 
Treatment Compliance and Extent of Exposure  
Compliance with study drug dosing will be determined based on tablet counts recorded on the 
eCRF. Compliance will be calculated by analyzing expected number of tablets returned versus 
actual number of tablets returned. Summaries of treatment exposure will also be produced.  
8.8 
Efficacy Analyses  
All efficacy endpoints will be summarized within the ITT and PP populations using 
descriptive statistics by time point and treatment. Results including averaged imputed values 
will be summarized at Baseline, Week 2 (if available), 4, 10 and Follow-up, and the change 
from baseline for these measures will be summarized at Week 2, 4, 10 and Follow-up. The 
WI-NRS and change from baseline will also be presented for each study day.  
8.8.1 
Primary Efficacy 
The difference in the primary efficacy outcome measure (WI-NRS 4-point responder rate at 
Week 10) will be tested using a CMH test controlling for the ‘as randomized’ stratification 
factors. Conceptually the hypotheses being tested are: 
H0:PPlacebo ≥ PSerlopitant  
Ha: PPlacebo < PSerlopitant 
where PPlacebo is the percent of placebo responders and PSerlopitant is the similar percent for 
serlopitant. The primary endpoint will utilize the missing data rules as outlined in 
Section 8.2.  
8.8.2 
Key Secondary Efficacy  
The differences between treatment groups for the key secondary efficacy endpoint, Week 4 
WI-NRS 4-point responder rate, will be the CMH test identical to the one used for the 
primary endpoint.  
Change from baseline in DLQI to Week 10 will be analyzed using an analysis of covariance 
(ANCOVA) model with treatment group and stratification factor as fixed effects and the baseline 
DLQI as a covariate.  Both least squares means and observed means will be presented. 
To confirm the assumptions for the ANCOVA model (i.e., that the errors are normally 
distributed with equal variances), residuals will be examined using the Shapiro-Wilk test. If 
there is overwhelmingly strong evidence that the assumptions are not satisfied, the data will 
be rank-transformed prior to submitting to the ANCOVA. Results of the rank-transformed 
analysis then will be considered the primary analysis; however, results of the non-rank-
transformed analysis will also be presented.  
The preceding tests are to be conducted for the ITT population and the PP populations. 
130


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 55 
8.8.3 
Additional Secondary Efficacy  
Additional secondary efficacy endpoints will include analyses analogous to the primary and 
key secondary efficacy analyses. Additional secondary efficacy endpoints which may be 
drawn from the primary and key secondary imputations (including all WI-NRS endpoints) 
will be analyzed using the imputed data. Additional secondary efficacy endpoints otherwise 
will be analyzed using available data. P-values will be included for descriptive purposes 
only. 
8.9 
Sensitivity Analyses  
8.9.1 
Last Observation Carried Forward  
In the first set of sensitivity analysis, missing values will be imputed using LOCF. Data will 
be imputed using LOCF unless the subject withdrew from the study due to a lack of efficacy, 
or the subject used an excluded therapy to treat worsening of pruritus or PN, in which case 
their responder status will be defined as non-responder. Each primary and key secondary 
endpoint will be analyzed as it was using the multiply imputed data.  
8.9.2 
Repeated Measures Analysis 
The second set of sensitivity analyses will be performed on observed data. 
The dichotomized primary and key secondary WI-NRS endpoints will be analyzed with a 
repeated measures logistic regression model (generalized estimating equations), with the 
dichotomized endpoint as the dependent variable and treatment, stratification factor and visit 
(Weeks 2, 4, 10) as independent factors 
Change from baseline in DLQI to Week 10 will be analyzed with a repeated measures 
ANCOVA, with treatment, stratification factor and applicable timepoints as independent 
factors and a covariate of baseline value. 
8.9.3 
Tipping Point Analysis 
A sensitivity analysis for the handling of missing data for the primary efficacy endpoint will 
be carried out using a tipping point analysis. 
8.10 
Safety Analyses  
8.10.1 
Adverse Events  
The incidence of all AEs and treatment-related AEs will be tabulated by treatment received. 
These AEs will be classified by system organ class and preferred term using the Medical 
Dictionary for Regulatory Activities (MedDRA). For incidence reporting, if a subject 
reported more than one AE that was coded to the same system organ class or preferred term, 
the subject will be counted only once for that specific system organ class or preferred term. 
An overview of AEs, which includes subject incidence of AEs, treatment-related AEs, AEs 
by severity, SAEs, deaths, and AEs leading to discontinuation, will be presented.  
131


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 56 
SAEs will be listed and summarized in a similar manner to AEs. 
8.10.2 
Clinical Safety Laboratory Results  
Clinical safety laboratory values will be measured by a central laboratory. Summary statistics 
for actual values and for changes from baseline will be tabulated for laboratory results by 
scheduled visit. Graphs of laboratory values over time will also be produced.  
Subjects with clinical laboratory values outside of the normal reference range at any 
post-baseline assessment will be summarized. Shifts from baseline laboratory values will be 
tabulated. 
8.10.3 
Vital Signs  
The observed data and change from baseline for each measurement day will be summarized 
with descriptive statistics.  
8.10.4 
Electrocardiograms  
The overall ECG assessment (abnormal or normal) will be summarized and descriptively 
characterized, along with a summary of how many subjects developed a post treatment 
abnormal result.  
8.10.5 
Physical Exams  
Physical exam finds will be recorded by the sites within medical history or adverse events and 
otherwise not summarized. 
8.10.6 
Menstrual Diaries 
Menstrual diary dates will be used to summarize number and duration of menses.  
8.10.7 
Hospital Anxiety and Depression Scale   
The observed data and change from baseline for the HADS will be summarized with 
descriptive statistics by scheduled visit. Both the Depression and the Anxiety subscales will 
be reported. 
8.10.8 
Epworth Sleepiness Scale   
The observed data and change from baseline for the ESS will be summarized with descriptive 
statistics by scheduled visit.  
8.11 
Interim Analyses  
An interim analysis may be performed once approximately 50% of subjects have available 
Week 10 efficacy assessments. The purpose of this is to assess the adequacy of the sample 
size assumptions. In order to maintain the integrity of the trial, no unblinding of investigators 
or Sponsor will occur. The interim analysis will be performed by an independent statistician. 
132


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 57 
No decrease in sample size will be considered; only an increase in sample size may be 
considered. Full details would be provided in a separate Interim Analysis Plan. 
8.12 
Population Pharmacokinetics Analysis  
The plasma concentrations of serlopitant and metabolites will be combined with the data 
from other serlopitant clinical studies for population PK analysis with PK endpoint of 
individual model parameter estimates and covariates identification. A specific population PK 
data analysis plan will be developed that will outline the detailed approach to data handling, 
model development and diagnostics, individual model parameter estimation, exploration of 
covariate effects, and final model evaluation techniques. The population PK analysis report 
will not be a part of the clinical study report. 
9 
ADMINISTRATIVE ASPECTS 
9.1 
Changes to the Protocol 
Protocol amendments must be made only with the prior written approval of the Sponsor. An 
investigator signature will be obtained for the initial protocol and any amendments. 
Substantial amendments will be provided to the appropriate regulatory authorities. No 
protocol changes affecting the following will be made without the written approval of the 
Sponsor and the responsible IRB or EC: 
• Safety and/or eligibility of subjects 
• Data integrity 
• Study design or conduct 
• Willingness of a subject to participate in the study 
9.2 
Study Termination 
The Sponsor has the right to terminate this study at any time. Reasons may include, but are 
not limited to, evidence of a potential safety risk in this study or other serlopitant studies or 
poor enrollment. The study may be terminated at the request of the US Food and Drug 
Administration, the European Medicines Agency, other Competent Authorities or regulatory 
agencies with appropriate jurisdiction, or if the approval to manufacture or to import study 
drug is revoked by those with jurisdiction. A written statement fully documenting the reasons 
for study termination will be provided to the IRB or EC. 
9.3 
Monitoring and Auditing Procedures 
The Sponsor will designate study monitors who will be responsible for monitoring the 
conduct of this study. A separate study Monitoring Plan will include details regarding the 
responsibilities of the study monitors, investigator responsibilities in providing access to 
records and addressing issues identified, the frequency and structure of monitoring visits, and 
adherence to subject confidentiality as outlined in the Informed Consent Form (ICF). 
133


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 58 
9.4 
Transfer of Obligations 
The Sponsor will delegate certain aspects of study oversight to Contract Research 
Organizations (CROs). The specific responsibilities will be detailed in Transfer of 
Obligations documents.  
9.5 
Informed Consent 
The purpose of the study, the procedures to be carried out, and any potential risks of study 
participation will be described in non-technical terms in the ICF. After having reviewed and 
understood the ICF, subjects will be required to read, sign, and date an IRB-approved or 
EC-approved consent form before any study-specific procedures are carried out. Subjects 
will be assured that they may withdraw from the study at any time without jeopardizing 
medical care related to or required as a result of study participation. The original signed 
consent form will be maintained in the investigator site file. Copies of signed consent forms 
will be provided to the subject. 
9.6 
Communication with the Institutional Review Board or Ethics Committee 
The IRB or EC is constituted and operates in accordance with the principles and 
requirements described in the ICH E6 guideline. The protocol, ICF, other written subject 
information, and any proposed study advertising material must be submitted to the IRB or 
EC for written approval. IRB or EC approval of these documents will be provided to the 
investigator. The study will not start until the IRB or EC has granted its approval of the study 
materials and procedures. 
Protocol amendments will be submitted to the IRB or EC as explained in Section 9.1. SAE 
information will be submitted to the IRB or EC as explained in Section 7.4.  
If the study is terminated by the Sponsor, a written statement fully documenting the reason(s) 
for study termination will be provided to the IRB or EC. 
9.7 
Disclosure and Confidentiality 
By signing this protocol, the investigator agrees to keep all information provided by the 
Sponsor in strict confidence and to require the same confidentiality from site staff and the 
IRB or EC. Study documents provided by the Sponsor (e.g. protocol, IB, eCRFs) will be 
stored appropriately to ensure their confidentiality. The information provided by the Sponsor 
to the investigator may not be disclosed to others without direct written authorization from 
the Sponsor, except to the extent necessary to obtain informed consent from subjects who 
wish to participate in the study.  
The investigator must ensure that the subjects be identified by a unique subject study 
number. Other study-related documents that may contain confidential participant information 
(e.g. signed ICFs) will be kept in strict confidence by the investigator and be stored in a 
secure location with access restricted to the study staff. 
134


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 59 
9.8 
Records and Electronic Case Report Forms 
All study data except central laboratory, PK, eDiary, photography and ECG data will be 
recorded in an eCRF system. Data will be entered at the site by the appropriately designated 
and trained site personnel. All source documents from which eCRF entries are derived should 
be placed in the subject’s medical records. eCRFs will be completed for every subject 
screened in the study. 
The study monitor will review all eCRFs in detail and will have access to participant medical 
records, laboratory data, and other source documentation to allow required eCRF fields to be 
verified by source data. 
Data consistency and plausibility checks against data entered into the eCRF will be included 
in the eCRF system. Data corrections can be performed in the eCRFs by the site. For each 
instance of data modification, the system requires a reason for change. The system keeps a 
full audit trail of the data values, the date and time of modification, and the electronic 
signature of the user who performed the change. 
After a full review of the eCRFs by the study monitor and resolution of any data 
clarifications, the investigator will review, sign, and approve the subject’s eCRF. All 
essential documents, source data, clinical records, and laboratory data will be retained by the 
site in accordance with the ICH E6 guideline and the site’s data retention policies. These 
records must be available for inspection by the Sponsor, monitor, and regulatory authorities. 
Further detail regarding data management and eCRFs is included in the Data Management 
Plan. 
9.9 
Good Clinical Practices and Ethical Study Conduct 
The study procedures outlined in this protocol will be conducted in accordance with 
applicable ICH Guidelines, including ICH E6: Good Clinical Practices. As this study is 
conducted under a US IND, the investigator will also ensure that the basic principles of 
“Good Clinical Practice”, as outlined in 21 CFR 312, subpart D, “Responsibilities of 
Sponsors and Investigators”, 21 CFR, part 50 and 21 CFR, part 56 are adhered to. 
The study procedures outlined in this protocol will also be conducted in accordance with the 
principles of the Declaration of Helsinki. 
9.10 
End of Study Notification 
The Sponsor will notify appropriate regulatory authorities and the IRB or EC within 90 days 
from the end of the clinical study. The end of the clinical study is defined as the last study 
visit for the last subject. 
9.11 
Publication of Results 
All publications (e.g. manuscripts, abstracts, oral/slide presentations, book chapters) based on 
this study or relying on data from this study must be submitted to the Sponsor for review and 
135


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 60 
release before submission for publication. The Sponsor is responsible for final approval of all 
publications. 
9.12 
Final Report 
A clinical trial summary report will be provided to the appropriate regulatory authorities 
within one year of the end of the clinical study. 
136


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 61 
10 
REFERENCES 
Abadía Molina F, Burrows NP, Jones RR, Terenghi G, Polak JM. Increased sensory 
neuropeptides in nodular prurigo: A quantitative immunohistochemical analysis. Br J 
Dermatol. 1992;127:344-351. 
Akiyama T, Nguyen T, Curtis E, et al. A central role for spinal dorsal horn neurons that express 
neurokinin-1 receptors in chronic itch. Pain. 2015;156(7):1240-1246. 
Andoh T, Nagasaw T, Satoh M, Kuraishi Y. Substance P induction of itch-associated response 
mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther. 
1998;286(3):1140-1145. 
Bergasa NV. The itch of liver disease. Semin Cutan Med Surg. 2011;30(2):93-98. 
Booken N, Heck M, Nicolay JP, et al. Oral aprepitant in the therapy of refractory pruritus in 
erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011;164(3):665-667. 
Common Terminology Criteria for Adverse Events (CTCAE). 4.03 ed: National Institutes of 
Health; 2010. 
Crowe R, Parkhouse N, MacGrouther D, Burnstock G. Neuropeptide-containing nerves in painful 
hypertrophic human scar tissue. Br J Dermatol. 1994;130:444-452. 
Dazzi C, Erma D, Piccinno R, Veraldi S, Caccialanza M. Psychological factors involved in 
prurigo nodularis: A pilot study. J Dermatolog Treat. 2011;22(4):211-214. 
Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Eng J Med. 
2009;361(14):1415-1416. 
El-Nour H, Lundeberg L, Al-Tawil R, Granlund A, Lonne-Rahm SB, Nordlind K. Upregulation 
of the axonal growth and the expression of substance P and its NK1 receptor in human 
allergic contact dermatitis. Immunopharmacol Immunotoxicol. 2006;28(4):621-631. 
Emend® (aprepitant) capsule for oral use. U.S. Prescribing Information. Merck Sharp and Dohme 
Corp. Revised August 2015. 
Examples of clinical inhibitors for P450-mediated metabolisms (for concomitant use clinical DDI 
studies and/or drug labeling) (9/26/2016). U.S. Food and Drug Administration; 2016. 
Feldmeyer L, Werner S, Kamarashev J, French LE, Hofbauer GF. Atopic prurigo nodularis 
responds to intravenous immunoglobulins. Br J Dermatol. 2012;166(2):461-462. 
Fostini AC, Girolomoni G, Tessari G. Prurigo nodularis: an update on etiopathogenesis and 
therapy. J Dermatolog Treat. 2013;24(6):458-462. 
Gerber PA, Buhren BA, Cevikbas F, et al. Preliminary evidence for a role of mast cells in 
epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol. 
2010;63(1):163-165. 
Goeksel T, Xie W, Ritzerfeld M, Heidenreich S, Mann H. Prurigo nodularis and dialyzer 
membrane. Blood Purif. 2013;35(2):26-27. 
Halvorsen JA, Aasebø W. Oral tacrolimus treatment of pruritus in prurigo nodularis. Acta Derm 
Venereol. 2015;95(7):866-867. 
Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol. 2001;33(6):555-576. 
137


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 62 
Hökfelt T, Pernow B, Wahren J. Substance P: A pioneer amongst neuropeptides. J Intern Med. 
2001;249(1):27-40. 
Hon KL, Lam MC, Wong KY, Leung TF, Ng PC. Pathophysiology of nocturnal scratching in 
childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance 
P. Br J Dermatol. 2007;157(5):922-925. 
Iking A, Grundmann S, Chatzigeorgakidis E, et al. Prurigo as a symptom of atopic and non-
atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad 
Dermatol Venereol. 2013;27(5):550-557. 
Jorgensen KM, Egeberg A, Gislason GH, Skov L, Thyssen JP. Anxiety, depression and suicide in 
patients with prurigo nodularis. J Eur Acad Dermatol Venereol. 2017;31(2):e106-107. 
Jorizzo JL, Gatti S, Smith EB. Prurigo: a clinical review. J Am Acad Dermatol. 1981;4(6): 
723-728. 
Lee MR, Shumack S. Prurigo nodularis: a review. Australas J Dermatol 2005;46:211-220. 
Lim VM, Maranda EL, Patel V, Simmons BJ, Jimenez JJ. A review of the efficacy of 
thalidomide and lenalidomide in the treatment of refractory prurigo nodularis. Dermatol 
Ther (Heidelb). 2016;6(3):397-411. 
Lotts T, Ständer S. Research in practice: substance P antagonism in chronic pruritus. J Dtsch 
Dermatol Ges. 2014;12(7):557-559. 
M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals. Food and Drug Administration; 2010. 
Matts JP, Lachin JM. Properties of permuted-block randomization in clinical trials. Control Clin 
Trials. 1988;9(4):327-344. 
Navigant Consulting, Inc. (2017). Report: Market Landscapes and Evaluation of Serlopitant for 
Use in Atopic Dermatitis and Prurigo Nodularis. (proprietary data). 
PASS 13 Power Analysis and Sample Size Software [computer program]. Kaysville, Utah, USA, 
ncss.com/software/pass.: NCSS, LLC; 2014. 
Recommendations related to contraception and pregnancy testing in clinical trials. Clinical Trial 
Facilitation Group; 2014. 
Rowland Payne CM, Wilkinson JD, McKee PH, Jurecka W, Black MM. Nodular prurigo – a 
clinicopathological study of 46 patients. Br J Dermatol. 1985;113(4):431-439. 
Saco M, Cohen G. Prurigo nodularis: Picking the right treatment. J Fam Pract. 2015;64(4):221-
226. 
Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to 
biological cancer treatments: a pilot study. Lancet Oncol. 2012;13(10):1020-1024. 
Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in 
lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical 
cutaneous neuropathy. Br J Dermatol. 2011;165(1):85-91. 
Slattery MJ, Essex MJ, Paletz EM, et al. Depression, anxiety, and dermatologic quality of life in 
adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011;128(3):668-671. 
138


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 3.0/21 March 2019 
 
Page 63 
Spring P, Gschwind I, Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with 
methotrexate. Clin Exp Dermatol. 2014;39:468-473. 
Ständer S, Pogatzki-Zahn E, Stumpf A, et al. Facing the challenges of chronic pruritus: a report 
from a multi-disciplinary medical itch centre in Germany. Acta Derm Venereol. 
2015b;95(3):266-271. 
Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 
1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968. doi: 
10.1371/journal.pone.0010968.  
Ständer S, Weisshaar E, Raap U. Emerging drugs for the treatment of pruritus. Exp Opin Emerg 
Drugs. 2015a;20:515-521. 
Ständer S, Stumpf A, Osada N, et al. Gender differences in chronic pruritus: women present 
different morbidity, more scratch lesions and higher burden. Br J Dermatol. 
2013;168(6):1273-1280. 
Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their 
receptors: contributions to physiological control and the mechanisms of disease. Physiol 
Rev. 2014;94(1):265-301. 
Tan WS, Tey HL. Extensive prurigo nodularis: characterization and etiology. Dermatol. 
2014;228(3):276-280. 
Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: Evidence of its effectiveness in 
patients with refractory pruritus continues. J Am Acad Dermatol. 2012;66(1):e14-15. doi: 
10.1016/j.jaad.2011.01.016. 
U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Vol 20172010. 
Vaidya DC, Schwartz RA. Prurigo nodularis: a benign dermatosis derived from a persistent 
pruritus. Acta Dermatovenerol Croat. 2008;16(1):38-44. 
Wallengren J. Prurigo: Diagnosis and management. Am J Clin Dermatol. 2004;5(2):85-95.  
Ward RS, Tuckett RP, English KB, Johansson O, Saffle JR. Substance P axons and sensory 
threshold increase in burn-graft human skin. J Surg Res. 2004;118(2):154-160. 
Zancanaro PC, McGirt LY, Mamelak AJ, Nguyen RH, Martins CR. Cutaneous manifestations of 
HIV in the era of highly active antiretroviral therapy: An institutional urban clinical 
experience. J Am Acad Dermatol. 2006;54(4):581-588. 
Zeidler C, Ständer S. The pathogenesis of prurigo nodularis--'Super-Itch' in exploration. Eu J 
Pain. 2016;20(1):37-40. 
 
139


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 64 
APPENDIX A  
SCHEDULE OF ACTIVITIES AND ASSESSMENTS 
Table 2 
Schedule of Visit Activities 
Examination 
Screening 
Mid-
ScreeningTC  
Baseline1  
Week 1TC 
(± 3 days) 
Week 2 
(± 3 days) 
Week 4 
(± 3 days) 
Week 6 
(± 3 days) 
Week 10 
(± 7 days) 
F/U2 
Early Treatment 
Discontinuation 
Demographics 
X 
 
 
 
 
 
 
 
 
 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
WI-NRS3 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
DLQI 
 
 
X 
 
 
X 
 
X 
 
X 
HADS, ESS 
 
 
X 
 
 
X 
 
X 
X 
X 
ECG 
X 
 
 
 
X 
X 
 
X 
X 
X 
Vital signs 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
Medical history (and prior medications)  
X 
X 
X 
 
 
 
 
 
 
 
Physical exam4 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
Concomitant medications  
 
 
X 
X 
X 
X 
X 
X 
X 
X 
Labs5  
X 
 
 
 
X 
 
  
X 
X 
X 
Urine pregnancy test6 
X 
 
X 
 
 
X 
 X 
X 
X 
X 
PK blood draw  
 
 
 
 
X 
X 
 
X 
 
 
Review of I/E criteria 
X 
X 
X 
 
 
 
 
 
 
 
IGA PN-A and IGA PN-S 
 
 
X 
 
X 
X 
 
X 
X 
X 
Photography (selected sites) 
 
 
X 
 
 
 
 
X 
X 
X 
Dispense/review menstrual diary (if 
applicable) 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
Dispense/collect eDiary  
X 
 
 
 
  
 
 
 
X  
X 
eDiary review/compliance7 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
Dispense and/or collect study drug 
 
 
X 
 
X 
X 
X 
X 
 
X 
Review study drug compliance 
 
 
 
 
X 
X 
X 
X 
 
 
AEs/SAEs8 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
TCTelephone Contact: The Mid-Screening telephone contact should only occur for subjects who require a washout longer than 2 weeks, at least 15 days prior to the scheduled Baseline visit.  
1All visits and windows should be scheduled based on the Baseline Visit (Day 1) 
2The Follow-up (F/U) visit occurs 21-35 days (+ 7 days) after the Week 10 visit or the last dose of study drug for subjects who discontinue study drug early.  
3WI-NRS at Screening visit will be collected manually on paper for Inclusion/Exclusion criteria. All subsequent WI-NRS are collected daily via eDiary. 
4Screening physical exam is complete and includes height and weight; other physical exams are targeted and include weight.  
5Labs are ideally performed in the morning, particularly at visits with endocrine assessments (including Reproductive Endocrinology for females under 55 at age of consent) at Screening, Week 10 
and Follow Up.  Iron Studies, serum IgE and Serology labs are done only at Screening visit; endomysial antibody test and other optional studies only performed at Screening;  
6Female subjects of childbearing potential only. Serum pregnancy test is required for positive or equivocal results 
7See Table 3 for eDiary assessments 
8During the period between informed consent and first study drug dose, only SAEs caused by a protocol-mandated intervention will be collected. 
140


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 65 
Table 3 
Schedule of eDiary Assessments 
An eDiary device is provided to subjects at the Screening visit and collected at the Follow-up visit.   
Device 
Assessment 
Frequency and Duration of Assessment 
eDiary 
WI-NRS 
Once daily from Screening/Mid-Screening visit through the Follow-up visit 
eDiary 
Dosing 
Once daily from Baseline visit through Week 10 visit or study drug discontinuation 
 
 
141


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 66 
APPENDIX B  
LIST OF STRONG CYP3A4 INHIBITORS 
The list of strong CYP3A4 inhibitors is based on the FDA list effective September 26, 2016, 
Examples of clinical inhibitors for P450-mediated metabolisms (for concomitant use clinical 
DDI studies and/or drug labeling (“Examples of clinical inhibitors for P450-mediated 
metabolisms (for concomitant use clinical DDI studies and/or drug labeling (9/26/2016)”).  
Note: This Appendix may be replaced if applicable (e.g., if updated by the FDA) through site 
communications without requiring a protocol amendment. 
1. 
boceprevir 
2. 
clarithromycin 
3. 
cobicistat 
4. 
conivaptan 
5. 
danoprevir and ritonavir 
6. 
diltiazem 
7. 
elvitegravir and ritonavir 
8. 
idelalisib 
9. 
indinavir and ritonavir 
10. 
itraconazolea 
11. 
ketoconazolea 
12. 
lopinavir and ritonavir 
13. 
nefazodone 
14. 
nelfinavir 
15. 
paritaprevir and ritonavir and (ombitasvir and/or dasabuvir) 
16. 
posaconazolea 
17. 
ritonavir 
18. 
saquinavir and ritonavir 
19. 
telaprevir 
20. 
tipranavir and ritonavir 
21. 
troleandomycin 
22. 
voriconazolea 
23. 
regular grapefruit juice consumption (note: The effect of grapefruit juice varies 
widely among brands and is concentration-, dose-, and preparation-dependent. 
Grapefruit juice may be a strong or a moderate CYP3A inhibitor depending on the 
preparation)b 
 
a 
When administered topically, it may not be considered a strong CYP3A4 inhibitor due to limited systemic 
absorption. 
b 
The occasional consumption of grapefruit juice or the consumption of grapefruit or other citrus fruits (e.g., 
pomelo, lemon, lime, Seville orange, bitter orange, starfruit) is not contraindicated. 
 
142


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 67 
APPENDIX C  
WORST ITCH NUMERIC RATING SCALE QUESTIONNAIRE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
   
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
143


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 68 
APPENDIX D 
INVESTIGATOR’S GLOBAL ASSESSMENT OF PRURIGO 
NODULARIS: ACTIVITY AND STAGE 
Score 
Category 
Description: Activity (IGA PN-A) 
0 
Clear 
No nodules have excoriations or crusts  
1 
Almost 
Clear 
Very small proportion of nodules have excoriations or crusts (up to 
approximately 10% of all nodules) 
2 
Mild 
Minority of nodules have excoriations or crusts (approximately 11- 25% of 
all nodules) 
3 
Moderate 
Many nodules have excoriations or crusts (approximately 26- 75% of all 
nodules) 
4 
Severe 
Majority of nodules have excoriations or crusts (approximately 76-100% of 
all nodules) 
 
Score 
Category 
Description: Stage (IGA PN-S) 
0 
Clear 
No nodules (0 nodules) 
1 
Almost 
Clear 
Rare, flattened lesions, with no more than 5 dome-shaped palpable nodules 
(approximately 1-5 nodules) 
2 
Mild 
Few, mostly flattened lesions, with small number of dome-shaped palpable 
nodules (approximately 6-19 nodules) 
3 
Moderate 
Many lesions, partially flattened, and dome-shaped palpable nodules 
(approximately 20-100 nodules) 
4 
Severe 
Abundant lesions, majority are dome-shaped palpable nodules (over 
100 nodules) 
 
144


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 69 
APPENDIX E 
DERMATOLOGY LIFE QUALITY INDEX 
Different language versions may be used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
145


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 70 
APPENDIX F 
HOSPITAL ANXIETY AND DEPRESSION SCALE 
 
To be used under license. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 3.0/21 March 2019 
 
Page 71 
APPENDIX G  
EPWORTH SLEEPINESS SCALE   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
  
 
  
 
  
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
147


 
1 
CLINICAL STUDY PROTOCOL MTI-106 
SUMMARY OF CHANGES 
 
Drug Product Name: 
Serlopitant 
 
Study Title:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, 
AND TOLERABILITY OF SERLOPITANT FOR THE 
TREATMENT OF PRURITUS IN ADULTS WITH 
PRURIGO NODULARIS  
 
IND No.: 
 
 
117780 
EudraCT No.:  
 
2017-004210-25 
ClinicalTrials.gov ID:  
NCT03677401 
Protocol Version: 
 
4.0 
Protocol Date: 
 
16 Dec 2019 
Replaces Version/Date: 
3.0 / 21 March 2019 
 
148


Serlopitant 
 
Menlo Therapeutics Inc. 
MTI-106 Protocol, Summary of Changes Version 3.0 to Version 4.0 
 
 
 
2 
The following changes were made to the MTI-106 Clinical Study Protocol from Version 3.0 to Version 4.0. 
KEY CHANGES: 
Section(s) 
Summary of Change 
Reason for Change 
Protocol Synopsis  
Updated consistent with changes to the protocol body. 
Ensure consistency between synopsis and protocol 
body.  
3.3.2 Key 
Secondary Efficacy 
Endpoints 
Removed ‘Change from Baseline in Dermatology Life 
Quality Index (DLQI) to Week 10’  
 
Added ‘WI-NRS 4-point responder rate at Week 2’ 
 As a mixed tool consisting of 10 questions, not all of 
which are specific to subjects with pruritus, the DLQI 
may have limited utility in the subject population. It is 
therefore removed from the multiplicity testing strategy 
as a Key Secondary Efficacy Endpoint, however is still 
retained as an Additional Secondary Efficacy Endpoint 
to enable an evaluation of the potential improvement in 
quality of life (see below). 
 
An improvement in pruritus (>4-point reduction in WI-
NRS) may be realized as early as  Week 2 of treatment 
and therefore is added as a Key Secondary Efficacy 
Endpoint and included in the multiplicity testing 
strategy. 
3.3.3 Additional 
Secondary Efficacy 
Endpoints’ 
Removed ‘WI-NRS 4-point responder rate at Week 2’ 
Added ‘Change from Baseline in DLQI to Week 10’  
Added ‘Change from Baseline in DLQI Question 1 to 
Week 10’    
Aligns with changes made to Section 3.3.2 Key 
Secondary Efficacy Endpoints, and retains ability to 
evaluate DLQI as an Additional Secondary Efficacy 
Endpoint 
Update due to prior change in SAP to analyze most 
relevant DLQI question as an additional secondary 
efficacy endpoint 
8.1 Decision Rule 
and Sample Size  
Removed ‘Change from Baseline in DLQI to Week 10’ 
Added ‘WI-NRS 4-point responder rate at Week 2’ 
Aligns with changes made to Section 3.3.2 Key 
Secondary Efficacy Endpoints. 
8.2 Handling of 
Missing Data 
Changed the minimum number of observations needed to 
compute a week’s average of WI-NRS from 1 observation 
to 4 observations. 
Removed the explanation for handling missing Week 10 
DLQI data. 
A requirement to use a minimum of 4 observations 
collected over the course of a week will better support 
computing a week’s average for the WI-NRS, instead 
of allowing for use of a single data point. 
149


Serlopitant 
 
Menlo Therapeutics Inc. 
MTI-106 Protocol, Summary of Changes Version 3.0 to Version 4.0 
 
 
 
3 
Section(s) 
Summary of Change 
Reason for Change 
Updated the number of random seeds needed to impute 
missing data. 
8.8.2 Key 
Secondary Efficacy 
Removed ‘Change from Baseline in DLQI to Week 10’ 
Added ‘WI-NRS 4-point responder rate at Week 2’ 
Removed information regarding the ANCOVA model 
 Aligns with changes made to Section 3.3.2 Key 
Secondary Efficacy Endpoints. 
8.8.3 Additional 
Secondary Efficacy 
Added information regarding the analysis of the secondary 
endpoints 
Aligns with changes made to 3.3.3 Additional 
Secondary Endpoints 
8.10.2 Clinical 
Safety Laboratory 
Results 
Removed ‘Graphs of laboratory values over time will also 
be produced.’ 
Update due to prior change in SAP  
 
ADMINISTRATIVE CHANGES: 
Section(s) 
Summary of Change 
Title page 
Added protocol version number and release date  
Signature Page for Investigator(s)   
Added protocol version number and release date 
Sponsor Protocol Approval Signature(s) 
Added protocol version number and release date  
Throughout  
Updated protocol version in footer; Edited formatting and corrected minor typos and 
inconsistencies 
 
150


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 4.0/16 December 2019 
 
Page 1 
CLINICAL STUDY PROTOCOL 
 
TITLE:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, AND 
TOLERABILITY OF SERLOPITANT FOR THE TREATMENT 
OF PRURITUS IN ADULTS WITH PRURIGO NODULARIS  
IND No.: 
 
 
117780 
Eudra CT: 
 
 
2017-004210-25 
ClinicalTrials.gov ID:  
NCT03677401 
Protocol No.:  
 
MTI-106   
Protocol Version/Date: 
Version 4.0/16 December 2019 
Development Phase:  
Phase 3 
Sponsor: 
 
 
Menlo Therapeutics Inc. 
200 Cardinal Way, 2nd Floor 
Redwood City, CA 94063 
USA  
 
 
 
 
Confidentiality Statement: 
This document is a confidential communication of Menlo Therapeutics Inc. As such, the 
recipients agree not to disclose or reproduce, without prior written approval, this document and 
any attachments, except to appropriate Ethics Committees, representatives of the US Food and 
Drug Administration, the European Medicines Agency, other Competent Authorities or 
regulatory agencies or as otherwise required by applicable laws or regulations.
151


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 4.0/16 December 2019 
 
Page 2 
SIGNATURE PAGE FOR PRINCIPAL INVESTIGATOR(S) 
 
TITLE:  
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, SAFETY, 
AND TOLERABILITY OF SERLOPITANT FOR THE 
TREATMENT OF PRURITUS IN ADULTS WITH 
PRURIGO NODULARIS  
IND No.: 
 
 
117780 
Eudra CT: 
 
 
2017-004210-25 
ClinicalTrials.gov ID:  
NCT03677401 
Protocol No.:  
 
MTI-106 
Protocol Version/Date: 
Verson 4.0/16 December 2019 
Development Phase:  
Phase 3 
Sponsor: 
 
 
Menlo Therapeutics Inc. 
200 Cardinal Way, 2nd Floor 
Redwood City, CA 94063 
USA  
 
I have read the protocol and agree to conduct this study in accordance with the protocol, all 
relevant laws and regulations in force at the time, International Conference on Harmonisation 
Guidelines for Good Clinical Practices, and the Declaration of Helsinki.  
 
 
 
Principal Investigator’s printed name 
 
 
 
 
 
 
Principal Investigator’s signature 
 
Date (DD-MMM-YYYY) 
 
  
152




Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
   
 
Version 4.0/16 December 2019 
 
Page 4 
PROTOCOL SYNOPSIS 
Study Title: 
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, 
Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults 
With Prurigo Nodularis  
Protocol Number: 
MTI-106 
Sponsor: 
Menlo Therapeutics Inc. 
Development Phase: 
Phase 3 
Study Objectives: 
Efficacy objective: To assess the efficacy of serlopitant for the treatment of 
pruritus in adults with prurigo nodularis. 
Safety objective: To assess the safety and tolerability of repeated oral doses of 
serlopitant in adults with prurigo nodularis.  
Study Design: 
This is a double-blind, randomized, placebo-controlled study to assess the 
efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in 
adults with prurigo nodularis (PN). Subjects who meet the study entry criteria 
will be randomized in a 1:1 ratio to receive daily oral doses of serlopitant 5 mg 
or placebo for 10 weeks. After completion of the treatment period or early 
discontinuation of study drug treatment, all subjects will enter a 3- or 5-week 
follow-up period.  
The study will consist of three periods, for a total study period of 15 to 
19 weeks: 
• 
Screening period: 2-4 weeks 
• 
Treatment period: 10 weeks 
• 
Follow-up period: 3 or 5 weeks  
 
During the screening period, all subjects will undergo eligibility evaluation and 
will be assessed for chronic pruritic conditions frequently associated with PN. 
Subjects who present with idiopathic PN at screening may require additional 
assessments as deemed necessary by the investigator (e.g. endomysial antibody 
with reflex to titer for subjects with signs or symptoms of dermatitis 
herpetiformis, skin biopsy for subjects with signs or symptoms of bullous 
pemphigoid or cutaneous T-cell lymphoma, urea breath test for 
Helicobacter pylori, or allergy testing).  
All screening procedures must be completed within 31 days before the Baseline 
visit. The minimum screening period for all subjects is 14 days to allow for 
collection of electronic diary (eDiary) screening data. Subjects who require a 
screening period longer than 14 days will have a telephone contact at least 15 
days prior to the scheduled Baseline visit to remind them to complete the eDiary 
as previously instructed at the Screening visit. 
Subjects will be provided an eDiary at the Screening visit. Subjects must be 
willing and able to complete the eDiary every day within a consistent 
timeframe, and comply with restrictions on allowable concomitant therapies, for 
the duration of the study.  
At the Baseline visit (Day 1), eligible subjects will be randomly assigned to 
receive study drug (serlopitant 5 mg or placebo). Subjects will take a loading 
dose (3 tablets taken orally) at the site on the first day of the treatment period 
(Day 1). Starting on Day 2, subjects will take one tablet per day. Study drug 
may be taken with or without food. 
154


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 5 
The primary efficacy endpoint will be assessed at Week 10 of treatment.  
Subjects who complete the 10-week treatment period and required follow-up 
period may be given the opportunity to enroll in a one-year open-label safety 
study with daily oral doses of serlopitant 5 mg. 
Safety Review: 
An internal safety monitoring team consisting of representatives from Menlo 
Therapeutics Inc. and its designees will monitor blinded safety data on a regular 
basis throughout the study. 
Planned Sample Size: 
Approximately 280 subjects will be randomized. 
Study Population: 
The study will consist of adult subjects with pruritus associated with PN.  
Inclusion Criteria (Subjects must meet the following criteria to be randomized 
into the study): 
1. Male or female, age 18 years or older at consent. 
2. A diagnosis of PN, defined by the presence of at least ten pruriginous 
nodules secondary to chronic pruritus present on at least two different body 
surface areas (e.g. both arms, one arm and one leg, one arm and the anterior 
trunk, or anterior and posterior trunk). 
3. The worst pruritus is identified to be within the areas of the PN lesions.  
4. Subject has idiopathic PN OR the subject has an identified pruritic 
condition associated with the PN and has persistent pruritus despite at least 
6 weeks of optimized and stable treatment of the underlying condition prior 
to the Baseline visit, and is willing to continue the treatment during the 
study.  
5. Worst-Itch Numeric Rating Scale (WI-NRS) score ≥ 7 in the 24-hour 
period prior to the Screening visit. 
6. Average weekly WI-NRS score ≥ 6.5 in each of the 2 weeks (14 days) 
immediately prior to Baseline visit, as recorded in the eDiary. 
7. All female subjects who are of childbearing potential must be willing to 
practice highly effective contraception (i.e., pregnancy prevention method 
with a failure rate of < 1% per year) from the time of the Screening visit 
until 5 weeks after last dose of study drug.   
8. Willing and able (as demonstrated by a ≥ 70% eDiary completion rate in 
the two weeks prior to Baseline visit) to complete daily eDiary entries 
within a consistent timeframe for the duration of the study. 
9. Willing and able (has adequate cognitive ability, in the investigator’s 
opinion) to comply with study visits and study related requirements 
including providing written informed consent. 
Exclusion Criteria (Subjects who meet any of the following criteria are not 
eligible for participation in the study): 
1. Prior treatment with serlopitant. 
2. Active pruritic skin disease, other than PN, within 6 months prior to 
randomization (with the exception of acute dermatoses such as contact 
dermatitis, sunburn, viral exanthem, which have been resolved for longer 
than 4 weeks).  
3. Treatment with any of the following therapies within 4 weeks prior to 
randomization. 
155


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 6 
a. 
Other neurokinin-1 receptor antagonists (e.g., aprepitant, 
fosaprepitant, rolapitant). 
b. Systemic or topical immunosuppressive/immunomodulatory 
therapies (including but not limited to corticosteroids, 
phosphodiesterase-4 inhibitors, cyclosporine, mycophenolate-
mofetil, tacrolimus, pimecrolimus, calcipotriene, methotrexate, 
azathioprine, interferon-gamma, thalidomide, or phototherapy).  
c. 
Systemic therapies with recognized anti-pruritic properties 
(including but not limited to H1 antihistamines, doxepin, 
gabapentin, pregabalin, cannabinoids, kappa-opioid receptor 
agonists, and mu-opioid receptor antagonists (e.g. naloxone, 
naltrexone)). 
d. Strong cytochrome-P 3A4 inhibitors. 
e. 
Use of an indoor tanning facility, or natural sun exposure resulting 
in significant tanning or sunburn. 
4. Treatment with topical anti-pruritic therapies (e.g., menthol, camphor, 
pramoxine, capsaicin) within 2 weeks prior to randomization. 
5. Treatment with biologic therapies within 8 weeks or 5 half-lives prior to 
randomization, whichever is longer. 
6. Treatment with any investigational therapy within 4 weeks (8 weeks for 
investigational biologic therapies) or 5 half-lives prior to randomization, 
whichever is longer. 
7. Serum creatinine, total bilirubin, alanine aminotransferase or aspartate 
aminotransferase > 2.5 times the upper limit of normal during screening. 
8. Untreated or inadequately treated thyroid, adrenal, or pituitary nodules or 
disease, or history of thyroid malignancy. 
9. History of malignancy within 5 years prior to randomization, with the 
exception of actinic keratosis, completely treated and non-metastatic 
cutaneous basal cell carcinoma or squamous cell carcinoma of the skin. 
10. Any known major psychiatric diagnosis, such as major depressive disorder, 
bipolar disorder, schizophrenia, psychotic disorder, intellectual disability, 
severe alcohol use disorder, which may confound the assessment of 
serlopitant safety or efficacy, or interfere with the subject’s ability to 
comply with protocol-mandated activities, within 3 years prior to 
randomization.  
11. Suicidal ideation within 3 years prior to randomization, or any history of 
suicide attempt. 
12. Documented history of parasitic infection, including skin parasites such as 
scabies, within 8 weeks prior to randomization. 
13. Presence of any medical condition or disability that, in the investigator’s 
opinion, could interfere with the assessment of safety or efficacy in this trial 
or compromise the safety of the subject. 
14. History of hypersensitivity to serlopitant or any of its components. 
15. Currently pregnant or breastfeeding female subject. 
16. Planned or anticipated major surgical procedure or other activity that would 
interfere with the subject’s ability to comply with protocol-mandated 
156


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 7 
assessments (e.g. extended international travel) during the subject’s 
participation in the study. 
Study Drug: 
Serlopitant 5 mg oral tablets and matching placebo. 
Dosage:  
Serlopitant: 5 mg once daily by mouth for 10 weeks, following a 3-tablet 
loading dose on the first day of the treatment period. 
Matching placebo: Once daily by mouth for 10 weeks, following a 3-tablet 
loading dose on the first day of the treatment period. 
Primary Efficacy 
Endpoint: 
The primary efficacy endpoint is the WI-NRS 4-point responder rate at Week 
10. 
Secondary Efficacy 
Endpoints: 
The key secondary efficacy endpoints are as follows: 
• 
WI-NRS 4-point responder rate at Week 4 
• 
WI-NRS 4-point responder rate at Week 2 
Additional secondary efficacy endpoints are as follows: 
• 
Change from baseline in WI-NRS to other timepoints 
• 
WI-NRS 3-point responder rate at Weeks 2, 4 and 10 
• 
Change from baseline in Dermatology Life Quality Index (DLQI) to Week 
10 
• 
Change from baseline in DLQI Question 1 to Week 10 
• 
Change from baseline in Investigator’s Global Assessment of PN Activity 
to Weeks 2, 4 and 10 
• 
Change from baseline in Investigator’s Global Assessment of PN Stage to 
Weeks 2, 4 and 10 
Safety Endpoints: 
Safety endpoints are as follows: 
• 
Incidence of treatment-emergent adverse events and serious adverse events 
(SAEs) 
• 
Changes from baseline in clinical laboratory parameters following study 
drug exposure 
• 
Changes from baseline in vital sign and electrocardiogram (ECG) 
parameters following study drug exposure 
• 
Changes from baseline in the Hospital Anxiety and Depression Scale 
(HADS)  
• 
Changes from baseline in the Epworth Sleepiness Scale (ESS) 
Decision Rule and 
Sample Size: 
This study will use a 5% two-sided alpha level. Hierarchical testing in which 
statistical significance for the key secondary efficacy endpoints requires 
statistical significance for the primary endpoint. 
The target sample size of 280 randomized and dosed subjects (140 per group) 
has been determined based upon a 1:1 allocation of subjects to treatment groups 
and a 5% alpha level. Completed Phase 2 studies indicate that placebo responder 
rates vary between 
% and 
% and serlopitant rates between 
% and 
%. 
A sample size of 280 subjects provides >90% power assuming a placebo 
responder rate of 
% and a serlopitant rate of 
%.  
Statistical Methods: 
Efficacy analyses will be based upon an intent-to-treat philosophy. The primary 
157
CCI
CCI
CCI
CCI
CCI
CCI


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 8 
efficacy population will be the Intent-to-Treat (ITT) population that will include 
all randomized subjects who were dispensed study drug. Analyses performed on 
the Per Protocol population will be considered supportive. Subjects will be 
analyzed within the treatment group to which they are randomized. 
Efficacy Analyses: 
The primary efficacy endpoint is a binary variable taking on values of responder 
or non-responder. Subjects will be considered a responder if they have at least a 
4-point reduction in WI-NRS between baseline and Week 10. Missing data 
imputation will be used for subjects who fail to complete the eDiary at Week 10, 
unless the subject withdrew from the study due to a lack of efficacy, or the 
subject used an excluded therapy to treat worsening of pruritus or PN, in which 
case their responder status will be defined as non-responder. The primary 
endpoint will be summarized with descriptive statistics by treatment group and 
study week.  
The difference in the primary efficacy outcome measure between treatment 
groups will be tested using a Cochran Mantel Haenszel test controlling for the 
stratification factors. Testing of the key secondary efficacy endpoints will also 
be employed. 
Safety Analyses: 
The incidence of all adverse events (AEs) and treatment-related AEs will be 
tabulated by treatment received. These AEs will be classified by system organ 
class and preferred term using the Medical Dictionary for Regulatory Activities. 
For incidence reporting, if a subject reported more than one AE that was coded 
to the same system organ class or preferred term, the subject will be counted 
only once for that specific system organ class or preferred term. An overview of 
AEs, which includes subject incidence of AEs, treatment-related AEs, AEs by 
severity, SAEs, deaths, and AEs leading to discontinuation, will be presented.  
Clinical safety laboratory values will be measured by a central laboratory. 
Summary statistics for actual values and for changes from baseline will be 
tabulated for laboratory results by scheduled visit.  
Subjects with clinical laboratory values outside of the normal reference range at 
any post-baseline assessment will be summarized. Shifts from baseline 
laboratory values will be tabulated. 
The overall ECG assessment (abnormal or normal) will be summarized along 
with a summary of how many subjects developed a post treatment abnormal 
result.  
Summary statistics for the HADS and ESS actual values and change from 
baseline will be presented by scheduled visit. 
Study Sites: 
Approximately 50 study sites. 
Expected Duration of 
Subject’s Participation 
15-19 weeks: 2-4 weeks of screening, 10 weeks of treatment, and a follow-up 
period of 3 or 5 weeks. 
 
This study will be conducted in accordance with the Guidelines of Good Clinical Practice (GCP). 
158


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 9 
TABLE OF CONTENTS 
CLINICAL STUDY PROTOCOL ............................................................................................1 
SIGNATURE PAGE FOR PRINCIPAL INVESTIGATOR(S) ................................................2 
SPONSOR PROTOCOL APPROVAL SIGNATURE(S) .........................................................3 
PROTOCOL SYNOPSIS...........................................................................................................4 
TABLE OF CONTENTS ...........................................................................................................9 
LIST OF APPENDICES ..........................................................................................................12 
LIST OF FIGURES .................................................................................................................13 
LIST OF TABLES ...................................................................................................................13 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ..........................................14 
1 
INTRODUCTION .................................................................................................16 
1.1 
Pruritus in Prurigo Nodularis ...........................................................................16 
1.2 
Conditions Associated With Prurigo Nodularis ...............................................16 
1.3 
Current Treatment Options for Prurigo Nodularis ...........................................17 
1.4 
Substance P and the Neurokinin-1 Receptor ...................................................17 
1.5 
Serlopitant ........................................................................................................18 
1.5.1 
Serlopitant Background and Nonclinical Summary ............................18 
1.5.2 
Serlopitant Clinical Summary ..............................................................19 
1.5.3 
Serlopitant in Pruritus-Related Studies ................................................19 
2 
STUDY OBJECTIVES ..........................................................................................21 
3 
STUDY DESIGN...................................................................................................21 
3.1 
Overall Study Design .......................................................................................21 
3.2 
Rationale for Study Design and Dose Selection ..............................................22 
3.3 
Study Endpoints ...............................................................................................23 
3.3.1 
Primary Efficacy Endpoint ..................................................................23 
3.3.2 
Key Secondary Efficacy Endpoints .....................................................23 
3.3.3 
Additional Secondary Efficacy Endpoints ...........................................23 
3.3.4 
Safety Endpoints ..................................................................................24 
3.4 
Safety Review ..................................................................................................24 
3.4.1 
Safety Monitoring Team ......................................................................24 
4 
SELECTION OF STUDY POPULATION ...........................................................24 
4.1 
Study Population ..............................................................................................24 
4.2 
Inclusion Criteria .............................................................................................24 
4.3 
Exclusion Criteria ............................................................................................25 
5 
STUDY DRUG ......................................................................................................26 
5.1 
Study Drug Supply, Route of Administration, and Storage.............................26 
5.2 
Labeling and Study Drug Accountability ........................................................27 
5.3 
Dosing Regimen...............................................................................................27 
159


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 10 
5.4 
Dose Modification ...........................................................................................27 
5.5 
Missed or Delayed Doses.................................................................................27 
5.6 
Study Drug Discontinuation ............................................................................27 
5.7 
Prior, Concomitant, and Excluded Therapies ..................................................28 
5.7.1 
Allowed Therapies and Treatment Goals for Underlying 
Conditions ............................................................................................28 
5.7.2 
Excluded Therapies ..............................................................................29 
5.7.3 
Rescue Therapies .................................................................................30 
5.8 
Assignment to Treatment .................................................................................30 
5.8.1 
Randomization .....................................................................................30 
5.8.2 
Blinding................................................................................................30 
5.9 
Treatment Compliance .....................................................................................31 
6 
STUDY SCHEDULE AND ASSESSMENTS ......................................................31 
6.1 
Efficacy Parameters .........................................................................................31 
6.1.1 
Itch Numeric Rating Scale ...................................................................31 
6.1.2 
Investigator’s Global Assessment of PN Activity ...............................31 
6.1.3 
Investigator’s Global Assessment of PN Stage ...................................32 
6.1.4 
Dermatology Life Quality Index ..........................................................32 
6.1.5 
PN Photographs ...................................................................................32 
6.2 
Safety Parameters .............................................................................................32 
6.2.1 
Vital Signs ............................................................................................32 
6.2.2 
Physical Examination...........................................................................33 
6.2.3 
Clinical Laboratory Assessments .........................................................33 
6.2.4 
Electrocardiogram ................................................................................34 
6.2.5 
Hospital Anxiety and Depression Scale ...............................................34 
6.2.6 
Epworth Sleepiness Scale ....................................................................34 
6.3 
Pharmacokinetic Measurements ......................................................................34 
6.4 
Subject Flow Diagram .....................................................................................35 
6.5 
Study Visits ......................................................................................................35 
6.5.1 
Screening Period ..................................................................................36 
6.5.2 
Screening Visit .....................................................................................36 
6.5.3 
Mid-Screening Telephone Contact (for subjects longer than 14 
days in Screening) ................................................................................37 
6.5.4 
Baseline Visit .......................................................................................38 
6.5.5 
Week 1 Telephone Contact Visit .........................................................39 
6.5.6 
Week 2 Visit ........................................................................................39 
6.5.7 
Week 4 Visit ........................................................................................40 
6.5.8 
Week 6 Visit ........................................................................................40 
6.5.9 
Week 10 Visit ......................................................................................41 
160


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 11 
6.5.10 
Follow-up Visit ....................................................................................42 
6.5.11 
Early Termination ................................................................................43 
7 
ASSESSMENT OF SAFETY ................................................................................43 
7.1 
Definitions........................................................................................................43 
7.1.1 
Adverse Event ......................................................................................43 
7.1.2 
Serious Adverse Event .........................................................................44 
7.1.3 
Abnormal Physical Exam, Laboratory, Vital Sign, and 
Electrocardiogram Findings .................................................................45 
7.1.4 
Deaths ..................................................................................................45 
7.1.5 
Pregnancies and Contraception Requirements for Females .................45 
7.1.6 
Worsening of Pruritus or PN................................................................46 
7.2 
Methods and Timing for Recording and Reporting Adverse Events ...............47 
7.2.1 
Adverse Event Reporting Period .........................................................47 
7.2.2 
Eliciting Adverse Events ......................................................................47 
7.2.3 
Assessment of Severity ........................................................................47 
7.2.4 
Assessment of Causality ......................................................................48 
7.3 
Follow-up of Adverse Events and Serious Adverse Events ............................49 
7.4 
Reporting Serious Adverse Events to the Sponsor and Institutional Review 
Board or Ethics Committee ..............................................................................49 
7.5 
Reporting Serious Adverse Events to Regulatory Authorities and Study 
Investigators .....................................................................................................49 
7.6 
Emergency Unblinding ....................................................................................49 
8 
STATISTICAL METHODS ..................................................................................50 
8.1 
Decision Rule and Sample Size .......................................................................50 
8.2 
Handling of Missing Data ................................................................................51 
8.3 
Analysis Populations ........................................................................................52 
8.4 
Subject Disposition ..........................................................................................53 
8.5 
Subject Characteristics .....................................................................................53 
8.6 
Prior and Concomitant Medications ................................................................53 
8.7 
Treatment Compliance and Extent of Exposure ..............................................53 
8.8 
Efficacy Analyses ............................................................................................53 
8.8.1 
Primary Efficacy ..................................................................................53 
8.8.2 
Key Secondary Efficacy ......................................................................54 
8.8.3 
Additional Secondary Efficacy ............................................................54 
8.9 
Sensitivity Analyses .........................................................................................54 
8.9.1 
Last Observation Carried Forward.......................................................54 
8.9.2 
Repeated Measures Analysis ...............................................................54 
8.9.3 
Tipping Point Analysis ........................................................................55 
8.10 
Safety Analyses ................................................................................................55 
161


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 12 
8.10.1 
Adverse Events ....................................................................................55 
8.10.2 
Clinical Safety Laboratory Results ......................................................55 
8.10.3 
Vital Signs ............................................................................................55 
8.10.4 
Electrocardiograms ..............................................................................55 
8.10.5 
Physical Exams ....................................................................................56 
8.10.6 
Menstrual Diaries .................................................................................56 
8.10.7 
Hospital Anxiety and Depression Scale ...............................................56 
8.10.8 
Epworth Sleepiness Scale ....................................................................56 
8.11 
Interim Analyses ..............................................................................................56 
8.12 
Population Pharmacokinetics Analysis ............................................................56 
9 
ADMINISTRATIVE ASPECTS ...........................................................................56 
9.1 
Changes to the Protocol ...................................................................................56 
9.2 
Study Termination ...........................................................................................57 
9.3 
Monitoring and Auditing Procedures...............................................................57 
9.4 
Transfer of Obligations ....................................................................................57 
9.5 
Informed Consent.............................................................................................57 
9.6 
Communication with the Institutional Review Board or Ethics Committee ...57 
9.7 
Disclosure and Confidentiality ........................................................................58 
9.8 
Records and Electronic Case Report Forms ....................................................58 
9.9 
Good Clinical Practices and Ethical Study Conduct ........................................59 
9.10 
End of Study Notification ................................................................................59 
9.11 
Publication of Results ......................................................................................59 
9.12 
Final Report .....................................................................................................59 
10 
REFERENCES ......................................................................................................60 
 
LIST OF APPENDICES 
Appendix A  
Schedule of Activities and Assessments ..............................................63 
Appendix B  
List of Strong CYP3A4 Inhibitors .......................................................65 
Appendix C  
Worst Itch Numeric Rating Scale Questionnaire .................................66 
Appendix D 
Investigator’s Global Assessment of Prurigo Nodularis: Activity 
and Stage ..........................................................................................................67 
Appendix E 
Dermatology Life Quality Index ..........................................................68 
Appendix F 
Hospital Anxiety and Depression Scale ...............................................69 
Appendix G  
Epworth Sleepiness Scale ....................................................................70 
 
162


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 13 
LIST OF FIGURES 
Figure 1 
Subject Flow Diagram ...............................................................................35 
 
LIST OF TABLES 
Table 1 
Adverse Event Grading ..............................................................................48 
Table 2 
Schedule of Visit Activities .......................................................................63 
Table 3 
Schedule of eDiary Assessments ...............................................................64 
  
163


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 14 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation 
Definition 
ACTH 
Adrenocorticotropic hormone, corticotropin 
AD 
Atopic dermatitis  
ADL 
Activities of daily living 
AE 
Adverse event 
ALT 
Alanine aminotransferase  
AMH 
Anti-Mullerian hormone 
ANOVA 
Analysis of variance 
AST 
Aspartate aminotransferase 
ATC 
Anatomical Therapeutic Classification 
CMH 
Cochran Mantel Haenszel test 
CNS 
Central Nervous System 
CRO 
Contract Research Organization 
CYP3A4 
Cytochrome-P 3A4 
DLQI 
Dermatology Life Quality Index 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eDiary 
Electronic diary 
ESS 
Epworth Sleepiness Scale 
FSH 
Follicle-stimulating hormone 
GCP 
Good Clinical Practice 
HAART 
Highly active antiretroviral therapy 
HADS 
Hospital Anxiety and Depression Scale 
HIV 
Human immunodeficiency virus 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonisation 
IGA PN-A 
Investigator’s Global Assessment of Prurigo Nodularis Activity 
IGA PN-S 
Investigator’s Global Assessment of Prurigo Nodularis Stage 
IRB 
Institutional Review Board 
ITT 
Intent-to-Treat 
IWRS 
Interactive Web Response System  
IVIG 
Intravenous immunoglobulin 
LDH 
Lactate dehydrogenase 
LFC 
Liquid filled capsule 
LH 
Luteinizing hormone 
LOCF 
Last Observation Carried Forward 
MCMC 
Markov Chain Monte Carlo 
MedDRA 
Medical Dictionary for Regulatory Activities  
NCI CTCAE 
National Cancer Institute Common Terminology Criteria for Adverse Events 
NK1-R 
Neurokinin-1 receptor 
164


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 15 
NOAEL 
No observed adverse effect level 
NRS 
Numeric Rating Scale  
PET 
Positron Emission Tomography 
PI 
Principal Investigator 
PD 
Pharmacodynamics 
PDE-4 
Phosphodiesterase-4 
PK 
Pharmacokinetics 
PN 
Prurigo nodularis 
PP 
Per Protocol 
QOL 
Quality of life 
RO 
Receptor occupancy 
SAE 
Serious adverse event 
SAP 
Statistical analysis plan 
SP 
Substance P 
TEAE 
Treatment-emergent adverse event 
TSH 
Thyroid stimulating hormone 
ULN 
Upper limit of normal 
US 
United States 
VAS 
Visual Analog Scale 
WI-NRS 
Worst-Itch Numeric Rating Scale 
165


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 16 
1 
INTRODUCTION 
1.1 
Pruritus in Prurigo Nodularis 
Prurigo nodularis (PN) is a distinctive and easily diagnosable chronic skin condition 
characterized by the presence of multiple highly pruritic and often symmetrically distributed 
nodules and papules on the skin (Jorizzo 1981). The nodules and papules in PN can range in 
size from approximately 0.5 to 3.0 cm and often appear hyperkeratotic, sometimes 
crateriform, in appearance. Plaques are occasionally present, and the lesions of PN frequently 
exhibit other features secondary to prolonged and severe scratching behavior, such as post-
inflammatory hyperpigmentation, erosion, ulceration, crusting, and bleeding (Zeidler 2016).   
PN, a long-term reaction to the chronic scratching and picking of patients with chronic 
pruritus (Zeidler 2016), is a skin condition seen predominantly in older adults, with median 
prevalence age in the 50s and 60s and a slight female preponderance (Iking 2013, Tan 2014,  
Ständer 2013). In one patient population survey, pediatric patients accounted for <2% of the 
total population, with the youngest patient 11.9 years of age (Iking 2013). Although only 
limited epidemiology data for PN have been published, a claims-based analysis 
commissioned by Menlo Therapeutics suggest that the United States (US) prevalence may be 
in the range of ~ 355,000 affected individuals. Based on a quantitative survey of 
73 dermatologists conducted in parallel with the claims-based analysis, approximately 
23% of patients with PN have an underlying atopy-related condition, while over 50% are 
considered to be idiopathic (Navigant 2017). The median duration of disease burden has been 
reported to be 6-7 years (Iking 2013, Tan 2014, Schuhknecht 2011).  
The dominant symptom in PN is an intense and chronic pruritus that is associated with a high 
degree of patient burden and restricted quality of life (QOL) (Zeidler 2016). As measured by 
global scales of pruritus intensity (numeric rating scale (NRS) and visual analog scale 
(VAS)), median levels of pruritus intensity have been reported to be 7-8 points (Iking 2013, 
Tan 2014, Schuhknecht 2011). The pruritus experienced in PN can often prevent patients 
from adequately performing their daily activities (Vaidya 2008), and patients with PN have 
been found to suffer from greater rates of depression and anxiety than control groups in 
numerous studies (Jorgensen 2016, Rowland Payne 1985, Dazzi 2011).  
1.2 
Conditions Associated With Prurigo Nodularis 
As PN is considered to be a disease induced by chronic pruritus and ongoing scratching 
activity, a variety of chronic pruritic conditions have been identified as potential underlying 
etiologies for the pruritus, including atopic dermatitis (AD), other inflammatory or bullous 
skin diseases, chronic renal failure, human immunodeficiency virus (HIV) infection, hepatitis 
C infection, and multifactorial disease (i.e. two or more co-existent conditions associated 
with chronic pruritus) (Fostini 2013, Lee 2005). The mechanisms linking chronic pruritus to 
the development of PN are not clear, as only a subset of patients with chronic pruritus 
develop PN, and over half of patients with PN have no underlying etiology identified. Even 
when specific underlying conditions are identified, management of these condition(s) does 
not usually result in resolution of PN signs or symptoms, nor can all underlying conditions be 
treated. For example, PN has been observed in patients with HIV adequately managed with 
166


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 17 
highly active antiretroviral therapy (HAART) (Zancanaro 2006), in patients with intractable 
cholestatic pruritus (Bergasa 2011), in patients with inactive hepatitis (Halvorsen 2015), and 
commonly in patients with renal failure despite hemodialysis therapy (Goeksel 2013). These 
data point to a high level of unmet medical need in the overall PN population, as the majority 
of patients with PN either have no underlying condition identified that can be treated, or 
treatment of the underlying condition is inadequate to control their PN (Wallengren 2004). 
1.3 
Current Treatment Options for Prurigo Nodularis 
Treatment of PN remains a challenging and extremely frustrating experience for both patients 
and physicians. In the majority of cases, responses are limited and unsatisfactory, and once 
the cycle of pruritus-excoriation-pruritus begins, it is difficult to stop. Identification and 
treatment of underlying chronic pruritic conditions is often the first step in management of 
PN. If this does not result in resolution of the pruritus, or if no underlying condition is 
identified, treatment specifically for PN and its associated pruritus is implemented.  
First-line pruritus therapies, including topical agents such as topical corticosteroids and 
calcineurin inhibitors, often provide inadequate response (Saco 2015) and the therapeutic 
ladder for PN involves systemic agents with progressively riskier safety profiles. These 
include naltrexone, gabapentin, mirtazapine, phototherapy, intravenous immunoglobulin 
(IVIG), powerful immunosuppressants such as methotrexate and cyclosporine, and 
thalidomide (Ständer 2015b, Spring 2014, Feldmeyer 2012, Lim 2016). None of these 
therapies are indicated for the treatment of PN, and their usage is often based on limited 
evidence, such as case reports or small open-label studies.  
1.4 
Substance P and the Neurokinin-1 Receptor 
Repeated itching, scratching, and picking over long time periods serve as the 
pathophysiological basis for the development of PN. Although different underlying disease 
states may be responsible for the chronic pruritus, the distinctive and easily recognizable 
features of PN point to a common final pathway resulting in this unique clinical presentation.  
Immunohistochemical staining studies of PN biopsies have demonstrated that nerve fibers 
immunoreactive for Substance P (SP) are found in increased numbers in lesional skin 
compared to non-lesional skin or controls (Abadía Molina 1992), suggesting a role for SP 
signaling in PN. These findings are consistent with the robust body of evidence indicating the 
key role of SP signaling through its primary receptor, the neurokinin-1 receptor (NK1-R), in 
the transmission of itch across multiple disease states (Santini 2012, Akiyama 2015, 
Crowe 1994, El-Nour 2006, Lotts 2014, Hon 2007, Ward 2004, Slattery 2011).   
SP is an undecapeptide that belongs to the tachykinin family of neuropeptides, a group that 
also includes neurokinin A and neurokinin B (Hökfelt 2001). SP has been implicated in a 
number of biological functions, both physiological and pathophysiological, including pruritus 
perception, vomiting reflex, pain perception, and immunomodulatory responses (Lotts 2014, 
Andoh 1998, Steinhoff 2014).  The biological actions of SP are mediated by tachykinin 
receptors, which consist of seven hydrophobic transmembrane domains coupled to G-
proteins. Three tachykinin receptors have been identified: the neurokinin-1, neurokinin-2, 
167


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 18 
and neurokinin-3 receptors (Harrison 2001). The NK1-R in particular has been studied in 
great detail. NK1-R is the primary receptor for SP in the human body, and is found on 
multiple cell types, include central and peripheral neurons, keratinocytes, and mast cells.  
NK1-R stimulation has been shown to be an important pathway for pruritus perception 
(Ständer 2015a). Inhibition of this pathway results in decreased pruritus and scratching 
reflexes in animal models (Akiyama 2015). Preceding the development of serlopitant for 
pruritus-related conditions, a commercially available NK1-R antagonist (Emend USPI) has 
been used as a therapy to decrease pruritus in patients with chronic pruritus due to etiologies 
such as cutaneous T-cell lymphoma (Duval 2009, Torres 2012, Booken 2011) and 
erlotinib-induced pruritus (Santini 2012, Gerber 2010). Additionally, in a study of 20 patients 
with chronic pruritus of various etiologies treated with aprepitant, 16/20 patients (80%) 
experienced a considerable reduction of itch intensity (Ständer 2010).  
1.5 
Serlopitant  
1.5.1 
Serlopitant Background and Nonclinical Summary 
Serlopitant is a small molecule, highly selective NK1-R antagonist that is administered orally 
and metabolized by cytochrome P-450 3A4 (CYP3A4), with a plasma half-life of 45-86 
hours. It binds with high affinity to the human NK1-R with a dissociation constant (Kd) of 
46 pM; displacing SP binding with a half-maximal inhibition concentration (IC50) of 61 pM. 
Serlopitant is a potent functional antagonist of SP-induced inositol phosphate generation. 
Serlopitant has been extensively studied in animal toxicology studies, including chronic 
toxicology and carcinogenicity studies. In non-clinical chronic toxicology studies in rats, 
mice and dogs, treatment related findings of potential clinical significance included increased 
salivation, decreased body weight gain and food consumption, slight changes in hematology 
and serum biochemistry parameters, mild increases in liver weight and mild 
histomorphologic changes. The histomorphologic changes were seen only in rats (not in dogs 
or mice) and included: very slight ovarian interstitial cell hypertrophy, mammary gland and 
uterine atrophy; decreased corpora lutea; increased histiocytes in lung and mesenteric lymph 
nodes; slight skeletal and cardiac muscle degeneration; slight increased hematopoiesis in 
bone marrow; and slight to moderate vacuolation in kidney tubules. These nonclinical 
findings occurred at systemic exposures exceeding those anticipated to provide efficacy of 
serlopitant for pruritus indications in humans (1 to 5 mg tablet daily). No cardiac lesions have 
been observed in dog toxicity studies up to 9 months in duration nor in a 3-month mouse 
range-finding study and 2-year mouse carcinogenicity study at exposure higher than the 
lowest level which caused cardiotoxicity in rats. The no observed adverse effect level 
(NOAEL) in rats for histomorphological changes in the reproductive tract, mammary gland 
and bone marrow provides a 2.5-fold margin for the maximum-targeted exposure (5 mg 
tablet daily). The rat NOAEL for histomorphological changes in muscle and kidney provides 
a 5-fold margin for the maximum-targeted exposure (5 mg tablet daily).  
In summary, the nonclinical toxicity noted with serlopitant provides no contraindications to 
the continuation of clinical trials via the oral route. Findings in the developmental toxicity 
168


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 19 
studies support inclusion of women of childbearing potential in clinical trials in accordance 
with the study protocol and local regulatory guidances.  
1.5.2 
Serlopitant Clinical Summary 
In humans, serlopitant has been administered to over 1000 individuals. Single doses up to 
400 mg have been well tolerated in young adult males and single doses up to 25 mg have 
been well tolerated in the elderly. Multiple doses of up to 50 mg a day for 4 weeks have been 
well tolerated in healthy young males, and a single (loading) dose of 15 mg followed by daily 
doses of 5 mg for 2 weeks have been well tolerated in elderly males and females. Forty-one 
(41) subjects received 4 mg liquid filled capsule (LFC) daily (bioequivalent to 5 mg tablets) 
for 1 year. Plasma concentrations of serlopitant appear to increase in a dose-proportional 
fashion in both young males and elderly subjects (males and females). Peak plasma 
concentrations after a single oral dose occurred at ~2 to 4 hours in both young and elderly 
subjects. A single loading dose of up to 15 mg followed by 6 to 8 weeks of up to 5 mg daily 
doses has been well tolerated in adults with chronic pruritus and PN. 
Pharmacokinetic data demonstrate good plasma exposures with oral dosing, linear dose-
dependent increases in plasma concentration and systemic exposure, a plasma t1/2 
appropriate for once daily dosing, and mild effects of concomitant food ingestion. Central 
nervous system (CNS) positron emission tomography (PET) studies have demonstrated good 
CNS penetrance and > 90% NK1 receptor occupancy (RO) at plasma exposures anticipated 
to be safe and well tolerated. Three long-lived active hydroxylated metabolites are observed 
in humans: M1/M1a 
, M2/M2a 
, and M3 
. 
These metabolites were present at lower concentrations and were 2- to 9-fold less potent in 
vivo than the parent compound. The integrated pharmacokinetic/pharmacodynamic (PK/PD) 
analysis concluded that these metabolites are unlikely to contribute significantly to 
occupancy of the CNS NK1-R in humans. 
1.5.3 
Serlopitant in Pruritus-Related Studies 
Serlopitant has been evaluated in two completed Phase 2 studies of subjects with chronic 
pruritus (TCP-101 and TCP-102).  
TCP-101 
TCP-101 was a double-blind, placebo-controlled, multi-center study that compared 
serlopitant 0.25 mg, 1 mg, or 5 mg vs. placebo for the treatment of chronic pruritus. A total 
of 257 adult subjects 18-65 years of age with chronic pruritus were randomized to receive 
one of the four dose groups in a 1:1:1:1 randomization. Subjects received a loading dose of 
3 tablets on Day 1 and thereafter received 1 tablet per day for 6 weeks. The primary efficacy 
endpoint was itch severity as measured on a VAS, summarized as a percentage change from 
baseline. 
Mean percent decreases from Baseline in VAS score were larger in the active-treatment 
groups versus placebo at every scheduled post-baseline study visit. Overall, the results were 
the most profound for the serlopitant 1 mg and 5 mg groups. For the percent change from 
Baseline in VAS pruritus scores (the primary efficacy variable), the Week 6 pairwise least 
169
CCI
CCI
CCI


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 20 
squares mean difference compared to placebo was 5.8 mm, 13.2 mm, and 14.2 mm for 
serlopitant 0.25 mg, 1 mg, and 5 mg, respectively.   
The frequency of treatment-emergent adverse events (TEAEs) and study drug related adverse 
events (AEs) was higher in the serlopitant 1 mg and 5 mg groups compared to the serlopitant 
0.25 mg group, and the frequency in all three treatment groups were higher than in the 
placebo group. The frequency of AEs leading to study drug discontinuation was comparable 
in the serlopitant 5 mg and placebo group and higher than in the serlopitant 0.25 mg and 
1 mg groups. There was one serious adverse event (SAE) reported in the serlopitant 1 mg 
group (spontaneous abortion, considered not related). There were no deaths. The most 
common AEs in the serlopitant groups were diarrhea (6.2%, 1 mg group), upper respiratory 
tract infection (4.7%, 0.25 mg group), somnolence (4.7%, 5 mg group), nasopharyngitis 
(4.6%, 1 mg group), headache (4.7%, 5 mg group), urinary tract infection (3.1%, 5 mg 
group), dry mouth (3.1%, 1 mg group), nausea (3.1%, 1 mg group), arthralgia (3.1%, 
0.25 mg group), musculoskeletal pain (3.1%, 1 mg group) and pruritus (3.1%, 1 mg group). 
The most common AEs in the placebo group were headache (6.3%), nasopharyngitis (3.2%), 
upper respiratory tract infection (3.2%), urinary tract infection (3.2%) and asthma (3.2%).  
TCP-102 
TCP-102 was a randomized, double-blind, placebo-controlled multi-center study that 
evaluated serlopitant 5 mg vs. placebo for the treatment of PN. A total of 128 adult subjects 
18-80 years of age with PN were randomized to receive serlopitant or placebo in a 1:1 
randomization. Subjects received a loading dose of 3 tablets on Day 1 followed by 1 tablet 
per day for 8 weeks. The primary efficacy endpoint was the average VAS score as recorded 
at the study visits. Results at Week 4 and Week 8 were the primary timepoints. 
Serlopitant 5 mg was superior to placebo for the reduction of pruritus as measured by change 
in average VAS from baseline. For the primary endpoint, change from baseline at Week 4 
and Week 8 by repeated measures analysis, the decrease from baseline was significantly 
greater in the serlopitant group than the placebo group, with a mean difference (serlopitant 
minus placebo) of -1.0 at Week 4 and -1.7 at Week 8. The mean difference at Week 2 was 
also significant, -0.9. In a post-hoc analysis of the percentage of subjects who were 4-point 
responders on average VAS at Week 8, 25.0% of placebo subjects and 54.4% of serlopitant 
subjects were 4-point responders. 
TEAEs were reported for 71.9% of serlopitant-treated subjects and 61.9% of placebo-treated 
subjects. The most frequently reported TEAEs in the serlopitant group were nasopharyngitis 
(17.2% serlopitant, 3.2% placebo), diarrhea (10.9% serlopitant, 4.8% placebo), and fatigue 
(9.4% serlopitant, 6.3% placebo). Treatment-related TEAEs were reported for 48.4% of 
serlopitant-treated subjects and 34.9% of placebo-treated subjects. The most frequently 
reported treatment-related TEAEs in the serlopitant group were fatigue (7.8%) and diarrhea, 
peripheral edema, dizziness, and headache (each 6.3%). Most TEAEs were mild or moderate; 
severe TEAEs were reported for 9.4% of serlopitant-treated subjects and 4.8% of 
placebo-treated subjects. There were no deaths during the study. Five subjects (3 serlopitant, 
2 placebo) had SAEs. The SAEs were actinic elastosis, depression, dizziness, and vertigo in 
170


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 21 
the serlopitant group; and bradycardia, syncope, respiratory failure, and neurodermatitis in 
the placebo group. Nine subjects (3 serlopitant, 6 placebo) discontinued due to TEAEs. 
No clinically relevant changes were observed in chemistry, hematology, vital signs, or 
electrocardiogram (ECG) results. 
Potential Risks and Benefits: The results of the Phase 2 studies in PN and chronic pruritus, 
together with the extensive nonclinical and clinical safety data and experience with 
serlopitant to date and the scientific rationale for NK1-R inhibition in the treatment of 
pruritus, serve to support further evaluation of serlopitant for the treatment of pruritus in 
patients with PN. The potential benefits of continued clinical study outweigh the potential 
risks. 
Please refer to the Investigator’s Brochure (IB) for further information regarding serlopitant. 
2 
STUDY OBJECTIVES  
The efficacy objective of this study is to assess the efficacy of serlopitant for the treatment of 
pruritus in adults with PN. 
The safety objective of this study is to assess the safety and tolerability of repeated oral doses 
of serlopitant in adults with PN.  
3 
STUDY DESIGN 
3.1 
Overall Study Design 
This is a double-blind, randomized, placebo-controlled study to assess the efficacy, safety, 
and tolerability of serlopitant for the treatment of pruritus in adults with PN. The study will 
be conducted at approximately 50 study sites. Subjects who meet the study entry criteria will 
be randomized in a 1:1 ratio to receive daily oral doses of serlopitant 5 mg or placebo for 
10 weeks. After completion of the treatment period or early discontinuation of study drug 
treatment, all subjects will enter a 3 or 5-week follow-up period. The required follow-up 
period is defined as a minimum of 3 weeks for those subjects who will enroll in the one-year 
open-label safety study (MTI-107) on the date of the follow-up visit, and as 5 weeks for 
those subjects who will not be enrolled in the one-year open-label safety study of serlopitant. 
Should a subject present for the follow-up visit prior to 5 weeks after the last dose of study 
drug and be excluded from participation in the one-year study for any reason, the subject will 
be required to return at 5 weeks after the last dose of study drug for a complete follow-up 
visit. 
This study will consist of three periods, for a total study period of 15-19 weeks: 
• Screening period: 2-4 weeks 
• Treatment period: 10 weeks 
• Follow-up period: 3 or 5 weeks 
171


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 22 
Informed consent will occur prior to any protocol-mandated procedures, including the 
stopping of any excluded therapies. This may occur prior to the Screening visit. 
During the screening period, all subjects will undergo eligibility evaluation and will be 
assessed for chronic pruritic conditions frequently associated with PN. Subjects who present 
with idiopathic PN at screening may require additional assessments as deemed necessary by 
the investigator (e.g. endomysial antibody with reflex to titer for subjects with signs or 
symptoms of dermatitis herpetiformis, skin biopsy for subjects with signs or symptoms of 
bullous pemphigoid or cutaneous T-cell lymphoma, urea breath test for Helicobacter pylori, 
or allergy testing).  
All screening procedures must be completed within 31 days before the Baseline visit. The 
minimum screening period for all subjects is 14 days to allow for collection of electronic 
diary (eDiary) screening data. Subjects who require screening period longer than 14 days will 
have a telephone contact at least 15 days prior to the scheduled Baseline visit to remind them 
to complete the eDiary as previously instructed at the Screening visit. 
Screening procedures may be deferred following discussion with the medical monitor should 
more than 31 days be required (e.g. to wash out of certain excluded therapies or to treat their 
underlying condition).  
Screening procedures may be repeated (i.e., the subject may be rescreened) following 
discussion with the medical monitor should the subject have had difficulty complying with 
eDiary assessments, require further training in the assessments, or have other relevant needs 
that may delay enrollment in the study but are not expected to impact safety or efficacy 
assessments. 
Subjects will be provided an eDiary at the Screening visit. Subjects must be willing and able 
to complete the eDiary every day within a consistent timeframe, and comply with restrictions 
on allowable concomitant therapies, for the duration of the study.  
At the Baseline visit (Day 1), eligible subjects will be randomly assigned to receive study 
drug (serlopitant 5 mg or placebo). Subjects will take a loading dose (3 tablets taken orally) 
at the site on the first day of the treatment period (Day 1). Starting on Day 2, subjects will 
take one tablet per day. Study drug may be taken with or without food. 
The primary efficacy endpoint will be assessed at Week 10 of treatment.  
Subjects who complete the 10-week treatment period and required follow-up period may be 
given the opportunity to enroll in a one-year open-label safety study (MTI-107) with daily 
oral doses of serlopitant 5 mg. 
3.2 
Rationale for Study Design and Dose Selection 
In the TCP-102 study in patients with PN, serlopitant 5 mg taken daily for 8 weeks was 
superior to placebo for the reduction of pruritus, in both the overall study population as well 
as the subgroup of subjects with an atopic diathesis. Similarly, in the TCP-101 study in 
patients with chronic pruritus, serlopitant 5 mg and 1 mg taken daily for 6 weeks were 
172


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 23 
superior to placebo for the reduction of pruritus, in both the overall study population and the 
subgroup of subjects with an atopic diathesis.  
In both the TCP-102 and TCP-101 studies, serlopitant was generally well-tolerated and 
demonstrated an overall favorable safety profile at the doses evaluated. 
The current MTI-106 study is designed to confirm the efficacy, safety, and tolerability of 
serlopitant for the treatment of pruritus in patients with PN. The 5 mg dose of serlopitant was 
selected for this study based on the favorable efficacy, safety, and tolerability profile of 
serlopitant at this dose level. Over 250 subjects have been exposed to serlopitant at doses of 
5 mg tablet-equivalent daily for at least 6 weeks, and ~ 40 subjects have been exposed up to 
one year. Human CNS PET RO data for serlopitant in healthy young males (Study P002) 
demonstrated that a serlopitant 5 mg LFC once daily dose is likely to achieve ~ 94% NK1 RO 
at steady state.  
3.3 
Study Endpoints 
3.3.1 
Primary Efficacy Endpoint 
The primary efficacy endpoint is the Worst-Itch Numeric Rating Scale (WI-NRS) 4-point 
responder rate at Week 10. 
3.3.2 
Key Secondary Efficacy Endpoints 
The key secondary efficacy endpoints are as follows: 
• WI-NRS 4-point responder rate at Week 4 
• WI-NRS 4-point responder rate at Week 2 
 
3.3.3 
Additional Secondary Efficacy Endpoints 
Additional secondary efficacy endpoints are as follows: 
• Change from baseline in WI-NRS to other timepoints 
• WI-NRS 3-point responder rate at Weeks 2, 4 and 10 
• Change from baseline in Dermatology Life Quality Index (DLQI) to Week 10 
• Change from baseline in DLQI Question 1 to Week 10 
• Change from baseline in Investigator’s Global Assessment of PN Activity (IGA PN-A) to 
Weeks 2, 4 and 10 
• Change from baseline in Investigator’s Global Assessment of PN Stage (IGA PN-S) to 
Weeks 2, 4 and 10 
173


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 24 
3.3.4 
Safety Endpoints 
Safety endpoints are as follows: 
• Incidence of TEAEs and SAEs 
• Change from baseline in clinical laboratory parameters following study drug exposure 
• Change from baseline in vital sign and ECG parameters following study drug exposure 
• Change from baseline in the Hospital Anxiety and Depression Scale (HADS)  
• Change from baseline in the Epworth Sleepiness Scale (ESS) 
 
3.4 
Safety Review 
3.4.1 
Safety Monitoring Team 
An internal safety monitoring team consisting of representatives from Menlo Therapeutics 
Inc. and its designees will monitor blinded safety data on a regular basis throughout the 
study. 
4 
SELECTION OF STUDY POPULATION 
4.1 
Study Population 
Approximately 280 adult subjects with pruritus associated with PN will be enrolled in this 
study. 
4.2 
Inclusion Criteria 
Subjects must meet the following criteria to be randomized into the study: 
1. Male or female, age 18 years or older at consent. 
2. A diagnosis of PN, defined by the presence of at least ten pruriginous nodules secondary 
to chronic pruritus present on at least two different body surface areas (e.g. both arms, one 
arm and one leg, one arm and the anterior trunk, or anterior and posterior trunk). 
3. The worst pruritus is identified to be within the areas of the PN lesions.  
4. Subject has idiopathic PN OR the subject has an identified pruritic condition associated 
with the PN and has persistent pruritus despite at least 6 weeks of optimized and stable 
174


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 25 
treatment of the underlying condition prior to the Baseline visit, and is willing to continue 
the treatment during the study. Please refer to Section 5.7.1. 
5. WI-NRS score ≥ 7 in the 24-hour period prior to the Screening visit. 
6. Average weekly WI-NRS score ≥ 6.5 in each of the 2 weeks (14 days) immediately prior 
to Baseline visit, as recorded in the eDiary. 
7. All female subjects who are of childbearing potential must be willing to practice highly 
effective contraception (i.e., pregnancy prevention method with a failure rate of < 1% per 
year) from the time of the Screening visit until 5 weeks after last dose of study drug.  Please 
refer to Section 7.1.5 for acceptable methods of contraception. 
8. Willing and able (as demonstrated by a ≥ 70% eDiary completion rate in the two weeks 
prior to Baseline visit) to complete daily eDiary entries within a consistent timeframe for 
the duration of the study.  
9. Willing and able (has adequate cognitive ability, in the investigator’s opinion) to comply 
with study visits and study related requirements including providing written informed 
consent. 
 
4.3 
Exclusion Criteria 
Subjects who meet any of the following criteria are not eligible for participation in the study: 
1. Prior treatment with serlopitant. 
2. Active pruritic skin disease, other than PN, within 6 months prior to randomization (with 
the exception of acute dermatoses such as contact dermatitis, sunburn, viral exanthem, 
which have been resolved for longer than 4 weeks). Please refer to Section 5.7.1. 
3. Treatment with any of the following therapies within 4 weeks prior to randomization. 
a. Other NK1-R antagonists (e.g., aprepitant, fosaprepitant, rolapitant). 
b. Systemic or topical immunosuppressive/immunomodulatory therapies (including 
but not limited to corticosteroids, phosphodiesterase-4 (PDE-4) inhibitors, 
cyclosporine, mycophenolate-mofetil, tacrolimus, pimecrolimus, calcipotriene, 
methotrexate, azathioprine, interferon-gamma, thalidomide, or phototherapy).  
c. Systemic therapies with recognized anti-pruritic properties (including but not 
limited to H1 antihistamines, doxepin, gabapentin, pregabalin, cannabinoids, 
kappa-opioid receptor agonists, and mu-opioid receptor antagonists (e.g. 
naloxone, naltrexone)). 
d. Strong CYP3A4 inhibitors (see Appendix B). 
e. Use of an indoor tanning facility, or natural sun exposure resulting in significant 
tanning or sunburn. 
4. Treatment with topical anti-pruritic therapies (e.g., menthol, camphor, pramoxine, 
capsaicin) within 2 weeks prior to randomization (see Section 5.7.2). 
175


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 26 
5. Treatment with biologic therapies within 8 weeks or 5 half-lives prior to randomization, 
whichever is longer. 
6. Treatment with any investigational therapy within 4 weeks (8 weeks for investigational 
biologic therapies) or 5 half-lives prior to randomization, whichever is longer. 
7. Serum creatinine, total bilirubin, alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) > 2.5 times the upper limit of normal (ULN) during screening. 
8. Untreated or inadequately treated thyroid, adrenal, or pituitary nodules or disease or 
history of thyroid malignancy.  
9. History of malignancy within 5 years prior to randomization, with the exception of 
actinic keratosis, completely treated and non-metastatic cutaneous basal cell carcinoma or 
squamous cell carcinoma of the skin. 
10. Any known major psychiatric diagnosis, such as major depressive disorder, bipolar 
disorder, schizophrenia, psychotic disorder, intellectual disability, severe alcohol use 
disorder, which may confound the assessment of serlopitant safety or efficacy, or 
interfere with the subject’s ability to comply with protocol-mandated activities, within 
3 years prior to randomization.  
11. Suicidal ideation within 3 years prior to randomization, or any history of suicide attempt. 
12. Documented history of parasitic infection, including skin parasites such as scabies, within 
8 weeks prior to randomization. 
13. Presence of any medical condition or disability that, in the investigator’s opinion, could 
interfere with the assessment of safety or efficacy in this trial or compromise the safety of 
the subject. 
14. History of hypersensitivity to serlopitant or any of its components. 
15. Currently pregnant or breastfeeding female subject. 
16. Planned or anticipated major surgical procedure or other activity that would interfere with 
the subject’s ability to comply with protocol-mandated assessments (e.g. extended 
international travel) during the subject’s participation in the study. 
5 
STUDY DRUG 
5.1 
Study Drug Supply, Route of Administration, and Storage 
The study drug in this study is serlopitant 5 mg or placebo in a film-coated tablet formulation 
for oral administration. The serlopitant tablets contain microcrystalline cellulose, mannitol, 
croscarmellose sodium, silicon dioxide, sodium lauryl sulfate, and magnesium stearate, and 
are film coated with Opadry® Brown. The placebo tablets contain microcrystalline cellulose, 
lactose monohydrate, and magnesium stearate, and are film coated with Opadry® Brown.  
The study drug will be provided in bottles that can be stored at room temperature (59-86°F, 
15-30°C). 
176


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 27 
The tablets will be supplied in bottles, with 18 tablets per bottle. One bottle will be issued via 
Interactive Web Response System (IWRS) at baseline and at Weeks 2 and 4, and two bottles 
will be issued via IWRS at Week 6. A total of 5 bottles will be dispensed to subjects 
completing 10 weeks of study drug treatment. 
Additional details regarding study drug supplies can be found in the Pharmacy Manual. 
5.2 
Labeling and Study Drug Accountability 
The study drug will be appropriately packaged and labeled in bottles with 18 tablets per 
bottle. The study drug supplied for this study is not to be used for any purpose other than this 
study, and study drug accountability must be maintained for all bottles distributed to the 
investigative site. 
Additional details regarding study drug labeling and accountability can be found in the 
Pharmacy Manual. 
5.3 
Dosing Regimen 
Subjects will take a loading dose (3 tablets taken orally) at the site on the first day of the 
treatment period (Study Day 1). Starting on Study Day 2, subjects will take one tablet per day 
taken orally. Subjects will be instructed to take all doses from Study Day 2 onward once a 
day. Study drug may be taken with or without food. 
5.4 
Dose Modification 
No dose modification of study drug will be allowed during this study. 
5.5 
Missed or Delayed Doses 
Each dose of study drug after the first dose must be administered once daily. If a dose is 
missed, that dose will be considered and documented as a missed dose. Dosing should 
resume the next day. 
5.6 
Study Drug Discontinuation 
Subjects should be discontinued from study drug treatment in the following situations: 
• A female subject desires to become pregnant at the current time, stops contraception or 
expels her intrauterine device/implant, or becomes pregnant  
• A female subject has new breast findings (e.g. a palpable mass or abnormal 
mammography, discharge), or has abnormal vaginal discharge or bleeding 
• The subject decides to discontinue study drug treatment, or withdraws consent from the 
study 
• The subject receives a strong CYP3A4 inhibitor (See Appendix B) 
177


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 28 
• Any medical condition that may jeopardize the subject’s safety if study drug is continued, 
in the investigator’s and/or Sponsor’s opinion; this may include the development of 
persistently (2 successive occasions) abnormal thyroid function tests (TSH >10, or 
TSH > 6 with low free T4; TSH <0.1, or TSH < 0.35 with high free T4); abnormal 
morning prolactin, cortisol, or corticotropin levels; or signs and symptoms of adrenal 
insufficiency 
• Discontinuation is deemed to be in the best interest of the subject, in the investigator’s 
and/or Sponsor’s opinion, including evidence that the subject does not meet 
inclusion/exclusion criteria intended primarily for safety reasons, or a persistent lack of 
adherence to study procedures 
 
The Sponsor or designee should be contacted within 24 hours of investigator’s awareness of 
any study drug treatment discontinuation. Investigators should make every effort to contact 
the Sponsor or designee before discontinuing study drug treatment, if possible. 
Subjects who discontinue treatment with study drug prior to completing the treatment period 
will enter a 5-week follow-up period following the last dose of study drug in addition to a 
Follow-up visit (see Section 3.1, Section 6.5.10). Every effort should be made for subjects to 
complete the Follow-up visit after a subject has discontinued from study drug.  
5.7 
Prior, Concomitant, and Excluded Therapies 
Prior therapies (including over-the-counter medications) used to treat the signs and 
symptoms of PN within the prior 2 years will be recorded for each subject at the Baseline 
visit. 
Concomitant therapies include any therapies (including over-the-counter medications and 
bland emollients) used by a subject from initiation of study drug treatment through the 
follow-up period. A record of all medications used will be maintained for each subject 
throughout the study. Reported information will include a description of the type of drug, 
treatment period, dosing regimen, the route of administration, and drug indication. The use of 
any concomitant medication must relate to the subject’s medical history or to an AE, except 
for vitamins/nutritional supplements, emollient use, and routine preventative immunizations.  
5.7.1 
Allowed Therapies and Treatment Goals for Underlying Conditions 
Treatment of an underlying, treatable chronic pruritic condition is allowed, if stable for at 
least 6 weeks prior to the Baseline visit, and continued throughout the treatment period.  
Treatment of the underlying systemic pruritic condition should be optimized per standard of 
care and treatment goals must be tailored based on age, sex, and concurrent health status and 
drug tolerance. While resolution of metabolic or endocrine disorders or eradication of an 
underlying infection may not always be feasible, every effort should be made to ensure the 
condition is well controlled, to prevent or reduce exacerbations and to prevent limitation on 
the activities of daily living. When applicable, laboratory evidence of control should be 
obtained. For example, if renal insufficiency is implicated as causal for pruritus, treatment 
178


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 29 
would be expected to have meaningfully reduced the creatinine (compared to that at the time 
of diagnosis) and to maintain the creatinine at < 2.5 the ULN; control of diabetes is supported 
by a hemoglobin-A1c of < 7.5%; control of thyroid disease is supported by normalization of 
the thyroid stimulating hormone (TSH) or by a TSH within 1.5 times the ULN in elderly 
patients; iron deficiency is corrected with a serum iron within 0.8 times the lower limit of 
normal; eradication of Helicobacter pylori infection generally requires a negative urea breath 
test and fecal antigen test and endoscopy; and the viral load should be undetectable if viral 
infections such as hepatitis B or hepatitis C, or HIV were previously diagnosed. Any 
previously active skin disease is considered to be well controlled if it is globally considered 
clear or almost clear (permissible to have post-inflammatory pigmentation, fine scale, faint 
pink erythema, barely perceptible induration/papulation, and no oozing or crusting).   
Use of gentle cleansers and bland emollients (including those with urea) is encouraged for all 
subjects. If bland emollient use is elected, it must be initiated at least 2 weeks (14 days) prior 
to Baseline visit, and continued throughout the treatment period.  
Treatment with non-systemic corticosteroids or antihistamines that do not involve skin 
application (e.g. inhaled, intranasal, ophthalmic, or intra-articular) is allowed.  
Leukotriene inhibitors will be permitted for treatment of conditions other than PN (e.g. 
asthma). 
5.7.2 
Excluded Therapies 
Initiation or use of topical therapy with corticosteroids, calcineurin inhibitors, calcipotriene, 
PDE-4 inhibitors is not permitted within 4 weeks prior to the Baseline visit or throughout the 
treatment period, but such therapy may be initiated during the follow-up period if needed.  
Initiation of bland emollient is not permitted within 2 weeks (14 days) prior to Baseline visit 
or throughout the treatment period, but such therapy may be initiated during the follow-up 
period if needed.  
The following therapies and activities are excluded from the Screening visit through the 
treatment period, and through the follow-up period: 
• NK1-R antagonists (other than study drug) 
• Systemic immunosuppressive/ immunomodulatory therapies (including but not limited to 
systemic corticosteroids, PDE-4 inhibitors, cyclosporine, mycophenolate-mofetil, 
methotrexate, azathioprine, thalidomide, interferon-gamma, or phototherapy) 
• Biologic therapies (other than therapies such as insulins, vaccines) 
• Strong CYP3A4 inhibitors (See Appendix B) 
• Use of an indoor tanning facility, or natural sun exposure resulting in significant tanning 
or sunburn 
• Any investigational therapy 
179


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 30 
The following therapies and activities are excluded from the Screening visit through the 
treatment period, and use is discouraged, though permitted, through the follow-up period: 
• Topical therapies or emollients with anti-pruritic properties (including but not limited to 
anti-histamines, menthol or menthol derivatives, polidocanol, camphor, pramoxine, and 
capsaicin) 
• Systemic therapies with recognized anti-pruritic properties (including but not limited to 
H1 antihistamines, doxepin, gabapentin, pregabalin, cannabinoids, kappa-opioid receptor 
agonists, and mu-opioid receptor antagonists)  
 
Use of any excluded therapies (including those for the treatment of pruritus or PN lesions, or 
as rescue therapy) should be reported as soon as possible, and will be recorded as protocol 
deviations for subjects who receive them.  
5.7.3 
Rescue Therapies 
The initiation of non-study drug therapy to treat worsening of pruritus or PN lesions, or flare 
of previously inactive skin disease, is strongly discouraged throughout the treatment period. 
However, should rescue therapy be required for the safety and well-being of the subject, such 
use will be recorded and analyzed (see Section 8.2). The subject may remain on study drug, 
unless the rescue therapy is an NK1-R antagonist, a systemic biologic therapy, a strong 
CYP3A4 inhibitor, an investigational therapy, or any therapy that may jeopardize the 
subject’s safety if study drug is continued, in the investigator’s and/or Sponsor’s opinion. 
5.8 
Assignment to Treatment  
5.8.1 
Randomization 
Eligible subjects will be randomized to receive serlopitant 5 mg or placebo in a 1:1 ratio. 
Stratified permuted block randomization will be used. Randomization will be stratified by the 
subject’s reported WI-NRS score for the 1-week period prior to the Baseline visit (6.5 to < 9, 
9 to 10).  
An IWRS will be used to perform the randomization.  
5.8.2 
Blinding 
This study will be conducted as a double-blind study with the treatment assignment 
concealed from the subjects, the investigators and their staff, the Sponsor, and any designees 
of the Sponsor as required. The placebo will be formulated to be indistinguishable from the 
active study product. Study materials will be packaged and issued in a manner designed to 
maintain the blind for subjects and all study personnel involved in the direction and 
execution of study procedures, study assessments, and collection of data. The randomization 
code for each subject will be available to the sites for use only in an emergency situation. For 
details of the procedure for unblinding of individual subjects in cases of emergency see 
Section 7.6.  
180


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 31 
5.9 
Treatment Compliance 
Records of study drug used, dosages administered, and intervals between visits will be kept 
during the study. Subjects will record in the eDiary the doses administered, as well as 
whether a dose was taken within 2 hours of eating a meal. Subjects will be asked to return all 
partially used and empty bottles to the study site at each visit. The site staff will count and 
record the number of remaining tablets in each returned bottle. The site staff will review the 
subject’s eDiary to help evaluate compliance with dosing at each study visit. Discrepancies 
between compliance as assessed by tablet counts and doses recorded in the eDiary will be 
reconciled and documented. Dosing dates and times will be recorded. A subject who has 
deviated significantly from the once-daily dosing regimen will be counseled. 
6 
STUDY SCHEDULE AND ASSESSMENTS 
When applicable, efficacy and safety instruments will be provided with instructions for 
administration, in study-specific manuals for site reference.  
6.1 
Efficacy Parameters 
6.1.1 
Itch Numeric Rating Scale 
The Itch NRS is a validated, self-reported instrument for measurement of itch intensity. It 
uses a 24-hour recall period and asks subjects to rate the intensity of their itch on an 11-point 
scale ranging from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicate greater 
itch intensity. In this study, the subject is asked to rate the intensity of their worst itch 
(WI-NRS) during a 24-hour recall period; the questionnaire is provided in Appendix C. 
Initial WI-NRS score collected during Screening visit will be collected on paper. All 
subsequent WI-NRS assessments will be reported by subject via eDiary. Subjects will record 
their WI-NRS scores once daily via eDiary at approximately the same time each day 
(+/- 3 hours) throughout the screening, treatment, and follow-up periods, as outlined in 
Appendix A. Subjects may be allowed to adjust the timing of eDiary completion within the 
first week of Screening as needed. Standardized training and instructions will be provided to 
all subjects prior to eDiary use.  
6.1.2 
Investigator’s Global Assessment of PN Activity  
The IGA PN-A is an instrument used to assess the overall activity of PN lesions at a given 
time point, as determined by the investigator. It consists of a 5-point scale ranging from 
0 (clear) to 4 (severe), as provided in Appendix D. The IGA PN-A uses clinical 
characteristics of excoriations, crusting, and/or bleeding as guidelines for the overall activity 
assessment. The number of pruriginous lesions should not be considered for this assessment. 
IGA PN-A scores will be captured as outlined in Appendix A. Each assessment during the 
study must be done by the Principal Investigator (PI) or designee. Every effort should be 
made to ensure that all assessments for a given subject are done by the same individual 
throughout the study. However, a change in assessor for a given subject, though not ideal, 
will not be considered a protocol deviation. 
181


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 32 
6.1.3 
Investigator’s Global Assessment of PN Stage  
The IGA PN-S is an instrument used to assess the overall number and thickness of PN 
lesions at a given time point, as determined by the investigator. It consists of a 5-point scale 
ranging from 0 (clear) to 4 (severe), as provided in Appendix D. The IGA-PN-S uses clinical 
characteristics of number of nodules and their thickness as guidelines for the overall severity 
assessment. IGA-PN-S scores will be captured as outlined in Appendix A. Each assessment 
during the study must be done by the PI or designee. Every effort should be made to ensure 
that all assessments for a given subject are done by the same individual throughout the study. 
However, a change in assessor for a given subject, though not ideal, will not be considered a 
protocol deviation. 
6.1.4 
Dermatology Life Quality Index  
Dermatology Life Quality Index (DLQI) is a dermatology specific QOL instrument designed 
to assess the impact of the skin disease on a subject’s QOL over the prior week. It is a ten-
item questionnaire that assesses overall QOL and six aspects that may affect QOL 
(symptoms and feelings, daily activities, leisure, work or school performance, personal 
relationships, and treatment), and is provided in Appendix E. The DLQI questionnaire will be 
collected as outlined in Appendix A. 
6.1.5 
PN Photographs 
At selected investigative sites, optional photographs of representative areas with PN 
involvement will be taken at multiple time points, as outlined in Appendix A. These areas 
may include the extensor surfaces of both arms and both legs (overview of both legs, detail 
of lower legs), and the abdomen and back. The central photography vendor will provide 
photographic equipment to the sites for use during the study. The PI and designees will be 
trained on the use of the camera and the appropriate lighting and positioning of the 
representative area with PN involvement. Detailed instructions will be provided in the 
Photography manual. 
6.2 
Safety Parameters 
Safety assessments will consist of monitoring and recording protocol-defined AEs and SAEs; 
vital signs; physical examinations; clinical laboratory assessments; ECGs; and other 
protocol-specified tests that are deemed critical to the safety evaluation of the study drug as 
outlined in Appendix A. 
6.2.1 
Vital Signs 
Vital signs will include measurements of heart rate, blood pressure, respiration rate, and 
temperature after the subject has been calmly resting (seated or supine) for a minimum of 
5 minutes. Vital signs will be assessed as outlined in Appendix A and at unscheduled study 
visits when clinically indicated. On study visits when clinical laboratory tests are performed, 
assessment of vital signs should precede blood draw.  
182


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 33 
6.2.2 
Physical Examination 
Physical examinations, including height and weight measurements, will be performed as 
outlined in Appendix A and at unscheduled study visits when clinically indicated. A 
complete physical examination will be performed at the screening visit, while subsequent 
examinations will be abbreviated and targeted to changes in disease activity and/or subjects’ 
symptoms. For female subjects with targeted breast examinations, please perform breast 
examination after blood draw for clinical laboratory tests.   
6.2.3 
Clinical Laboratory Assessments 
Samples for clinical laboratory assessments will be collected as outlined in Appendix A and 
at unscheduled study visits when clinically indicated, and analyzed at a central laboratory 
unless otherwise specified.  
Detailed instructions regarding sample collection, preparation, and shipment can be found in 
the laboratory manual. Laboratory assessments will include the following, and are ideally 
performed in the morning, particularly at visits with endocrine assessments (Screening, Week 
10, Follow-up): 
• Hematology: hematocrit, hemoglobin, red blood cell count, red blood cell indices, 
platelets, white blood cell count, white blood cell differential (neutrophils, lymphocytes, 
monocytes, basophils, eosinophils) 
• Chemistry: sodium, potassium, chloride, bicarbonate, glucose, blood urea nitrogen, 
creatinine, calcium, phosphorus, magnesium, albumin, uric acid, total protein, ALT, 
AST, alkaline phosphatase, total bilirubin, lactate dehydrogenase (LDH), lipid panel 
• Iron studies: ferritin, serum iron  
• Serology: hepatitis B and C serology, HIV 
• Serum IgE 
• Pregnancy testing: all females of childbearing potential will have a local urine pregnancy 
test performed. Positive or equivocal urine pregnancy test results will be confirmed by a 
serum pregnancy test analyzed at a central laboratory 
• Endocrine: TSH, free T4, cortisol, corticotropin (adrenocorticotropic hormone, ACTH), 
prolactin  
• Reproductive endocrinology (for all female subjects under 55 years of age at consent): 
serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, 
progesterone, anti-Mullerian hormone (AMH)  
• Optional study provided in lab test kits for use at Screening only: endomysial antibody 
with reflex to titer for subjects with signs or symptoms of dermatitis herpetiformis 
183


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 34 
• Additional optional studies will be supported through local procedural and/or laboratory 
assessments, including, but not limited to, skin biopsy and pathology interpretation, urea 
breath test for Helicobacter pylori, and allergy testing (patch, prick, or blood testing); the 
investigator should discuss the need for such studies with the medical monitor during the 
Screening period. 
• Standard cosyntropin stimulation testing should be performed on subjects with low 
cortisol level (i.e. < 3.0 mcg/dL); the investigator should discuss low cortisol (and 
relevant low corticotropin) results with the medical monitor. 
 
6.2.4 
Electrocardiogram  
A standard 12-lead ECG will be performed after the subject has been calmly resting in a 
supine position for a minimum of 5 minutes before obtaining the ECG. ECGs should precede 
measurement of vital signs and blood draw for clinical laboratory tests and will be performed 
as outlined in Appendix A and at unscheduled study visits when clinically indicated and read 
centrally. ECG machine and detailed instructions will be provided by the ECG vendor. 
6.2.5 
Hospital Anxiety and Depression Scale 
The HADS is a QOL instrument designed to assess the severity of anxiety and depression 
over the prior week, developed in a hospital outpatient clinic, but also valid in community 
settings and primary care medical practice.  The questionnaire takes approximately 2 to 5 
minutes to complete, and is provided in Appendix F. The HADS questionnaire will be 
collected as outlined in Appendix A. 
6.2.6 
Epworth Sleepiness Scale 
The ESS is a QOL instrument intended to measure daytime sleepiness by use of a very short 
questionnaire. The questionnaire takes approximately 2 to 3 minutes to complete, and is 
provided in Appendix G. The ESS questionnaire will be collected as outlined in Appendix A. 
6.3 
Pharmacokinetic Measurements 
Sparse PK sampling will involve collecting one PK sample at each of the Week 2, Week 4, 
and Week 10 visits as outlined in Appendix A. The date and time of dosing prior to PK 
sample collection and date and time of PK sample collection will be collected. The plasma 
concentrations of serlopitant and metabolites will be determined and data used for population 
PK analysis. Detailed instructions regarding PK sample collection, preparation, and shipment 
can be found in the laboratory manual. 
184


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 35 
6.4 
Subject Flow Diagram 
The visit schedule and assessments are summarized in Appendix A. The following subject 
flow diagram provides a summary of assessments and decision points for each subject. The 
eDiary assessments are performed throughout the study and are not confined to scheduled 
visits.  
Figure 1 
Subject Flow Diagram   
   
 
6.5 
Study Visits 
The following sections describe the procedures and assessments to be performed at each 
study visit. Details of each procedure and assessment can be found in Sections 6.1, 6.2, and 
6.3. The timing of each study visit is relative to the day of randomization (Baseline). 
Unscheduled visits may be performed as necessary, and may include procedures or 
assessments deemed necessary by the investigator. 
The eDiary assessments are performed throughout the study and are not confined to 
scheduled visits. Refer to Appendix A for frequency and duration of these assessments. 
Female subjects who report periodic menstruation will be asked to complete a menstrual 
diary (paper form) throughout the study. 
185


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 36 
6.5.1 
Screening Period 
Informed consent will occur prior to any protocol-mandated procedures, including the 
stopping of any excluded therapies. This may occur prior to the Screening visit. 
All screening procedures must be completed within 31 days before the Baseline visit. The 
minimum screening period for all subjects is 14 days to allow for collection of eDiary 
screening data. Subjects who require screening period longer than 14 days will have a 
telephone contact at least 15 days prior to the scheduled Baseline visit to remind them to 
complete the eDiary as previously instructed at the Screening visit. 
Screening procedures may be deferred following discussion with the medical monitor should 
more than 31 days be required (e.g. to wash out of certain excluded therapies or to treat their 
underlying condition).  
Screening procedures may be repeated (i.e., the subject may be rescreened) following 
discussion with the medical monitor should the subject have had difficulty complying with 
eDiary assessments, require further training in the WI-NRS assessments, or have other 
relevant needs that may delay enrollment in the study but are not expected to impact safety or 
efficacy assessments. 
6.5.2 
Screening Visit 
The following screening procedures are to be performed at the Screening visit, preferably in 
the order shown below: 
• Obtain written informed consent prior to any protocol-mandated procedures, including 
the stopping of any excluded therapies 
• Collect demographic information (sex, date of birth, race, ethnicity)  
• Ask subject to complete the WI-NRS scale on paper 
• Register Screening visit into the IWRS 
• Obtain ECG  
• Obtain vital signs  
• Review subject’s medical history (including prior medications) 
- 
Record only significant/relevant medical history, to include the onset date of PN (as 
specifically as known) and presence of an underlying condition (if any) 
- 
Designate the primary and any concurrent medical conditions that are identified as 
pruritic conditions underlying the PN  
- 
Female subjects should be queried regarding history of, or current, breast masses or 
abnormal discharge, and history of mammography (if applicable), and history of 
abnormal vaginal bleeding or discharge 
186


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 37 
• Perform complete physical examination (including height and weight) and confirm 
clinical diagnosis of PN  
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent  
- 
Endocrine  
- 
Hematology 
- 
Chemistry 
- 
Serology 
- 
Serum IgE 
- 
Iron studies 
- 
Optional: endomysial antibody with reflex to titer for subjects with signs or 
symptoms of dermatitis herpetiformis 
- 
Optional: additional assessments (refer to Section 6.2.3) 
• Review subject’s tentative eligibility according to the Inclusion/Exclusion criteria 
- 
The results of all screening evaluations, including laboratory and ECG results, must 
be reviewed for clinical significance by the PI or designee, and may require further 
evaluation, prior to randomization of the subject on Baseline visit 
• Schedule the Baseline visit and all future study visits to ensure subject’s availability and 
visit compliance with the protocol visit windows 
• Provide a menstrual diary to female subjects who report periodic menstruation   
• Provide eDiary with instructions 
• Confirm next scheduled visit 
 
6.5.3 
Mid-Screening Telephone Contact (for subjects longer than 14 days in 
Screening) 
During this telephone contact the following procedures are to be performed: 
• Assess and record any changes in medications since the Screening visit 
• Review subject’s tentative eligibility according to Inclusion/Exclusion criteria 
• Assess AEs and record SAEs caused by protocol-mandated interventions 
187


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 38 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
6.5.4 
Baseline Visit 
The Baseline visit occurs between 14 to 31 days after the screening visit, depending on the 
required washout period following discontinuation of excluded therapies. Eligibility must be 
confirmed prior to randomization. At the Baseline visit, the following procedures and 
assessments are to be performed, preferably in the order shown below: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires  
• Assess and record any changes in the subject’s concomitant medications 
• Assess and record any changes in the subject’s medical history  
- 
Female subjects should be queried regarding history of, or current, breast masses or 
abnormal discharge, and history of mammography (if applicable), and history of 
abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Assess AE’s and record SAEs caused by protocol-mandated interventions 
• Obtain vital signs  
• Perform a urine pregnancy test for females of childbearing potential and confirm the 
subject has a negative urine pregnancy test result prior to randomization (with positive or 
equivocal results confirmed by a serum pregnancy test) 
• Confirm subject’s eligibility based on the inclusion/exclusion criteria (to include review 
of eDiary compliance for eligibility) 
• Randomize subject in IWRS if eligibility confirmed 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Dispense study drug; subjects will take loading dose of 3 tablets while on site 
• Review eDiary for compliance, re-train subject as needed 
• Assess and record any post-dose AEs and SAEs 
• Confirm next scheduled visit 
188


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 39 
6.5.5 
Week 1 Telephone Contact Visit 
The Week 1 visit is a telephone visit that occurs 7 days (± 3 days) after the Baseline visit. At 
the Week 1 visit, the following procedures and assessments are to be performed:  
• Assess and record any changes in the subject’s concomitant medications 
• Assess and record any AEs and SAEs 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
6.5.6 
Week 2 Visit 
The Week 2 visit occurs 14 days (± 3 days) after the Baseline visit. At the Week 2 visit, the 
following procedures and assessments are to be performed:  
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Draw blood for clinical laboratory tests 
- 
Hematology 
- 
Chemistry 
• Collect PK blood sample  
• Assess and record any AEs and SAEs 
• Review eDiary for compliance, re-train subject as needed 
• Review study drug compliance with re-training as required 
• Collect returned study drug 
189


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 40 
• Utilize IWRS to assign new bottle of study drug 
• Confirm next scheduled visit date 
 
6.5.7 
Week 4 Visit 
The Week 4 visit occurs 28 days (± 3 days) after the Baseline visit. At the Week 4 visit, the 
following procedures and assessments are to be performed: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test)  
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Collect PK blood sample  
• Assess and record any AEs and SAEs 
• Collect returned study drug 
• Utilize IWRS to assign new bottle of study drug 
• Review eDiary for compliance, re-train subject as needed 
• Review study drug compliance with re-training as required 
• Confirm next scheduled visit date 
 
6.5.8 
Week 6 Visit 
The Week 6 visit occurs 42 days (± 3 days) after the Baseline visit. At the Week 6 visit, the 
following procedures and assessments are to be performed: 
190


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 41 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain vital signs 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test)  
• Perform targeted physical examination, including weight 
• Assess and record any AEs and SAEs 
• Collect returned study drug 
• Utilize IWRS to assign new bottle of study drug 
• Review eDiary for compliance, re-train subject as needed 
• Confirm next scheduled visit 
 
6.5.9 
Week 10 Visit 
The Week 10 visit occurs 70 days (± 7 days) after the Baseline visit. At the Week 10 visit, 
the following procedures and assessments are to be performed: 
• Ask the subject to complete the DLQI, HADS, and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain ECG  
• Obtain vital signs 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
191


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 42 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent 
- 
Endocrine 
- 
Hematology 
- 
Chemistry 
• Collect PK blood sample 
• Assess and record any AEs and SAEs 
• Collect returned study drug  
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Review eDiary for compliance, inform subject to continue entering WI-NRS score until 
Follow-up visit 
• Review study drug compliance with re-training as required 
• Confirm next scheduled visit date 
 
6.5.10 
Follow-up Visit 
The required Follow-up visit occurs 21 or 35 (+7 days) after the Week 10 visit or the last 
dose of study drug for subjects who discontinue study drug early. The required follow-up 
period is defined as a minimum of 3 weeks for those subjects who will enroll in the one-year 
open-label safety study on the date of the follow-up visit, and as 5 weeks for those subjects 
who will not be enrolled in the one-year open-label safety study of serlopitant. Should a 
subject present for the follow-up visit prior to 5 weeks after the last dose of study drug and be 
excluded from participation in the one-year study for any reason, the subject will be required 
to return at 5 weeks after the last dose of study drug for a complete follow-up visit. 
At the Follow-up visit, the following procedures and assessments are to be performed: 
• Register visit into the IWRS 
• Ask the subject to complete the HADS and ESS questionnaires 
• Assess and record any changes in the subject’s concomitant medications 
• Female subjects should be queried for presence of new breast masses or abnormal 
discharge, and abnormal vaginal bleeding or discharge 
• Review menstrual diary and record dates of menstrual flow (if applicable) 
• Obtain vital signs 
192


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 43 
• Perform targeted physical examination, including weight 
• Perform IGA PN-A 
• Perform IGA PN-S 
• Obtain ECG  
• Obtain photos (at selected sites, only subjects that signed photography consent) 
• Perform a urine pregnancy test for females of childbearing potential (with positive or 
equivocal results confirmed by a serum pregnancy test) 
• Draw blood for clinical laboratory tests (morning blood sampling due to Endocrine 
assessments) 
- 
Reproductive endocrine labs for females under 55 years of age at consent  
- 
Endocrine  
- 
Hematology 
- 
Chemistry 
• Assess and record any AEs and SAEs 
• Collect eDiary device, review eDiary for compliance 
 
6.5.11 
Early Termination 
Early termination of a subject from the study may occur due to loss to follow-up or 
withdrawal of consent by the subject. In accordance with legal requirements and 
International Conference on Harmonization (ICH) –GCP guidelines, every subject or his/her 
legal representative has the right to withdraw from the study at any time and without 
providing reasons. If provided, the reason (adverse event, study burden, lack of efficacy, 
other) a subject withdrew consent will be recorded in the electronic Case Report Form 
(eCRF). The PI or site staff must make every effort to contact subjects who are suspected of 
being lost to follow-up. Attempts to contact such subjects must be documented in the 
subject’s source documents. 
7 
ASSESSMENT OF SAFETY 
7.1 
Definitions 
7.1.1 
Adverse Event 
An AE is any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. An AE can be any unfavorable and unintended sign 
(e.g. an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a drug, without any judgment about causality. 
193


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 44 
AEs include treatment emergent exacerbations of pre-existing illnesses and AEs that occur as 
a result of protocol-mandated interventions. 
7.1.2 
Serious Adverse Event  
An AE is considered “serious” if it results in any of the following outcomes: 
• Death 
• Life-threatening AE (i.e. the subject was at immediate risk of death from the event as it 
occurred. An event that might have led to death if it had occurred with greater severity is 
not “life-threatening”) 
• Inpatient hospitalization or prolongation of existing hospitalization  
• Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
• Congenital anomaly/ birth defect 
• Important medical event (i.e. an event that may not result in death, be life-threatening, or 
require hospitalization, but which may be considered serious by the investigator or 
Sponsor, as it may jeopardize the subject and may require medical/surgical intervention 
to prevent one of the outcomes listed above). Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, 
blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse. 
 
The following are not considered SAEs: a visit to the emergency room or other hospital 
department < 24 hours that does not result in admission (unless considered an important 
medical or life-threatening event), an elective surgery planned prior to signing consent, 
admission as per protocol for planned medical/surgical procedure, and/or routine health 
assessments requiring admission for baseline/trending of health status (e.g. routine 
colonoscopy). 
The terms “severe” and “serious” are not synonymous. Severity refers to the intensity of an 
AE (e.g. mild, moderate, or severe pain); the event itself may be of minor medical 
significance (e.g. severe back pain). “Serious” is a regulatory definition, as defined above. 
Seriousness (not severity) serves as the basis for defining regulatory reporting obligations.  
Severity and seriousness should be independently assessed when recording AEs and SAEs on 
the eCRF. 
194


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 45 
7.1.3 
Abnormal Physical Exam, Laboratory, Vital Sign, and Electrocardiogram 
Findings  
Abnormal physical exam findings that are clinically significant and are identified prior to the 
first dose of study drug should be recorded as medical history. New or worsening clinically 
significant abnormal physical exam findings identified after the first dose of study drug 
should be recorded as AEs.   
Only abnormal laboratory, vital sign, and ECG findings that are considered clinically 
significant by the investigator (e.g. require active management or are associated with 
accompanying symptoms/signs) will be recorded as medical history or AEs on the eCRF. 
Abnormal laboratory, vital sign, and ECG findings that occur prior to the first dose of study 
drug should be recorded as medical history, and abnormal findings that occur after the first 
dose of study drug should be recorded as AEs. 
If the clinically significant laboratory, vital sign, or ECG abnormality is a sign associated 
with a confirmed disease or condition (e.g. elevated creatinine in a subject diagnosed with 
chronic kidney disease), only the diagnosis (chronic kidney disease) needs to be recorded on 
the AE eCRF (rather than listing individual test findings as AEs).  
Separate instances of the same clinically significant laboratory, vital sign, or ECG 
abnormality across visits should not be recorded as separate AEs or SAEs. 
7.1.4 
Deaths  
Any deaths that occur from the time of informed consent to the follow-up visit, regardless of 
attribution, must be reported within 24 hours of investigator’s awareness of the death. See 
Safety Form Completion Instructions for complete instructions. 
The Sponsor should be provided a copy of any post-mortem findings and/or relevant medical 
reports, including histopathology. 
7.1.5 
Pregnancies and Contraception Requirements for Females 
For the purposes of this study, a female of childbearing potential is defined as any female 
who has experienced menarche and is pre-menopausal, unless permanently surgically sterile 
(e.g., hysterectomy, bilateral salpingectomy, bilateral oophorectomy). A postmenopausal 
state is defined as no menses for 12 months without an alternative medical cause in a 
previously menstruating female.  
For the purposes of this study, acceptable contraception is defined below based on 
Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals: ICH M3(R2) dated January 2010, and other available 
guidelines (“U.S. Medical Eligibility Criteria for Contraceptive Use” 2010; 
“Recommendations related to contraception and pregnancy testing in clinical trials” 2014; 
“M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals” 2010):  
195


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 46 
All female subjects of childbearing potential must use highly effective contraception, which 
includes the use of one or more of the following acceptable methods:  
1. Surgical sterilization (e.g., bilateral tubal occlusion or ligation, hysterectomy, bilateral 
salpingectomy, bilateral oophorectomy) 
2. Total (as opposed to periodic or cyclic) abstinence from heterosexual intercourse, 
only if planned for the entire duration of the study period and consistent with the 
preferred and usual lifestyle for the subject 
3. Hormonal contraception associated with consistent inhibition of ovulation; these may 
include (but are not necessarily limited to) oral, intravaginal, implantable, injectable, 
or transdermal delivery methods  
4. Intrauterine device/system  
5. Exclusive (sole) monogamous intercourse with a sterilized (i.e., vasectomized) or 
otherwise non-fertile (e.g., castrated) male partner; the male partner must have 
received medical assessment of the surgical success 
Progesterone-only oral contraceptives are excluded as a highly effective method of 
contraception, as they do not consistently inhibit ovulation. Male or female condoms with or 
without spermicide, and female caps, diaphragms, and sponges with spermicide, or 
combinations (double barrier) are also excluded as highly effective contraceptive methods. 
Any pregnancy occurring in a female subject or the female partner of a male subject, from 
the first study drug administration through the required follow-up visit must be reported 
within 24 hours of the investigator’s awareness of the pregnancy. See Safety Form 
Completion Instructions for complete instructions.  
The investigator will follow the pregnancy to delivery or other pregnancy outcome.  
Pregnancy in a female clinical trial subject or female partner of a male clinical trial subject is 
not an SAE per se. Complications of such pregnancies (for example, spontaneous abortion) 
may qualify as SAEs and should be reported as such even if they occur after the Follow-up 
visit. Any congenital anomalies/birth defects must be recorded and reported as SAEs. See 
Safety Form Completion Instructions for complete instructions.  
7.1.6 
Worsening of Pruritus or PN 
Pruritus or PN should be recorded as an AE or SAE only if considered by the investigator to 
have worsened in severity beyond the subject’s typical fluctuations. It is important to include 
a description of the nature of the unexpected worsening when recording the AE or SAE (e.g. 
new PN lesions in previously uninvolved skin). 
196


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 47 
7.2 
Methods and Timing for Recording and Reporting Adverse Events 
7.2.1 
Adverse Event Reporting Period 
Any AE occurrence during the study must be recorded on source documentation and eCRF at 
the site, in accordance with protocol instructions.  
AEs and SAEs will be recorded from the first study drug administration through the 
follow-up visit. After the required follow-up visit, only SAEs that are believed to be drug-
related should be reported. 
After informed consent, but prior to initiation of study drug, only SAEs considered by the 
investigator to be caused by a protocol-mandated intervention will be collected (e.g. SAEs 
related to invasive procedures such as blood collection). These procedure-related SAEs 
should only be reported on the source documents and SAE form, not on the AE eCRF. 
Subjects who undergo screening procedures but are not randomized into the study will not 
have SAEs recorded in the clinical database. 
7.2.2 
Eliciting Adverse Events 
Investigators will seek information on AEs and SAEs at each subject contact through the 
follow-up visit. All AEs and SAEs, whether reported by the subject or noted by authorized 
study personnel, will be recorded in the subject’s medical record and on the AE eCRF page, 
and, if serious, on the SAE form. For each AE and SAE recorded, the investigator will make 
an assessment of seriousness, severity, and causality. 
7.2.3 
Assessment of Severity 
All AEs entered into the eCRF will be graded for severity using the National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 (“Common 
Terminology Criteria for Adverse Events (CTCAE)” 2010) to describe the maximum 
intensity of the adverse event.   
If the AE cannot be found in the event-specific NCI CTCAE grading criteria, the investigator 
should use the definitions for Grade 1, 2, 3, and 4 in Table 1. 
197


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 48 
Table 1 
Adverse Event Grading 
Grade 
Severity 
Alternate Descriptiona 
1 
Mild (apply event-specific NCI 
CTCAE grading criteria) 
Asymptomatic or mild symptoms; clinical 
or diagnostic observations only; 
intervention not indicated. 
2 
Moderate (apply event-specific NCI 
CTCAE grading criteria) 
Minimal, local or noninvasive intervention 
indicated; limiting age-appropriate 
instrumental activities of daily living 
(ADLb) 
3 
Severe (apply event-specific NCI 
CTCAE grading criteria) 
Severe or medically significant but not 
immediately life-threatening; 
hospitalization or prolongation of 
hospitalization indicated; disabling; 
limiting self care ADLc 
4 
Very severe, life threatening, or 
disabling (apply event-specific NCI 
CTCAE grading criteria) 
Life-threatening consequences; urgent 
intervention indicated. 
5 
Death related to AE 
 
a 
Use these alternative definitions for Grade 1, 2, 3, and 4 events when the observed or reported AE is not 
in the NCI CTCAE listing. A semi-colon indicates ‘or’ within the alternate description of the grade. 
b 
Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc. 
c 
Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
Source: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 
 
Note that severity, a measure of intensity, is not equivalent to seriousness, a regulatory 
definition of outcome. Regardless of severity, some AEs may meet the criteria for 
seriousness. See Section 7.1.2 for the definition of an SAE. 
If an adverse event changes in severity during the same study period (e.g., treatment period), 
only the highest severity grade will be recorded on the eCRF.  
7.2.4 
Assessment of Causality 
The investigator’s assessment of causality must be provided for all AEs (serious and 
non-serious). An investigator’s causality assessment is the determination of whether there 
exists a reasonable possibility that the investigational product caused or contributed to an AE. 
Causality of an AE will be assessed by the investigator using the following terms: 
• Likely Related: A reaction that follows a reasonable temporal sequence from 
administration of the study drug; that follows a known or expected response pattern to the 
suspected study drug; and for which other potential etiologies are considered less likely 
factors than the study drug. 
• Likely Unrelated: A reaction that, considering all potential etiologies, is most likely due 
to factors other than the study drug. 
198


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 49 
7.3 
Follow-up of Adverse Events and Serious Adverse Events 
The investigator must make every effort to follow all AEs and SAEs regardless of attribution 
until judged resolved or stabilized, the subject is lost to follow-up, or it has been determined 
that study drug treatment or participation in the study is not the cause of the AE or SAE. 
7.4 
Reporting Serious Adverse Events to the Sponsor and Institutional 
Review Board or Ethics Committee   
The Sponsor or designee is under obligation to report certain SAEs to regulatory authorities 
related to investigational drugs in clinical trials. The Sponsor or designee must be notified 
within 24 hours of an AE when the investigator determines that an AE meets the protocol 
definition of an SAE, regardless of the cause or relationship to study drug.  
An SAE related to study participation occurring before study drug administration and after 
informed consent should be promptly reported to the Sponsor. If the investigator learns of 
any SAE at any time after a participant has been discharged from the study, and the SAE is 
considered likely related to study drug, the SAE should be promptly reported to the Sponsor. 
Please see the Safety Form Report Completion Instructions for safety reporting instructions.  
The investigator must also comply with applicable requirements concerning reporting of 
SAEs to the IRB or Ethics Committee (EC). This may include initial or follow-up 
notification of an SAE or other safety information. 
7.5 
Reporting Serious Adverse Events to Regulatory Authorities and Study 
Investigators 
The Sponsor, or its designee, is responsible for submitting reports of serious, unexpected 
related adverse events to regulatory authorities on an expedited basis, according to the ICH 
E2A Guideline and to other regulatory authorities according to national and local regulations 
as required. The Sponsor, or its designee, is responsible for prompt submission to the IRB or 
EC of any expedited SAE reports submitted to regulatory authorities. All investigators 
participating in ongoing clinical studies with serlopitant will receive copies of the SAE 
reports submitted on an expedited basis to regulatory authorities. 
7.6 
Emergency Unblinding 
Emergency unblinding is available 24 hours per day/7 days per week and will be performed 
via IVRS. An investigator may unblind a subject’s treatment assignment only when 
knowledge of the investigational product is essential for the welfare of a subject. There is no 
specific antidote for serlopitant and usual supportive medical management is recommended 
in the case of a medical emergency. 
199


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 50 
8 
STATISTICAL METHODS  
All statistical processing will be performed using SAS® unless otherwise stated. One interim 
analysis may be performed. Endpoints will be summarized with descriptive statistics by 
treatment group and visit. For continuous variables, the following information will be 
presented: n (number of subjects), mean, standard deviation, median, minimum and 
maximum. For categorical variables counts and percentages will be used. Summary statistics 
for imputed efficacy data will be reported based upon imputed data. 
The primary method of handling missing efficacy data will be the method of Markov Chain 
Monte Carlo (MCMC) multiple imputation. Subjects who withdrew from the study due to a 
lack of efficacy, or used an excluded therapy to treat worsening of pruritus or PN, will be 
defined as non-responder.  
As one sensitivity analysis, the last observation carried forward method (LOCF) will be used 
(i.e., the last available on-therapy observation for a subject will be used to estimate 
subsequent missing data points). As a second sensitivity analysis, a repeated measures model 
will be used on observed data. Additionally, a tipping point analysis will be done as a 
sensitivity analysis for the primary endpoint. 
Baseline for measures other than the eDiary daily measures will be the last recorded value 
prior to the start of treatment. For daily measures including the WI-NRS, baseline will be the 
average result measured over the week prior to treatment.  
A statistical analysis plan (SAP), describing all statistical analyses will be provided as a 
separate document. The SAP will be finalized prior to unblinding of the study treatments. 
8.1 
Decision Rule and Sample Size  
This study will use a 5% two-sided alpha level. While the alpha level is two-sided, clinically 
relevant results require a serlopitant benefit. Statistical significance for the key secondary 
efficacy endpoints requires statistical significance for the primary efficacy endpoint (i.e. 
stepdown testing from primary to key secondary endpoints). The key secondary efficacy 
endpoints will be tested in order starting with the Week 4 WI-NRS 4-point responder rate, 
and then the Week 2 WI-NRS 4-point responder rate.  
The target sample size of 280 randomized and dosed subjects (140 per group) has been 
determined based upon a 1:1 allocation of subjects to treatment groups and a 5% alpha level. 
Completed Phase 2 studies indicate that placebo responder rates vary between 
% and 
% 
and serlopitant rates between 
% and 
%. A sample size of 280 subjects provides >90% 
power assuming a placebo responder rate of 
% and a serlopitant rate of 
%. 
The sample size calculations have been performed in PASS 13 (“PASS 13 Power Analysis 
and Sample Size Software” 2014) and use a Chi-Squared test. The primary analysis will 
control for the stratification factors. It is expected that this unstratified power estimate will 
under-estimate the true power as it does not take the variance reduction resulting from 
stratification into account (Matts 1988).  
200
CCI
CCI
CCI
CCI
CCI
CCI


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 51 
8.2 
Handling of Missing Data  
Should a determination of treatment period (on treatment, pre-treatment, follow-up) be 
required for adverse events or concomitant medication but the corresponding date is missing, 
or is a partial date, the event/medication will be considered on treatment unless the portions 
of the date that are available indicate this is not possible. 
The primary method of handling missing efficacy data will be MCMC multiple imputation. 
Subjects who withdrew from the study due to a lack of efficacy, or used an excluded therapy 
to treat worsening of pruritus or PN, will be defined as non-responder. Imputation will be 
conducted within each treatment group independently, so the pattern of missing observations 
in one treatment group cannot influence missing value estimations in another. For each 
imputation process, 25 imputations will be performed. 
If a subject fails to complete their eDiary for the week prior to Week 10, the primary 
endpoint (WI-NRS) data will be missing, unless the subject withdrew from the study due to a 
lack of efficacy, or the subject used an excluded therapy to treat worsening of pruritus or PN, 
in which case their responder status will be defined as non-responder. If the Week 10 value is 
missing for any other reason, the change from baseline value will be based on imputed data. 
Missing Week 10 WI-NRS values from which the 4-point responder status is derived will be 
estimated by MCMC. 
Missing WI-NRS data will be derived for the analysis using the method of MCMC multiple 
imputation. Since both primary and key secondary efficacy endpoints require WI-NRS, the 
following steps will be followed: 
1. Using the daily eDiary data, calculate Baseline and Week 2 through Week 10 
values by averaging available values. In order to compute a week’s average, a 
minimum of 4 values must be available for that week. The weekly average will be 
imputed when there are fewer than 4 values available.  
2. From step 1, create a dataset for each treatment group, of subjects with observed 
values and those needing estimation by MCMC. The missing WI-NRS values in each 
dataset will be filled in using the MCMC method to generate 25 datasets. The 
resulting datasets for each treatment arm will be combined into one complete dataset. 
Syntax: 
proc mi data=datain out=dataout seed=&seed. Nimpute=25 <options>; 
  where trtpn=(TRT);   /* Note TRT = [1, 2]; depending on treatment group */; 
  mcmc chain=single; 
  var baseline week1 week2 week3 week4 week5 week6 week7 week8 week9 
week10; 
run; 
 
3. From each complete dataset, the dichotomous responder rate will be determined. 
Each complete dataset will be analyzed as specified for the particular analysis. 
201


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 52 
Each complete dataset formed by multiply imputed data will be analyzed as specified for the 
particular analysis. The results from the analyses will be combined into a single inference 
using SAS® PROC MIANALYZE. In the case of the primary analysis and the secondary 
responder analyses, the Cochran Mantel Haenszel (CMH) statistics computed in the analyses 
of WI-NRS responder rates will be normalized using the Wilson-Hilferty transformation 
prior to combining them using SAS® PROC MIANALYZE 
A total of 2 random seeds will be needed to impute missing data. Those random seeds have 
been pre-specified by using a random number generator: 
  
 
8.3 
Analysis Populations  
The primary efficacy population will be the Intent-to-Treat (ITT) and will include all 
randomized subjects who were dispensed study drug. Subjects will be analyzed within the 
treatment group to which they are randomized.  
The primary safety population will be all treated subjects with at least one post-baseline 
assessment. For safety analyses, subjects will be classified based upon the treatment 
received.  
The Per Protocol (PP) population will include all subjects in the safety population who 
complete the Week 10 evaluations without any significant protocol violations (i.e., any 
subject or investigator activity that could have possibly interfered with the therapeutic 
administration of the treatment or the precise evaluation of treatment efficacy). Analyses 
performed on the Per Protocol population will be considered supportive. The PP population 
will include subjects in the safety population who do not meet any of the following criteria: 
• Violated the inclusion/exclusion criteria; 
• Receives a strong CYP3A4 inhibitor (See Appendix B); 
• Receives an excluded medication for treatment of pruritus or PN; 
• Have not been compliant with the dosing regimen (i.e. subjects must comply with 
80−120% of the expected dosage of study medication during participation in the study); 
• Out of visit window at the Week 10 visit by ±7 days 
 
Subjects that discontinue from the study drug due to an adverse event related to study 
treatment or documented lack of treatment effect will be included in the PP population. Prior 
to breaking the blind, other additional criteria may be added to the list to accommodate for 
unforeseen events that occurred during the conduct of the trial that result in noteworthy study 
protocol violations. 
202
CCI


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 53 
8.4 
Subject Disposition  
An accounting of all randomized subjects by disposition will be presented. Subjects who 
discontinue study drug prematurely or withdraw from the study will be summarized and 
listed, with a description of the reason for early termination/withdrawal. 
8.5 
Subject Characteristics  
Demographic and other baseline characteristics will be summarized. 
8.6 
Prior and Concomitant Medications  
Prior and concomitant medications will be coded by the World Health Organization Drug 
Dictionary to Anatomical Therapeutic Classification (ATC) and preferred drug name.  
Prior therapies (including over-the-counter medications) used to treat the signs and 
symptoms of PN within the prior 2 years will be reported. Prior medications will be 
summarized by ATC level and preferred drug name and listed. 
Concomitant medications will be summarized by ATC level and preferred drug name and 
listed. Concomitant medication use will be quantified and analyzed. 
8.7 
Treatment Compliance and Extent of Exposure  
Compliance with study drug dosing will be determined based on tablet counts recorded on the 
eCRF. Compliance will be calculated by analyzing expected number of tablets returned versus 
actual number of tablets returned. Summaries of treatment exposure will also be produced.  
8.8 
Efficacy Analyses  
All efficacy endpoints will be summarized within the ITT and PP populations using 
descriptive statistics by time point and treatment. Results including averaged imputed values 
will be summarized at Baseline, Week 2 (if available), 4, 10 and Follow-up, and the change 
from baseline for these measures will be summarized at Week 2, 4, 10 and Follow-up. The 
WI-NRS and change from baseline will also be presented for each study day.  
8.8.1 
Primary Efficacy 
The difference in the primary efficacy outcome measure (WI-NRS 4-point responder rate at 
Week 10) will be tested using a CMH test controlling for the ‘as randomized’ stratification 
factors. Conceptually the hypotheses being tested are: 
H0:PPlacebo ≥ PSerlopitant  
Ha: PPlacebo < PSerlopitant 
 
where PPlacebo is the percent of placebo responders and PSerlopitant is the similar percent for 
serlopitant. The primary endpoint will utilize the missing data rules as outlined in 
Section 8.2.  
203


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 54 
8.8.2 
Key Secondary Efficacy  
The differences between treatment groups for the key secondary efficacy endpoints, Week 2 WI-
NRS 4-point responder rate and Week 4 WI-NRS 4-point responder rate, will be the CMH test 
identical to the one used for the primary endpoint.  
The preceding tests are to be conducted for the ITT population and the PP populations. 
8.8.3 
Additional Secondary Efficacy  
Additional secondary efficacy endpoints which may be drawn from the primary and key 
secondary imputations (including all WI-NRS endpoints) will be analyzed using the imputed 
data. Additional secondary efficacy endpoints otherwise will be analyzed using available 
data. P-values will be included for descriptive purposes only. 
Additional secondary efficacy endpoints which are dichotomous (responder) will include 
analyses analogous to the primary and key secondary efficacy analyses.  
Additional secondary efficacy endpoints based on change from baseline will be analyzed 
using an analysis of covariance (ANCOVA) model with treatment group and stratification 
factor as fixed effects and the baseline value as a covariate. Both least squares means and 
observed means will be presented.  
To confirm the assumptions for the ANCOVA model (i.e., that the errors are normally 
distributed with equal variances), residuals will be examined using the Shapiro-Wilk test.  If 
there is overwhelmingly strong evidence that the assumptions are not satisfied, the data will 
be rank-transformed prior to submitting to the ANCOVA.  Results of the rank-transformed 
analysis then will be considered the primary analysis; however, results of the non-rank-
transformed analysis will also be presented. 
8.9 
Sensitivity Analyses  
8.9.1 
Last Observation Carried Forward  
In the first set of sensitivity analysis, missing values will be imputed using LOCF. Data will 
be imputed using LOCF unless the subject withdrew from the study due to a lack of efficacy, 
or the subject used an excluded therapy to treat worsening of pruritus or PN, in which case 
their responder status will be defined as non-responder. Each primary and key secondary 
endpoint will be analyzed as it was using the multiply imputed data.  
8.9.2 
Repeated Measures Analysis 
The second set of sensitivity analyses will be performed on observed data. 
The dichotomized primary and key secondary WI-NRS endpoints will be analyzed with a 
repeated measures logistic regression model (generalized estimating equations), with the 
204


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 55 
dichotomized endpoint as the dependent variable and treatment, stratification factor and visit 
(Weeks 2, 4, 10) as independent factors 
Change from baseline in DLQI to Week 10 will be analyzed with a repeated measures 
ANCOVA, with treatment, stratification factor and applicable timepoints as independent 
factors and a covariate of baseline value. 
8.9.3 
Tipping Point Analysis 
A sensitivity analysis for the handling of missing data for the primary efficacy endpoint will 
be carried out using a tipping point analysis. 
8.10 
Safety Analyses  
8.10.1 
Adverse Events  
The incidence of all AEs and treatment-related AEs will be tabulated by treatment received. 
These AEs will be classified by system organ class and preferred term using the Medical 
Dictionary for Regulatory Activities (MedDRA). For incidence reporting, if a subject 
reported more than one AE that was coded to the same system organ class or preferred term, 
the subject will be counted only once for that specific system organ class or preferred term. 
An overview of AEs, which includes subject incidence of AEs, treatment-related AEs, AEs 
by severity, SAEs, deaths, and AEs leading to discontinuation, will be presented.  
SAEs will be listed and summarized in a similar manner to AEs. 
8.10.2 
Clinical Safety Laboratory Results  
Clinical safety laboratory values will be measured by a central laboratory. Summary statistics 
for actual values and for changes from baseline will be tabulated for laboratory results by 
scheduled visit.  
Subjects with clinical laboratory values outside of the normal reference range at any 
post-baseline assessment will be summarized. Shifts from baseline laboratory values will be 
tabulated. 
8.10.3 
Vital Signs  
The observed data and change from baseline for each measurement day will be summarized 
with descriptive statistics.  
8.10.4 
Electrocardiograms  
The overall ECG assessment (abnormal or normal) will be summarized and descriptively 
characterized, along with a summary of how many subjects developed a post treatment 
abnormal result.  
205


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 56 
8.10.5 
Physical Exams  
Physical exam finds will be recorded by the sites within medical history or adverse events and 
otherwise not summarized. 
8.10.6 
Menstrual Diaries 
Menstrual diary dates will be used to summarize number and duration of menses.  
8.10.7 
Hospital Anxiety and Depression Scale   
The observed data and change from baseline for the HADS will be summarized with 
descriptive statistics by scheduled visit. Both the Depression and the Anxiety subscales will 
be reported. 
8.10.8 
Epworth Sleepiness Scale   
The observed data and change from baseline for the ESS will be summarized with descriptive 
statistics by scheduled visit.  
8.11 
Interim Analyses  
No interim analysis is planned.  
8.12 
Population Pharmacokinetics Analysis  
The plasma concentrations of serlopitant and metabolites will be combined with the data 
from other serlopitant clinical studies for population PK analysis with PK endpoint of 
individual model parameter estimates and covariates identification. A specific population PK 
data analysis plan will be developed that will outline the detailed approach to data handling, 
model development and diagnostics, individual model parameter estimation, exploration of 
covariate effects, and final model evaluation techniques. The population PK analysis report 
will not be a part of the clinical study report. 
9 
ADMINISTRATIVE ASPECTS 
9.1 
Changes to the Protocol 
Protocol amendments must be made only with the prior written approval of the Sponsor. An 
investigator signature will be obtained for the initial protocol and any amendments. 
Substantial amendments will be provided to the appropriate regulatory authorities. No 
protocol changes affecting the following will be made without the written approval of the 
Sponsor and the responsible IRB or EC: 
• Safety and/or eligibility of subjects 
• Data integrity 
206


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 57 
• Study design or conduct 
• Willingness of a subject to participate in the study 
 
9.2 
Study Termination 
The Sponsor has the right to terminate this study at any time. Reasons may include, but are 
not limited to, evidence of a potential safety risk in this study or other serlopitant studies or 
poor enrollment. The study may be terminated at the request of the US Food and Drug 
Administration, the European Medicines Agency, other Competent Authorities or regulatory 
agencies with appropriate jurisdiction, or if the approval to manufacture or to import study 
drug is revoked by those with jurisdiction. A written statement fully documenting the reasons 
for study termination will be provided to the IRB or EC. 
9.3 
Monitoring and Auditing Procedures 
The Sponsor will designate study monitors who will be responsible for monitoring the 
conduct of this study. A separate study Monitoring Plan will include details regarding the 
responsibilities of the study monitors, investigator responsibilities in providing access to 
records and addressing issues identified, the frequency and structure of monitoring visits, and 
adherence to subject confidentiality as outlined in the Informed Consent Form (ICF). 
9.4 
Transfer of Obligations 
The Sponsor will delegate certain aspects of study oversight to Contract Research 
Organizations (CROs). The specific responsibilities will be detailed in Transfer of 
Obligations documents.  
9.5 
Informed Consent 
The purpose of the study, the procedures to be carried out, and any potential risks of study 
participation will be described in non-technical terms in the ICF. After having reviewed and 
understood the ICF, subjects will be required to read, sign, and date an IRB-approved or 
EC-approved consent form before any study-specific procedures are carried out. Subjects 
will be assured that they may withdraw from the study at any time without jeopardizing 
medical care related to or required as a result of study participation. The original signed 
consent form will be maintained in the investigator site file. Copies of signed consent forms 
will be provided to the subject. 
9.6 
Communication with the Institutional Review Board or Ethics Committee 
The IRB or EC is constituted and operates in accordance with the principles and 
requirements described in the ICH E6 guideline. The protocol, ICF, other written subject 
information, and any proposed study advertising material must be submitted to the IRB or 
EC for written approval. IRB or EC approval of these documents will be provided to the 
207


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 58 
investigator. The study will not start until the IRB or EC has granted its approval of the study 
materials and procedures. 
Protocol amendments will be submitted to the IRB or EC as explained in Section 9.1. SAE 
information will be submitted to the IRB or EC as explained in Section 7.4.  
If the study is terminated by the Sponsor, a written statement fully documenting the reason(s) 
for study termination will be provided to the IRB or EC. 
9.7 
Disclosure and Confidentiality 
By signing this protocol, the investigator agrees to keep all information provided by the 
Sponsor in strict confidence and to require the same confidentiality from site staff and the 
IRB or EC. Study documents provided by the Sponsor (e.g. protocol, IB, eCRFs) will be 
stored appropriately to ensure their confidentiality. The information provided by the Sponsor 
to the investigator may not be disclosed to others without direct written authorization from 
the Sponsor, except to the extent necessary to obtain informed consent from subjects who 
wish to participate in the study.  
The investigator must ensure that the subjects be identified by a unique subject study 
number. Other study-related documents that may contain confidential participant information 
(e.g. signed ICFs) will be kept in strict confidence by the investigator and be stored in a 
secure location with access restricted to the study staff. 
9.8 
Records and Electronic Case Report Forms 
All study data except central laboratory, PK, eDiary, photography and ECG data will be 
recorded in an eCRF system. Data will be entered at the site by the appropriately designated 
and trained site personnel. All source documents from which eCRF entries are derived should 
be placed in the subject’s medical records. eCRFs will be completed for every subject 
screened in the study. 
The study monitor will review all eCRFs in detail and will have access to participant medical 
records, laboratory data, and other source documentation to allow required eCRF fields to be 
verified by source data. 
Data consistency and plausibility checks against data entered into the eCRF will be included 
in the eCRF system. Data corrections can be performed in the eCRFs by the site. For each 
instance of data modification, the system requires a reason for change. The system keeps a 
full audit trail of the data values, the date and time of modification, and the electronic 
signature of the user who performed the change. 
After a full review of the eCRFs by the study monitor and resolution of any data 
clarifications, the investigator will review, sign, and approve the subject’s eCRF. All 
essential documents, source data, clinical records, and laboratory data will be retained by the 
site in accordance with the ICH E6 guideline and the site’s data retention policies. These 
records must be available for inspection by the Sponsor, monitor, and regulatory authorities. 
208


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 59 
Further detail regarding data management and eCRFs is included in the Data Management 
Plan. 
9.9 
Good Clinical Practices and Ethical Study Conduct 
The study procedures outlined in this protocol will be conducted in accordance with 
applicable ICH Guidelines, including ICH E6: Good Clinical Practices. As this study is 
conducted under a US IND, the investigator will also ensure that the basic principles of 
“Good Clinical Practice”, as outlined in 21 CFR 312, subpart D, “Responsibilities of 
Sponsors and Investigators”, 21 CFR, part 50 and 21 CFR, part 56 are adhered to. 
The study procedures outlined in this protocol will also be conducted in accordance with the 
principles of the Declaration of Helsinki. 
9.10 
End of Study Notification 
The Sponsor will notify appropriate regulatory authorities and the IRB or EC within 90 days 
from the end of the clinical study. The end of the clinical study is defined as the last study 
visit for the last subject. 
9.11 
Publication of Results 
All publications (e.g. manuscripts, abstracts, oral/slide presentations, book chapters) based on 
this study or relying on data from this study must be submitted to the Sponsor for review and 
release before submission for publication. The Sponsor is responsible for final approval of all 
publications. 
9.12 
Final Report 
A clinical trial summary report will be provided to the appropriate regulatory authorities 
within one year of the end of the clinical study. 
209


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 60 
10 
REFERENCES 
Abadía Molina F, Burrows NP, Jones RR, Terenghi G, Polak JM. Increased sensory 
neuropeptides in nodular prurigo: A quantitative immunohistochemical analysis. Br J 
Dermatol. 1992;127:344-351. 
Akiyama T, Nguyen T, Curtis E, et al. A central role for spinal dorsal horn neurons that express 
neurokinin-1 receptors in chronic itch. Pain. 2015;156(7):1240-1246. 
Andoh T, Nagasaw T, Satoh M, Kuraishi Y. Substance P induction of itch-associated response 
mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther. 
1998;286(3):1140-1145. 
Bergasa NV. The itch of liver disease. Semin Cutan Med Surg. 2011;30(2):93-98. 
Booken N, Heck M, Nicolay JP, et al. Oral aprepitant in the therapy of refractory pruritus in 
erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011;164(3):665-667. 
Common Terminology Criteria for Adverse Events (CTCAE). 4.03 ed: National Institutes of 
Health; 2010. 
Crowe R, Parkhouse N, MacGrouther D, Burnstock G. Neuropeptide-containing nerves in painful 
hypertrophic human scar tissue. Br J Dermatol. 1994;130:444-452. 
Dazzi C, Erma D, Piccinno R, Veraldi S, Caccialanza M. Psychological factors involved in 
prurigo nodularis: A pilot study. J Dermatolog Treat. 2011;22(4):211-214. 
Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Eng J Med. 
2009;361(14):1415-1416. 
El-Nour H, Lundeberg L, Al-Tawil R, Granlund A, Lonne-Rahm SB, Nordlind K. Upregulation 
of the axonal growth and the expression of substance P and its NK1 receptor in human 
allergic contact dermatitis. Immunopharmacol Immunotoxicol. 2006;28(4):621-631. 
Emend® (aprepitant) capsule for oral use. U.S. Prescribing Information. Merck Sharp and Dohme 
Corp. Revised August 2015. 
Examples of clinical inhibitors for P450-mediated metabolisms (for concomitant use clinical DDI 
studies and/or drug labeling) (9/26/2016). U.S. Food and Drug Administration; 2016. 
Feldmeyer L, Werner S, Kamarashev J, French LE, Hofbauer GF. Atopic prurigo nodularis 
responds to intravenous immunoglobulins. Br J Dermatol. 2012;166(2):461-462. 
Fostini AC, Girolomoni G, Tessari G. Prurigo nodularis: an update on etiopathogenesis and 
therapy. J Dermatolog Treat. 2013;24(6):458-462. 
Gerber PA, Buhren BA, Cevikbas F, et al. Preliminary evidence for a role of mast cells in 
epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol. 
2010;63(1):163-165. 
Goeksel T, Xie W, Ritzerfeld M, Heidenreich S, Mann H. Prurigo nodularis and dialyzer 
membrane. Blood Purif. 2013;35(2):26-27. 
Halvorsen JA, Aasebø W. Oral tacrolimus treatment of pruritus in prurigo nodularis. Acta Derm 
Venereol. 2015;95(7):866-867. 
Harrison S, Geppetti P. Substance P. Int J Biochem Cell Biol. 2001;33(6):555-576. 
210


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 61 
Hökfelt T, Pernow B, Wahren J. Substance P: A pioneer amongst neuropeptides. J Intern Med. 
2001;249(1):27-40. 
Hon KL, Lam MC, Wong KY, Leung TF, Ng PC. Pathophysiology of nocturnal scratching in 
childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance 
P. Br J Dermatol. 2007;157(5):922-925. 
Iking A, Grundmann S, Chatzigeorgakidis E, et al. Prurigo as a symptom of atopic and non-
atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad 
Dermatol Venereol. 2013;27(5):550-557. 
Jorgensen KM, Egeberg A, Gislason GH, Skov L, Thyssen JP. Anxiety, depression and suicide in 
patients with prurigo nodularis. J Eur Acad Dermatol Venereol. 2017;31(2):e106-107. 
Jorizzo JL, Gatti S, Smith EB. Prurigo: a clinical review. J Am Acad Dermatol. 1981;4(6): 
723-728. 
Lee MR, Shumack S. Prurigo nodularis: a review. Australas J Dermatol 2005;46:211-220. 
Lim VM, Maranda EL, Patel V, Simmons BJ, Jimenez JJ. A review of the efficacy of 
thalidomide and lenalidomide in the treatment of refractory prurigo nodularis. Dermatol 
Ther (Heidelb). 2016;6(3):397-411. 
Lotts T, Ständer S. Research in practice: substance P antagonism in chronic pruritus. J Dtsch 
Dermatol Ges. 2014;12(7):557-559. 
M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing 
Authorization for Pharmaceuticals. Food and Drug Administration; 2010. 
Matts JP, Lachin JM. Properties of permuted-block randomization in clinical trials. Control Clin 
Trials. 1988;9(4):327-344. 
Navigant Consulting, Inc. (2017). Report: Market Landscapes and Evaluation of Serlopitant for 
Use in Atopic Dermatitis and Prurigo Nodularis. (proprietary data). 
PASS 13 Power Analysis and Sample Size Software [computer program]. Kaysville, Utah, USA, 
ncss.com/software/pass.: NCSS, LLC; 2014. 
Recommendations related to contraception and pregnancy testing in clinical trials. Clinical Trial 
Facilitation Group; 2014. 
Rowland Payne CM, Wilkinson JD, McKee PH, Jurecka W, Black MM. Nodular prurigo – a 
clinicopathological study of 46 patients. Br J Dermatol. 1985;113(4):431-439. 
Saco M, Cohen G. Prurigo nodularis: Picking the right treatment. J Fam Pract. 2015;64(4):221-
226. 
Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to 
biological cancer treatments: a pilot study. Lancet Oncol. 2012;13(10):1020-1024. 
Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in 
lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical 
cutaneous neuropathy. Br J Dermatol. 2011;165(1):85-91. 
Slattery MJ, Essex MJ, Paletz EM, et al. Depression, anxiety, and dermatologic quality of life in 
adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011;128(3):668-671. 
211


Menlo Therapeutics Inc. 
Confidential 
 
Protocol MTI-106 
 
Version 4.0/16 December 2019 
 
Page 62 
Spring P, Gschwind I, Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with 
methotrexate. Clin Exp Dermatol. 2014;39:468-473. 
Ständer S, Pogatzki-Zahn E, Stumpf A, et al. Facing the challenges of chronic pruritus: a report 
from a multi-disciplinary medical itch centre in Germany. Acta Derm Venereol. 
2015b;95(3):266-271. 
Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 
1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5(6):e10968. doi: 
10.1371/journal.pone.0010968.  
Ständer S, Weisshaar E, Raap U. Emerging drugs for the treatment of pruritus. Exp Opin Emerg 
Drugs. 2015a;20:515-521. 
Ständer S, Stumpf A, Osada N, et al. Gender differences in chronic pruritus: women present 
different morbidity, more scratch lesions and higher burden. Br J Dermatol. 
2013;168(6):1273-1280. 
Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their 
receptors: contributions to physiological control and the mechanisms of disease. Physiol 
Rev. 2014;94(1):265-301. 
Tan WS, Tey HL. Extensive prurigo nodularis: characterization and etiology. Dermatol. 
2014;228(3):276-280. 
Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: Evidence of its effectiveness in 
patients with refractory pruritus continues. J Am Acad Dermatol. 2012;66(1):e14-15. doi: 
10.1016/j.jaad.2011.01.016. 
U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Vol 20172010. 
Vaidya DC, Schwartz RA. Prurigo nodularis: a benign dermatosis derived from a persistent 
pruritus. Acta Dermatovenerol Croat. 2008;16(1):38-44. 
Wallengren J. Prurigo: Diagnosis and management. Am J Clin Dermatol. 2004;5(2):85-95.  
Ward RS, Tuckett RP, English KB, Johansson O, Saffle JR. Substance P axons and sensory 
threshold increase in burn-graft human skin. J Surg Res. 2004;118(2):154-160. 
Zancanaro PC, McGirt LY, Mamelak AJ, Nguyen RH, Martins CR. Cutaneous manifestations of 
HIV in the era of highly active antiretroviral therapy: An institutional urban clinical 
experience. J Am Acad Dermatol. 2006;54(4):581-588. 
Zeidler C, Ständer S. The pathogenesis of prurigo nodularis--'Super-Itch' in exploration. Eu J 
Pain. 2016;20(1):37-40. 
 
212


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 63 
APPENDIX A  
SCHEDULE OF ACTIVITIES AND ASSESSMENTS 
Table 2 
Schedule of Visit Activities 
Examination 
Screening 
Mid-
ScreeningTC  
Baseline1  
Week 1TC 
(± 3 days) 
Week 2 
(± 3 days) 
Week 4 
(± 3 days) 
Week 6 
(± 3 days) 
Week 10 
(± 7 days) 
F/U2 
Early Treatment 
Discontinuation 
Demographics 
X 
 
 
 
 
 
 
 
 
 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
WI-NRS3 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
DLQI 
 
 
X 
 
 
X 
 
X 
 
X 
HADS, ESS 
 
 
X 
 
 
X 
 
X 
X 
X 
ECG 
X 
 
 
 
X 
X 
 
X 
X 
X 
Vital signs 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
Medical history (and prior medications)  
X 
X 
X 
 
 
 
 
 
 
 
Physical exam4 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
Concomitant medications  
 
 
X 
X 
X 
X 
X 
X 
X 
X 
Labs5  
X 
 
 
 
X 
 
  
X 
X 
X 
Urine pregnancy test6 
X 
 
X 
 
 
X 
 X 
X 
X 
X 
PK blood draw  
 
 
 
 
X 
X 
 
X 
 
 
Review of I/E criteria 
X 
X 
X 
 
 
 
 
 
 
 
IGA PN-A and IGA PN-S 
 
 
X 
 
X 
X 
 
X 
X 
X 
Photography (selected sites) 
 
 
X 
 
 
 
 
X 
X 
X 
Dispense/review menstrual diary (if 
applicable) 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
Dispense/collect eDiary  
X 
 
 
 
  
 
 
 
X  
X 
eDiary review/compliance7 
 
X 
X 
X 
X 
X 
X 
X 
X 
 
Dispense and/or collect study drug 
 
 
X 
 
X 
X 
X 
X 
 
X 
Review study drug compliance 
 
 
 
 
X 
X 
X 
X 
 
 
AEs/SAEs8 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
TCTelephone Contact: The Mid-Screening telephone contact should only occur for subjects who require a washout longer than 2 weeks, at least 15 days prior to the scheduled Baseline visit.  
1All visits and windows should be scheduled based on the Baseline Visit (Day 1) 
2The Follow-up (F/U) visit occurs 21-35 days (+ 7 days) after the Week 10 visit or the last dose of study drug for subjects who discontinue study drug early.  
3WI-NRS at Screening visit will be collected manually on paper for Inclusion/Exclusion criteria. All subsequent WI-NRS are collected daily via eDiary. 
4Screening physical exam is complete and includes height and weight; other physical exams are targeted and include weight.  
5Labs are ideally performed in the morning, particularly at visits with endocrine assessments (including Reproductive Endocrinology for females under 55 at age of consent) at Screening, Week 10 
and Follow Up.  Iron Studies, serum IgE and Serology labs are done only at Screening visit; endomysial antibody test and other optional studies only performed at Screening;  
6Female subjects of childbearing potential only. Serum pregnancy test is required for positive or equivocal results 
7See Table 3 for eDiary assessments 
8During the period between informed consent and first study drug dose, only SAEs caused by a protocol-mandated intervention will be collected. 
213


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 64 
Table 3 
Schedule of eDiary Assessments 
An eDiary device is provided to subjects at the Screening visit and collected at the Follow-up visit.   
Device 
Assessment 
Frequency and Duration of Assessment 
eDiary 
WI-NRS 
Once daily from Screening/Mid-Screening visit through the Follow-up visit 
eDiary 
Dosing 
Once daily from Baseline visit through Week 10 visit or study drug discontinuation 
 
 
214


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 65 
APPENDIX B  
LIST OF STRONG CYP3A4 INHIBITORS 
The list of strong CYP3A4 inhibitors is based on the FDA list effective September 26, 2016, 
Examples of clinical inhibitors for P450-mediated metabolisms (for concomitant use clinical 
DDI studies and/or drug labeling (“Examples of clinical inhibitors for P450-mediated 
metabolisms (for concomitant use clinical DDI studies and/or drug labeling (9/26/2016)”).  
Note: This Appendix may be replaced if applicable (e.g., if updated by the FDA) through site 
communications without requiring a protocol amendment. 
1. 
boceprevir 
2. 
clarithromycin 
3. 
cobicistat 
4. 
conivaptan 
5. 
danoprevir and ritonavir 
6. 
diltiazem 
7. 
elvitegravir and ritonavir 
8. 
idelalisib 
9. 
indinavir and ritonavir 
10. 
itraconazolea 
11. 
ketoconazolea 
12. 
lopinavir and ritonavir 
13. 
nefazodone 
14. 
nelfinavir 
15. 
paritaprevir and ritonavir and (ombitasvir and/or dasabuvir) 
16. 
posaconazolea 
17. 
ritonavir 
18. 
saquinavir and ritonavir 
19. 
telaprevir 
20. 
tipranavir and ritonavir 
21. 
troleandomycin 
22. 
voriconazolea 
23. 
regular grapefruit juice consumption (note: The effect of grapefruit juice varies 
widely among brands and is concentration-, dose-, and preparation-dependent. 
Grapefruit juice may be a strong or a moderate CYP3A inhibitor depending on the 
preparation)b 
 
a 
When administered topically, it may not be considered a strong CYP3A4 inhibitor due to limited systemic 
absorption. 
b 
The occasional consumption of grapefruit juice or the consumption of grapefruit or other citrus fruits (e.g., 
pomelo, lemon, lime, Seville orange, bitter orange, starfruit) is not contraindicated. 
 
215


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 66 
APPENDIX C  
WORST ITCH NUMERIC RATING SCALE QUESTIONNAIRE 
 
216


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 67 
APPENDIX D 
INVESTIGATOR’S GLOBAL ASSESSMENT OF PRURIGO 
NODULARIS: ACTIVITY AND STAGE 
Score 
Category 
Description: Activity (IGA PN-A) 
0 
Clear 
No nodules have excoriations or crusts  
1 
Almost 
Clear 
Very small proportion of nodules have excoriations or crusts (up to 
approximately 10% of all nodules) 
2 
Mild 
Minority of nodules have excoriations or crusts (approximately 11- 25% of 
all nodules) 
3 
Moderate 
Many nodules have excoriations or crusts (approximately 26- 75% of all 
nodules) 
4 
Severe 
Majority of nodules have excoriations or crusts (approximately 76-100% of 
all nodules) 
 
Score 
Category 
Description: Stage (IGA PN-S) 
0 
Clear 
No nodules (0 nodules) 
1 
Almost 
Clear 
Rare, flattened lesions, with no more than 5 dome-shaped palpable nodules 
(approximately 1-5 nodules) 
2 
Mild 
Few, mostly flattened lesions, with small number of dome-shaped palpable 
nodules (approximately 6-19 nodules) 
3 
Moderate 
Many lesions, partially flattened, and dome-shaped palpable nodules 
(approximately 20-100 nodules) 
4 
Severe 
Abundant lesions, majority are dome-shaped palpable nodules (over 
100 nodules) 
 
217


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 68 
APPENDIX E 
DERMATOLOGY LIFE QUALITY INDEX 
Different language versions may be used. 
 
218


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 69 
APPENDIX F 
HOSPITAL ANXIETY AND DEPRESSION SCALE 
 
To be used under license. 
  
219


Menlo Therapeutics Inc 
Confidential 
 
Protocol MTI-106 
 
 
Version 4.0/16 December 2019 
 
Page 70 
APPENDIX G  
EPWORTH SLEEPINESS SCALE   
 
220

SAP_000.pdf: 
Protocol: MTI-106 
Confidential - Proprietary Information 
 Protocol number: MTI-106. 
 Document title: A randomized, double-blind, placebo-controlled study of 
the efficacy, safety, and tolerability of serlopitant for the treatment of 
pruritus in adults with prurigo nodularis. 
 Version number: SAP Version 4. 
 Date of the document: 16 December 2019. 
 NCT number: NCT03677401 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 1 
Protocol Number: MTI-106 
 
 16 December 2019 
STATISTICAL ANALYSIS PLAN 
Protocol Number: 
MTI-106 
 
 
Study Title: 
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF THE EFFICACY, 
SAFETY, AND TOLERABILITY OF 
SERLOPITANT FOR THE TREATMENT OF 
PRURITUS IN ADULTS WITH PRURIGO 
NODULARIS 
 
 
Development Phase of Study: 
Phase 3 
 
 
Sponsor: 
Menlo Therapeutics Inc. 
200 Cardinal Way, 2nd Floor 
Redwood City, CA 94063 
USA 
Sponsor Contact: 
 
 
 
Statistical Analysis Plan based on 
Protocol Version: 
Version 4.0, 16 December 2019 
 
 
Statistical Analysis Plan Date: 
16 December 2019 
Statistical Analysis Plan Version: 
Version 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confidentiality Statement: 
This document is a confidential communication of Menlo Therapeutics Inc. As such, the recipients agree not to 
disclose or reproduce, without prior written approval, this document and any attachments, except to appropriate 
Institutional Review Boards, Ethics Committees, representatives of the US Food and Drug Administration, other 
regulatory agencies or as otherwise required by applicable laws or regulations. 
 
 
PPD




 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 3 
Protocol Number: MTI-106 
 
 16 December 2019 
TABLE OF CONTENTS 
1. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ....................................6 
2. 
INTRODUCTION .................................................................................................................7 
3. 
STUDY OBJECTIVES .........................................................................................................7 
4. 
STUDY DESIGN ...................................................................................................................7 
4.1 Overall Study Design ......................................................................................................7 
4.1.1 
Schedule of Visits and Assessments .................................................................8 
4.1.2 
Method of Assigning Subjects to Treatment Groups ........................................8 
4.1.3 
Blinding .............................................................................................................8 
5. 
EFFICACY AND SAFETY ENDPOINTS .........................................................................8 
5.1 Efficacy Endpoints ..........................................................................................................8 
5.1.1 
Primary Efficacy Endpoint ................................................................................8 
5.1.2 
Key Secondary Efficacy Endpoints ...................................................................8 
5.1.3 
Additional Secondary Efficacy Endpoints ........................................................9 
5.2 Safety Endpoints .............................................................................................................9 
6. 
STATISTICAL AND ANALYTICAL PLANS ..................................................................9 
6.1 General Methodology .....................................................................................................9 
6.1.1 
Statistical Analysis ..........................................................................................10 
6.1.2 
Baseline Definition ..........................................................................................10 
6.1.3 
Visit Windowing .............................................................................................10 
6.1.4 
Adjustments for Covariates .............................................................................11 
6.1.5 
Handling of Dropouts or Missing Data ...........................................................11 
6.1.6 
Interim Analyses and Data Monitoring ...........................................................13 
6.1.7 
Multicenter Studies ..........................................................................................13 
6.1.8 
Multiple Comparisons/Multiplicity .................................................................13 
6.1.9 
Examination of Subgroups ..............................................................................13 
6.2 Disposition of Subjects .................................................................................................13 
6.3 Protocol Deviations .......................................................................................................13 
6.4 Data Sets Analyzed .......................................................................................................13 
6.4.1 
Intent-to-Treat (ITT) Population .....................................................................14 
6.4.2 
Safety Population ............................................................................................14 
6.4.3 
Per Protocol Population ...................................................................................14 
6.5 Demographic and Other Baseline Characteristics ........................................................15 
6.6 Prior and Concomitant Medications .............................................................................15 
6.7 Analysis of Efficacy ......................................................................................................15 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 4 
Protocol Number: MTI-106 
 
 16 December 2019 
6.7.1 
Primary Efficacy Analysis ...............................................................................15 
6.7.2 
Key Secondary Efficacy Analysis ...................................................................16 
6.7.3 
Additional Secondary Efficacy Analysis.........................................................16 
6.8 Sensitivity Analysis ......................................................................................................16 
6.8.1 
Last Observation Carried Forward ..................................................................16 
6.8.2 
Repeated Measures Analysis ...........................................................................16 
6.8.3 
Tipping Point Analysis ....................................................................................17 
6.9 Safety Evaluation ..........................................................................................................17 
6.9.1 
Extent of Exposure ..........................................................................................17 
6.9.2 
Adverse Events ................................................................................................18 
6.9.3 
Clinical Laboratory Evaluation .......................................................................18 
6.9.4 
Other Observations Related to Safety .............................................................18 
6.9.4.1 
ECG Measurements .....................................................................18 
6.9.4.2 
Vital Signs ....................................................................................19 
6.9.4.3 
Physical Exams ............................................................................19 
6.9.4.4 
Menstrual Diaries .........................................................................19 
6.9.4.5 
Hospital Anxiety and Depression Scale (HADS) ........................19 
6.9.4.6 
Epworth Sleepiness Scale (ESS) ..................................................19 
6.10 Pharmacokinetic Analysis .............................................................................................19 
7. 
DETERMINATION OF SAMPLE SIZE .........................................................................19 
8. 
CHANGES IN THE PLANNED ANALYSES..................................................................20 
9. 
REFERENCES ....................................................................................................................20 
10. INDEX OF PLANNED END-OF-TEXT TABLES AND FIGURES .............................21 
11. INDEX OF PLANNED LISTINGS .................................................................................116 
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 5 
Protocol Number: MTI-106 
 
 16 December 2019 
Revision History: 
 Version  
Date 
Summary of Changes 
Author 
Version 1 
13 November 2018 Original document 
Brian Armstrong 
Version 2 
03 April 2019 
Updated title page to reflect current 
version of protocol.  Updated SAP 
version and date. 
Sections 5.1.2 and 6.1.8 (previously 
6.1.7), 6.7.2, 6.8.2 updated to remove 
Day 7 and Day 3 key secondary 
endpoints. 
Section 6.1 updated, Section 6.1.6 added 
to reflect potential interim analysis. 
Section 6.1.3, 6.1.5, 6.7 updated to 
include Week 1 for WI-NRS data. 
Sections 6.1.6 – 6.1.9 renumbered to 
allow for additional section added as 
6.1.6. 
Section 7 updated sample size per Phase 
2 information. 
Brian Armstrong 
Version 3 
30 August 2019 
Updated SAP version and date. 
Editorial and grammatical updates 
including abbreviations and references. 
DLQI Question 1 included as Additional 
Seconary Endpoint; modified changes to 
planned analysis section. 
Clarified visit nomenclature for follow-
up period. 
Modified language to indicate no 
interim analysis will be performed. 
Added subgroup summaries of primary 
efficacy endpoint.   
Added table, figure and listing shells. 
Brian Armstrong 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 6 
Protocol Number: MTI-106 
 
 16 December 2019 
Version 4 
16 December 2019 
Updated SAP version and date. 
Modified WI-NRS Weekly average 
computation to require a minimum of 4 
values to compute average. 
DLQI moved from Key Secondary 
Endpoint to Additional Secondary 
Endpoint; removed multiple imputation 
of DLQI. 
WI-NRS 4-point responder at Week 2 
added as Key Secondary Endpoint. 
Updated changes to planned analysis 
section to reflect no changes, as protocol 
was amended. 
Updated table, figure and listing shells. 
Brian Armstrong 
1. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
AE(s) 
Adverse event(s) 
ANCOVA 
Analysis of covariance 
CMH 
Cochran-Mantel-Haenszel 
DLQI 
Dermatology Life Quality Index 
ECG 
Electrocardiogram 
eDiary 
Electronic diary 
ESS 
Epworth Sleepiness Scale 
HADS 
Hospital Anxiety and Depression Scale 
IGA PN-A 
Investigator’s Global Assessment of Prurigo Nodularis Activity 
IGA PN-S 
Investigator’s Global Assessment of Prurigo Nodularis Stage 
ITT 
Intent-to-treat 
LOCF 
Last observation carried forward 
MedDRA 
Medical Dictionary for Regulatory Activities 
MCMC 
Markov Chain Monte Carlo 
PN 
Prurigo Nodularis 
PP 
Per Protocol 
SAE(s) 
Serious adverse event(s) 
SAS® 
Statistical Analysis System (SAS® Institute Inc., Cary, NC) 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 7 
Protocol Number: MTI-106 
 
 16 December 2019 
TEAE(s) 
Treatment-emergent adverse event(s) 
WHO-DDE 
World Health Organization Drug Dictionary Enhanced 
WI-NRS 
Worst-Itch Numeric Rating Scale 
2. INTRODUCTION 
Prurigo nodularis (PN) is a distinctive and easily diagnosable chronic skin condition 
characterized by the presence of multiple highly pruritic and often symmetrically distributed 
nodules and papules on the skin (Jorizzo 1981). The nodules and papules in PN can range in size 
from approximately 0.5 to 3.0 cm and often appear hyperkeratotic, sometimes crateriform, in 
appearance. Plaques are occasionally present, and the lesions of PN frequently exhibit other 
features secondary to prolonged and severe scratching behavior, such as post-inflammatory 
hyperpigmentation, erosion, ulceration, crusting, and bleeding (Zeidler 2016). 
Menlo Therapeutics Inc. is pursuing the development of serlopitant for treatment of itch. The 
MTI-106 study described herein is a double-blind, randomized, placebo-controlled study to 
assess the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults 
with PN. 
3. STUDY OBJECTIVES 
The efficacy objective of this study is to assess the efficacy of serlopitant for the treatment of 
pruritus in adults with PN. 
The safety objective of this study is to assess the safety and tolerability of repeated oral doses of 
serlopitant in adults with PN. 
4. STUDY DESIGN 
4.1 
Overall Study Design 
This is a double-blind, randomized, placebo-controlled study to assess the efficacy, safety, and 
tolerability of serlopitant for the treatment of pruritus in adults with PN. The study will be 
conducted at approximately 50 study sites. Subjects who meet the study entry criteria will be 
randomized in a 1:1 ratio to receive daily oral doses of serlopitant 5 mg or placebo for 10 weeks. 
After completion of the treatment period or early discontinuation of study drug treatment, all 
subjects will enter a 3 or 5-week follow-up period. The required follow-up period is defined as a 
minimum of 3 weeks for those subjects who will enroll in the one-year open-label safety study 
(MTI-107) on the date of the follow-up visit, and as 5 weeks for those subjects who will not be 
enrolled in the one-year open-label safety study of serlopitant. Should a subject present for the 
follow-up visit prior to 5 weeks after the last dose of study drug and be excluded from 
participation in the one-year study for any reason, the subject will be required to return at 5 
weeks after the last dose of study drug for a complete follow-up visit. 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 8 
Protocol Number: MTI-106 
 
 16 December 2019 
This study will consist of three periods, for a total study period of 15-19 weeks: 
• Screening period: 2-4 weeks 
• Treatment period: 10 weeks 
• Follow-up period: 3 or 5 weeks 
4.1.1 
Schedule of Visits and Assessments 
The schedule of assessments can be found in Section 6.5 and Appendix A of the Protocol.  
4.1.2 
Method of Assigning Subjects to Treatment Groups 
Eligible subjects will be randomized to receive serlopitant 5 mg or placebo in a 1:1 ratio. 
Stratified permuted block randomization will be used. Randomization will be stratified by the 
subject’s reported Worst-Itch Numeric Rating Scale (WI-NRS) score for the 1-week period prior 
to the Baseline visit (6.5 to < 9, 9 to 10). 
An interactive web response system will be used to perform the randomization. 
4.1.3 
Blinding 
This study will be conducted as a double-blind study with the treatment assignment concealed 
from the subjects, the investigators and their staff, the Sponsor, and any designees of the Sponsor 
as required. The placebo will be formulated to be indistinguishable from the active study 
product(s). Study materials will be packaged and issued in a manner designed to maintain the 
blind for subjects and all study personnel involved in the direction and execution of study 
procedures, study assessments, and collection of data. The randomization code for each subject 
will be available to the sites for use only in an emergency situation. For details of the procedure 
for unblinding of individual subjects in cases of emergency see Section 7.6 of the Protocol and 
the Blinding Plan.  
5. EFFICACY AND SAFETY ENDPOINTS 
5.1 
Efficacy Endpoints 
5.1.1 
Primary Efficacy Endpoint 
The primary efficacy endpoint is the WI-NRS 4-point responder rate at Week 10. 
5.1.2 
Key Secondary Efficacy Endpoints 
The key secondary efficacy endpoints are as follows: 
• The WI-NRS 4-point responder rate at Week 4 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 9 
Protocol Number: MTI-106 
 
 16 December 2019 
• The WI-NRS 4-point responder rate at Week 2 
5.1.3 
Additional Secondary Efficacy Endpoints 
Additional secondary efficacy endpoints include the following: 
• Change from baseline in WI-NRS to Weeks 2, 4, 6 and 8 
• WI-NRS 3-point responder rate at Weeks 2, 4 and 10 
• Change from baseline in Investigator’s Global Assessment of PN Activity (IGA PN-A) to 
Weeks 2, 4, 10 
• Change from baseline in Investigator’s Global Assessment of PN Stage (IGA PN-S) to 
Weeks 2, 4, 10 
• Change from baseline in Dermatology Life Quality Index (DLQI) to Week 10 
• Change from baseline in DLQI Question 1 to Week 10 
5.2 
Safety Endpoints 
Safety endpoints include the following: 
• Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events 
(SAEs) 
• Changes from baseline in clinical laboratory parameters following study drug exposure 
• Changes from baseline in vital sign and electrocardiogram (ECG) parameters following 
study drug exposure 
• Change from baseline in the Hospital Anxiety and Depression Scale (HADS) 
• Change from baseline in the Epworth Sleepiness Scale (ESS) 
6. STATISTICAL AND ANALYTICAL PLANS 
6.1 
General Methodology 
All statistical processing will be performed using SAS® Version 9.3 or later, unless otherwise 
stated. Endpoints will be summarized with descriptive statistics by treatment group and visit. For 
continuous variables, the following information will be presented: n (number of subjects), mean, 
standard deviation (SD), median, minimum and maximum. For categorical variables, counts and 
percentages will be used. 
Reported adverse events (AEs), medical history, and prior and concomitant procedures and 
therapies will be classified on the basis of Medical Dictionary for Regulatory Activities 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 10 
Protocol Number: MTI-106 
 
 16 December 2019 
(MedDRA) terminology. Concomitant medications will be classified on the basis of World 
Health Organization Drug Dictionary Enhanced (WHO-DDE) terminology. 
6.1.1 
Statistical Analysis 
All summary tables and data listings will be prepared by QST Consultations, Ltd., utilizing 
SAS® Version 9.3 or later software. All relevant data collected within the CRF will be included 
in data listings. 
The standard operating procedures of QST Consultations, Ltd. will be followed in the creation 
and quality control of all data displays. 
6.1.2 
Baseline Definition 
Baseline, for measures other than those collected daily, will be the last recorded value prior to 
the start of treatment. For daily WI-NRS data captured via electronic diary (eDiary), baseline 
will be the average result measured over the 7 days prior to treatment.  
6.1.3 
Visit Windowing 
Data will be summarized based on nominal visit indications. Data collected during post-
treatment follow-up will be summarized as 
Protocol 
Version(s) 
Nominal Visit 
Analysis Visit 
V2.0; V2.1 
3-Week Follow-up 
3-Week Follow-up 
V2.0; V2.1 
5-Week Follow-up 
5-Week Follow-up 
In addition, a “Latest Follow-up” visit will be summarized, which will include the latest 
available follow-up information for each subject from the 3-, 5- Week Follow-up visits. 
Information collected at early treatment discontinuation visits will be mapped to the most 
appropriate visit based on the midpoints between scheduled visits.  
Visits: Baseline 
Week 2 
Week 4 
Week 6 
Week 10 
 
 
(Day 1) 
(Day 15) 
(Day 29) 
(Day 43) 
(Day 71) 
 
 
 
 
 
 
 
 
Midpoints: 
Day 8 
Day 22 
Day 36 
Day 57 
  
For example, if a subject terminates use of study drug on or after Day 22 but before Day 36, data 
collected at the early end of treatment visit will be mapped to the Week 4 evaluation for 
summaries. If the subject has Week 4 values present, the data collected at the early end of 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 11 
Protocol Number: MTI-106 
 
 16 December 2019 
treatment visit will not replace the data collected at Week 4. For the sensitivity efficacy analyses, 
last observation carried forward (LOCF) will be applied subsequent to mapping the information 
to the appropriate visit.  
Additionally, WI-NRS will be summarized at Weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 3- and 5-
Week Follow-up by averaging the daily results for the 7 days prior to each week. The weekly 
average values will be calculated if a subject has at least four responses during the 7 day range, 
as defined below: 
Week/Visit 
Study Day Range 
Week 1 
2-7 (as Day 1 may be pre or post first dose) 
Week 2 
8-14 
Week 3 
15-21 
Week 4 
22-28 
Week 5 
29-35 
Week 6 
36-42 
Week 7 
43-49 
Week 8 
50-56 
Week 9 
57-63 
Week 10 
64-70 
3-Week Follow-up Post-treatment days 15-21 
5-Week Follow-up Post-treatment days 29-35 
6.1.4 
Adjustments for Covariates 
Analysis of covariance will include baseline value as a covariate.   
6.1.5 
Handling of Dropouts or Missing Data 
Should a determination of treatment period (on treatment, pre-treatment, post-treatment) be 
required for AEs or concomitant medication but the corresponding date is missing, or is a partial 
date, the event/medication will be considered on treatment unless the portions of the date that are 
available indicate this is not possible.        
The primary method of handling missing efficacy data will be Markov Chain Monte Carlo 
(MCMC) multiple imputation. Imputation will be conducted within each treatment group 
independently, so the pattern of missing observations in one treatment group cannot influence 
missing value estimations in another. For each imputation process, 25 imputations will be 
performed. 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 12 
Protocol Number: MTI-106 
 
 16 December 2019 
Subjects that withdrew from the study due to lack of efficacy will have missing values imputed, 
however, the WI-NRS responder status will be defined as non-responder. Subjects that used an 
excluded therapy to treat worsening of pruritus or PN will have data values collected after the 
use of the excluded therapy set to missing and subsequently imputed. These subjects will also 
have the WI-NRS responder status defined as non-responder.  
Missing WI-NRS data will be derived for the analysis using the method of MCMC multiple 
imputation. The 4-point responder status will be derived from imputed WI-NRS values. Since 
both primary and key secondary endpoints require WI-NRS, the following steps will be 
followed: 
1. Using the daily eDiary data, calculate Baseline and Week 1 through Week 10 values by 
averaging available values. In order to compute a week’s average, a minimum of 4 values 
must be available for that week. The weekly average will be imputed when there are 
fewer than 4 values available. 
2. From step 1, create a dataset for each treatment group, of subjects with observed values 
and those needing estimation by MCMC. The missing WI-NRS values in each dataset 
will be filled in using the MCMC method to generate 25 datasets. The resulting datasets 
for each treatment group will be combined into one complete dataset. 
Syntax: 
proc mi data=datain out=dataout seed=&seed. Nimpute=25 <options>;  
  where trtpn=(TRT); /* Note TRT = [1, 2]; depending on treatment group */; 
  mcmc chain=single; 
  var baseline week1 week2 week3 week4 week5 week6 week7 week8 week9        
         week10; 
run; 
 
3. From each complete dataset, the dichotomous responder rate will be determined. Each 
complete dataset will be analyzed as specified for the particular analysis.  
The results from the analyses will be combined into a single inference using SAS® PROC 
MIANALYZE. In the case of the primary analysis and the secondary responder analyses, the 
Cochran Mantel Haenszel (CMH) statistics computed in the analyses of WI-NRS responder rates 
will be normalized using the Wilson-Hilferty transformation prior to combining them using 
SAS® PROC MIANALYZE. 
A total of 2 random seeds will be needed to impute missing data. Those random seeds have been 
pre-specified by using a random number generator: 
CCI


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 13 
Protocol Number: MTI-106 
 
 16 December 2019 
6.1.6 
Interim Analyses and Data Monitoring 
No interim analyses will be performed. 
6.1.7 
Multicenter Studies 
The clinical study will be conducted under a common protocol for each investigational site with 
the intention of pooling all data for analysis. Every effort will be made to promote consistency in 
study execution at each study site. 
6.1.8 
Multiple Comparisons/Multiplicity 
The primary and key secondary endpoints will be analyzed. However, the statistical significance 
of the key secondary endpoints will only be considered should statistical significance be reached 
for the primary endpoint. Similarly, statistical significance within the key secondary endpoints 
will be considered based on a hierarchical approach, starting with the WI-NRS Week 4 
responder rate followed by the WI-NRS Week 2 responder rate. If the first key secondary 
endpoint fails to reach statistical significance at a level of 0.05, then subsequent endpoints will 
not be considered statistically significant. 
6.1.9 
Examination of Subgroups 
Descriptive summaries of the primary efficacy endpoint will be created for subgroups of the 
Intent-to-Treat (ITT) population. Subgroups include age (< median age; >= median age), sex, 
ethnicity, race and Baseline WI-NRS randomization strata. 
6.2 
Disposition of Subjects 
An accounting of all randomized subjects by disposition will be presented. Subjects who 
discontinue study drug prematurely or withdraw from the study will be summarized and listed, 
with a description of the reason for early termination/withdrawal. 
The number of subjects included in each population will be summarized. Subjects who are 
excluded from a population will be summarized by the reasons for exclusion. 
6.3 
Protocol Deviations 
Protocol deviations leading to exclusion from an analysis population will be tabulated.  Other 
protocol deviations will be presented in a data listing.  
6.4 
Data Sets Analyzed 
The following analysis populations will be reviewed and approved by the Sponsor prior to 
unblinding the study. 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 14 
Protocol Number: MTI-106 
 
 16 December 2019 
6.4.1 
Intent-to-Treat (ITT) Population 
The primary efficacy population will be the ITT population, which will include all randomized 
subjects who were dispensed study drug. Subjects will be analyzed within the treatment group to 
which they are randomized. 
6.4.2 
Safety Population 
The primary safety population will be all treated subjects with at least one post-baseline 
assessment or a reported TEAE. For safety analyses, subjects will be classified based upon 
treatment received. In the case that a subject received both treatments, subjects will be 
summarized within the serlopitant 5 mg group. 
6.4.3 
Per Protocol Population 
Additional analyses performed on the Per Protocol (PP) population will be considered 
supportive. The PP population will include all subjects in the safety population who complete the 
Week 10 evaluations without any significant protocol deviations/violations (i.e., any subject or 
investigator activity that could have possibly interfered with the therapeutic administration of the 
treatment or the precise evaluation of treatment efficacy). The PP population will include 
subjects in the safety population who do not meet any of the following criteria: 
• Violated the inclusion/exclusion criteria; 
• Received a strong CYP3A4 inhibitor (See Appendix B in the Protocol); 
• Received an excluded medication which may plausibly impact the primary endpoint at 
Week 10 (e.g. was provided to treat pruritus or PN); 
• Have not been compliant with the dosing regimen (i.e. subjects must comply with 80-
120% of the expected dosage of study medication during participation in the study); 
• Have not completed Week 10 visit within  ±7 days window 
• Have not completed the eDiary to provide the Week 10 WI-NRS Primary Endpoint  
Subjects who discontinue from the study drug due to an adverse event related to study treatment 
or documented lack of treatment effect, or who met protocol-defined non-responder criteria, will 
be included in the PP population. Prior to breaking the blind other additional criteria may be 
added to the lists above to accommodate for unforeseen events that occurred during the conduct 
of the trial that result in noteworthy study protocol deviations. 
Subjects will be analyzed within the treatment group to which they are randomized. 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 15 
Protocol Number: MTI-106 
 
 16 December 2019 
6.5 
Demographic and Other Baseline Characteristics 
Demographic and baseline characteristics summaries will be done for the ITT, Safety, and PP 
populations. 
Sex, race, and ethnicity will be summarized by counts and percentages. Age, height (cm), and 
weight (kg) will be summarized with descriptive statistics. 
IGA PN-A, and IGA PN-S will be summarized by counts and percentages. WI-NRS (average 
result measured over the week prior to treatment) and DLQI will be summarized with descriptive 
statistics.    
Medical histories will be coded using MedDRA, tabulated by System Organ Class and Preferred 
Term for the Safety population, and presented in a by-subject listing. 
PN history and prior PN therapies will be presented in by-subject listings. 
6.6 
Prior and Concomitant Medications 
Prior and concomitant medications will be coded by the WHO-DDE to Anatomical Therapeutic 
Classification (ATC) and preferred drug name. Concomitant medications will be summarized by 
ATC level 2 term and preferred drug name. 
A by-subject listing of all prior and concomitant medications will be presented.  The associated 
by-subject listing will have a prior/concomitant determination that is based on the date of first 
dose. 
6.7 
Analysis of Efficacy 
The efficacy endpoints will be summarized within the ITT and PP populations using descriptive 
statistics by time point and treatment. Available results including averaged imputed values, as 
well as change from baseline, will be summarized for each applicable time point. The WI-NRS 
and change from baseline will also be presented for each study day in a by-subject listing.  
For the 4- and 3-point responder rate endpoints, subjects will be considered responders if they 
have at least a 4- / 3-point reduction between baseline and the corresponding week. Subjects that 
discontinued study drug due to lack of efficacy or used an excluded medication to treat 
worsening of pruritus or PN will be considered non-responders. 
6.7.1 
Primary Efficacy Analysis 
The difference in the primary efficacy outcome measure (WI-NRS 4-point responder rate at 
Week 10) will be tested using a CMH test controlling for the ‘as randomized’ stratification 
factors. Conceptually the hypotheses being tested are:  
H0: PPlacebo ≥ PSerlopitant  
 
Ha: PPlacebo < PSerlopitant 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 16 
Protocol Number: MTI-106 
 
 16 December 2019 
where PPlacebo is the percent of placebo responders and PSerlopitant is the similar percent for 
serlopitant.   
6.7.2 
Key Secondary Efficacy Analysis 
The WI-NRS 4-point responder rates at Week 4 and Week 2 will be analyzed using methods 
consistent with testing the primary endpoint.  
The preceding analyses are to be conducted for the ITT and PP populations.     
6.7.3 
Additional Secondary Efficacy Analysis 
Additional secondary efficacy endpoints which may be drawn from the primary and key 
secondary imputations (including all WI-NRS endpoints) will be analyzed using the imputed 
data. Additional secondary efficacy endpoints otherwise will be analyzed using available data. P-
values will be included for descriptive purposes only. 
Additional secondary efficacy endpoints which are dichotomous (responder) will include 
analyses analogous to the primary and key secondary efficacy analyses.  
Additional secondary efficacy endpoints based on change from baseline will be analyzed using 
an analysis of covariance (ANCOVA) model with treatment group and stratification factor as 
fixed effects and the baseline value as a covariate. Both least squares means and observed means 
will be presented.  
To confirm the assumptions for the ANCOVA model (i.e., that the errors are normally 
distributed with equal variances), residuals will be examined using the Shapiro-Wilk test. If there 
is overwhelmingly strong evidence that the assumptions are not satisfied, the data will be rank-
transformed prior to submitting to the ANCOVA. Results of the rank-transformed analysis then 
will be considered the primary analysis; however, results of the non-rank transformed analysis 
will also be presented. 
6.8 
Sensitivity Analysis 
6.8.1 
Last Observation Carried Forward 
In the first set of sensitivity analyses, missing values will be imputed using LOCF. Data will be 
imputed using LOCF unless the subject withdrew from the study due to lack of efficacy, or the 
subject used an excluded therapy to treat worsening of pruritus or PN, in which case their 
responder status will be defined as non-responder. Each primary and key secondary endpoint will 
be analyzed as it was using the multiply imputed data. 
6.8.2 
Repeated Measures Analysis 
The second set of sensitivity analyses will be performed on observed data. 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 17 
Protocol Number: MTI-106 
 
 16 December 2019 
The dichotomized primary and key secondary WI-NRS endpoints will each be analyzed with a 
repeated measures logistic regression model (generalized estimating equations), with the 
dichotomized endpoint as the dependent variable and treatment, stratification factor and visit 
(Weeks 1-10) as independent factors. 
6.8.3 
Tipping Point Analysis 
A sensitivity analysis for the handling of missing data for the primary efficacy endpoint will be 
carried out using a tipping point analysis. Specifically, a range of response rates for both groups 
will be explored to determine the tipping point(s) at which the combinations result in no longer 
reaching statistical significance. 
6.9 
Safety Evaluation 
6.9.1 
Extent of Exposure 
The extent of exposure to study drug in each treatment group will be summarized by days with 
exposure and total number of tablets used. 
A subject will be considered compliant with the dosing regimen if the subject takes 80% to 120% 
of the expected number of doses while enrolled in the study. Total number of days of exposure 
will be computed as follows: 
Total Exposure  = Date of Last Dose – Date of First Dose + 1 
Total Doses  = (Date of Last Dose – Date of First Dose + 1 + 2)  
 
 – Missed Doses + Extra Doses 
Treatment compliance will be based on the expected number of doses given the treatment period 
duration. The number of expected doses will be computed from the Baseline/Day 1 visit date and 
the Week 10 visit date. If a subject does not have a Week 10 visit, the number of expected doses 
will be calculated based on end of treatment period date given available information (e.g., date of 
last dose, last completed visit date).  
Expected Doses = End of Treatment Period Date – Day 1 Date + 2  
If the subject is documented as dosing on the End of Treatment Period Date, a dose will be added 
to the Expected Doses. To allow for the +7 day window around Week 10 that is used for defining 
PP population, if the number of expected doses exceeds 80, the number of expected doses will be 
considered 80 doses. 
Percent compliance will be calculated from total number of doses and total number of expected 
doses as follows: 
Percent Compliance = 100*(Total Doses/Expected Doses). 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 18 
Protocol Number: MTI-106 
 
 16 December 2019 
Percent compliance will not be calculated for subjects who are lost to follow-up during the 
treatment period. 
6.9.2 
Adverse Events 
The incidence of all AEs and TEAEs will be tabulated by treatment received. These AEs will be 
classified by system organ class and preferred term using MedDRA. For incidence reporting, if a 
subject reported more than one AE that was coded to the same system organ class or preferred 
term, the subject will be counted only once for the specific system organ class or preferred term. 
An overview of AEs, which includes subject incidence of AEs, treatment-related AEs, AEs by 
severity, SAEs, deaths, and AEs leading to discontinuation, will be presented. 
Assessment of AEs reported after study drug discontinuation will be summarized separately by 
treatment group. AEs during post-drug follow-up will be summarized by weekly periods and sex. 
SAEs will be listed and summarized in a similar manner to AEs. 
6.9.3 
Clinical Laboratory Evaluation 
Clinical safety laboratory values will be measured by a central laboratory. Summary statistics for 
actual values and for changes from baseline will be tabulated for laboratory results by scheduled 
visit.  
Subjects with clinical laboratory values outside of the normal reference range at any post- 
baseline assessment will be summarized. Shifts from baseline laboratory values will be tabulated, 
with the exception of most reproductive endocrinology laboratory values. 
Serum follicle-stimulating hormone, luteinizing hormone, estradiol, progesterone and anti-
mullerian hormone will be summarized separately for women using hormonal 
contraception/therapies and those not using hormonal contraception/therapies. 
By-subject listings of all laboratory data, as well as abnormal laboratory results, will be 
presented. 
6.9.4 
Other Observations Related to Safety 
6.9.4.1 
ECG Measurements 
Summary statistics for actual values and for changes from baseline will be tabulated for ECG 
parameter results by scheduled visit. The overall ECG assessment (abnormal or normal) will be 
summarized along with a summary of how many subjects developed a post treatment abnormal 
result. The study relevance of the finding (i.e. clinical significance as determined by the 
investigator) will be provided in a by-subject listing. 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 19 
Protocol Number: MTI-106 
 
 16 December 2019 
6.9.4.2 
Vital Signs 
The observed data and change from baseline for each measurement day will be summarized with 
descriptive statistics, as well as provided in a by-subject listing. 
6.9.4.3 
Physical Exams 
Clinically significant physical exam findings will be recorded by the sites within medical history 
or adverse events and otherwise not summarized. 
6.9.4.4 
Menstrual Diaries 
Menstrual diary dates will be used to summarize number and duration of menses. 
6.9.4.5 
Hospital Anxiety and Depression Scale (HADS) 
The observed data and change from baseline for the HADS will be summarized with descriptive 
statistics by scheduled visit. Both the Depression and Anxiety subscales will be reported. 
6.9.4.6 
Epworth Sleepiness Scale (ESS) 
The observed data and change from baseline for the ESS will be summarized with descriptive 
statistics by scheduled visit. 
6.10 
Pharmacokinetic Analysis 
The plasma concentrations of serlopitant and metabolites will be summarized using descriptive 
statistics. 
By-subject listings of the plasma concentrations of serlopitant and metabolites will be presented. 
7. DETERMINATION OF SAMPLE SIZE 
This study will use a 5% two-sided alpha level. While the alpha level is two-sided, clinically relevant 
results require a serlopitant benefit. 
The target sample size of 280 randomized and dosed subjects (140 per group) has been determined 
based upon a 1:1 allocation of subjects to treatment groups and a 5% alpha level. Completed Phase 2 
studies indicate that placebo responder rates vary between 
% and 
% and serlopitant rates 
between 
% and 
%. A sample size of 280 subjects provides >90% power assuming a placebo 
responder rate of 
% and serlopitant rate of 
%. 
The sample size calculations have been performed in PASS 13 (“PASS 13 Power Analysis and 
Sample Size Software” 2014) and use a Chi-Squared test. The primary analysis will control for 
the stratification factors. It is expected that this unstratified power estimate will under-estimate 
CCI
CCI
CCI
CCI
CCI
CCI


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 20 
Protocol Number: MTI-106 
 
 16 December 2019 
the true power as it does not take the variance reduction resulting from stratification into account 
(Matts 1988). 
8. CHANGES IN THE PLANNED ANALYSES 
No changes to planned analyses. 
9. REFERENCES 
Jorizzo JL, Gatti S, Smith EB. Prurigo: a clinical review. J Am Acad Dermatol. 1981;4(6): 723-
728. 
Matts JP LJ. Properties of permuted-block randomization in clinical trials. Control ClinTrials. 
1988;9(4):327-344. 
PASS 13 Power Analysis and Sample Size Software [computer program]. Kaysville, Utah, USA, 
ncss.com/software/pass.: NCSS, LLC; 2014. 
Zeidler C, Ständer S. The pathogenesis of prurigo nodularis--'Super-Itch' in exploration. Eu J 
Pain. 2016;20(1):37-40. 
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 21 
Protocol Number: MTI-106 
 
 16 December 2019 
10. INDEX OF PLANNED END-OF-TEXT TABLES AND FIGURES 
Table 14.0.1: Summary of Subject Completion/Discontinuation (Randomized Subjects) ...........26 
Table 14.0.2: Summary of Subjects Excluded from Analyses (Randomized Subjects) ................27 
Table 14.0.3: Summary of Subject Visit Attendance  (Randomized Subjects) .............................28 
Table 14.1.1.1: Summary of Subject Demographics (Intent-to-Treat Population) ........................29 
Table 14.1.1.2: Summary of Subject Demographics (Per-Protocol Population) ...........................30 
Table 14.1.1.3: Summary of Subject Demographics (Safety Population) .....................................30 
Table 14.1.2.1: Subject Baseline Characteristics (Intent-to-Treat Population) .............................31 
Table 14.1.2.2: Subject Baseline Characteristics (Per-Protocol Population).................................32 
Table 14.1.2.3: Subject Baseline Characteristics (Safety Population)...........................................32 
Table 14.1.3: Summary of Medical History by MedDRA System Organ Class and Preferred 
Term (Intent-to-Treat Population).........................................................33 
Table 14.1.4: Summary of Concomitant Medications by ATC Level 2 Term and Preferred Drug 
Name (Intent-to-Treat Population) ........................................................34 
Table 14.2.1.1: Analysis of the Primary Efficacy Endpoint: Worst-Itch Numeric Rating Scale 
(WI-NRS) 4-Point Responder at Week 10 (Intent-to-Treat 
Population) ............................................................................................35 
Table 14.2.1.2: Analysis of the Primary Efficacy Endpoint: Worst-Itch Numeric Rating Scale 
(WI-NRS) 4-Point Responder at Week 10 (Per-Protocol Population) .35 
Table 14.2.1.3: Sensitivity Analyses of the Primary Efficacy Endpoint: Worst-Itch Numeric 
Rating Scale (WI-NRS) 4-Point Responder at Week 10 (Intent-to-Treat 
Population) ............................................................................................36 
Figure 14.2.1.4: Sensitivity Tipping-Point Analyses of the Primary Efficacy Endpoint: Worst-
Itch Numeric Rating Scale (WI-NRS)  4-Point Responder at Week 10 
(Intent-to-Treat Population) ..................................................................37 
Table 14.2.1.4: Subgroup Summaries of Primary Efficacy Endpoint: Worst-Itch Numeric Rating 
Scale (WI-NRS) 4-Point Responder at Week 10  (Intent-to-
Treat Population) ...................................................................................38 
Table 14.2.2.1: Analysis of Key Secondary Efficacy Endpoints (Intent-to-Treat Population) .....41 
Table 14.2.2.2: Analysis of Key Secondary Efficacy Endpoints (Per-Protocol Population) ........41 
Table 14.2.2.3: Sensitivity Analyses of Key Secondary Efficacy Endpoints (Intent-to-Treat 
Population) ............................................................................................42 
Table 14.2.3.1: Analysis of Additional Secondary Efficacy Endpoints (Intent-to-Treat 
Population) ............................................................................................44 
Table 14.2.3.2: Analysis of Additional Secondary Efficacy Endpoints (Per-Protocol 
Population) ............................................................................................50 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 22 
Protocol Number: MTI-106 
 
 16 December 2019 
Table 14.2.4.1: Summary of Worst Itch Numeric Rating Scale (WI-NRS)  (Intent-to-Treat 
Population) ............................................................................................51 
Table 14.2.4.2: Summary of Worst Itch Numeric Rating Scale (WI-NRS) (Per-Protocol 
Population) ............................................................................................57 
Table 14.2.4.3: Summary of Worst Itch Numeric Rating Scale (WI-NRS) – Observed Data with 
Follow-up  (Intent-to-Treat Population with Observed Week 10 
Data) ......................................................................................................58 
Table 14.2.5.1.1: Summary of Dermatology Life Quality Index (DLQI) (Intent-to-Treat 
Population) ............................................................................................60 
Table 14.2.5.1.2: Summary of Dermatology Life Quality Index (DLQI) (Per-Protocol 
Population) ............................................................................................61 
Table 14.2.5.2.1: Summary of Dermatology Life Quality Index (DLQI) Individual Questions 
(Intent-to-Treat Population) ..................................................................62 
Table 14.2.5.2.2: Summary of Dermatology Life Quality Index (DLQI) – Individual Questions 
(Per-Protocol Population)......................................................................64 
Table 14.2.6.1: Summary of Investigator’s Global Assessment of Prurigo Nodularis Activity 
(IGA PN-A) (Intent-to-Treat Population) .............................................65 
Table 14.2.6.2: Summary of Investigator’s Global Assessment of Prurigo Nodularis Activity 
(IGA PN-A) (Per-Protocol Population) ................................................70 
Table 14.2.7.1: Summary of Investigator’s Global Assessment of Prurigo Nodularis Stage (IGA 
PN-S) (Intent-to-Treat Population) .......................................................71 
Table 14.2.7.2: Summary of Investigator’s Global Assessment of Prurigo Nodularis Stage (IGA 
PN-S) (Per-Protocol Population) ..........................................................76 
Table 14.3.0.1: Summary of Extent of Exposure (Intent-to-Treat Population) .............................77 
Table 14.3.0.2: Summary of Extent of Exposure (Per-Protocol Population) ................................77 
Table 14.3.0.3: Summary of Extent of Exposure (Safety Population) ..........................................77 
Table 14.3.1.1.1: Overall Summary of Treatment-Emergent Adverse Events (TEAEs) (Safety 
Population) ............................................................................................78 
Table 14.3.1.1.2: Summary of Subjects Reporting Treatment-Emergent Adverse Events (TEAEs) 
by MedDRA System Organ Class and Preferred Term (Safety 
Population) ............................................................................................79 
Table 14.3.1.1.3: Summary of Treatment-Emergent Adverse Events (TEAEs) Leading to 
Discontinuation of Study Drug (Safety Population) .............................80 
Table 14.3.1.1.4: Summary of Subjects Reporting Treatment-Emergent Adverse Events (TEAEs) 
by Severity (Safety Population) ............................................................81 
Table 14.3.1.1.5: Summary of Subjects Reporting Treatment-Emergent Adverse Events (TEAEs) 
by Relationship to Study Drug (Safety Population) ..............................82 
Table 14.3.1.2.1.1: Overall Summary of Post-Drug Adverse Event (AEs)  (Safety Population) ..83 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 23 
Protocol Number: MTI-106 
 
 16 December 2019 
Table 14.3.1.2.1.2: Overall Summary of Post-Drug Adverse Events (AEs) Occurring 1-7 Days 
Post Last Dose (Safety Population).......................................................84 
Table 14.3.1.2.1.3: Overall Summary of Post-Drug Adverse Events (AEs) Occurring 8-14 Days 
Post Last Dose (Safety Population).......................................................85 
Table 14.3.1.2.1.4: Overall Summary of Post-Drug Adverse Events (AEs) Occurring 15-21 Days 
Post Last Dose (Safety Population).......................................................85 
Table 14.3.1.2.1.5: Overall Summary of Post-Drug Adverse Events (AEs) Occurring 22-28 Days 
Post Last Dose (Safety Population).......................................................85 
Table 14.3.1.2.1.6: Overall Summary of Post-Drug Adverse Events (AEs) Occurring 29-35 Days 
Post Last Dose (Safety Population).......................................................85 
Table 14.3.1.2.2.1: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) by 
MedDRA System Organ Class and Preferred Term (Safety 
Population) ............................................................................................86 
Table 14.3.1.2.2.2: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
1-7 Days Post Last Dose  by MedDRA System Organ Class and 
Preferred Term (Safety Population) ......................................................87 
Table 14.3.1.2.2.3: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
8-14 Days Post Last Dose by MedDRA System Organ Class and 
Preferred Term (Safety Population) ......................................................88 
Table 14.3.1.2.2.4: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
15-21 Days Post Last Dose by MedDRA System Organ Class and 
Preferred Term (Safety Population) ......................................................88 
Table 14.3.1.2.2.5: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
22-28 Days Post Last Dose by MedDRA System Organ Class and 
Preferred Term (Safety Population) ......................................................88 
Table 14.3.1.2.2.6: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
29-35 Days Post Last Dose by MedDRA System Organ Class and 
Preferred Term (Safety Population) ......................................................88 
Table 14.3.1.2.3.1: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) by 
Severity (Safety Population) .................................................................89 
Table 14.3.1.2.3.2: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
1-7 Days Post Last Dose by Severity (Safety Population) ....................90 
Table 14.3.1.2.3.3: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
8-14 Days Post Last Dose by Severity (Safety Population) ..................91 
Table 14.3.1.2.3.4: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
15-21 Days Post Last Dose by Severity (Safety Population) ................91 
Table 14.3.1.2.3.5: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
22-28 Days Post Last Dose by Severity (Safety Population) ................91 
Table 14.3.1.2.3.6: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
29-35 Days Post Last Dose by Severity (Safety Population) ................91 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 24 
Protocol Number: MTI-106 
 
 16 December 2019 
Table 14.3.1.2.4.1: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) by 
Relationship to Study Drug (Safety Population) ...................................92 
Table 14.3.1.2.4.2: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
1-7 Days Post Last Dose by Relationship to Study Drug  (Safety 
Population) ............................................................................................93 
Table 14.3.1.2.4.3: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
8-14 Days Post Last Dose by Relationship to Study Drug 
(Safety Population)................................................................................94 
Table 14.3.1.2.4.4: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
15-21 Days Post Last Dose by Relationship to Study Drug 
(Safety Population)................................................................................94 
Table 14.3.1.2.4.5: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
22-28 Days Post Last Dose by Relationship to Study Drug 
(Safety Population)................................................................................94 
Table 14.3.1.2.4.6: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 
29-35 Days Post Last Dose by Relationship to Study Drug 
(Safety Population)................................................................................94 
Table 14.3.1.3.1: Summary of Subjects Reporting Serious Treatment-Emergent Adverse Events 
(TEAEs) by MedDRA System Organ Class and Preferred Term (Safety 
Population) ............................................................................................95 
Table 14.3.1.3.2: Summary of Subjects Reporting Serious Treatment-Emergent Adverse Events 
(TEAEs) by Severity (Safety Population) .............................................96 
Table 14.3.1.3.3: Summary of Subjects Reporting Serious Treatment-Emergent Adverse Events 
(TEAEs) by Relationship to Study Drug (Safety Population) ..............97 
Table 14.3.1.4.1.1: Summary of Hematology Laboratory Results  (Safety Population) ...............98 
Table 14.3.1.4.1.2: Shift Summary of Hematology Laboratory Results (Safety Population) .......99 
Table 14.3.1.4.2.1: Summary of Chemistry Laboratory Results  (Safety Population) ................100 
Table 14.3.1.4.2.2: Shift Summary of Chemistry Laboratory Results (Safety Population) ........101 
Table 14.3.1.4.3.1.1: Summary of Endocrine/Reproductive Endocrine Laboratory 
Results  (Safety Population) ................................................................102 
Table 14.3.1.4.3.1.2: Summary of Reproductive Endocrine Laboratory 
Results  (Safety Population – Females Using Hormonal 
Contraception/Therapy) ......................................................................103 
Table 14.3.1.4.3.1.3: Summary of Reproductive Endocrine Laboratory 
Results  (Safety Population – Females Not Using Hormonal 
Contraception/Therapy) ......................................................................104 
Table 14.3.1.4.3.2: Shift Summary of Endocrine/Reproductive Endocrine Laboratory Results 
(Safety Population)..............................................................................105 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 25 
Protocol Number: MTI-106 
 
 16 December 2019 
Table 14.3.1.5.1.1: Summary of Treatment-Emergent Electrocardiogram (ECG) Parameter 
Abnormalities (Safety Population) ......................................................106 
Table 14.3.1.5.1.2: Summary of Electrocardiogram Parameters  (Safety Population) ................108 
Table 14.3.1.5.1.3: Shift Summary of Overall Electrocardiogram (ECG) Assessments (Safety 
Population) ..........................................................................................109 
Table 14.3.1.6.1: Summary of Vital Signs  (Safety Population) .................................................111 
Table 14.3.1.7.1: Summary of Hospital Anxiety and Depression Scale 
(HADS)   (Safety Population) .............................................................112 
Table 14.3.1.8.1: Summary of Epworth Sleepiness Scale (ESS)   (Safety Population) ..............113 
Table 14.3.1.9: Summary of Pharmacokinetic Concentrations   (Safety Population) .................114 
Table 14.3.1.10: Summary of Menstrual Cycles   (Safety Population) .......................................115 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 26 
Protocol Number: MTI-106  
16 December 2019 
Table 14.0.1: Summary of Subject Completion/Discontinuation  
(Randomized Subjects) 
 
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
Completed Treatment 
Yes 
xx ( xx.x%) 
xx ( xx.x%) 
No 
xx ( xx.x%) 
xx ( xx.x%) 
Reason for Discontinuation from Treatment 
Adverse Event 
xx ( xx.x%) 
xx ( xx.x%) 
Lack of Efficacy 
xx ( xx.x%) 
xx ( xx.x%) 
Pregnancy  
xx ( xx.x%) 
xx ( xx.x%) 
Investigator Decision 
xx ( xx.x%) 
xx ( xx.x%) 
Withdrawal by Subject from Treatment 
xx ( xx.x%) 
xx ( xx.x%) 
Protocol Deviation 
xx ( xx.x%) 
xx ( xx.x%) 
Sponsor Decision 
xx ( xx.x%) 
xx ( xx.x%) 
Other 
xx ( xx.x%) 
xx ( xx.x%) 
Completed Follow-up 
Yes 
xx ( xx.x%) 
xx ( xx.x%) 
No 
xx ( xx.x%) 
xx ( xx.x%) 
Reason for Discontinuation from Follow-up 
Withdrawal by Subject from Study 
xx ( xx.x%) 
xx ( xx.x%) 
Lost to Follow-up  
xx ( xx.x%) 
xx ( xx.x%) 
Other 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 27 
Protocol Number: MTI-106  
16 December 2019 
Table 14.0.2: Summary of Subjects Excluded from Analyses  
(Randomized Subjects) 
 
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
Intent-to-Treat Population 
Number of Subjects Included 
xx ( xx.x%) 
xx ( xx.x%) 
Number of Subjects Excluded 
xx ( xx.x%) 
xx ( xx.x%) 
Reason for Exclusion 
Not Dispensed Study Drug 
xx ( xx.x%) 
xx ( xx.x%) 
Safety Population 
Number of Subjects Included 
xx ( xx.x%) 
xx ( xx.x%) 
Number of Subjects Excluded 
xx ( xx.x%) 
xx ( xx.x%) 
Reason for Exclusion 
No Evidence of Subject Dosing 
xx ( xx.x%) 
xx ( xx.x%) 
No Post-Baseline Assessment/TEAE 
xx ( xx.x%) 
xx ( xx.x%) 
Per-Protocol Population 
Number of Subjects Included 
xx ( xx.x%) 
xx ( xx.x%) 
Number of Subjects Excluded 
xx ( xx.x%) 
xx ( xx.x%) 
Reason for Exclusion 
No Evidence of Subject Dosing 
xx ( xx.x%) 
xx ( xx.x%) 
No Post-Baseline Assessment/TEAE 
xx ( xx.x%) 
xx ( xx.x%) 
Violated the Inclusion/Exclusion Criteria 
xx ( xx.x%) 
xx ( xx.x%) 
Received a Strong CYP3A4 Inhibitor 
xx ( xx.x%) 
xx ( xx.x%) 
Received an Excluded Medication 
xx ( xx.x%) 
xx ( xx.x%) 
Was not Compliant with the Dosing Regimen 
xx ( xx.x%) 
xx ( xx.x%) 
Week 10 WI-NRS Data Not Available 
xx ( xx.x%) 
xx ( xx.x%) 
Did not Attend the Week 10 Visit 
xx ( xx.x%) 
xx ( xx.x%) 
Week 10 Visit not within +/- 7 days Window 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
Note: TEAE = Treatment Emergent Adverse Event; WI-NRS=Worst-Itch Numeric Rating Scale 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 28 
Protocol Number: MTI-106  
16 December 2019 
Table 14.0.3: Summary of Subject Visit Attendance  
(Randomized Subjects) 
 
Subjects Attending 
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
Screening 
xx ( xx.x%) 
xx ( xx.x%) 
Baseline 
xx ( xx.x%) 
xx ( xx.x%) 
Week 2 
xx ( xx.x%) 
xx ( xx.x%) 
Week 4 
xx ( xx.x%) 
xx ( xx.x%) 
Week 6 
xx ( xx.x%) 
xx ( xx.x%) 
Week 10 
xx ( xx.x%) 
xx ( xx.x%) 
3-Week Follow-up 
xx ( xx.x%) 
xx ( xx.x%) 
5-Week Follow-up 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 29 
Protocol Number: MTI-106  
16 December 2019 
Table 14.1.1.1: Summary of Subject Demographics  
(Intent-to-Treat Population) 
(Page 1 of 2) 
 
 
Placebo 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
(N=xxx) 
 
 
Total 
 
(N=xxx) 
 
Age (years) 
n 
xxx 
xxx 
xxx 
Mean 
xx.x 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
xx to xx 
Sex 
n 
xxx 
xxx 
xxx 
Male 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Female 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Ethnicity 
n 
xxx 
xxx 
xxx 
Hispanic or Latino 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Not Hispanic or Latino 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Race 
n 
xxx 
xxx 
xxx 
American Indian or Alaska Native 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Asian 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Black or African American 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Native Hawaiian or Other Pacific Islander 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
White 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Multiple/Other 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 30 
Protocol Number: MTI-106  
16 December 2019 
Table 14.1.1.1: Summary of Subject Demographics  
(Intent-to-Treat Population) 
(Page 2 of 2) 
 
 
Placebo 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
(N=xxx) 
 
 
Total 
 
(N=xxx) 
 
Height (cm) 
n 
xxx 
xxx 
xxx 
Mean 
xxx.x 
xxx.x 
xxx.x 
SD 
xxx.xx 
xxx.xx 
xxx.xx 
Median 
xxx.x 
xxx.x 
xxx.x 
Min. to Max. 
xxx to xxx 
xxx to xxx 
xxx to xxx 
Weight (kg) 
n 
xxx 
xxx 
xxx 
Mean 
xx.x 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
xx.x 
Min. to Max. 
xx to xxx 
xx to xxx 
xx to xxx 
 
 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Repeat Table 14.1.1.1 for the following: 
 
Table 14.1.1.2: Summary of Subject Demographics (Per-Protocol Population) 
Table 14.1.1.3: Summary of Subject Demographics (Safety Population) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 31 
Protocol Number: MTI-106  
16 December 2019 
Table 14.1.2.1: Subject Baseline Characteristics  
(Intent-to-Treat Population) 
(Page 1 of 2) 
 
 
Placebo 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
(N=xxx) 
 
 
Total 
 
(N=xxx) 
 
Baseline WI-NRS (1-Week Average Prior to 
Baseline) 
n 
xxx 
xxx 
xxx 
Mean 
xx.x 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
xx to xx 
Investigator’s Global Assessment of Prurigo 
Nodularis Activity 
n 
xxx 
xxx 
xxx 
 Grade 0  
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3  
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4  
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Investigator’s Global Assessment of Prurigo 
Nodularis Stage 
n 
xxx 
xxx 
xxx 
 Grade 0  
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3  
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4  
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 32 
Protocol Number: MTI-106  
16 December 2019 
Table 14.1.2.1: Subject Baseline Characteristics 
(Intent-to-Treat Population) 
(Page 2 of 2) 
 
 
Placebo 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
(N=xxx) 
 
 
Total 
 
(N=xxx) 
 
Dermatology Life Quality Index 
n 
xxx 
xxx 
xxx 
Mean 
xx.x 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
xx to xx 
 
 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
Repeat Table 14.1.2.1 for the following: 
 
Table 14.1.2.2: Subject Baseline Characteristics (Per-Protocol Population) 
Table 14.1.2.3: Subject Baseline Characteristics (Safety Population) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 33 
Protocol Number: MTI-106  
16 December 2019 
Table 14.1.3: Summary of Medical History by MedDRA System Organ Class and Preferred Term  
(Intent-to-Treat Population) 
(Page 1 of xx) 
  
System Organ Classa 
Preferred Term  
 
Placebo 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
(N=xxx) 
 
 
Total 
 
(N=xxx) 
 
System Organ Class 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
System Organ Class 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more medical histories that map to MedDRA. At each level of summarization (System Organ Class  
 or Preferred Term) subjects are counted once. 
Note: MedDRA Version 21.1. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 34 
Protocol Number: MTI-106  
16 December 2019 
Table 14.1.4: Summary of Concomitant Medications by ATC Level 2 Term and Preferred Drug Name  
(Intent-to-Treat Population) 
(Page 1 of xx) 
  
ATC Level 2 Terma 
Preferred Drug Name 
 
Placebo 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
(N=xxx) 
 
 
Total 
 
(N=xxx) 
 
ATC Level 2 Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Drug Name 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Drug Name 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Drug Name 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Drug Name 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Drug Name 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Drug Name 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Drug Name 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Drug Name 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ATC Level 2 Term 
Preferred Drug Name 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Drug Name 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Drug Name 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Drug Name 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more concomitant medications that map to the WHO-DDE. At each  level of summarization (ATC  
Level 2 Term or Standard Medication Name) subjects are counted once. 
Note: WHO Drug Dictionary, Version September 1, 2018.  
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 35 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.1.1: Analysis of the Primary Efficacy Endpoint: Worst-Itch Numeric Rating Scale (WI-NRS) 4-Point Responder at Week 10  
(Intent-to-Treat Population) 
  
 
Placebo 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
(N=xxx) 
  
P-valuea  
 
At Least 4-Point Reduction from Baseline in 
Weekly Average WI-NRS at Week 10 
    Success 
xx.xx% 
xx.xx% 
x.xxx 
    Failure 
xx.xx% 
xx.xx% 
 
 
a   P-value from a Cochran Mantel Haenszel (CMH) test stratified by Baseline WI-NRS used for randomization stratification. Value has been adjusted 
for multiple imputation. 
Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained by averaging the summary statistics  
 
generated from each imputed dataset.  
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Repeat Table 14.2.1.1 for the following: 
 
Table 14.2.1.2: Analysis of the Primary Efficacy Endpoint: Worst-Itch Numeric Rating Scale (WI-NRS) 4-Point Responder at Week 10 (Per-
Protocol Population) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 36 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.1.3: Sensitivity Analyses of the Primary Efficacy Endpoint: Worst-Itch Numeric Rating Scale (WI-NRS) 4-Point Responder at Week 10  
(Intent-to-Treat Population) 
  
 
Placebo 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
(N=xxx) 
  
P-value 
 
Missing Values Imputed using Last 
Observation Carried Forward (LOCF) 
At Least 4-Point Reduction from Baseline in 
Weekly Average WI-NRS at Week 10 
    Success 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
x.xxxa 
    Failure 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Repeated Measures Analysis on Observed 
Data 
At Least 4-Point Reduction from Baseline in 
Weekly Average WI-NRS at Week 10 
    Success 
xx.xx% 
xx.xx% 
x.xxxb 
    Failure 
xx.xx% 
xx.xx% 
 
 
a    P-value from a Cochran Mantel Haenszel (CMH) test stratified by Baseline WI-NRS randomization stratification. 
b  P-value from a repeated measures logistic regression with factors of treatment group, randomization stratification, visit and treatment group by  
visit interaction. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 37 
Protocol Number: MTI-106  
16 December 2019 
Figure 14.2.1.4: Sensitivity Tipping-Point Analyses of the Primary Efficacy Endpoint: Worst-Itch Numeric Rating Scale (WI-NRS)  
4-Point Responder at Week 10  
(Intent-to-Treat Population) 
  
  
 
 
 
 
Note:  The horizontal and vertical axes indicate the potential number of successes among subjects with missing data in each treatment group. 
 
Each plotted point indicates the number of imputed successes in each treatment group that results in p-value greater than 0.05. 
 
The red lines represent average number of imputed successes from the primary analysis using multiple imputation (MCMC) to impute missing values. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 38 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.1.4: Subgroup Summaries of Primary Efficacy Endpoint: Worst-Itch Numeric Rating Scale (WI-NRS) 4-Point Responder at Week 10  
(Intent-to-Treat Population) 
(Page 1 of 3) 
 
Sex 
 
Male 
   
Female 
 
  
Placebo 
 
(N=xxx)  
 
  
Serlopitant 5mg  
 
(N=xxx)  
 
  
Placebo 
 
(N=xxx)  
 
  
Serlopitant 5mg  
 
(N=xxx)  
 
At Least 4-Point Reduction from Baseline in 
Weekly Average WI-NRS at Week 10 
Success 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 xx.xx% 
Failure 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 xx.xx% 
Age 
 
Age < Median Age (xx) 
   
Age >= Median Age (xx) 
 
  
Placebo 
 
(N=xxx)  
 
  
Serlopitant 5mg  
 
(N=xxx)  
 
  
Placebo 
 
(N=xxx)  
 
  
Serlopitant 5mg  
 
(N=xxx)  
 
At Least 4-Point Reduction from Baseline in 
Weekly Average WI-NRS at Week 10 
Success 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 xx.xx% 
Failure 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 xx.xx% 
WI-NRS Randomization Strata 
 
WI-NRS of 6.5 to <9 
   
WI-NRS of 9 to 10 
 
  
Placebo 
 
(N=xxx)  
 
  
Serlopitant 5mg  
 
(N=xxx)  
 
  
Placebo 
 
(N=xxx)  
 
  
Serlopitant 5mg  
 
(N=xxx)  
 
At Least 4-Point Reduction from Baseline in 
Weekly Average WI-NRS at Week 10 
Success 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 xx.xx% 
Failure 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 
 
Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained by averaging the summary statistics  
 
generated from each imputed dataset. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 39 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.1.4: Subgroup Summary of Primary Efficacy Endpoint: Worst-Itch Numeric Rating Scale (WI-NRS) 4-Point Responder at Week 10  
 (Intent-to-Treat Population) 
(Page 2 of 3) 
 
Ethnicity 
 
Hispanic or Latino 
   
Not Hispanic or Latino 
 
  
Placebo 
 
(N=xxx)  
 
  
Serlopitant 5mg  
 
(N=xxx)  
 
  
Placebo 
 
(N=xxx)  
 
  
Serlopitant 5mg  
 
(N=xxx)  
 
At Least 4-Point Reduction from Baseline in 
Weekly Average WI-NRS at Week 10 
Success 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 xx.xx% 
Failure 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 xx.xx% 
Race 
 
Black or African American 
   
White 
 
  
Placebo 
 
(N=xxx)  
 
  
Serlopitant 5mg  
 
(N=xxx)  
 
  
Placebo 
 
(N=xxx)  
 
  
Serlopitant 5mg  
 
(N=xxx)  
 
At Least 4-Point Reduction from Baseline in 
Weekly Average WI-NRS at Week 10 
Success 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 xx.xx% 
Failure 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 xx.xx% 
Race (continued) 
 
American Indian or Alaska Native 
   
Asian 
 
  
Placebo 
 
(N=xxx)  
 
  
Serlopitant 5mg  
 
(N=xxx)  
 
  
Placebo 
 
(N=xxx)  
 
  
Serlopitant 5mg  
 
(N=xxx)  
 
At Least 4-Point Reduction from Baseline in 
Weekly Average WI-NRS at Week 10 
Success 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 xx.xx% 
Failure 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 
 
Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained by averaging the summary statistics  
 
generated from each imputed dataset. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 40 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.1.4: Subgroup Summary of Primary Efficacy Endpoint: Worst-Itch Numeric Rating Scale (WI-NRS) 4-Point Responder at Week 10  
 (Intent-to-Treat Population) 
(Page 3 of 3) 
 
Race (continued) 
 
Native Hawaiian or Other Pacific Islander 
   
Multiple/Other 
 
  
Placebo 
 
(N=xxx)  
 
  
Serlopitant 5mg  
 
(N=xxx)  
 
  
Placebo 
 
(N=xxx)  
 
  
Serlopitant 5mg  
 
(N=xxx)  
 
At Least 4-Point Reduction from Baseline in 
Weekly Average WI-NRS at Week 10 
Success 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 xx.xx% 
Failure 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 xx.xx% 
 
 
Note: Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained by averaging the summary statistics  
 
generated from each imputed dataset. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 41 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.2.1: Analysis of Key Secondary Efficacy Endpoints 
(Intent-to-Treat Population) 
 
 
Placebo 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
(N=xxx) 
  
P-valuea  
 
At Least 4-Point Reduction from Baseline in 
Weekly Average Worst Itch Numeric Rating 
Scale (WI-NRS) at Week 4 
    Success 
xx.xx% 
xx.xx% 
x.xxx 
    Failure 
xx.xx% 
xx.xx% 
At Least 4-Point Reduction from Baseline in 
Weekly Average Worst Itch Numeric Rating 
Scale (WI-NRS) at Week 2 
    Success 
xx.xx% 
xx.xx% 
x.xxx 
    Failure 
xx.xx% 
xx.xx% 
 
a    P-value from a Cochran Mantel Haenszel (CMH) test stratified by Baseline WI-NRS used for randomization stratification. Value has been  
adjusted for multiple imputation. 
Note:  Multiple imputation (MCMC) used to impute missing values. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Repeat Table 14.2.2.1 for the following: 
 
Table 14.2.2.2: Analysis of Key Secondary Efficacy Endpoints (Per-Protocol Population) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 42 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.2.3: Sensitivity Analyses of Key Secondary Efficacy Endpoints  
(Intent-to-Treat Population) 
(Page 1 of 2) 
 
Missing Values Imputed using Last 
Observation Carried Forward (LOCF) 
 
Placebo 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
(N=xxx) 
  
P-value 
 
At Least 4-Point Reduction from Baseline in 
Weekly Average Worst Itch Numeric Rating 
Scale (WI-NRS) at Week 4 
    Success 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
x.xxxa 
    Failure 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
At Least 4-Point Reduction from Baseline in 
Weekly Average Worst Itch Numeric Rating 
Scale (WI-NRS) at Week 2 
    Success 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
x.xxxa 
    Failure 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
 
a    P-value from a Cochran Mantel Haenszel (CMH) test stratified by Baseline WI-NRS used for randomization stratification. 
b    P-value from a repeated measures logistic regression with factors of treatment group, randomization stratification, visit and treatment group by  
visit interaction. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 43 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.2.3: Sensitivity Analyses of Key Secondary Efficacy Endpoints 
(Intent-to-Treat Population) 
(Page 2 of 2) 
 
Repeated Measures Analysis on Observed 
Data 
 
Placebo 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
(N=xxx) 
  
P-value 
 
At Least 4-Point Reduction from Baseline in 
Weekly Average Worst Itch Numeric Rating 
Scale (WI-NRS) at Week 4 
    Success 
xx.xx% 
xx.xx% 
x.xxxb 
    Failure 
xx.xx% 
xx.xx% 
At Least 4-Point Reduction from Baseline in 
Weekly Average Worst Itch Numeric Rating 
Scale (WI-NRS) at Week 2 
    Success 
xx.xx% 
xx.xx% 
x.xxxb 
    Failure 
xx.xx% 
xx.xx% 
 
a    P-value from a Cochran Mantel Haenszel (CMH) test stratified by Baseline WI-NRS used for randomization stratification. 
b    P-value from a repeated measures logistic regression with factors of treatment group, randomization stratification, visit and treatment group by  
visit interaction. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 44 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.3.1: Analysis of Additional Secondary Efficacy Endpoints  
(Intent-to-Treat Population) 
(Page 1 of 6) 
 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
 
Normality 
 
P-Value 
 
 
Treatment 
 
 
P-Value 
 
Weekly Average Worst Itch Numeric Rating 
Scale (WI-NRS) – Absolute Change from 
Baseline to Week 2 
  LS Meana  
x.xx 
x.xx 
x.xxxb 
x.xxxa 
  LS SDa  
x.xxx 
x.xxx 
 
x.xxxc 
Mediand 
x.xx 
x.xx 
Min. to Max.d 
x.x to x.x 
x.x to x.x 
Weekly Average Worst Itch Numeric Rating 
Scale (WI-NRS) – Absolute Change from 
Baseline to Week 4 
  LS Meana  
x.xx 
x.xx 
x.xxxb 
x.xxxa 
  LS SDa  
x.xxx 
x.xxx 
 
x.xxxc 
Mediand 
x.xx 
x.xx 
Min. to Max.d 
x.x to x.x 
x.x to x.x 
 
a    P-values, least squares means (LS Mean) and standard deviations (LS SD) from an analysis of covariance (ANCOVA) with treatment group and stratification  
factor as fixed effects, and baseline value as a covariate. Values have been adjusted for multiple imputation. 
b   P-value from a Shapiro-Wilk test for normality. Average p-value across imputations is presented. 
c    P-value from a ranked analysis of covariance (ANCOVA) with treatment group and stratification factor as fixed effects, and baseline value as a  
covariate. Value has been adjusted for multiple imputation. 
d   Median, minimum and maximum represent average values, obtained from averaging the summary statistics generated from each imputed dataset. 
Note:  Multiple imputation (MCMC) used to impute missing values. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 45 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.3.1: Analysis of Additional Secondary Efficacy Endpoints 
(Intent-to-Treat Population) 
(Page 2 of 6) 
 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
 
Normality 
 
P-Value 
 
 
Treatment 
 
 
P-Value 
 
Weekly Average Worst Itch Numeric Rating 
Scale (WI-NRS) – Absolute Change from 
Baseline to Week 6 
  LS Meana  
x.xx 
x.xx 
x.xxxb 
x.xxxa 
  LS SDa  
x.xxx 
x.xxx 
 
x.xxxc 
Mediand 
x.xx 
x.xx 
Min. to Max.d 
x.x to x.x 
x.x to x.x 
Weekly Average Worst Itch Numeric Rating 
Scale (WI-NRS) – Absolute Change from 
Baseline to Week 10 
  LS Meana  
x.xx 
x.xx 
x.xxxb 
x.xxxa 
  LS SDa  
x.xxx 
x.xxx 
 
x.xxxc 
Mediand 
x.xx 
x.xx 
Min. to Max.d 
x.x to x.x 
x.x to x.x 
 
a    P-values, least squares means (LS Mean) and standard deviations (LS SD) from an analysis of covariance (ANCOVA) with treatment group and stratification  
factor as fixed effects, and baseline value as a covariate. Values have been adjusted for multiple imputation. 
b   P-value from a Shapiro-Wilk test for normality. Average p-value across imputations is presented. 
c    P-value from a ranked analysis of covariance (ANCOVA) with treatment group and stratification factor as fixed effects, and baseline value as a  
covariate. Value has been adjusted for multiple imputation. 
d   Median, minimum and maximum represent average values, obtained from averaging the summary statistics generated from each imputed dataset. 
e    P-value from a Cochran Mantel Haenszel (CMH) test stratified by Baseline WI-NRS used for randomization stratification. Value has been  
adjusted for multiple imputation. 
Note:  Multiple imputation (MCMC) used to impute missing values. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 46 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.3.1: Analysis of Additional Secondary Efficacy Endpoints 
(Intent-to-Treat Population) 
(Page 3 of 6) 
 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
 
Normality 
 
P-Value 
 
 
Treatment 
 
 
P-Value 
 
At Least 3-Point Reduction from Baseline in 
Weekly Average Worst Itch Numeric Rating 
Scale (WI-NRS) at Week 2 
    Success 
xx.xx% 
xx.xx% 
N/A 
x.xxxa 
    Failure 
xx.xx% 
xx.xx% 
At Least 3-Point Reduction from Baseline in 
Weekly Average Worst Itch Numeric Rating 
Scale (WI-NRS) at Week 4 
    Success 
xx.xx% 
xx.xx% 
N/A 
x.xxxa 
    Failure 
xx.xx% 
xx.xx% 
At Least 3-Point Reduction from Baseline in 
Weekly Average Worst Itch Numeric Rating 
Scale (WI-NRS) at Week 10 
    Success 
xx.xx% 
xx.xx% 
N/A 
x.xxxa 
    Failure 
xx.xx% 
xx.xx% 
 
a    P-value from a Cochran Mantel Haenszel (CMH) test stratified by Baseline WI-NRS used for randomization stratification. Value has been  
adjusted for multiple imputation. 
Note:  Multiple imputation (MCMC) used to impute missing values.  
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 47 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.3.1: Analysis of Additional Secondary Efficacy Endpoints 
(Intent-to-Treat Population) 
(Page 4 of 6) 
 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
 
Normality 
 
P-Value 
 
 
Treatment 
 
 
P-Value 
 
Investigator’s Global Assessment of Prurigo 
Nodularis Activity (IGA PN-A) – Absolute 
Change from Baseline to Week 2 
  LS Meana  
x.xx 
x.xx 
x.xxxb 
x.xxxa 
  LS SDa  
x.xxx 
x.xxx 
 
x.xxxc 
Mediand 
x.xx 
x.xx 
Min. to Max.d 
x.x to x.x 
x.x to x.x 
Investigator’s Global Assessment of Prurigo 
Nodularis Activity (IGA PN-A) – Absolute 
Change from Baseline to Week 4 
  LS Meana  
x.xx 
x.xx 
x.xxxb 
x.xxxa 
  LS SDa  
x.xxx 
x.xxx 
 
x.xxxc 
Mediand 
x.xx 
x.xx 
Min. to Max.d 
x.x to x.x 
x.x to x.x 
Investigator’s Global Assessment of Prurigo 
Nodularis Activity (IGA PN-A) – Absolute 
Change from Baseline to Week 10 
  LS Meana  
x.xx 
x.xx 
x.xxxb 
x.xxxa 
  LS SDa  
x.xxx 
x.xxx 
 
x.xxxc 
Mediand 
x.xx 
x.xx 
Min. to Max.d 
x.x to x.x 
x.x to x.x 
 
a    P-values, least squares means (LS Mean) and standard deviations (LS SD) from an analysis of covariance (ANCOVA) with treatment group and stratification  
factor as fixed effects, and baseline value as a covariate.  
b   P-value from a Shapiro-Wilk test for normality.  
c    P-value from a ranked analysis of covariance (ANCOVA) with treatment group and stratification factor as fixed effects, and baseline value as a  
covariate.  
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 48 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.3.1: Analysis of Additional Secondary Efficacy Endpoints 
(Intent-to-Treat Population) 
(Page 5 of 6) 
 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
 
Normality 
 
P-Value 
 
 
Treatment 
 
 
P-Value 
 
Investigator’s Global Assessment of Prurigo 
Nodularis Stage (IGA PN-S) – Absolute Change 
from Baseline to Week 2 
  LS Meana  
x.xx 
x.xx 
x.xxxb 
x.xxxa 
  LS SDa  
x.xxx 
x.xxx 
 
x.xxxc 
Mediand 
x.xx 
x.xx 
Min. to Max.d 
x.x to x.x 
x.x to x.x 
Investigator’s Global Assessment of Prurigo 
Nodularis Stage (IGA PN-S) – Absolute Change 
from Baseline to Week 4 
  LS Meana  
x.xx 
x.xx 
x.xxxb 
x.xxxa 
  LS SDa  
x.xxx 
x.xxx 
 
x.xxxc 
Mediand 
x.xx 
x.xx 
Min. to Max.d 
x.x to x.x 
x.x to x.x 
Investigator’s Global Assessment of Prurigo 
Nodularis Stage (IGA PN-S) – Absolute Change 
from Baseline to Week 10 
  LS Meana  
x.xx 
x.xx 
x.xxxb 
x.xxxa 
  LS SDa  
x.xxx 
x.xxx 
 
x.xxxc 
Mediand 
x.xx 
x.xx 
Min. to Max.d 
x.x to x.x 
x.x to x.x 
 
a    P-values, least squares means (LS Mean) and standard deviations (LS SD) from an analysis of covariance (ANCOVA) with treatment group and stratification  
factor as fixed effects, and baseline value as a covariate. 
b   P-value from a Shapiro-Wilk test for normality.  
c    P-value from a ranked analysis of covariance (ANCOVA) with treatment group and stratification factor as fixed effects, and baseline value as a  
covariate.  
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 49 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.3.1: Analysis of Additional Secondary Efficacy Endpoints 
(Intent-to-Treat Population) 
(Page 6 of 6) 
 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
 
Normality 
 
P-Value 
 
 
Treatment 
 
 
P-Value 
 
Dermatology Life Quality Index (DLQI) – 
Absolute Change from Baseline to Week 10 
  LS Meana  
x.xx 
x.xx 
x.xxxb 
x.xxxa 
  LS SDa  
x.xxx 
x.xxx 
 
x.xxxc 
Mediand 
x.xx 
x.xx 
Min. to Max.d 
x.x to x.x 
x.x to x.x 
Dermatology Life Quality Index (DLQI) 
Question 1 – Absolute Change from Baseline to 
Week 10 
  LS Meana  
x.xx 
x.xx 
x.xxxb 
x.xxxa 
  LS SDa  
x.xxx 
x.xxx 
 
x.xxxc 
Mediand 
x.xx 
x.xx 
Min. to Max.d 
x.x to x.x 
x.x to x.x 
 
a    P-values, least squares means (LS Mean) and standard deviations (LS SD) from an analysis of covariance (ANCOVA) with treatment group and stratification  
factor as fixed effects, and baseline value as a covariate. 
b   P-value from a Shapiro-Wilk test for normality.  
c    P-value from a ranked analysis of covariance (ANCOVA) with treatment group and stratification factor as fixed effects, and baseline value as a  
covariate.  
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 50 
Protocol Number: MTI-106  
16 December 2019 
 
Repeat Table 14.2.3.1 for the following: 
 
Table 14.2.3.2: Analysis of Additional Secondary Efficacy Endpoints (Per-Protocol Population) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 51 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.4.1: Summary of Worst Itch Numeric Rating Scale (WI-NRS)  
(Intent-to-Treat Population) 
(Page 1 of 6) 
 
WI-NRS 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Baseline 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained by averaging the summary statistics  
generated from each imputed dataset. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 52 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.4.1: Summary of Worst Itch Numeric Rating Scale (WI-NRS)  
(Intent-to-Treat Population) 
(Page 2 of 6) 
 
WI-NRS 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Week 1 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 >= 3 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 >= 4 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
Week 2 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 >= 3 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 >= 4 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 
Note:  Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained by averaging the summary statistics  
generated from each imputed dataset. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 53 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.4.1: Summary of Worst Itch Numeric Rating Scale (WI-NRS)  
(Intent-to-Treat Population) 
(Page 3 of 6) 
 
WI-NRS 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Week 3 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 >= 3 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 >= 4 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
Week 4 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 >= 3 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 >= 4 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 
Note:  Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained by averaging the summary statistics  
generated from each imputed dataset. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 54 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.4.1: Summary of Worst Itch Numeric Rating Scale (WI-NRS)  
(Intent-to-Treat Population) 
(Page 4 of 6) 
 
WI-NRS 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Week 5 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 >= 3 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 >= 4 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
Week 6 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 >= 3 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 >= 4 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 
Note:  Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained by averaging the summary statistics  
generated from each imputed dataset. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 55 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.4.1: Summary of Worst Itch Numeric Rating Scale (WI-NRS)  
(Intent-to-Treat Population) 
(Page 5 of 6) 
 
WI-NRS 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Week 7 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 >= 3 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 >= 4 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
Week 8 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 >= 3 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 >= 4 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 
Note:  Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained by averaging the summary statistics  
generated from each imputed dataset. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 56 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.4.1: Summary of Worst Itch Numeric Rating Scale (WI-NRS)  
(Intent-to-Treat Population) 
(Page 6 of 6) 
 
WI-NRS 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Week 9 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 N 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 >= 3 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 >= 4 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
Week 10 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 >= 3 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 >= 4 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 
Note:  Multiple imputation (MCMC) used to impute missing values. Summary statistics represent average values, obtained by averaging the summary statistics  
generated from each imputed dataset. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 57 
Protocol Number: MTI-106  
16 December 2019 
Repeat Table 14.2.4.1 for the following: 
Table 14.2.4.2: Summary of Worst Itch Numeric Rating Scale (WI-NRS) (Per-Protocol Population) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 58 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.4.3: Summary of Worst Itch Numeric Rating Scale (WI-NRS) – Observed Data with Follow-up  
(Intent-to-Treat Population with Observed Week 10 Data) 
(Page 1 of 2) 
 
WI-NRS 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Baseline 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Week 10 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 >= 3 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 >= 4 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 59 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.4.3: Summary of Worst Itch Numeric Rating Scale (WI-NRS) – Observed Data with Follow-up  
(Intent-to-Treat Population with Observed Week 10 Data) 
(Page 2 of 2) 
 
WI-NRS 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
3-Week Follow-up (Observed Data) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 >= 3 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 >= 4 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
5-Week Follow-up (Observed Data) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 >= 3 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 >= 4 Point Reduction from Baseline 
xx.xx% 
xx.xx% 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 60 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.5.1.1: Summary of Dermatology Life Quality Index (DLQI)  
(Intent-to-Treat Population) 
(Page 1 of 2) 
 
DLQI 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Baseline 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Week 4 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 61 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.5.1.1: Summary of Dermatology Life Quality Index (DLQI) 
(Intent-to-Treat Population) 
(Page 2 of 2) 
 
DLQI 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Week 10 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
Repeat Table 14.2.5.1.1 for the following: 
Table 14.2.5.1.2: Summary of Dermatology Life Quality Index (DLQI) (Per-Protocol Population) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 62 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.5.2.1: Summary of Dermatology Life Quality Index (DLQI) Individual Questions  
(Intent-to-Treat Population) 
(Page 1 of 2) 
 
DLQI Question 1: Over the last week, how itchy, sore, 
painful or stinging has your skin been?   
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Baseline 
 n 
xx  
xx  
 Very much 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
A lot  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
A little  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Not at all  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Week 4 
 n 
xx 
xx 
 Very much 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
A lot  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
A little  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Not at all  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 63 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.5.2.1: Summary of Dermatology Life Quality Index (DLQI) – Individual Questions 
(Intent-to-Treat Population) 
(Page 2 of 2) 
 
DLQI Question 1: Over the last week, how itchy, sore, 
painful or stinging has your skin been?   
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Week 10 
 n 
xx 
xx 
 Very much 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
A lot  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
A little  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Not at all  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Include all questions: 
Question 2: Over the last week, how embarrassed or self-conscious have you been because of your skin?       
Question 3: Over the last week, how much has your skin interfered with you going shopping or looking after your home or yard?       
Question 4: Over the last week, how much has your skin influenced the clothes you wear?       
Question 5: Over the last week, how much has your skin affected any social or leisure activities?       
Question 6: Over the last week, how much has your skin made it difficult for you to do any sport?       
Question 7: Over the last week, has your skin prevented you from working or studying?      
Question 8: Over the last week, how much has your skin created problems with your partner or any of your close friends or relatives?       
Question 9: Over the last week, how much has your skin caused any sexual difficulties?      
Question 10: Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy, or by taking 
up time?  


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 64 
Protocol Number: MTI-106  
16 December 2019 
 
Repeat Table 14.2.5.2.1 for the following: 
Table 14.2.5.2.2: Summary of Dermatology Life Quality Index (DLQI) – Individual Questions (Per-Protocol Population) 
 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 65 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.6.1: Summary of Investigator’s Global Assessment of Prurigo Nodularis Activity (IGA PN-A)  
(Intent-to-Treat Population) 
(Page 1 of 6) 
 
IGA PN-A 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Baseline 
N 
xx 
xx 
 Grade 0  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 1 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 2 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 3  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 4  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Week 2 
n 
xx 
xx 
 Grade 0  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 1 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 2 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 3  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 4  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the latest available follow-up 
information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 66 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.6.1: Summary of Investigator’s Global Assessment of Prurigo Nodularis Activity (IGA PN-A)  
(Intent-to-Treat Population) 
(Page 2 of 6) 
 
IGA PN-A 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Week 4 
n 
xx 
xx 
 Grade 0  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 1 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 2 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 3  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 4  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the latest available follow-up 
information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 67 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.6.1: Summary of Investigator’s Global Assessment of Prurigo Nodularis Activity (IGA PN-A) 
(Intent-to-Treat Population) 
(Page 3 of 6) 
 
IGA PN-A 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Week 10 
n 
xx 
xx 
 Grade 0  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 1 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 2 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 3  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 4  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the latest available follow-up 
information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 68 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.6.1: Summary of Investigator’s Global Assessment of Prurigo Nodularis Activity (IGA PN-A) 
(Intent-to-Treat Population) 
(Page 4 of 6) 
 
IGA PN-A 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
3-Week Follow-up 
n 
xx 
xx 
 Grade 0  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 1 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 2 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 3  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 4  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the latest available follow-up 
information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 69 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.6.1: Summary of Investigator’s Global Assessment of Prurigo Nodularis Activity (IGA PN-A) 
(Intent-to-Treat Population) 
(Page 5 of 6) 
 
IGA PN-A 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
5-Week Follow-up 
n 
xx 
xx 
 Grade 0  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 1 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 2 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 3  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 4  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the latest available follow-up 
information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 70 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.6.1: Summary of Investigator’s Global Assessment of Prurigo Nodularis Activity (IGA PN-A) 
(Intent-to-Treat Population) 
(Page 6 of 6) 
 
IGA PN-A 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Latest Follow-up 
n 
xx 
xx 
 Grade 0  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 1 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 2 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 3  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 4  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the latest available follow-up 
information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
Repeat Table 14.2.6.1 for the following: 
 
Table 14.2.6.2: Summary of Investigator’s Global Assessment of Prurigo Nodularis Activity (IGA PN-A) (Per-Protocol Population) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 71 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.7.1: Summary of Investigator’s Global Assessment of Prurigo Nodularis Stage (IGA PN-S)  
(Intent-to-Treat Population) 
(Page 1 of 6) 
 
IGA PN-S 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Baseline 
n 
xx 
xx 
 Grade 0  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 1 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 2 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 3  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 4  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Week 2 
n 
xx 
xx 
 Grade 0  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 1 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 2 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 3  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 4  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the latest available follow-up 
information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 72 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.7.1: Summary of Investigator’s Global Assessment of Prurigo Nodularis Stage (IGA PN-S) 
(Intent-to-Treat Population) 
(Page 2 of 6) 
 
IGA PN-S 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Week 4 
n 
xx 
xx 
 Grade 0  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 1 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 2 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 3  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 4  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the latest available follow-up 
information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 73 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.7.1: Summary of Investigator’s Global Assessment of Prurigo Nodularis Stage (IGA PN-S) 
(Intent-to-Treat Population) 
(Page 3 of 6) 
 
IGA PN-S 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Week 10 
n 
xx 
xx 
 Grade 0  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 1 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 2 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 3  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 4  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the latest available follow-up 
information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 74 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.7.1: Summary of Investigator’s Global Assessment of Prurigo Nodularis Stage (IGA PN-S) 
(Intent-to-Treat Population) 
(Page 4 of 6) 
 
IGA PN-S 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
3-Week Follow-up 
n 
xx 
xx 
 Grade 0  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 1 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 2 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 3  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 4  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the latest available follow-up 
information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 75 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.7.1: Summary of Investigator’s Global Assessment of Prurigo Nodularis Stage (IGA PN-S) 
(Intent-to-Treat Population) 
(Page 5 of 6) 
 
IGA PN-S 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
5-Week Follow-up 
n 
xx 
xx 
 Grade 0  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 1 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 2 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 3  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 4  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the latest available follow-up 
information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 76 
Protocol Number: MTI-106  
16 December 2019 
Table 14.2.7.1: Summary of Investigator’s Global Assessment of Prurigo Nodularis Stage (IGA PN-S) 
(Intent-to-Treat Population) 
(Page 6 of 6) 
 
IGA PN-S 
 
Placebo 
 
 
(N=xxx) 
 
 
Serlopitant 5 mg 
 
 
(N=xxx) 
 
Latest Follow-up 
n 
xx 
xx 
 Grade 0  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 1 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 2 
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 3  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
Grade 4  
xx ( 
xx.x%) 
xx ( 
xx.x%) 
n 
xxx 
xxx 
Mean 
x.xx 
x.xx 
SD 
x.xxx 
x.xxx 
Median 
x.xx 
x.xx 
Min. to Max. 
x.x to x.x 
x.x to x.x 
Absolute Change from Baseline 
 n 
xxx 
xxx 
 Mean 
x.xx 
x.xx 
 SD 
x.xxx 
x.xxx 
 Median 
x.xx 
x.xx 
 Min. to Max. 
x.x to x.x 
x.x to x.x 
 
Note:  No imputation of missing values. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the latest available follow-up 
information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
Repeat Table 14.2.7.1 for the following: 
 
Table 14.2.7.2: Summary of Investigator’s Global Assessment of Prurigo Nodularis Stage (IGA PN-S) (Per-Protocol Population) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 77 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.0.1: Summary of Extent of Exposure  
(Intent-to-Treat Population) 
 
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
Total Number of Tablets Useda 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Total Number of Days of Exposure 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Compliantb 
n 
xx 
xx 
Yes 
xx ( xx.x%) 
xx ( xx.x%) 
No 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Subjects were to dose with 3 tablets on Day 1/Date of First Dose. 
b A subject was considered compliant with the dosing regimen if the subject took at least 80% but no more than 120% of expected doses. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Repeat Table 14.3.0.1 for the following: 
Table 14.3.0.2: Summary of Extent of Exposure (Per-Protocol Population) 
Table 14.3.0.3: Summary of Extent of Exposure (Safety Population) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 78 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.1.1: Overall Summary of Treatment-Emergent Adverse Events (TEAEs)  
(Safety Population) 
  
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
Subjects with any TEAE 
xx ( xx.x%) 
xx ( xx.x%) 
   Number of TEAEs 
xx  
xx  
Subjects with any Related TEAE 
xx ( xx.x%) 
xx ( xx.x%) 
   Number of Related TEAEs 
xx  
xx  
Subjects with any Serious TEAE 
xx ( xx.x%) 
xx ( xx.x%) 
   Number of Serious TEAEs 
xx  
xx  
Subjects with any Related Serious TEAE 
xx ( xx.x%) 
xx ( xx.x%) 
   Number of Related Serious TEAEs 
xx  
xx  
Subjects who Died 
xx ( xx.x%) 
xx ( xx.x%) 
Subjects who Discontinued Study Drug Due to TEAE 
xx ( xx.x%) 
xx ( xx.x%) 
Maximum Severity by Subject 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
Maximum Relationship by Subject 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
Note: TEAEs are AEs with an onset after first dose of study drug. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 79 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.1.2: Summary of Subjects Reporting Treatment-Emergent Adverse Events (TEAEs) by MedDRA System Organ Class and Preferred Term  
(Safety Population) 
(Page 1 of xx) 
  
System Organ Classa 
Preferred Term  
 
 
Placebo  
 
(N=xxx)  
 
 
Serlopitant 5 mg  
 
(N=xxx)  
 
Total 
xx ( xx.x%) 
xx ( xx.x%) 
System Organ Class 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more TEAEs that map to MedDRA. At each level of summarization (System Organ Class or Preferred  
Term) subjects are counted once. 
Note: TEAEs are AEs with an onset date after first dose of study drug. 
         MedDRA Version 21.1. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 80 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.1.3: Summary of Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation of Study Drug  
(Safety Population) 
(Page 1 of xx) 
  
System Organ Classa 
Preferred Term  
 
 
Placebo  
 
(N=xxx)  
 
 
Serlopitant 5 mg  
 
(N=xxx)  
 
Total 
xx ( xx.x%) 
xx ( xx.x%) 
System Organ Class 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more TEAEs that map to MedDRA. At each level of summarization (System Organ Class or Preferred  
Term) subjects are counted once. 
Note: TEAEs are AEs with an onset date after first dose of study drug. 
         MedDRA Version 21.1. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 81 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.1.4: Summary of Subjects Reporting Treatment-Emergent Adverse Events (TEAEs) by Severity  
(Safety Population) 
(Page 1 of xx) 
  
System Organ Classa 
Preferred Term 
 Severityb 
 
Placebo 
  
(N=xxx)  
 
 
Serlopitant 5 mg 
  
(N=xxx)  
 
Total 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
System Organ Class 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more TEAEs that map to MedDRA. At each level of summarization (System Organ Class or Preferred 
Term) subjects are counted once under the greatest reported severity. 
b  Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life Threatening; Grade 5 = Death. 
Note: TEAEs are AEs with an onset after first dose of study drug. 
         MedDRA Version 21.1. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 82 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.1.5: Summary of Subjects Reporting Treatment-Emergent Adverse Events (TEAEs) by Relationship to Study Drug  
(Safety Population) 
(Page 1 of xx) 
  
System Organ Classa 
Preferred Term  
 Relationship 
 
Placebo 
  
(N=xxx)  
 
 
Serlopitant 5 mg 
  
(N=xxx)  
 
Total 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
System Organ Class 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more TEAEs that map to MedDRA. At each level of summarization (System Organ Class or Preferred 
Term) subjects are counted once under the greatest reported relationship. 
Note: TEAEs are AEs with an onset after first dose of study drug. 
         MedDRA Version 21.1. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 83 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.2.1.1: Overall Summary of Post-Drug Adverse Event (AEs)  
(Safety Population) 
  
 
Placebo 
 
 
Serlopitant 5 mg 
 
 
Males 
 
(N=xxx) 
 
 
Females 
 
(N=xxx) 
 
 
Overall 
 
(N=xxx) 
 
 
Males 
 
(N=xxx) 
 
 
Females 
 
(N=xxx) 
 
 
Overall 
 
(N=xxx) 
 
Subjects with any Post-Drug AE 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
   Number of Post-Drug AEs 
xx 
xx 
xx 
xx 
xx 
xx 
Subjects with any Related Post-Drug AE 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
   Number of Related Post-Drug AEs 
xx 
xx 
xx 
xx 
xx 
xx 
Subjects with any Serious Post-Drug AE 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
   Number of Serious Post-Drug AEs 
xx 
xx 
xx 
xx 
xx 
xx 
Subjects with any Related Serious Post-Drug AE 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
   Number of Related Serious Post-Drug AEs 
xx 
xx 
xx 
xx 
xx 
xx 
Subjects who Died 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Maximum Severity by Subject 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Maximum Relationship by Subject 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
Note: Table includes AEs with an onset after last dose of study drug. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 84 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.2.1.2: Overall Summary of Post-Drug Adverse Events (AEs) Occurring 1-7 Days Post Last Dose  
(Safety Population) 
  
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
Subjects with any Post-Drug AE 
xx ( xx.x%) 
xx ( xx.x%) 
   Number of Post-Drug AEs 
xx  
xx  
Subjects with any Related Post-Drug AE 
xx ( xx.x%) 
xx ( xx.x%) 
   Number of Related Post-Drug AEs 
xx  
xx  
Subjects with any Serious Post-Drug AE 
xx ( xx.x%) 
xx ( xx.x%) 
   Number of Serious Post-Drug AEs 
xx  
xx  
Subjects with any Related Serious Post-Drug AE 
xx ( xx.x%) 
xx ( xx.x%) 
   Number of Related Serious Post-Drug AEs 
xx  
xx  
Subjects who Died 
xx ( xx.x%) 
xx ( xx.x%) 
Maximum Severity by Subject 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
Maximum Relationship by Subject 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
Note: Table includes AEs with an onset date within 1 to 7 days after last dose of study drug. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 85 
Protocol Number: MTI-106  
16 December 2019 
Repeat Table 14.3.1.2.1.2 for the following, with adjusted foonotes: 
Table 14.3.1.2.1.3: Overall Summary of Post-Drug Adverse Events (AEs) Occurring 8-14 Days Post Last Dose (Safety Population) 
Note: Table includes AEs with an onset date within 8 to 14 days after last dose of study drug. 
Table 14.3.1.2.1.4: Overall Summary of Post-Drug Adverse Events (AEs) Occurring 15-21 Days Post Last Dose (Safety Population) 
Note: Table includes AEs with an onset date within 15 to 21 days after last dose of study drug. 
Table 14.3.1.2.1.5: Overall Summary of Post-Drug Adverse Events (AEs) Occurring 22-28 Days Post Last Dose (Safety Population) 
Note: Table includes AEs with an onset date within 22 to 28 days after last dose of study drug. 
Table 14.3.1.2.1.6: Overall Summary of Post-Drug Adverse Events (AEs) Occurring 29-35 Days Post Last Dose (Safety Population)  
Note: Table includes AEs with an onset date within 29 to 35 days after last dose of study drug. 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 86 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.2.2.1: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) by MedDRA System Organ Class and Preferred Term  
(Safety Population) 
(Page 1 of xx) 
  
 
Placebo 
 
 
Serlopitant 5 mg 
 
System Organ Classa 
Preferred Term 
 
 
Males 
 
(N=xxx) 
 
 
Females 
 
(N=xxx) 
 
 
Overall 
 
(N=xxx) 
 
 
Males 
 
(N=xxx) 
 
 
Females 
 
(N=xxx) 
 
 
Overall 
 
(N=xxx) 
 
Total 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
System Organ Class 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more AEs that map to MedDRA. At each level of summarization (System Organ Class or Preferred  
Term) subjects are counted once. 
Note: Table includes AEs with an onset after last dose of study drug. 
         MedDRA Version 21.1. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 87 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.2.2.2: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 1-7 Days Post Last Dose  
by MedDRA System Organ Class and Preferred Term  
(Safety Population) 
(Page 1 of xx) 
  
System Organ Classa 
Preferred Term  
 
 
Placebo  
 
(N=xxx)  
 
 
Serlopitant 5 mg  
 
(N=xxx)  
 
Total 
xx ( xx.x%) 
xx ( xx.x%) 
System Organ Class 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more AEs that map to MedDRA. At each level of summarization (System Organ Class or Preferred  
Term) subjects are counted once. 
Note: Table includes AEs with an onset date within 1 to 7 days after last dose of study drug. 
         MedDRA Version 21.1. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 88 
Protocol Number: MTI-106  
16 December 2019 
Repeat Table 14.3.1.2.2.2 for the following, with adjusted foonotes: 
Table 14.3.1.2.2.3: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 8-14 Days Post Last Dose by MedDRA System Organ Class and 
Preferred Term (Safety Population) 
Note: Table includes AEs with an onset date within 8 to 14 days after last dose of study drug. 
Table 14.3.1.2.2.4: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 15-21 Days Post Last Dose by MedDRA System Organ Class 
and Preferred Term (Safety Population) 
Note: Table includes AEs with an onset date within 15 to 21 days after last dose of study drug. 
Table 14.3.1.2.2.5: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 22-28 Days Post Last Dose by MedDRA System Organ Class 
and Preferred Term (Safety Population) 
Note: Table includes AEs with an onset date within 22 to 28 days after last dose of study drug. 
Table 14.3.1.2.2.6: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 29-35 Days Post Last Dose by MedDRA System Organ Class 
and Preferred Term (Safety Population)  
Note: Table includes AEs with an onset date within 29 to 35 days after last dose of study drug. 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 89 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.2.3.1: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) by Severity  
(Safety Population) 
(Page 1 of xx) 
  
 
Placebo 
 
 
Serlopitant 5 mg 
System Organ Classa 
Preferred Term 
 
Severityb 
 
Males 
 
(N=xxx) 
 
 
Females 
 
(N=xxx) 
 
 
Overall 
 
(N=xxx) 
 
 
Males 
 
(N=xxx) 
 
 
Females 
 
(N=xxx) 
 
 
Overall 
 
(N=xxx) 
Total 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
System Organ Class 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more AEs that map to MedDRA. At each level of summarization (System Organ Class or Preferred 
Term) subjects are counted once under the greatest reported severity. 
b  Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life Threatening; Grade 5 = Death. 
Note: Table includes AEs with an onset after last dose of study drug. 
         MedDRA Version 21.1. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 90 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.2.3.2: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 1-7 Days Post Last Dose by Severity  
(Safety Population) 
(Page 1 of xx) 
  
System Organ Classa 
Preferred Term 
 Severityb 
 
Placebo 
  
(N=xxx)  
 
 
Serlopitant 5 mg 
  
(N=xxx)  
 
Total 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
System Organ Class 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more AEs that map to MedDRA. At each level of summarization (System Organ Class or Preferred 
Term) subjects are counted once under the greatest reported severity. 
b  Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life Threatening; Grade 5 = Death. 
Note: Table includes AEs with an onset date within 1 to 7 days after last dose of study drug. 
         MedDRA Version 21.1. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 91 
Protocol Number: MTI-106  
16 December 2019 
Repeat Table 14.3.1.2.3.2 for the following, with adjusted foonotes: 
Table 14.3.1.2.3.3: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 8-14 Days Post Last Dose by Severity (Safety Population) 
Note: Table includes AEs with an onset date within 8 to 14 days after last dose of study drug. 
Table 14.3.1.2.3.4: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 15-21 Days Post Last Dose by Severity (Safety Population) 
Note: Table includes AEs with an onset date within 15 to 21 days after last dose of study drug. 
Table 14.3.1.2.3.5: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 22-28 Days Post Last Dose by Severity (Safety Population) 
Note: Table includes AEs with an onset date within 22 to 28 days after last dose of study drug. 
Table 14.3.1.2.3.6: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 29-35 Days Post Last Dose by Severity (Safety Population)  
Note: Table includes AEs with an onset date within 29 to 35 days after last dose of study drug. 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 92 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.2.4.1: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) by Relationship to Study Drug  
(Safety Population) 
(Page 1 of xx) 
  
 
Placebo 
 
 
Serlopitant 5 mg 
 
System Organ Classa 
Preferred Term 
 Relationship 
 
Males 
 
(N=xxx) 
 
 
Females 
 
(N=xxx) 
 
 
Overall 
 
(N=xxx) 
 
 
Males 
 
(N=xxx) 
 
 
Females 
 
(N=xxx) 
 
 
Overall 
 
(N=xxx) 
 
Total 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
System Organ Class 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more AEs that map to MedDRA. At each level of summarization (System Organ Class or Preferred 
Term) subjects are counted once under the greatest reported relationship. 
Note: Table includes AEs with an onset after last dose of study drug. 
         MedDRA Version 21.1. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 93 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.2.4.2: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 1-7 Days Post Last Dose by Relationship to Study Drug  
(Safety Population) 
(Page 1 of xx) 
  
System Organ Classa 
Preferred Term  
 Relationship 
 
Placebo 
  
(N=xxx)  
 
 
Serlopitant 5 mg 
  
(N=xxx)  
 
Total 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
System Organ Class 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more AEs that map to MedDRA. At each level of summarization (System Organ Class or Preferred 
Term) subjects are counted once under the greatest reported relationship. 
Note: Table includes AEs with an onset date within 1 to 7 days after last dose of study drug. 
         MedDRA Version 21.1. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 94 
Protocol Number: MTI-106  
16 December 2019 
Repeat Table 14.3.1.2.4.2 for the following, with adjusted foonotes: 
Table 14.3.1.2.4.3: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 8-14 Days Post Last Dose by Relationship to Study Drug 
(Safety Population) 
Note: Table includes AEs with an onset date within 8 to 14 days after last dose of study drug. 
Table 14.3.1.2.4.4: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 15-21 Days Post Last Dose by Relationship to Study Drug 
(Safety Population) 
Note: Table includes AEs with an onset date within 15 to 21 days after last dose of study drug. 
Table 14.3.1.2.4.5: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 22-28 Days Post Last Dose by Relationship to Study Drug 
(Safety Population) 
Note: Table includes AEs with an onset date within 22 to 28 days after last dose of study drug. 
Table 14.3.1.2.4.6: Summary of Subjects Reporting Post-Drug Adverse Events (AEs) Occurring 29-35 Days Post Last Dose by Relationship to Study Drug 
(Safety Population)  
Note: Table includes AEs with an onset date within 29 to 35 days after last dose of study drug. 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 95 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.3.1: Summary of Subjects Reporting Serious Treatment-Emergent Adverse Events (TEAEs) by MedDRA System Organ Class and Preferred Term 
(Safety Population) 
(Page 1 of xx) 
  
System Organ Classa 
Preferred Term  
 
 
Placebo  
 
(N=xxx)  
 
 
Serlopitant 5 mg  
 
(N=xxx)  
 
Total 
xx ( xx.x%) 
xx ( xx.x%) 
System Organ Class 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more TEAEs that map to MedDRA. At each level of summarization (System Organ Class or Preferred  
Term) subjects are counted once. 
Note: TEAEs are AEs with an onset date after first dose of study drug. 
         MedDRA Version 21.1. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 96 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.3.2: Summary of Subjects Reporting Serious Treatment-Emergent Adverse Events (TEAEs) by Severity 
(Safety Population) 
(Page 1 of xx) 
  
System Organ Classa 
Preferred Term 
 Severity 
 
Placebo 
  
(N=xxx)  
 
 
Serlopitant 5 mg 
  
(N=xxx)  
 
Total 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
System Organ Class 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
Grade 5 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 4 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 3 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 2 
xx ( xx.x%) 
xx ( xx.x%) 
Grade 1 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more serious TEAEs  that map to MedDRA. At each level of summarization (System Organ Class or  
Preferred Term) subjects are counted once under the greatest reported severity. 
b  Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life Threatening; Grade 5 = Death. 
Note: TEAEs are AEs with an onset after first dose of study drug. 
         MedDRA Version 21.1. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 97 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.3.3: Summary of Subjects Reporting Serious Treatment-Emergent Adverse Events (TEAEs) by Relationship to Study Drug 
(Safety Population) 
(Page 1 of xx) 
  
System Organ Classa 
Preferred Term  
 Relationship 
 
Placebo 
  
(N=xxx)  
 
 
Serlopitant 5 mg 
  
(N=xxx)  
 
Total 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
System Organ Class 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
Preferred Term 
Likely Related 
xx ( xx.x%) 
xx ( xx.x%) 
Likely Unrelated 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
a Counts reflect numbers of subjects reporting one or more TEAEs that map to the MedDRA. At each level of summarization (System Organ Class or  
Preferred Term) subjects are counted once under the greatest reported relationship. 
Note: TEAEs are AEs with an onset after first dose of study drug. 
         MedDRA Version 21.1. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 98 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.4.1.1: Summary of Hematology Laboratory Results 
 (Safety Population) 
(Page 1 of xx) 
  
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
<Test Name>  (<units>) 
Baseline 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Week 2 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Absolute Change from Baseline 
 n 
xx 
xx 
 Mean 
xx.x 
xx.x 
 SD 
xx.xx 
xx.xx 
 Median 
xx.x 
xx.x 
 Min. to Max. 
xx to xx 
xx to xx 
 
 
Note: No imputation of missing values. Baseline is the latest recorded value prior to first dose of study drug. Change calculated as post-baseline – baseline. 
 
“Latest Follow-up” visit includes the latest available follow-up information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Table to include post-baseline visits of “Week 2”, “Week 10”, “3-Week Follow-up”, “5-Week Follow-up”, “Latest Follow-up”. 
Table to include following lab tests: “BASOPHILS”, “EOSINOPHILS”, “HCT”, “HGB”, “LYMPHOCYTES”, “MCH”, “MCHC”, “MCV”, 
“MONOCYTES”, “NEUTROPHILS”, “PLATELET COUNT”, “RBC”, “WBC”. 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 99 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.4.1.2: Shift Summary of Hematology Laboratory Results 
(Safety Population) 
(Page 1 of xx) 
 
<Test Name> (<units>) 
 
 Placebo 
 
 (N=xxx) 
 
 
 Serlopitant 5 mg 
 
 (N=xxx) 
 
 
Week 2 
 
 
Week 2 
 
Baseline 
 
BNL 
 
 
WNL 
 
 
ANL 
 
 
BNL 
 
 
WNL 
 
 
ANL 
 
BNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
WNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ANL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
Week 10 
 
 
Week 10 
 
Baseline 
 
BNL 
 
 
WNL 
 
 
ANL 
 
 
BNL 
 
 
WNL 
 
 
ANL 
 
BNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
WNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ANL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
3-Week Follow-up 
 
 
3-Week Follow-up 
 
Baseline 
 
BNL 
 
 
WNL 
 
 
ANL 
 
 
BNL 
 
 
WNL 
 
 
ANL 
 
BNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
WNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ANL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
5-Week Follow-up 
 
 
5-Week Follow-up 
 
Baseline 
 
BNL 
 
 
WNL 
 
 
ANL 
 
 
BNL 
 
 
WNL 
 
 
ANL 
 
BNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
WNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ANL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
Latest Follow-up 
 
 
Latest Follow-up 
 
Baseline 
 
BNL 
 
 
WNL 
 
 
ANL 
 
 
BNL 
 
 
WNL 
 
 
ANL 
 
BNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
WNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ANL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
Note: BNL=Below Normal Limit, WNL=Within Normal Limits, ANL=Above Normal Limit. 
 
No imputation of missing values. Baseline is the latest recorded value prior to first dose of study drug. “Latest Follow-up” visit includes the latest available 
 
follow-up information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Table to include the same lab tests used in Table 14.3.1.4.1.1.  
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 100 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.4.2.1: Summary of Chemistry Laboratory Results 
 (Safety Population) 
(Page 1 of xx) 
  
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
<Test Name>  (<units>) 
Baseline 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Week 2 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Absolute Change from Baseline  
 n 
xx 
xx 
 Mean 
xx.x 
xx.x 
 SD 
xx.xx 
xx.xx 
 Median 
xx.x 
xx.x 
 Min. to Max. 
xx to xx 
xx to xx 
 
 
Note: No imputation of missing values. Baseline is the latest recorded value prior to first dose of study drug. Change calculated as post-baseline – baseline. 
 
“Latest Follow-up” visit includes the latest available follow-up information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Table to include post-baseline visits of “Week 2”, “Week 10”, “3-Week Follow-up”, “5-Week Follow-up”, “Latest Follow-up”. 
Table to include following lab tests: “ALBUMIN”, “ALKALINE PHOSPHATASE”, “ALT”, “AST”, “BICARBONATE”, “BILIRUBIN, TOTAL”, 
“BUN”, “CALCIUM”, “CHLORIDE”, “CHOLESTEROL, TOTAL”, “CREATININE”, “GLUCOSE, RANDOM”, “HDL-CHOLESTEROL”, “LDH”, 
“LDL-CHOLESTEROL”, “MAGNESIUM”, “PHOSPHORUS”, “POTASSIUM”, “PROTEIN, TOTAL”, “SODIUM”, “TRIGLYCERIDES”, “URIC 
ACID”. 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 101 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.4.2.2: Shift Summary of Chemistry Laboratory Results 
(Safety Population) 
(Page 1 of xx) 
 
<Test Name> (<units>) 
 
 Placebo 
 
 (N=xxx) 
 
 
 Serlopitant 5 mg 
 
 (N=xxx) 
 
 
Week 2 
 
 
Week 2 
 
Baseline 
 
BNL 
 
 
WNL 
 
 
ANL 
 
 
BNL 
 
 
WNL 
 
 
ANL 
 
BNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
WNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ANL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
Week 10 
 
 
Week 10 
 
Baseline 
 
BNL 
 
 
WNL 
 
 
ANL 
 
 
BNL 
 
 
WNL 
 
 
ANL 
 
BNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
WNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ANL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
3-Week Follow-up 
 
 
3-Week Follow-up 
 
Baseline 
 
BNL 
 
 
WNL 
 
 
ANL 
 
 
BNL 
 
 
WNL 
 
 
ANL 
 
BNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
WNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ANL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
5-Week Follow-up 
 
 
5-Week Follow-up 
 
Baseline 
 
BNL 
 
 
WNL 
 
 
ANL 
 
 
BNL 
 
 
WNL 
 
 
ANL 
 
BNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
WNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ANL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
Latest Follow-up 
 
 
 Latest Follow-up 
 
Baseline 
 
BNL 
 
 
WNL 
 
 
ANL 
 
 
BNL 
 
 
WNL 
 
 
ANL 
 
BNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
WNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ANL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
Note: BNL=Below Normal Limit, WNL=Within Normal Limits, ANL=Above Normal Limit. 
 
No imputation of missing values. Baseline is the latest recorded value prior to first dose of study drug. “Latest Follow-up” visit includes the latest available 
 
follow-up information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Table to include the same lab tests used in Table 14.3.1.4.2.1.  
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 102 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.4.3.1.1: Summary of Endocrine/Reproductive Endocrine Laboratory Results 
 (Safety Population) 
(Page 1 of xx) 
  
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
<Test Name>  (<units>) 
Baseline 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Week 10 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Absolute Change from Baseline  
 n 
xx 
xx 
 Mean 
xx.x 
xx.x 
 SD 
xx.xx 
xx.xx 
 Median 
xx.x 
xx.x 
 Min. to Max. 
xx to xx 
xx to xx 
 
 
Note: No imputation of missing values. Baseline is the latest recorded value prior to first dose of study drug. Change calculated as post-baseline – baseline. 
 
“Latest Follow-up” visit includes the latest available follow-up information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Table to include post-baseline visits of “Week 10”, “3-Week Follow-up”, “5-Week Follow-up”, “Latest Follow-up”. 
Table to include following lab tests: “TSH ULTRASENSITIVE”, “THYROXINE, FREE”, “CORTISOL, SERUM RANDOM”, “ACTH, PLASMA”, 
“ANTI-MULLERIAN HORMONE”, “FSH”, “ESTRADIOL”, “LUTEINIZING HORMONE”, “PROGESTERONE”. 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 103 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.4.3.1.2: Summary of Reproductive Endocrine Laboratory Results 
 (Safety Population – Females Using Hormonal Contraception/Therapy) 
(Page 1 of xx) 
  
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
<Test Name>  (<units>) 
Baseline 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Week 10 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Absolute Change from Baseline  
 n 
xx 
xx 
 Mean 
xx.x 
xx.x 
 SD 
xx.xx 
xx.xx 
 Median 
xx.x 
xx.x 
 Min. to Max. 
xx to xx 
xx to xx 
 
 
Note: No imputation of missing values. Baseline is the latest recorded value prior to first dose of study drug. Change calculated as post-baseline – baseline. 
 
“Latest Follow-up” visit includes the latest available follow-up information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Table to include post-baseline visits of “Week 10”, “3-Week Follow-up”, “5-Week Follow-up”, “Latest Follow-up”. 
Table to include following lab tests: “ANTI-MULLERIAN HORMONE”, “FSH”, “ESTRADIOL”, “LUTEINIZING HORMONE”, 
“PROGESTERONE”. 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 104 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.4.3.1.3: Summary of Reproductive Endocrine Laboratory Results 
 (Safety Population – Females Not Using Hormonal Contraception/Therapy) 
(Page 1 of xx) 
  
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
<Test Name>  (<units>) 
Baseline 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Week 10 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Absolute Change from Baseline  
 n 
xx 
xx 
 Mean 
xx.x 
xx.x 
 SD 
xx.xx 
xx.xx 
 Median 
xx.x 
xx.x 
 Min. to Max. 
xx to xx 
xx to xx 
 
 
Note: No imputation of missing values. Baseline is the latest recorded value prior to first dose of study drug. Change calculated as post-baseline – baseline. 
 
“Latest Follow-up” visit includes the latest available follow-up information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Table to include post-baseline visits of “Week 10”, “3-Week Follow-up”, “5-Week Follow-up”, “Latest Follow-up”. 
Table to include following lab tests: “ANTI-MULLERIAN HORMONE”, “FSH”, “ESTRADIOL”, “LUTEINIZING HORMONE”, 
“PROGESTERONE”. 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 105 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.4.3.2: Shift Summary of Endocrine/Reproductive Endocrine Laboratory Results 
(Safety Population) 
(Page 1 of xx) 
 
<Test Name> (<units>) 
 
 Placebo 
 
 (N=xxx) 
 
 
 Serlopitant 5 mg 
 
 (N=xxx) 
 
 
Week 10 
 
 
Week 10 
 
Baseline 
 
BNL 
 
 
WNL 
 
 
ANL 
 
 
BNL 
 
 
WNL 
 
 
ANL 
 
BNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
WNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ANL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
3-Week Follow-up 
 
 
3-Week Follow-up 
 
Baseline 
 
BNL 
 
 
WNL 
 
 
ANL 
 
 
BNL 
 
 
WNL 
 
 
ANL 
 
BNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
WNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ANL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
5-Week Follow-up 
 
 
5-Week Follow-up 
 
Baseline 
 
BNL 
 
 
WNL 
 
 
ANL 
 
 
BNL 
 
 
WNL 
 
 
ANL 
 
BNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
WNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ANL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
Latest Follow-up 
 
 
Latest Follow-up 
 
Baseline 
 
BNL 
 
 
WNL 
 
 
ANL 
 
 
BNL 
 
 
WNL 
 
 
ANL 
 
BNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
WNL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
ANL 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
Note: BNL=Below Normal Limit, WNL=Within Normal Limits, ANL=Above Normal Limit. 
 
No imputation of missing values. Baseline is the latest recorded value prior to first dose of study drug. “Latest Follow-up” visit includes the latest available 
 
follow-up information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Table to include following lab tests: “TSH ULTRASENSITIVE”, “THYROXINE, FREE”, “CORTISOL, SERUM RANDOM”, “ACTH, PLASMA”, 
“ANTI-MULLERIAN HORMONE”. 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 106 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.5.1.1: Summary of Treatment-Emergent Electrocardiogram (ECG) Parameter Abnormalities 
(Safety Population) 
(Page 1 of 2) 
  
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
Number of Subjects with Treatment-Emergent ECG 
Results 
xxx 
xxx 
PR Interval 
> 200 msec 
xx ( xx.x%) 
xx ( xx.x%) 
> 220 msec 
xx ( xx.x%) 
xx ( xx.x%) 
Change from Baseline in PR Interval 
>= 25% and > 200 msec 
xx ( xx.x%) 
xx ( xx.x%) 
QRS Interval 
> 110 msec 
xx ( xx.x%) 
xx ( xx.x%) 
> 120 msec 
xx ( xx.x%) 
xx ( xx.x%) 
Change from Baseline in QRS Interval 
>= 25% and > 110 msec 
xx ( xx.x%) 
xx ( xx.x%) 
>= 25% and > 120 msec 
xx ( xx.x%) 
xx ( xx.x%) 
QTcF Interval 
> 450 - 470 msec 
xx ( xx.x%) 
xx ( xx.x%) 
> 470 - 500 msec 
xx ( xx.x%) 
xx ( xx.x%) 
> 500 msec 
xx ( xx.x%) 
xx ( xx.x%) 
Change from Baseline in QTcF Interval 
> 30 - 60 msec 
xx ( xx.x%) 
xx ( xx.x%) 
> 60 msec 
xx ( xx.x%) 
xx ( xx.x%) 
QTcF Interval > 500 msec and Change from Baseline > 60 
msec 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
Note: No imputation of missing values. Baseline is the latest recorded value prior to first dose of study drug. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 107 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.5.1.1: Summary of Treatment-Emergent Electrocardiogram (ECG) Abnormalities 
(Safety Population) 
(Page 2 of 2) 
  
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
Number of Subjects with Treatment-Emergent ECG 
Results 
xxx 
xxx 
QTcB Interval 
> 450 - 470 msec 
xx ( xx.x%) 
xx ( xx.x%) 
> 470 - 500 msec 
xx ( xx.x%) 
xx ( xx.x%) 
> 500 msec 
xx ( xx.x%) 
xx ( xx.x%) 
Change from Baseline in QTcB Interval 
> 30 - 60 msec 
xx ( xx.x%) 
xx ( xx.x%) 
> 60 msec 
xx ( xx.x%) 
xx ( xx.x%) 
QTcB Interval > 500 msec and Change from Baseline > 60 
msec 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
Note: No imputation of missing values. Baseline is the latest recorded value prior to first dose of study drug. Change calculated as post-baseline – baseline. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 108 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.5.1.2: Summary of Electrocardiogram Parameters  
(Safety Population) 
(Page 1 of xx) 
  
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
<Parameter>  (<units>) 
Baseline 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Week 2 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Absolute Change from Baseline 
 n 
xx 
xx 
 Mean 
xx.x 
xx.x 
 SD 
xx.xx 
xx.xx 
 Median 
xx.x 
xx.x 
 Min. to Max. 
xx to xx 
xx to xx 
 
 
Note: No imputation of missing values. Baseline is the latest recorded value prior to first dose of study drug. Change calculated as post-baseline – baseline. 
 
“Latest Follow-up” visit includes the latest available follow-up information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Table to include parameters “ECG Mean Heart Rate (beats/min)”, “PR Interval, Aggregate (msec)”, “QRS Duration, Aggregate (msec)”, “QT Interval, 
Aggregate (msec)”, “QTcB Interval, Aggregate (msec)”, “QTcF Interval, Aggregate (msec)”, “RR Interval, Aggregate (msec)”. 
Table to include post-baseline visits of “Week 2”, “Week 4”, “Week 10”, “3-Week Follow-up”, “5-Week Follow-up”, “Latest Follow-up”. 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 109 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.5.1.3: Shift Summary of Overall Electrocardiogram (ECG) Assessments  
(Safety Population) 
(Page 1 of 2) 
  
Overall ECG Assessment (per Investigator) 
 
 Placebo 
 
 (N=xxx) 
 
 
 Serlopitant 5 mg 
 
 (N=xxx) 
 
 
Week 2 
 
 
Week 2 
 
Baseline 
 
Normal 
 
Abnormal, NCS   Abnormal, CS  
 
Normal 
 
Abnormal, NCS   Abnormal, CS  
Normal 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Abnormal, NCS 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Abnormal, CS 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
Week 4 
 
 
Week 4 
 
Baseline 
 
Normal 
 
Abnormal, NCS   Abnormal, CS  
 
Normal 
 
Abnormal, NCS   Abnormal, CS  
Normal 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Abnormal, NCS 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Abnormal, CS 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
Week 10 
 
 
Week 10 
 
Baseline 
 
Normal 
 
Abnormal, NCS   Abnormal, CS  
 
Normal 
 
Abnormal, NCS   Abnormal, CS  
Normal 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Abnormal, NCS 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Abnormal, CS 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
3-Week Follow-up 
 
 
3-Week Follow-up 
 
Baseline 
 
Normal 
 
Abnormal, NCS   Abnormal, CS  
 
Normal 
 
Abnormal, NCS   Abnormal, CS  
Normal 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Abnormal, NCS 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Abnormal, CS 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
5-Week Follow-up 
 
 
5-Week Follow-up 
 
Baseline 
 
Normal 
 
Abnormal, NCS   Abnormal, CS  
 
Normal 
 
Abnormal, NCS   Abnormal, CS  
Normal 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Abnormal, NCS 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Abnormal, CS 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
Note: No imputation of missing values. Baseline is the latest recorded value prior to first dose of study drug. “Latest Follow-up” visit includes the latest available 
 
follow-up information for each subject from the 3-Week or 5-Week Follow-up visits. 
 
NCS=Not Clinically Significant; CS=Clinically Significant. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 110 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.5.1.3: Shift Summary of Overall Electrocardiogram (ECG) Assessments  
(Safety Population) 
(Page 2 of 2) 
  
Overall ECG Assessment (per Investigator) 
 
 Placebo 
 
 (N=xxx) 
 
 
 Serlopitant 5 mg 
 
 (N=xxx) 
 
 
Latest Follow-up 
 
 
Latest Follow-up 
 
Baseline 
 
Normal 
 
Abnormal, NCS   Abnormal, CS  
 
Normal 
 
Abnormal, NCS   Abnormal, CS  
Normal 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Abnormal, NCS 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
Abnormal, CS 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
xx ( xx.x%) 
 
 
Note: No imputation of missing values. Baseline is the latest recorded value prior to first dose of study drug. “Latest Follow-up” visit includes the latest available 
 
follow-up information for each subject from the 3-Week or 5-Week Follow-up visits. 
 
NCS=Not Clinically Significant; CS=Clinically Significant. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 
 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 111 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.6.1: Summary of Vital Signs  
(Safety Population) 
(Page 1 of xx) 
  
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
<Parameter>  (<units>) 
Baseline 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Week 2 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Absolute Change from Baseline 
 n 
xx 
xx 
 Mean 
xx.x 
xx.x 
 SD 
xx.xx 
xx.xx 
 Median 
xx.x 
xx.x 
 Min. to Max. 
xx to xx 
xx to xx 
 
 
Note: Baseline is the latest recorded value prior to first dose of study drug. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the 
 
latest available follow-up information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
Table to include parameters in following order: “Temperature (degrees Celsius)”, “Respiration Rate (breaths/min)”, “Heart Rate (beats/min)”, 
“Systolic Blood Pressure (mmHg)”, “Diastolic Blood Pressure (mmHg)”. 
Table to include post-baseline visits of “Week 2”, “Week 4”, “Week 6”, “Week 10”, “3-Week Follow-up”, ‘”5-Week Follow-up”, “Latest Follow-up”. 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 112 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.7.1: Summary of Hospital Anxiety and Depression Scale (HADS)  
(Safety Population) 
(Page 1 of xx) 
  
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
<Subscale>  
Baseline 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Week 4 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Absolute Change from Baseline 
 n 
xx 
xx 
 Mean 
xx.x 
xx.x 
 SD 
xx.xx 
xx.xx 
 Median 
xx.x 
xx.x 
 Min. to Max. 
xx to xx 
xx to xx 
 
 
Note: Baseline is the latest recorded value prior to first dose of study drug. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the 
 
latest available follow-up information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
Table to include subscales in following order: “Anxiety Subscale”, “Depression Subscale”. 
Table to include post-baseline visits of “Week 4”, “Week 10”, “3-Week Follow-up”, ‘”5-Week Follow-up”, “Latest Follow-up”. 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 113 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.8.1: Summary of Epworth Sleepiness Scale (ESS)  
(Safety Population) 
(Page 1 of xx) 
  
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
ESS 
Baseline 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Week 4 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Absolute Change from Baseline 
 n 
xx 
xx 
 Mean 
xx.x 
xx.x 
 SD 
xx.xx 
xx.xx 
 Median 
xx.x 
xx.x 
 Min. to Max. 
xx to xx 
xx to xx 
 
 
Note: Baseline is the latest recorded value prior to first dose of study drug. Change calculated as post-baseline – baseline. “Latest Follow-up” visit includes the 
 
latest available follow-up information for each subject from the 3-Week or 5-Week Follow-up visits. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
Table to include post-baseline visits of “Week 4”, “Week 10”, “3-Week Follow-up”, ‘”5-Week Follow-up”, “Latest Follow-up”. 
 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 114 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.9: Summary of Pharmacokinetic Concentrations  
(Safety Population) 
 
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
<Analyte>  (<units>) 
Week 2 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Week 4 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Week 10 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
 
 
Note: No imputation of missing values.  
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
Table to include analytes in following order: “M1/M1a”, “M2/M2a”, “M3”, “Serlopitant”. 
 
 


 
CONFIDENTIAL 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 115 
Protocol Number: MTI-106  
16 December 2019 
Table 14.3.1.10: Summary of Menstrual Cycles  
(Safety Population) 
 
  
Placebo  
 
(N=xxx)  
 
  
Serlopitant 5 mg  
 
(N=xxx)  
 
Number of Menstrual Cycles 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
Duration of Menstrual Cycles 
n 
xx 
xx 
Mean 
xx.x 
xx.x 
SD 
xx.xx 
xx.xx 
Median 
xx.x 
xx.x 
Min. to Max. 
xx to xx 
xx to xx 
 
 
Note: No imputation of missing values.  
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE,TIME) 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 116 
Protocol Number: MTI-106   
 
16 December 2019 
11. INDEX OF PLANNED LISTINGS 
Listing 16.1.7: Randomization Scheme .......................................................................................118 
Listing 16.2.1.1: Subject Disposition Information.......................................................................119 
Listing 16.2.1.2: Discontinued Subjects ......................................................................................120 
Listing 16.2.2.1: Inclusion/Exclusion Criteria Not Met ..............................................................121 
Listing 16.2.3: Analysis Populations ...........................................................................................122 
Listing 16.2.4.1: Subject Demographic Information ...................................................................123 
Listing 16.2.4.2.1: Unique Medical History Coded to MedDRA System Organ Classes and 
Preferred Terms ...................................................................................124 
Listing 16.2.4.2.2: Medical History .............................................................................................125 
Listing 16.2.4.3.1: Prurigo Nodularis History .............................................................................126 
Listing 16.2.4.3.2: Prior Therapies ..............................................................................................127 
Listing 16.2.4.4.1: Unique Medication Names Coded to WHO DDE ATC Level 2 Terms and 
Preferred Names ..................................................................................128 
Listing 16.2.4.4.2: Concomitant Medications ..............................................................................129 
Listing 16.2.4.5: Concomitant Procedures/Therapies ..................................................................130 
Listing 16.2.4.6: Physical Examination .......................................................................................131 
Listing 16.2.5.1: Study Visit/Phone Call Compliance .................................................................132 
Listing 16.2.5.2: Study Drug Dispensing and Return ..................................................................133 
Listing 16.2.5.3: Dosing Deviations ............................................................................................134 
Listing 16.2.6.1.1: Worst Itch Numeric Rating Scale (WI-NRS) at Screening ...........................135 
Listing 16.2.6.1.2: Worst Itch Numeric Rating Scale (WI-NRS) ................................................136 
Listing 16.2.6.2: IGA PN-A and IGA PN-S Results ...................................................................137 
Listing 16.2.6.3: Dermatology Life Quality Index (DLQI) .........................................................138 
Listing 16.2.6.4: Photography ......................................................................................................139 
Listing 16.2.7.1.1: Unique Adverse Events Coded to MedDRA System Organ Classes and 
Preferred Terms ...................................................................................140 
Listing 16.2.7.1.2: Treatment-Emergent Adverse Events ............................................................141 
Listing 16.2.7.1.3: Serious Adverse Events .................................................................................142 
Listing 16.2.7.1.4: Subjects Who Permanently Discontinued Study Drug Due to Adverse 
Events ..................................................................................................143 
Listing 16.2.7.2.1: Hospital Anxiety and Depression Scale ........................................................144 
Listing 16.2.7.2.2: Epworth Sleepiness Scale ..............................................................................145 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
 
Page 117 
Protocol Number: MTI-106   
 
16 December 2019 
Listing 16.2.7.3: Menstrual Diary ................................................................................................146 
Listing 16.2.8.1: Pregnancy Test Results.....................................................................................147 
Listing 16.2.8.2.1: Laboratory Test Results .................................................................................148 
Listing 16.2.8.2.2: Out of Range Laboratory Results ..................................................................149 
Listing 16.2.8.2.3: Common Laboratory Comments Including Reference Ranges for Specific 
Laboratory Tests..................................................................................150 
Listing 16.2.8.3: Electrocardiogram Test Results ........................................................................151 
Listing 16.2.8.4: Vital Signs ........................................................................................................152 
Listing 16.2.8.5: Pharmacokinetics Blood Sample Collection and Plasma Concentrations ........153 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 118 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.1.7: Randomization Scheme 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                                Randomization  Randomization  Assigned               Was the subject previously  Previous Screening 
Subject    Age/Sex  Evaluable   Strata         Date           Treatment Group        a Screen Fail?              Subject Number 
______________________________________________________________________________________________________________________________________ 
 
xxxxxx     xxxx     xxxxxxxxx   xxxx           xxxxxxxxxx     xxxxxxx xxxxxx         xxx                         xxxxxx 
 
xxxxxx     xxxx     xxxxxxxxx   xxxx           xxxxxxxxxx     xxxxxxx xxxxxx         xxx                         xxxxxx 
 
xxxxxx     xxxx     xxxxxxxxx   xxxx           xxxxxxxxxx     xxxxxxx xxxxxx         xxx                         xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject. 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 119 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.1.1: Subject Disposition Information 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                F: Date of First                                       E: Follow-up Discontinuation 
S: Subject         Dose             R: Reason for Treatment               Date (Day)¹                D: Date of Last Contact 
A: Age/Sex      L: Date of Last        Discontinuation                 R: Reason for Follow-up       P: Primary AE Number/Specify 
E: Evaluable       Dose             P: Primary AE Number/Specify          Discontinuation            C: Continuing into MTI-107? 
______________________________________________________________________________________________________________________________________ 
 
S: xxxxxx       F: xxxx-xx-xx       R: xxxxxxxxxx xx xxxxxxxxxxxxxxx   E: xxxx-xx-xx (xx)            D: xxxx-xx-xx           
A: xxxx         L: xxxx-xx-xx       P: xxxxxxxxxx                      R: xxxxxxxxxx xx xxxxxxxxxx   P: xxxxxxxxxxx                
E: xxxxxxxxx                                                                                         C: xxx 
 
S: xxxxxx       F: xxxx-xx-xx       R: xxxxxxxxxx xx xxxxxxxxxxxxxxx   E: xxxx-xx-xx (xx)            D: xxxx-xx-xx           
A: xxxx         L: xxxx-xx-xx       P: xxxxxxxxxx                      R: xxxxxxxxxx xx xxxxxxxxxx   P: xxxxxxxxxxx                
E: xxxxxxxxx                                                                                         C: xxx 
 
S: xxxxxx       F: xxxx-xx-xx       R: xxxxxxxxx xxxx xxxxxxxx xxxxx   E: xxxx-xx-xx (xx)            D:                            
A: xxxx         L: xxxx-xx-xx       P: xxxxxxxxxx                      R: xxxx xx xxxxxxxxx          P: xxxxxxxxxxx                
E: xxxxxxxxx                                                                                         C: xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose.  Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject. 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 120 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.1.2: Discontinued Subjects 
                                                             Treatment Group   
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                F: Date of First                                       E: Follow-up Discontinuation 
S: Subject         Dose             R: Reason for Treatment               Date (Day)¹                D: Date of Last Contact 
A: Age/Sex      L: Date of Last        Discontinuation                 R: Reason for Follow-up       P: Primary AE Number/Specify 
E: Evaluable       Dose             P: Primary AE Number/Specify          Discontinuation            C: Continuing into MTI-107? 
______________________________________________________________________________________________________________________________________ 
 
S: xxxxxx       F: xxxx-xx-xx       R: xxxxxxxxxx xx xxxxxxxxxxxxxxx   E: xxxx-xx-xx (xx)            D: xxxx-xx-xx           
A: xxxx         L: xxxx-xx-xx       P: xxxxxxxxxx                      R: xxxxxxxxxx xx xxxxxxxxxx   P: xxxxxxxxxxx                
E: xxxxxxxxx                                                                                         C: xxx 
 
S: xxxxxx       F: xxxx-xx-xx       R: xxxxxxxxxx xx xxxxxxxxxxxxxxx   E: xxxx-xx-xx (xx)            D: xxxx-xx-xx           
A: xxxx         L: xxxx-xx-xx       P: xxxxxxxxxx                      R: xxxxxxxxxx xx xxxxxxxxxx   P: xxxxxxxxxxx                
E: xxxxxxxxx                                                                                         C: xxx 
 
S: xxxxxx       F: xxxx-xx-xx       R: xxxxxxxxx xxxx xxxxxxxx xxxxx   E: xxxx-xx-xx (xx)            D:                            
A: xxxx         L: xxxx-xx-xx       P: xxxxxxxxxx                      R: xxxx xx xxxxxxxxx          P: xxxxxxxxxxx                
E: xxxxxxxxx                                                                                         C: xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose.  Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject. 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 121 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.2.1: Inclusion/Exclusion Criteria Not Met 
                                                             Treatment Group   
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
Subject     Age/Sex     Evaluable     Criterion Failed    Description 
______________________________________________________________________________________________________________________________________ 
 
xxxxxx      xxxx        xxxxxxxxx     xxxxxx              xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxx xxxxxxxx  
 
xxxxxx      xxxx        xxxxxxxxx     xxxxx               xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxx xxxxxxxx  
 
xxxxxx      xxxx        xxxxxxxxx     xxxxx               xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxx xxxxxxxx  
 
                                      xxxxx               xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxx xxxxxxxx  
 
                                      xxxxx               xxxxx xxx xx xxxxxxxx xxxx xxxxxxxxxxxxxxxxxxx xxxxxxxx  
                                                          xxxxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxxxxxxxx xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject and Criterion Failed. 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 122 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.3: Analysis Populations 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
Subject    Age/Sex     Population           Included        Reason(s) Excluded                      Exception(s) 
______________________________________________________________________________________________________________________________________ 
 
xxxxxx     xxxx        Intent-to-Treat      xxx 
                       Safety               xxx 
                       Per-Protocol         xx              xxxxxxxxxxx xxxxxxx xxxxxxxxx 
                                                            xxxxxxxxxxx xxxxxxx xxxxxxxxx 
 
xxxxxx     xxxx        Intent-to-Treat      xxx 
                       Safety               xxx 
                       Per-Protocol         xxx               
 
xxxxxx     xxxx        Intent-to-Treat      xxx 
                       Safety               xxx 
                       Per-Protocol         xx              xxxxxxxxxxx xxxxxxx xxxxxxxxx           xxxxxxxxxxx xxxxxxx xxxxxxxxx 
                                                            xxxxxxxxxxx xxxxxxx xxxxxxxxx 
 
xxxxxx     xxxx        Intent-to-Treat      xxx 
                       Safety               xx              xxxxxxxxxxx xxxxxxx xxxxxxxxx 
                       Per-Protocol         xx              xxxxxxxxxxx xxxxxxx xxxxxxxxx 
                                                            xxxxxxxxxxx xxxxxxx xxxxxxxxx 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject and Population (as ordered above). 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 123 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.4.1: Subject Demographic Information 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
 _____________________________________________________________________________________________________________________________________ 
                                                                                
                    B: Date of Birth                                                                                     
                    A: Age            R: Race                  C: Childbearing Potential    I: Informed Consent Date/Protocol Version    
 Subject  Evaluable S: Sex            E: Ethnicity             M: Method of Contraception   P: Did subject consent to photography?  
 _____________________________________________________________________________________________________________________________________ 
 
 xxxxxx   xxxxxxxxx B: xxxx-xx-xx     R: xxxxxx xxxxxxxx       C: xxx                       I: V2.1/xxxx-xx-xx               
                    A: xx                xx xxxxx xxxxxxx      M: xxxxxxxxx xxxxxxxxxx         V3/xxxx-xx-xx 
                    S: xxxxxx            xxxxxxxx xxxxxxxxxx      xxxxxxxxxxxxx xxxxxxxxx   P: xxx 
                                      E: xxx xxxxxxxx xx          xxxx x xxxxxxxxxx xx  
                                         xxxxxx                   xxxxxxxxx xxxxxxxxxx 
                                                                  xxxx xxxxxxx 
 
 
 xxxxxx   xxxxxxxxx B: xxxx-xx-xx      R: xxxxx                C: xx                        I: V2/xxxx-xx-xx                 
                    A: xx              E: xxxxxxxx xx xxxxxx   M:                           P: xxx       
                    S: xxxx                                                                  
 
 xxxxxx   xxxxxxxxx B: xxxx-xx-xx      R: xxxxx                C: xxx                       I: V3/xxxx-xx-xx                      
                    A: xx              E: xxxxxxxx xx xxxxxx   M: xxxxxxxx xxxxxxxxxxxxx    P: xxx                                 
                    S: xxxxxx            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 _____________________________________________________________________________________________________________________________________ 
 Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
 SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject. Include all instances of informed consents and associated protocol versions. 
  
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 124 
Protocol Number: MTI-106  
16 December 2019 
        Listing 16.2.4.2.1: Unique Medical History Coded to MedDRA System Organ Classes and Preferred Terms 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
MedDRA System Organ Class                     MedDRA Preferred Term                       Medical History Verbatim Term 
______________________________________________________________________________________________________________________________________ 
 
xxxx xxx xxxxx                                xxxx xxx xxxxx                              xxxx 
 
                                                                                          xxxxxx xxxxxxxxxx xx xxxxxx 
 
                                                                                          xxxxxx xxxxxxxxxx xx xxxxx 
 
 
xxxx xxx xxxxx                                xxxx xxx xxxxx                              xxxx 
 
                                                                                          xxxxxx xxxxxxxxxx xx xxxxxx 
 
                                                                                          xxxxxx xxxxxxxxxx xx xxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                           
______________________________________________________________________________________________________________________________________ 
Note: System Organ Class and Preferred Term map to the MedDRA dictionary (Version 21.1). 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by MedDRA System Organ Class, MedDRA Preferred Term, and Medical History Verbatim Term. 
 
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 125 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.4.2.2: Medical History 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
        
                                                                                                       
 
                                   M: Medical Condition                            
 
                                   A: Pruritic Condition Associated  P: MedDRA Preferred Term         
S: Onset Date 
Subject    Age/Sex    Evaluable       with Prurigo Nodularis         S: MedDRA System Organ Class         
E: End Date 
______________________________________________________________________________________________________________________________________ 
 
xxxxxx     xxxx       xxxxxxxx     M: xxxx xxxxxxx (xxxxxxxx xxxxx)  P: xxxxxx xxxxxxxxxx               
S: xxxx-xx-xx 
                                   A: xxx                            S: xxxxxxxxxxx xxxxxxx             
E:  
 
 
 
 
 
                            
                                                        M: xxxx xxxxxxx (xxxxxxxx xxxxx)  P: xxxxxx xxxxxxxxxx               
S: xxxx-xx-xx 
                                   A: xxx                            S: xxxxxxxxxxx xxxxxxx             
E:  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                    
           
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
      System Organ Class and Preferred Term map to MedDRA (Version 21.1). 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Medical Condition/Surgery Verbatim Term, Onset Date, and End Date. 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 126 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.4.3.1: Prurigo Nodularis History 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
        
                                                                                          In the 7 days prior to screening, have you 
                             Date of Prurigo      Body Locations of                       had sensation of stinging or burning with  
Subject  Age/Sex  Evaluable  Nodularis Diagnosis  Prurigo Nodularis                       your prurigo nodularis? 
______________________________________________________________________________________________________________________________________ 
 
xxxxxx   xxxx     xxxxxxxx   xxxx-xx-xx           xxxxxxxxx xxxxx; xxxxxx; xxxx                             xxx 
                                                  xxx xxxx; xxxxxxxxx              
   
xxxxxx   xxxx     xxxxxxxx   xxxx-xx-xx           xxxxxxxxx xxxxx; xxxxx xxxxx;                              xx 
                                                  xxxxx; xxxxxxxxx                 
                                                   
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject. 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 127 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.4.3.2: Prior Therapies 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                                                                          Estimated                         Reason for 
Subject   Age/Sex   Evaluable   Therapy Type         Name                 Duration (unit)  Route            Discontinuing Therapy 
______________________________________________________________________________________________________________________________________ 
 
xxxxxx   xxxx       xxxxxxxx    xxxxxxxxxxx xxxx     xxxxxxxxxxxxxxx      xx               xxxxxxxxxxxxx    xxxx xx xxxxxxxx  
                                                                                                                      
 
                                xxxxxx xxxxxxx       xxxxx                xxxx             xxxxxxxxxxxxx    xxxxxxxxxxx 
                                                                                                                      
 
                                xxxx xx xxxxxx       xxxxxxxx xxxxx       xxxxxxxxx        xxxxxxxxxxxxxx   xxxxxx 
                                xxxxxxxx                                                                     
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Therapy Type, Name. 
 
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 128 
Protocol Number: MTI-106  
16 December 2019 
                  Listing 16.2.4.4.1: Unique Medication Names Coded to WHO DDE ATC Level 2 Terms and Preferred Names 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                                                                                                             I: Indication 
ATC Level 2 Term                 Standardized Medication Name           Medication Name                      R: Route 
______________________________________________________________________________________________________________________________________ 
 
xxxxxxxxxxxxxx                   xxxxxxxxxxxxxx                         xxxxxxxx                             I: xxxxxxxxxxx 
                                                                                                             R: xxxxxxxxxxx 
 
                                                                        xxxxxxxxx                            I: xxxxxxxxxxx 
                                                                                                             R: xxxxxxxxxxx 
 
 
xxxxxxxxxxxxxx                   xxxxxxxxxxxxxx                         xxxxxxxx                             I: xxxxxxxxxxx 
                                                                                                             R: xxxxxxxxxxx 
 
                                                                        xxxxxxxxx                            I: xxxxxxxxxxx 
                                                                                                             R: xxxxxxxxxxx 
                                                                                                               
 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                             
______________________________________________________________________________________________________________________________________ 
Note: Standardized Medication Name and ATC Level 2 Term map to the WHO DDE (Version September 1, 2018). 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by ATC Level 2 Term, Standardized Medication Name, Medication Name, Indication, and Route. 
 
Note to Programmer: If Indication or Route is ‘Other’ then the applicable variable is ‘OTHER: <specification of other>’.  
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 129 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.4.4.2: Concomitant Medications 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                                      M: Medication Name                      T: Prior/Concomitant            D: Dose 
                                      P: Standardized Medication Name         F: Date of First Dose           U: Units 
                                      A: ATC Level 2 Term                     S: Start Date (Day)¹            F: Frequency 
Subject     Age/Sex    Evaluable      I: Indication                           E: End Date (Day)¹              R: Route  
______________________________________________________________________________________________________________________________________ 
 
xxxxxx      xxxx       xxxxxxxxxx     M: xxxxxxxxxxxxx                        T: xxxxxxxxxx                    D: xx 
                                      P: xxxxxxxxxxxxx                        F: xxxx-xx-xx                    U: xx 
                                      A: xxxxxxxxxxxxx                        S: xxxx-xx-xx (xx)               F: xxxx 
                                      I: xxxxxxxx                             E: xxxx-xx-xx (xx)               R: xxxxxx  
                                                                                                               
 
                                      M: xxxxxxxxxxxxx                        T: xxxxxxxxxx                    D: xxxxx 
                                      P: xxxxxxxxxxxxx                        F: xxxx-xx-xx                    U: xx 
                                      A: xxxxxxxxxxxxx                        S: xxxx-xx                       F: xx 
                                      I: xxxxxxxx                             E:                               R: xxxx 
                                                                                                               
 
xxxxxx      xxxx       xxxxxxxxxx     M: xxxxxxxxxxxxx                        T: xxxxxxxxxx                    D: xxx 
                                      P: xxxxxxxxxxxxx                        F: xxxx-xx-xx                    U: xx 
                                      A: xxxxxxxxxxxxx                        S: xxxx-xx-xx (x)                F: xx 
                                      I: xxxxxxxx                             E: xxxx-xx-xx (xx)               R: xxxx 
                                                                                                             
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose.  Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
      Standardized Medication Name and ATC Level 2 Term map to the WHO DDE (Version September 1, 2018). 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
Listing sorted by Subject, Start Date, End Date, Medication Name, Indication, and Route. If ongoing, include ‘Ongoing’ in place of End 
Date. 
Note to Programmer: If Units, Frequency, Indication, or Route is ‘Other’ then the applicable variable is ‘OTHER: <specification of 
other>’. 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 130 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.4.5: Concomitant Procedures/Therapies 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                                    T: Procedure/Therapy                 F: Date of First Dose 
                                    P: MedDRA Preferred Term             S: Start Date (Day)¹        Reason for Procedure 
Subject    Age/Sex    Evaluable     S: MedDRA System Organ Class         E: End Date (Day)¹          or Therapies 
______________________________________________________________________________________________________________________________________ 
 
xxxxxx      xxxx      xxxxxxxxxx    T: xxxxxxxxxxxxxxxxxx                F: xxxx-xx-xx               x xxxxxx xxxx xxxxxx  
                                    P: xxxxxxxxxxxxxxxxxxxxxxxxxx        S: xxxx-xx-xx (xx)          xxxxxxxxx 
                                    S: xxxxxxxxxxxxxxxxxxxxxxxxxx        E: xxxx-xx-xx (xx)                               
                                                                                                               
xxxxxx      xxxx      xxxxxxxxxx    T: xxxxxxxxxxxxxxxxxx                F: xxxx-xx-xx               x xxxxxx xxxx xxxxxx  
                                    P: xxxxxxxxxxxxxxxxxxxxxxxxxx        S: xxxx-xx-xx (xx)          xxxxxxxxx 
                                    S: xxxxxxxxxxxxxxxxxxxxxxxxxx        E: xxxx-xx-xx (xx)                               
                                                                                                               
xxxxxx      xxxx      xxxxxxxxxx    T: xxxxxxxxxxxxxxxxxx                F: xxxx-xx-xx               x xxxxxx xxxx xxxxxx  
                                    P: xxxxxxxxxxxxxxxxxxxxxxxxxx        S: xxxx-xx-xx (xx)          xxxxxxxxx 
                                    S: xxxxxxxxxxxxxxxxxxxxxxxxxx        E: xxxx-xx-xx (xx)                               
                                                                                                             
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose.  Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
      System Organ Class and Preferred Term map to MedDRA (Version 21.1). 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Start Date, End Date, and Procedure/Therapy. If ongoing, include ‘Ongoing’ in place of End Date. 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 131 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.4.6: Physical Examination 
                                                            Treatment Group 
                                                            (Page x of xx) 
 
 _____________________________________________________________________________________________________________________________________ 
 
 Subject        Age/Sex     Evaluable   Visit           Date of Assessment (Day)¹   Physical Exam Completed      
 _____________________________________________________________________________________________________________________________________ 
 
 xxxxxxxxxx     xxxx        xxxxxxxxx   xxxxxxxxxx      xxxx-xx-xx (xx)             xxxxxxxx                                                    
 
 xxxxxxxxxx     xxxx        xxxxxxxxx   xxxxxxxxxx      xxxx-xx-xx (xx)             xxxxxxxx                                               
 
 xxxxxxxxxx     xxxx        xxxxxxxxx   xxxxxxxxxx      xxxx-xx-xx (xx)             xxxxxxxx                                               
 
 xxxxxxxxxx     xxxx        xxxxxxxxx   xxxxxxxxxx      xxxx-xx-xx (x)              xxxxxxxx                                               
 
 xxxxxxxxxx     xxxx        xxxxxxxxx   xxxxxxxxxx      xxxx-xx-xx (xx)             xxxxxxx                                                        
                                                                                                                                                       
 
 xxxxxxxxxx     xxxx        xxxxxxxxx   xxxxxxxxxx      xxxx-xx-xx (xx)             xxxxxxxx                                                   
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Visit, and Date of Assessment. 
 
                                                
 
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 132 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.5.1: Study Visit/Phone Call Compliance 
                                                            Treatment Group 
                                                           (Page xx of yy) 
 
_____________________________________________________________________________________________________________________________________ 
 
                                                                          Within  Continuing                                   
                                                                 Study    Visit   into         Visit Not Done/  
Subject  Age/Sex  Evaluable Visit                Visit Date      Day¹     Window  MTI-107?     Reason for Unscheduled Visit 
_____________________________________________________________________________________________________________________________________ 
 
xxxxxx    xxxx    xxxxxxxx  xxxxxxxxx            xxxx-xx-xx      xx       xxx       xxx 
 
                            xxxxxxxx             xxxx-xx-xx      xx       xxx       xxx 
 
                            xxxxxx               xxxx-xx-xx      xx       xxx       xxx 
 
                            xxxxxx               xxxx-xx-xx      xx       xxx       xxx        xxxxxxx x xxxxxx xxxxxxx xxxxx xxxxxx 
                                                                                               xx xxxx xxx xxxx xx xxx xxxx 
 
                            xxxxxx               xxxx-xx-xx      xx       xxx       xxx 
 
                            xxxxxxxxxxxxxxx      xxxx-xx-xx      xx       xxx       xxx 
 
 
xxxxxx    xxxx    xxxxxxxx  xxxxxxxxx            xxxx-xx-xx      xx       xxx       xxx 
 
                            xxxxxx               xxxx-xx-xx      xx       xxx       xxx 
 
                            xxxxxxxxxxxxxxx      xxxx-xx-xx      xx       xxx       xxx 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – baseline date for dates prior to baseline date. Otherwise, day is calculated as 
  date – baseline date + 1 for dates on or after baseline date. For follow-up visits, Week 10 date is used in place of baseline. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME)  
 
Listing sorted by Subject, Visit, and Visit Date. 
 
Note to Programmer: If a visit is ranged present the ‘Visit Date’ column as ‘<Start Date> to <End Date>’ same with the Study Day 
column. 
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 133 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.5.2: Study Drug Dispensing and Return 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
 _____________________________________________________________________________________________________________________________________  
                                    
                                              
                                   Bottle     Date Bottle  Date Bottle    Number of Tablets    Number of Tablets                      
 Subject   Age/Sex    Evaluable    Number     Dispensed    Returned           Dispensed            Returned            Tablets Used 
 _____________________________________________________________________________________________________________________________________ 
 
 xxxxxx    xxxx       xxxxxxxxx    xxxxxx     xxxx-xx-xx   xxxx-xx-xx             xx                   xx                   xx               
                                   xxxxxx     xxxx-xx-xx   xxxx-xx-xx             xx                   xx                   xx               
 
 xxxxxx    xxxx       xxxxxxxxx    xxxxxx     xxxx-xx-xx   xxxx-xx-xx             xx                   xx                   xx               
                                   xxxxxx     xxxx-xx-xx   xxxx-xx-xx             xx                   xx                   xx               
 
         
 
  
 
 
 
 
 
 
 
 _____________________________________________________________________________________________________________________________________ 
 Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
 SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Date Bottle Dispensed, and Date Bottle Returned. 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 134 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.5.3: Dosing Deviations 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
_____________________________________________________________________________________________________________________________________  
                              
Subject      Age/Sex      Evaluable      Date of Deviation          Reason for Deviation        Number of Tablets Taken                   
_____________________________________________________________________________________________________________________________________ 
 
xxxxxx       xxxx         xxxxxxxxx      xxxx-xx-xx                 xxxxxx                      xxxxxxxxxxxxxxxxxxxxxxx              
 
xxxxxx       xxxx         xxxxxxxxx      xxxx-xx-xx                 xxxxxx                      x        
                                         xxxx-xx-xx                 xxxxxx                      xxxxxxxxxxxxxxxxxxxxxxx        
                                         xxxx-xx-xx                 xxxxxx                      xxxxxxxxxxxxxxxxxxxxxxx  
                                         xxxx-xx-xx                 xxxxxx                      xxxxxxxxxxxxxxxxxxxxxxx 
 
xxxxxx       xxxx         xxxxxxxxx      xxxx-xx-xx                 xxxx                                      
                                         xxxx-xx-xx                 xxxxxx                      x        
 
         
 
  
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Date of Deviation, Type of Deviation, and Number of Tablets Taken. 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 135 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.6.1.1: Worst Itch Numeric Rating Scale (WI-NRS) at Screening 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
Subject              Age/Sex              Evaluable             Date of Assessment (Day)¹          WI-NRS² in the past 24 hours 
______________________________________________________________________________________________________________________________________ 
   
xxxxxxxx             xxxx                 xxxxxxxxx             xxxx-xx-xx (xx)                    xx 
 
xxxxxxxx             xxxx                 xxxxxxxxx             xxxx-xx-xx (xx)                    xx 
 
xxxxxxxx             xxxx                 xxxxxxxxx             xxxx-xx-xx (xx)                    xx 
 
xxxxxxxx             xxxx                 xxxxxxxxx             xxxx-xx-xx (xx)                    xx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
² Scaled from 0 - No Itch to 10 - Worst Itch Imaginable. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject and Date of Assessment. 
 
 
 
 
  
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 136 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.6.1.2: Worst Itch Numeric Rating Scale (WI-NRS) 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                                                                                         WI-NRS in        Change from 
Subject    Age/Sex   Evaluable    Timepoint               Date of Assessment (Day)¹      past 24 hrs²     Baseline³ 
______________________________________________________________________________________________________________________________________ 
 
xxxxxx     xxxx      xxxxxxxx                             xxxx-xx-xxTxx:xx:xx  (xxx)     x 
                                                          xxxx-xx-xxTxx:xx:xx  (xxx)     x 
                                                          xxxx-xx-xxTxx:xx:xx  (xxx)     x 
                                                          xxxx-xx-xxTxx:xx:xx  (xxx)     x 
                                                          xxxx-xx-xxTxx:xx:xx  (xxx)     x 
                                                          xxxx-xx-xxTxx:xx:xx  (xxx)     x 
 
                                  xxxxxxxx                xxxx-xx-xxTxx:xx:xx  (xxx)     x 
                                  xxxxxxxx                xxxx-xx-xxTxx:xx:xx  (xxx)     x 
                                  xxxxxxxx                xxxx-xx-xxTxx:xx:xx  (xxx)     x 
                                  xxxxxxxx                xxxx-xx-xxTxx:xx:xx  (xxx)     x 
                                  xxxxxxxx                Average                        xxxxx 
 
                                  xxxxxxxx                xxxx-xx-xxTxx:xx:xx  (xxx)     x                 xxxx 
                                  xxxxxxxx                xxxx-xx-xxTxx:xx:xx  (xxx)     x                 xxxx 
                                  xxxxxxxx                xxxx-xx-xxTxx:xx:xx  (xxx)     x                 xxxx 
                                  xxxxxxxx                xxxx-xx-xxTxx:xx:xx  (xxx)     x                 xxxx 
                                  xxxxxxxx                Average                        xxxxx             xxxx 
 
 
 
_____________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
² Scaled from 0 – No Itch to 10 – Worst Itch Imaginable 
³ The WI-NRS Baseline is the average of the results for the week prior to starting the study drug (Timepoint = BASELINE). 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Date of Assessment, Timepoint (where the Average over a given Timepoint is presented in the order above), 
and WI-NRS in past 24 hours. 
 
 
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 137 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.6.2: IGA PN-A and IGA PN-S Results 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                                                                   Investigator’s Global Assessement Investigator’s Global Assessement 
Subject   Age/Sex  Evaluable   Visit    Date of Assessment (Day)¹  of Prurigo Nodularis Activity     of Prurigo Nodularis Stage 
______________________________________________________________________________________________________________________________________ 
   
xxxxxxxx  xxxx     xxxxxxxxx   xxxxxxx  xxxx-xx-xx (xx)                         xxxxx x                         xxxxx x 
                                        xxxx-xx-xx (xx)                         xxxxx x                         xxxxx x            
                                        xxxx-xx-xx (xx)                         xxxxx x                         xxxxx x                   
                                        xxxx-xx-xx (xx)                         xxxxx x                         xxxxx x                   
                                        xxxx-xx-xx (xx)                         xxxxx x                         xxxxx x                   
                                        xxxx-xx-xx (xx)                         xxxxx x                         xxxxx x              
 
xxxxxxxx  xxxx     xxxxxxxxx   xxxxxxx  xxxx-xx-xx (xx)                         xxxxx x                         xxxxx x 
                                        xxxx-xx-xx (xx)                         xxxxx x                         xxxxx x            
                                        xxxx-xx-xx (xx)                         xxxxx x                         xxxxx x                   
                                        xxxx-xx-xx (xx)                         xxxxx x                         xxxxx x                   
                                        xxxx-xx-xx (xx)                         xxxxx x                         xxxxx x                   
                                        xxxx-xx-xx (xx)                         xxxxx x                         xxxxx x              
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Visit, and Date of Assessment. 
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 138 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.6.3: Dermatology Life Quality Index (DLQI) 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                           V: Visit                      Question 
Subject  Age/Sex Evaluable D: Date of Assessment (Day)¹   Number  Question                                                Result 
______________________________________________________________________________________________________________________________________ 
 
xxxxxxxx xxxx    xxxxxxx   V: xxxxxxxxxx                     1    Over the last week, how itchy, sore, painful or         xxxxxx 
                           D: xxxx-xx-xx (xx)                     stinging has your skin been? 
                                                             2    Over the last week, how embarrassed or self conscious   xxxxxx 
                                                                  have you been because of your skin? 
                                                             3    Over the last week, how much has your skin interfered   xxxxxx 
                                                                  with you going shopping or looking after your home or 
                                                                  garden? 
                                                             4    Over the last week, how much has your skin influenced   xxxxxx 
                                                                  the clothes you wear? 
                                                             5    Over the last week, how much has your skin affected     xxxxxx 
                                                                  any social or leisure activities? 
                                                             6    Over the last week, how much has your skin made it      xxxxxx 
                                                                  difficult for you to do any sport? 
                                                             7    Over the last week, has your skin prevented you from    xxxxxx 
                                                                  working or studying? 
                                                            7A    If "No", over the last week how much has your skin      xxxxxx 
                                                                  been a problem at work or studying? 
                                                             8    Over the last week, how much has your skin created      xxxxxx 
                                                                  problems with your partner or any of your close 
                                                                  friends or relatives? 
                                                             9    Over the last week, how much has your skin caused any   xxxxxx 
                                                                  sexual difficulties? 
                                                            10    Over the last week, how much of a problem has the       xxxxxx 
                                                                  treatment for your skin been, for example by making 
                                                                  your home messy, or by taking up time? 
                                                                  Questionnaire Score                                     xx 
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Visit, and Date of Assessment. 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 139 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.6.4: Photography 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
 
 
______________________________________________________________________________________________________________________________________ 
 
                           V: Visit                       
Subject  Age/Sex Evaluable D: Date of Assessment (Day)¹  Body Areas Photographed 
______________________________________________________________________________________________________________________________________ 
 
xxxxxxxx xxxx    xxxxxxx   V: xxxxxxxxxx                 xxxxxxxx; xxxxxxxxxxx; xxxxxxxx 
                           D: xxxx-xx-xx (xx)             
                                                          
                                                          
                           V: xxxxxxxxxx                 xxxxxxxx; xxxxxxxxxxx; xxxxxxxx 
                           D: xxxx-xx-xx (xx)             
                                 
                                 
                           V: xxxxxxxxxx                 xxxxxxxx; xxxxxxxxxxx; xxxxxxxx 
                           D: xxxx-xx-xx (xx)             
                                 
                                 
                           V: xxxxxxxxxx                 xxxxxxxx; xxxxxxxxxxx; xxxxxxxx 
                           D: xxxx-xx-xx (xx)             
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
                                                          
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Visit, and Date of Assessment. 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 140 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.7.1.1: Unique Adverse Events Coded to MedDRA System Organ Classes and Preferred Terms 
                                                             (Page xx of yy) 
 
 _____________________________________________________________________________________________________________________________________ 
 
 MedDRA System Organ Class                    MedDRA Preferred Term                        Adverse Event 
 _____________________________________________________________________________________________________________________________________ 
 
 xxxxx xxxxx xxxxx                            xxxxx xxxxx xxxxx                            xxxxxxxxxx 
 
                                                                                           xxxxxxxx xxxxxxxx xxxxxxxxxxx 
 
                                                                                           xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxxxx 
 
 
                                              xxxxx xxxxx xxxxx                            xxxxxxxxxx 
 
                                                                                           xxxxxxxx xxxxxxxx xxxxxxxxxxx 
 
                                                                                           xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxxxx 
 
                                                                                            
                                              xxxxxxxxxx                                   xxxxx xxxxx xxxxx                             
 
                                                                                           xxxxxxxx xxxxxxxx xxxxxxxxxxx 
 
                                                                                           xxxxxxxx xxxxxxxxx xxxxxxxxxxxxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 _____________________________________________________________________________________________________________________________________ 
 Note: System Organ Class and Preferred Term map to MedDRA (Version 21.1). 
 SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by MedDRA System Organ Class, Preferred Term, and Adverse Event. 
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 141 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.7.1.2: Treatment-Emergent Adverse Events 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                                                                                                     S: Is AE Serious? 
                                                                         S: Grade²                   R: Reason(s) for Serious 
S: Subject         A: Event                   F: Date of First Dose      R: Relationship to Study    T: Action Taken with 
A: Age/Sex         C: System Organ Class      S: Start Date (Day)¹          Treatment                   Study Treatment 
E: Evaluable       P: Preferred Term          E: End Date (Day)¹         O: Outcome                  A: Any Other Action(s) 
______________________________________________________________________________________________________________________________________ 
 
S: xxxxxx          A: xxxxxxxxxxxxxxx         F: xxxx-xx-xx              S: xxxx                     S: xx 
A: xxxx            C: xxxxxxxxxxxxxxx         S: xxxx-xx-xx (xx)         R: xxxxxxxxxx               R: xxxx xxx xxxxxxx 
E: xxxxxxxxx       P: xxxxxxxxxxxxxxx         E: xxxx-xx-xx (xx)         O: xxxxxxxxxx               T: xxx 
                                                                                                     A: xxxxxxx 
 
                   A: xxxxxxxxxxxxxxx         F: xxxx-xx-xx              S: xxxx                     S: xx 
                   C: xxxxxxxxxxxxxxx         S: xxxx-xx-xx (x)          R: xxxxxxxxxx               R: xxxx xxx xxxxxxx 
                   P: xxxxxxxxxxxxxxx         E: xxxx-xx-xx (xx)         O: xxxxxxxxxx               T: xxx 
                                                                                                     A: xxxxxxx 
 
S: xxxxxx          A: xxxxxxxxxxxxxxx         F: xxxx-xx-xx              S: xxxx                     S: xx 
A: xxxx            C: xxxxxxxxxxxxxxx         S: xxxx-xx-xx (xx)         R: xxxxxxxxxx               R: xxxx xxx xxxxxxx 
E: xxxxxxxxx       P: xxxxxxxxxxxxxxx         E: xxxx-xx-xx (xx)         O: xxxxxxxxxx               T: xxx 
                                                                                                     A: xxxxxxx 
S: xxxxxx          A: xxxxxxxxxxxxxxx         F: xxxx-xx-xx              S: xxxx                     S: xx 
A: xxxx            C: xxxxxxxxxxxxxxx         S: xxxx-xx-xx (xx)         R: xxxxxxxxxx               R: xxxx xxx xxxxxxx 
E: xxxxxxxxx       P: xxxxxxxxxxxxxxx         E: xxxx-xx-xx (xx)         O: xxxxxxxxxx               T: xxx 
                                                                                                     A: xxxxxxx 
 
 
 
 
 
 
  
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose.  Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
2 Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life Threatening; Grade 5 = Death. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
      System Organ Class and Preferred Term map to MedDRA (Version 21.1). 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Start Date, End Date, and Adverse Event. 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 142 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.7.1.3: Serious Adverse Events 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
                                                                                    
                                                                                                     S: Is AE Serious? 
                                                                         S: Grade2                    R: Reason(s) for Serious    
S: Subject         A: Event                   F: Date of First Dose      R: Relationship to Study    T: Action Taken with     
A: Age/Sex         C: System Organ Class      S: Start Date (Day)¹          Treatment                   Study Treatment 
E: Evaluable       P: Preferred Term          E: End Date (Day)1          O: Outcome                  A: Any Other Action(s)  
______________________________________________________________________________________________________________________________________ 
 
S: xxxxxx          A: xxxxxxxxxxxxxxx         F: xxxx-xx-xx              S: xxxx                     S: xx 
A: xxxx            C: xxxxxxxxxxxxxxx         S: xxxx-xx-xx (xx)         R: xxxxxxxxxx               R: xxxx xxx xxxxxxx 
E: xxxxxxxxx       P: xxxxxxxxxxxxxxx         E: xxxx-xx-xx (xx)         O: xxxxxxxxxx               T: xxx 
                                                                                                     A: xxxxxxx 
 
                   A: xxxxxxxxxxxxxxx         F: xxxx-xx-xx              S: xxxx                     S: xx 
                   C: xxxxxxxxxxxxxxx         S: xxxx-xx-xx (x)          R: xxxxxxxxxx               R: xxxx xxx xxxxxxx 
                   P: xxxxxxxxxxxxxxx         E: xxxx-xx-xx (xx)         O: xxxxxxxxxx               T: xxx 
                                                                                                     A: xxxxxxx 
 
S: xxxxxx          A: xxxxxxxxxxxxxxx         F: xxxx-xx-xx              S: xxxx                     S: xx 
A: xxxx            C: xxxxxxxxxxxxxxx         S: xxxx-xx-xx (xx)         R: xxxxxxxxxx               R: xxxx xxx xxxxxxx 
E: xxxxxxxxx       P: xxxxxxxxxxxxxxx         E: xxxx-xx-xx (xx)         O: xxxxxxxxxx               T: xxx 
                                                                                                     A: xxxxxxx 
S: xxxxxx          A: xxxxxxxxxxxxxxx         F: xxxx-xx-xx              S: xxxx                     S: xx 
A: xxxx            C: xxxxxxxxxxxxxxx         S: xxxx-xx-xx (xx)         R: xxxxxxxxxx               R: xxxx xxx xxxxxxx 
E: xxxxxxxxx       P: xxxxxxxxxxxxxxx         E: xxxx-xx-xx (xx)         O: xxxxxxxxxx               T: xxx 
                                                                                                     A: xxxxxxx 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose.  Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
2 Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life Threatening; Grade 5 = Death. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
      System Organ Class and Preferred Term map to MedDRA (Version 21.1). 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Start Date, End Date, and Adverse Event. 
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 143 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.7.1.4: Subjects Who Permanently Discontinued Study Drug Due to Adverse Events 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                                      _______Completion/Discontinuation________ 
                                      D: Date of Study Discontinuation (Day)¹   ____________________Adverse Events____________________ 
                   F: Date of First   T: Primary Reason for Treatment           A: Event                   S: Start Date (Day)¹ 
S: Subject            Dose               Discontinuation                        S: Grade²                  E: End Date (Day)¹ 
A: Age/Sex         L: Date of Last    S: Primary Reason for Study               R: Relationship to         A: Action Taken with Study 
E: Evaluable          Dose               Discontinuation                           Study Treatment            Treatment 
______________________________________________________________________________________________________________________________________ 
 
S: xxxxxx          F: xxxx-xx-xx      D: xxxx-xx-xx (xx)                        A: xxxxxxxxxx              S: xxxx-xx-xx (xx) 
A: xxxx            L: xxxx-xx-xx      T: xxxxxx                                 S: xxxxxxx                 E: xxxx-xx-xx (xx) 
E: xxxxxxx                            S: xxxxxxxxxxxxxx                         R: xxxxxxxxxxxxxxxx        A: xxxxxxxxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
² Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life Threatening; Grade 5 = Death. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Start Date, End Date, and Adverse Event. 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 144 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.7.2.1: Hospital Anxiety and Depression Scale 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                           V: Visit                       
Subject  Age/Sex Evaluable D: Date of Assessment (Day)¹  Question                                             Result 
______________________________________________________________________________________________________________________________________ 
 
xxxxxxxx xxxx    xxxxxxx   V: xxxxxxxxxx                 I feel tense or ‘wound up’                           xxxxxxxxxxxxxxxxxxxx 
                           D: xxxx-xx-xx (xx)            I still enjoy the things I used to enjoy             xxxxxxxxxxxxxxxxxxxx 
                                                         I get a sort of frightened feeling as if something 
                                                         awful is about to happen                             xxxxxxxxxxxxxxxxxxxx 
                                                         I can laugh and see the funny side of things         xxxxxxxxxxxxxxxxxxxx 
                                                         Worrying thoughts go through my mind                 xxxxxxxxxxxxxxxxxxxx 
                                                         I feel cheerful                                      xxxxxxxxxxxxxxxxxxxx 
                                                         I can sit at ease and feel relaxed                   xxxxxxxxxxxxxxxxxxxx 
                                                         Depression Subscale                                  xx 
                                                         Anxiety Subscale                                     xx 
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 145 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.7.2.2: Epworth Sleepiness Scale 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                           V: Visit                       
Subject  Age/Sex Evaluable D: Date of Assessment (Day)¹  Situation                                                Result 
______________________________________________________________________________________________________________________________________ 
 
xxxxxxxx xxxx    xxxxxxx   V: xxxxxxxxxx                 Sitting and reading                                      xxxxxxxxxxxxxxxxxxxx 
                           D: xxxx-xx-xx (xx)            Watching TV                                              xxxxxxxxxxxxxxxxxxxx 
                                                         Sitting, inactive in a public place (e.g. a theatre  
                                                         or a meeting)                                            xxxxxxxxxxxxxxxxxxxx 
                                                         As a passenger in a car for an hour without a break      xxxxxxxxxxxxxxxxxxxx 
                                                         Lying down to rest in the afternoon when circumstances  
                                                         permit                                                   xxxxxxxxxxxxxxxxxxxx 
                                                         Sitting and talking to someone                           xxxxxxxxxxxxxxxxxxxx 
                                                         Sitting quietly after a lunch without alcohol            xxxxxxxxxxxxxxxxxxxx 
                                                         In a car, while stopped for a few minutes in the  
                                                         traffic                                                  xxxxxxxxxxxxxxxxxxxx 
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 146 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.7.3: Menstrual Diary 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                            
Subject  Age/Sex Evaluable    Childbearing Potential      Start Date of Period (Day)¹       End Date of Period (Day)¹ 
______________________________________________________________________________________________________________________________________ 
 
xxxxxxxx xxxx    xxxxxxx      xxxxxxxxxxxxx               xxxx-xx-xx (xx)                   xxxx-xx-xx (xx) 
                                                          xxxx-xx-xx (xx)                   xxxx-xx-xx (xx) 
                                                          xxxx-xx-xx (xx)                   xxxx-xx-xx (xx) 
                            
                            
                            
                            
                            
                            
                            
                            
                            
                            
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 147 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.8.1: Pregnancy Test Results 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
                                                                                S: Was a Serum Pregnancy 
S: Subject                                                                         Test Ordered? 
A: Age/Sex        V: Visit                       S: Specimen²                   E: If no, but was required, 
E: Evaluable      D: Date (Day)¹                 R: Result                         explain                            Comments 
______________________________________________________________________________________________________________________________________ 
 
S: xxxxxx         V: xxxxxxxxx                   S: xxxxx                       S: xxx                                xxxxxxxxxxxxxx 
A: xxxx           D: xxxx-xx-xx (xxx)            R: xxxxxxxx                    E: 
E: xxxxxxxx 
                                                     
                  V: xxxxxxxxx                   S: xxxxx                       S: xx 
                  D: xxxx-xx-xx (xxx)            R: xxxxxxxx                    E: 
 
                  V: xxxxxxxxx                   S: xxxxx                       S: xx 
                  D: xxxx-xx-xx (xxx)            R: xxxxxxxx                    E: 
 
                  V: xxxxxxxxx                   S: xxxxx                       S: xx 
                  D: xxxx-xx-xx (xxx)            R: xxxxxxxx                    E: 
 
S: xxxxxx         V: xxxxxxxxx                   S: xxxxx                       S: xx 
A: xxxx           D: xxxx-xx-xx (xxx)            R: xxxxxxxx                    E: xxxxxxxxxxxxxxxxxxxxxxxxxx 
E: xxxxxxxx 
 
 
 
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
² For Serum pregnancy results: HCG levels less than 10 mIU/mL are considered negative for pregnancy. Levels between 10 - 24.9 mIU/mL 
  are equivocal and a redraw of the patient after 48 hours is suggested. Levels greater than or equal to 25 mUI/mL are considered 
  positive for pregnancy. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Visit, Date, and Specimen.  NOTE: Serum Pregnancy Questions (S: E:) are only applicable to Urine Pregnancy 
test records. 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 148 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.8.2.1: Laboratory Test Results 
                                                            Treatment Group 
                                                           (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
S: Subject   V: Visit 
A: Age/Sex   D: Date (Day)¹                                       Results       _______Reference Range________ 
E: Evaluable C: Category                   Laboratory Test        (Units)       Low   High  Indicator(CS²)     Comments 
______________________________________________________________________________________________________________________________________ 
 
S: xxxxxx    V: xxxxxxxxx                  xxxxxxxxxxxxxxxxxxxxxx xxxx (xxxxxx)                                xxxxxxxxxxxxxxxxxxxx 
A: xxxx      D: xxxx-xx-xxTxx:xx:xx (xxx)                                                                      xxxxxxxxxxxxxxxxxx 
E: xxxxxxxx  C: xxxxxxxxxxxxxxxxxxxxxx                                                                         xxxxxxxxxxxxxx 
 
             V: xxxxxxxxx                  xxxxxxxxxxxxxxxxxxxxxx xxxx (xxxxxx) x     xx    xxxxxxxxxxx (xxx)  xxxxxxxxxxxxxxx 
             D: xxxx-xx-xxTxx:xx:xx (xxx)                                                                      xxxxxxxxxxxxxxxxxx 
             C: xxxxxxxxxxxxxxxxxxxxxx                                                                         xxxxxxxxxxxxxx 
 
             V: xxxxxxxxx                  xxxxxxxxxxxxxxxxxxxxxx xxxx (xxxxxx) x     xx    xxxxxxxxxxx (xxx)   
             D: xxxx-xx-xxTxx:xx:xx (xxx)                                                                       
             C: xxxxxxxxxxxxxxxxxxxxxx                                                                          
 
                                                                         
 
 
 
 
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
² Clinical significance based on Investigator interpretation. CS = Clinically Significant; NCS = Not Clinically Significant. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Visit, Date, Category, and Lab Test.  
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 149 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.8.2.2: Out of Range Laboratory Results 
                                                             Treatment Group 
                                                            (Page xx of yy) 
 
______________________________________________________________________________________________________________________________________ 
 
S: Subject   V: Visit 
A: Age/Sex   D: Date (Day)¹                                       Results       _______Reference Range________ 
E: Evaluable C: Category                   Laboratory Test        (Units)       Low   High  Indicator(CS²)     Comments 
______________________________________________________________________________________________________________________________________ 
 
S: xxxxxx    V: xxxxxxxxx                  xxxxxxxxxxxxxxxxxxxxxx xxxx (xxxxxx)                                xxxxxxxxxxxxxxxxxxxx 
A: xxxx      D: xxxx-xx-xxTxx:xx:xx (xxx)                                                                      xxxxxxxxxxxxxxxxxx 
E: xxxxxxxx  C: xxxxxxxxxxxxxxxxxxxxxx                                                                         xxxxxxxxxxxxxx 
 
             V: xxxxxxxxx                  xxxxxxxxxxxxxxxxxxxxxx xxxx (xxxxxx) x     xx    xxxxxxxxxxx (xxx)  xxxxxxxxxxxxxxx 
             D: xxxx-xx-xxTxx:xx:xx (xxx)                                                                      xxxxxxxxxxxxxxxxxx 
             C: xxxxxxxxxxxxxxxxxxxxxx                                                                         xxxxxxxxxxxxxx 
 
             V: xxxxxxxxx                  xxxxxxxxxxxxxxxxxxxxxx xxxx (xxxxxx) x     xx    xxxxxxxxxxx (xxx)   
             D: xxxx-xx-xxTxx:xx:xx (xxx)                                                                       
             C: xxxxxxxxxxxxxxxxxxxxxx                                                                          
 
                                                                         
 
 
 
 
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
² Clinical significance based on Investigator interpretation. CS = Clinically Significant; NCS = Not Clinically Significant. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Visit, Date, Category, and Lab Test. 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 150 
Protocol Number: MTI-106  
16 December 2019 
               Listing 16.2.8.2.3: Common Laboratory Comments Including Reference Ranges for Specific Laboratory Tests 
                                                            (Page 1 of 1) 
 
______________________________________________________________________________________________________________________________________ 
 
Category               Laboratory Test        Comments 
______________________________________________________________________________________________________________________________________ 
 
xxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
                       xxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
xxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
xxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
                                              xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
______________________________________________________________________________________________________________________________________ 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Category and Lab Test. 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 151 
Protocol Number: MTI-106  
16 December 2019 
 
Listing 16.2.8.3: Electrocardiogram Test Results 
                                                            Treatment Group 
                                                            (Page x of xx) 
 
_____________________________________________________________________________________________________________________________________ 
 
S: Subject 
A: Age/Sex                                   V: Visit                                                Clinical 
E: Evaluable    Category    ECG Parameter    D: Date/Time of ECG (Day)¹      Result (unit)         Significance2   Comments      
_____________________________________________________________________________________________________________________________________ 
 
S: xxxxxxxxx    xxxxxxxxxx xxxxxxxxxx        V: xxxxxxxxx                    xxxx xxxxx xx (xxx)       xxx 
A: xxxx                                      D: xxxx-xx-xxTxx:xx:xx (xx) 
E: xxx/xx/xxx    
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
2  Clinical significance based on Investigator interpretation. CS = Clinically Significant; NCS = Not Clinically Significant. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Category, Parameter, Visit, and Date. Note: for interpretation records, EGEVAL should be concatenated into 
ECG Parameter as EGTEST (EGEVAL). 
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 152 
Protocol Number: MTI-106  
16 December 2019 
Listing 16.2.8.4: Vital Signs 
                                                            Treatment Group 
                                                            (Page x of xx) 
 
______________________________________________________________________________________________________________________________________ 
 
Subject    Age/Sex    Evaluable    Visit          Date of Measurements (Day)¹     Vital Sign                Result       Units 
______________________________________________________________________________________________________________________________________ 
 
xxxxxxxxx  xxxx        xxxxx        xxxxxxxxxx    xxxx-xx-xx (xxx)                 xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
 
                                    xxxxxxxxxx    xxxx-xx-xx (xxx)                 xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
 
xxxxxxxxx  xxxx        xxxxx        xxxxxxxxxx    xxxx-xx-xx (xxx)                 xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
 
                                    xxxxxxxxxx    xxxx-xx-xx (xxx)                 xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
                                                                                   xxxxx xxx                xx           xxxx 
 
 
_____________________________________________________________________________________________________________________________________ 
¹ Day is calculated as date – date of first dose for dates prior to first dose. Otherwise, day is calculated as 
  date – date of first dose + 1 for dates on or after first dose. 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Visit, Date, and Vital Sign (ordered as: Height, Weight, Temperature, Respiration Rate, Heart Rate, 
Systolic Blood Pressure, Diastolic Blood Pressure).  
 
 
 


 
CONFIDENTIAL 
 
Statistical Analysis Plan for Menlo Therapeutics Inc. 
Page 153 
Protocol Number: MTI-106  
16 December 2019 
  Listing 16.2.8.5: Pharmacokinetics Blood Sample Collection and Plasma Concentrations 
                                                            Treatment Group 
                                                            (Page x of xx) 
 
______________________________________________________________________________________________________________________________________ 
 
S: Subject 
A: Age/Sex                                     Date/Time of Pre-PK    Date/Time PK           Concentration 
E: Evaluable   Analyte          Visit          Study Drug Dose        Sample Obtained        (ng/mL)           Reason Not Done 
______________________________________________________________________________________________________________________________________ 
 
S: xxxxxx      xxxxxxxxxxx      xxxxxxxxxx     xxxx-xx-xxTxx:xx       xxxx-xx-xxTxx:xx        xxxxxxxxxx        xxxxxxxxx 
A: xxxx                     
E: xxxxx 
 
                                xxxxxxxxxx     xxxx-xx-xxTxx:xx       xxxx-xx-xxTxx:xx        xxxxxxxxxx        xxxxxxxxx 
 
                                xxxxxxxxxx     xxxx-xx-xxTxx:xx       xxxx-xx-xxTxx:xx        xxxxxxxxxx        xxxxxxxxx 
 
                                xxxxxxxxxx     xxxx-xx-xxTxx:xx       xxxx-xx-xxTxx:xx        xxxxxxxxxx        xxxxxxxxx 
 
 
               xxxxxxxxxxx      xxxxxxxxxx     xxxx-xx-xxTxx:xx       xxxx-xx-xxTxx:xx        xxxxxxxxxx        xxxxxxxxx 
 
                                xxxxxxxxxx     xxxx-xx-xxTxx:xx       xxxx-xx-xxTxx:xx        xxxxxxxxxx        xxxxxxxxx 
                                                              
                                            
S: xxxxxx      xxxxxxxxxxx      xxxxxxxxxx     xxxx-xx-xxTxx:xx       xxxx-xx-xxTxx:xx        xxxxxxxxxx        xxxxxxxxx 
A: xxxx                     
E: xxxxx 
 
                                xxxxxxxxxx     xxxx-xx-xxTxx:xx       xxxx-xx-xxTxx:xx        xxxxxxxxxx        xxxxxxxxx 
 
                                xxxxxxxxxx     xxxx-xx-xxTxx:xx       xxxx-xx-xxTxx:xx        xxxxxxxxxx        xxxxxxxxx 
 
_____________________________________________________________________________________________________________________________________ 
Note: ITT = Intent-to-Treat Population; S = Safety Population; PP = Per-Protocol Population. 
SOURCE: USERNAME\SPONSOR\PROJECT\JOBNAME (DATE, TIME) 
 
Listing sorted by Subject, Analyte, Visit, Date.